bkjobcmkgmbilihgiakcdqxaymjqqcecrgqseouo length 6 864983 page 864983 

<!DOCTYPE html>

<html id="doc" lang="en" class="page-article">
<head id="Head1">
    <!-- charset must appear in the first 1024 bytes of the document -->
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />

<script>
      var SCM = SCM || {};
      if (SCM.AMA && SCM.AMA.DataLayerAsync) {
        SCM.AMA.DataLayerAsync.push("arrSisAffinity", "", "array");
        SCM.AMA.DataLayerAsync.push("SubStatus", "no", "string");
      }

      var googletag = window.googletag || {};
      googletag.cmd = googletag.cmd || [];

          
          if (typeof Storage !== "undefined")
          {
              var targetingParamStr = localStorage.getItem("bcDFPTargetingParams");
              if (targetingParamStr)
              {
                  var targetingParameters = JSON.parse(targetingParamStr);     // set page-level targeting parameters
                  jQuery.each(targetingParameters, function (index, param) {
                      googletag.cmd.push(function () {
                          window.googletag.pubads().setTargeting(param.key, param.value);
                      });
                  });
              }
          }
          
      if (!googletag.pubads) {
        (function () {
          var gads = document.createElement('script');
          var useSSL = 'https:' == document.location.protocol;
          gads.src = (useSSL ? 'https:' : 'http:') +
            '//securepubads.g.doubleclick.net/tag/js/gpt.js';
              gads.setAttribute("async", "");
              gads.setAttribute("defer", "");
          var node = document.getElementsByTagName('script')[0];
          node.parentNode.insertBefore(gads, node);
          })();

        var App = App || {};
        App.Ads = App.Ads || {};
        App.Ads.adPath = App.Ads.adPath || '/6479/' + 'ama.jama';
        App.Ads.Mappings = App.Ads.Mappings || {};
        App.Ads.slots = App.Ads.slots || [];
        App.Ads.fromGoogle = !('yes' === 'yes');

        App.isCollection = App.isCollection || !!document.getElementsByClassName('pg_collection').length;

        
        googletag.cmd.push(function () {

          googletag.pubads()
            .setTargeting('environment', ['newjama'])
            .setTargeting('site', ['ama.jama'])
            .setTargeting('sect', ['scholarly'])
            .setTargeting('sub', ['no'])
            .setTargeting('device', ['cis5550-crawler'])
            .setTargeting('usaphys', ['no'])
            .setTargeting('memberstat', ['no'])
            .setTargeting('pracset', [''])
            .setTargeting('specialty', ['other'])
            .setTargeting('occupation', [''])
            .setTargeting('useraffinity', [''])
            .setTargeting('direct', ['yes'])
            .setTargeting('bot', ['yes'])
            .setTargeting('datacenter', ['no'])
            .setTargeting('selfMPA', [''])
            .setTargeting('selfSpecialty', ['']);

          if (App.isCollection) {
            googletag.pubads().setTargeting('collection', ['']);
          }

          var testParam = getQueryVariable('test');

          if (testParam) {
            googletag.pubads().setTargeting('test', [testParam]);
          }

          function getQueryVariable(variable) {
            var query = window.location.search.substring(1);
            var vars = query.split('&');
            for (var i = 0; i < vars.length; i++) {
              var pair = vars[i].split('=');
              if (decodeURIComponent(pair[0]) == variable) {
                return decodeURIComponent(pair[1]);
              }
            }
          }

          googletag.pubads().disableInitialLoad();
          googletag.enableServices();
        });
      }
</script>


<meta name="viewport" content="width=device-width, initial-scale=1" /><meta name="format-detection" content="telephone=no" /><link rel="shortcut icon" href="//cdn.jamanetwork.com/UI/app/img/favicons/jama/favicon.ico">
<link rel="icon" type="image/png" href="//cdn.jamanetwork.com/UI/app/img/favicons/jama/favicon-192x192.png" sizes="192x192">
<link rel="apple-touch-icon" sizes="180x180" href="//cdn.jamanetwork.com/UI/app/img/favicons/jama/apple-touch-icon-180x180.png">
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
    
    <link rel="stylesheet" href="//cdn.jamanetwork.com/UI/app/dist/app.min.css?v=638488852237037766">
    
    
    
    
    <link href="//cdn.jsdelivr.net/chartist.js/latest/chartist.min.css" type="text/css" rel="stylesheet" />
    

    <meta property="og:title" content="Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults" />
    <meta property="og:type" content="Article" />
    <meta property="og:url" content="https://jamanetwork.com/journals/jama/fullarticle/2799240" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/jsc220007t1_1671563383.33715.png?Expires=2147483647&amp;Signature=p0zclh43akXnCakfnnTcDoGFeOCoecjixKrh~QaIxsbCrztm-VdggBrhoeBxI27BOee4sGxiV3Lly-~JJo0noyKCp0~Fp2HSTY7470bmQFxpAeNJm39un9AS4jpeTbUsTZAzREomUU8pUhoHvUTKqoaTuK6IYglb9jnCmHOLa~hQx76glxojssosXqc37jiC4j~hTTbuzVsr9bJeGaa4kqsThhvQBARipByT9Ji0y2IzNzFrDrmx9PySx9sj-IGxsd2Xsoz09fIKPalV8x6R~VzpXkPyt6qkCWzOYxpyn79W3gky5EO1bgsOF0uCU9MIpQPOMJ0NMWKohBDFzi0EGA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/jsc220007t2_1671563383.42957.png?Expires=2147483647&amp;Signature=H5o3bg6Rxw4FEwYCtZALR4jwmeijSryweSCRk3yhRVtrnHGHtiViPHfkecf1-xobrYRHInlvmtd7uHn2bO~jurb05DuBWH7SYa9SPkuN9g4A4Vp5CYpxmUp88n69wMsjnvbDIYw489Vw6os9Xr2j-2prCN5D5nioPgpULNdz9ObN6NvV6QsVQtfrS5ydZ2LMabjGfuXz1DDOm1re49GCuOxca9zYPor8l04KTthVC8XbV7-1TmiedUIM90wuiglYYA2mvLPS3JqfRe7b6rJKlzOmTBgWxLaJHbRqgiSI~ZGZhuwya1qng2digrF4kZtSIHq5swX3OoittX6aZX~8ww__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/jsc220007t3_1671563383.50744.png?Expires=2147483647&amp;Signature=yki9HmuVzdLhx23ANnxyvCx8eCtoxV4BjX~XNKYrXb~umtlp23yx1yH9m7XeqdsVqhU8VD~nA3KvBTrQ8r4w1Qv87nRlRZAASIGqursUWzdg76-uipFoiR7TGSTnGB-mjF7mkBcifkAxKkG7vl31XeSsuxVULCd9cC6untF6Ype6PXc5G2YfQhW98xOfyC3rm04IckL0iZwepknTVJyETBZhJ~bGHKW4Y6w~SoaZBJWBFsOC8ncOmJYBBZNIbpB5aP~-4o65PIItVUeCnncN3tM-m5tO~oUq5G93hF6qyV5WBThSXVb4QlPDDIwn94o0RmyApUre8hq1mJ2tm-bD-g__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/jsc220007t4_1671563383.59186.png?Expires=2147483647&amp;Signature=3s6-tYUCBZj-MoC2aVBoFUrqEdDJlJfmegT~Gy9rZaYULsCXMuzE8hNhgI4ewRCvEFmBjfZkPfODeShBN6uxgA-BKY3QMwNu4t-JB0w3wVYidjMSXsx~twNf5Ly1TodMQ1ttSHx-p1MnGRQznGCJgOaUpkljKdaEs1c5dfTk-TZu2h47z2K8cRd2Uaezb~67z4U5ISd78npUtlZxOyNU71Refa1kqw8wFCmUDNHinvHkVAyyQXGpq5-UsNpF1nMQFfcjFXxS532p~q5J2pa-2dnPN1cXh2RuV5-Bf2EseTK7ogfvUGrKRog2JQ9qr6Vcne~eigSBRMfLC6d1s2NYBw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:description" content="This guideline from the International Antiviral (formerly AIDS) Society–USA updates practice recommendations for managing HIV infection, including when to change antiviral regimens; use of preexposure prophylaxis to prevent infection in at-risk persons; care of pregnant persons with HIV, people..." />
        <meta property="fb:pages" content="87087958340" />
        <meta property="fb:pages" content="122228711814384" />
        <meta property="fb:pages" content="1648414928738217" />
        <meta property="fb:pages" content="117506346528" />
        <meta property="fb:pages" content="97538728726" />
        <meta property="fb:pages" content="114116793520" />
        <meta property="fb:pages" content="100679858757" />
        <meta property="fb:pages" content="759822190741773" />
        <meta property="fb:pages" content="100265333750" />
        <meta property="fb:pages" content="234770525256" />
        <meta property="fb:pages" content="98784919862" />
        <meta property="fb:pages" content="120829458202" />
        <meta property="fb:pages" content="124842870398" />
        <meta property="fb:pages" content="110245330325636" />
        <meta name="twitter:card" content="summary_large_image" />
        <meta name="twitter:site" content="@JAMA_current" />
        <meta name="twitter:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/jsc220007t1_1671563383.33715.png?Expires=2147483647&amp;Signature=p0zclh43akXnCakfnnTcDoGFeOCoecjixKrh~QaIxsbCrztm-VdggBrhoeBxI27BOee4sGxiV3Lly-~JJo0noyKCp0~Fp2HSTY7470bmQFxpAeNJm39un9AS4jpeTbUsTZAzREomUU8pUhoHvUTKqoaTuK6IYglb9jnCmHOLa~hQx76glxojssosXqc37jiC4j~hTTbuzVsr9bJeGaa4kqsThhvQBARipByT9Ji0y2IzNzFrDrmx9PySx9sj-IGxsd2Xsoz09fIKPalV8x6R~VzpXkPyt6qkCWzOYxpyn79W3gky5EO1bgsOF0uCU9MIpQPOMJ0NMWKohBDFzi0EGA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />




<script type="application/ld+json">
    {
  "@context": "https://schema.org/",
  "@type": "Article",
  "headline": "Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the",
  "author": "Rajesh T. Gandhi, MD",
  "url": "https://jamanetwork.com/journals/jama/fullarticle/2799240",
  "datePublished": "2023-01-03",
  "description": "This guideline from the International Antiviral (formerly AIDS) Society–USA updates practice recommendations for managing HIV infection, including when to change antiviral regimens; use of preexposure prophylaxis to prevent infection in at-risk persons; care of pregnant persons with HIV, people aging with HIV, and people with substance use disorder and HIV; and new challenges in people with HIV, including COVID-19 and monkeypox virus infection.",
  "publisher": {
    "@type": "Organization",
    "name": "JAMA Network",
    "logo": {
      "@type": "ImageObject",
      "url": "//cdn.jamanetwork.com/UI/app/img/favicons/jama/favicon.ico"
    }
  },
  "image": [
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/jsc220007t1_1671563383.33715.png?Expires=2147483647&Signature=p0zclh43akXnCakfnnTcDoGFeOCoecjixKrh~QaIxsbCrztm-VdggBrhoeBxI27BOee4sGxiV3Lly-~JJo0noyKCp0~Fp2HSTY7470bmQFxpAeNJm39un9AS4jpeTbUsTZAzREomUU8pUhoHvUTKqoaTuK6IYglb9jnCmHOLa~hQx76glxojssosXqc37jiC4j~hTTbuzVsr9bJeGaa4kqsThhvQBARipByT9Ji0y2IzNzFrDrmx9PySx9sj-IGxsd2Xsoz09fIKPalV8x6R~VzpXkPyt6qkCWzOYxpyn79W3gky5EO1bgsOF0uCU9MIpQPOMJ0NMWKohBDFzi0EGA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/jsc220007t2_1671563383.42957.png?Expires=2147483647&Signature=H5o3bg6Rxw4FEwYCtZALR4jwmeijSryweSCRk3yhRVtrnHGHtiViPHfkecf1-xobrYRHInlvmtd7uHn2bO~jurb05DuBWH7SYa9SPkuN9g4A4Vp5CYpxmUp88n69wMsjnvbDIYw489Vw6os9Xr2j-2prCN5D5nioPgpULNdz9ObN6NvV6QsVQtfrS5ydZ2LMabjGfuXz1DDOm1re49GCuOxca9zYPor8l04KTthVC8XbV7-1TmiedUIM90wuiglYYA2mvLPS3JqfRe7b6rJKlzOmTBgWxLaJHbRqgiSI~ZGZhuwya1qng2digrF4kZtSIHq5swX3OoittX6aZX~8ww__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/jsc220007t3_1671563383.50744.png?Expires=2147483647&Signature=yki9HmuVzdLhx23ANnxyvCx8eCtoxV4BjX~XNKYrXb~umtlp23yx1yH9m7XeqdsVqhU8VD~nA3KvBTrQ8r4w1Qv87nRlRZAASIGqursUWzdg76-uipFoiR7TGSTnGB-mjF7mkBcifkAxKkG7vl31XeSsuxVULCd9cC6untF6Ype6PXc5G2YfQhW98xOfyC3rm04IckL0iZwepknTVJyETBZhJ~bGHKW4Y6w~SoaZBJWBFsOC8ncOmJYBBZNIbpB5aP~-4o65PIItVUeCnncN3tM-m5tO~oUq5G93hF6qyV5WBThSXVb4QlPDDIwn94o0RmyApUre8hq1mJ2tm-bD-g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/jsc220007t4_1671563383.59186.png?Expires=2147483647&Signature=3s6-tYUCBZj-MoC2aVBoFUrqEdDJlJfmegT~Gy9rZaYULsCXMuzE8hNhgI4ewRCvEFmBjfZkPfODeShBN6uxgA-BKY3QMwNu4t-JB0w3wVYidjMSXsx~twNf5Ly1TodMQ1ttSHx-p1MnGRQznGCJgOaUpkljKdaEs1c5dfTk-TZu2h47z2K8cRd2Uaezb~67z4U5ISd78npUtlZxOyNU71Refa1kqw8wFCmUDNHinvHkVAyyQXGpq5-UsNpF1nMQFfcjFXxS532p~q5J2pa-2dnPN1cXh2RuV5-Bf2EseTK7ogfvUGrKRog2JQ9qr6Vcne~eigSBRMfLC6d1s2NYBw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
  ],
  "articleSection": [
    "Introduction",
    "Methods",
    "Appointment of the Panel",
    "Identification of the Evidence",
    "Process",
    "Initiation of ART",
    "Initial ART Regimens for Individuals With HIV",
    "Initiation of ART in the Setting of PrEP Failure",
    "ART and Pregnancy",
    "Initiating ART in the Setting of Active Opportunistic Infections and Cancer",
    "Other Recommended Regimens",
    "When and How to Switch ART Regimens",
    "Switching in the Setting of Viral Suppression",
    "Switches to Long-acting Cabotegravir and Rilpivirine",
    "Switching for Virologic Failure",
    "Laboratory Monitoring in Individuals With Established HIV at HIV Diagnosis and Starting ART",
    "During ART",
    "At the Time of Virologic Failure and Before Starting New ART Regimen",
    "Weight Gain and Metabolic Complications With ART",
    "HIV and Aging",
    "Prevention of HIV Infection",
    "Choosing the PrEP Regimen",
    "Oral PrEP Regimens",
    "Same-Day or Rapid PrEP Start",
    "Injectable PrEP Regimen",
    "Laboratory Testing in People Receiving PrEP",
    "Adherence to PrEP and Persistence/Retention",
    "ART Choice for PrEP Breakthrough Infections",
    "Postexposure Prophylaxis for HIV and Bacterial STIs",
    "Substance Use in Persons at Risk for and With HIV",
    "COVID-19 and HIV",
    "Monkeypox Virus Infection",
    "Promoting Equity in HIV Treatment and Prevention",
    "Limitations",
    "Conclusions",
    "Article Information",
    "References"
  ],
  "keyWords": ""
}
</script>
<meta name="citation_author" content="Rajesh T. Gandhi" /><meta name="citation_author_institution" content="Massachusetts General Hospital and Harvard Medical School, Boston" /><meta name="citation_author" content="Roger Bedimo" /><meta name="citation_author_institution" content="University of Texas Southwestern Medical Center, Dallas" /><meta name="citation_author" content="Jennifer F. Hoy" /><meta name="citation_author_institution" content="The Alfred Hospital and Monash University, Melbourne, Australia" /><meta name="citation_author" content="Raphael J. Landovitz" /><meta name="citation_author_institution" content="University of California Los Angeles" /><meta name="citation_author" content="Davey M. Smith" /><meta name="citation_author_institution" content="University of California San Diego School of Medicine" /><meta name="citation_author" content="Ellen F. Eaton" /><meta name="citation_author_institution" content="University of Alabama at Birmingham" /><meta name="citation_author" content="Clara Lehmann" /><meta name="citation_author_institution" content="University of Cologne and German Center for Infection Research (DZIF), Bonn-Cologne" /><meta name="citation_author" content="Sandra A. Springer" /><meta name="citation_author_institution" content="Yale University School of Medicine, New Haven, Connecticut" /><meta name="citation_author_institution" content="The Veterans Administration Connecticut Healthcare System, West Haven" /><meta name="citation_author" content="Paul E. Sax" /><meta name="citation_author_institution" content="Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts" /><meta name="citation_author" content="Melanie A. Thompson" /><meta name="citation_author_institution" content="Thacker &amp; Thompson, Atlanta, Georgia" /><meta name="citation_author" content="Constance A. Benson" /><meta name="citation_author_institution" content="University of California San Diego School of Medicine" /><meta name="citation_author" content="Susan P. Buchbinder" /><meta name="citation_author_institution" content="Department of Public Health, San Francisco, California" /><meta name="citation_author" content="Carlos del Rio" /><meta name="citation_author_institution" content="Emory University School of Medicine and Grady Health System, Atlanta, Georgia" /><meta name="citation_author" content="Joseph J. Eron" /><meta name="citation_author_institution" content="The University of North Carolina School of Medicine at Chapel Hill" /><meta name="citation_author" content="Huldrych F. Günthard" /><meta name="citation_author_institution" content="University Hospital Zurich and Institute of Medical Virology, University of Zurich, Zurich, Switzerland" /><meta name="citation_author" content="Jean-Michel Molina" /><meta name="citation_author_institution" content="University of Paris Cité, Saint-Louis and Lariboisière Hospitals, Assistance Publique Hopitaux de Paris, France" /><meta name="citation_author" content="Donna M. Jacobsen" /><meta name="citation_author_institution" content="International Antiviral Society–USA, San Francisco, California" /><meta name="citation_author" content="Michael S. Saag" /><meta name="citation_author_institution" content="University of Alabama at Birmingham" /><meta name="citation_title" content="Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society–USA Panel" /><meta name="citation_firstpage" content="63" /><meta name="citation_lastpage" content="84" /><meta name="citation_doi" content="10.1001/jama.2022.22246" /><meta name="citation_abstract" content="&lt;h3&gt;Importance&lt;/h3&gt;&lt;p&gt;Recent advances in treatment and prevention of HIV warrant updated recommendations to guide optimal practice.&lt;/p&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;p&gt;Based on a critical evaluation of new data, to provide clinicians with recommendations on use of antiretroviral drugs for the treatment and prevention of HIV, laboratory monitoring, care of people aging with HIV, substance use disorder and HIV, and new challenges in people with HIV, including COVID-19 and monkeypox virus infection.&lt;/p&gt;&lt;h3&gt;Evidence Review&lt;/h3&gt;&lt;p&gt;A panel of volunteer expert physician scientists were appointed to update the 2020 consensus recommendations. Relevant evidence in the literature (PubMed and Embase searches, which initially yielded 7891 unique citations, of which 834 were considered relevant) and studies presented at peer-reviewed scientific conferences between January 2020 and October 2022 were considered.&lt;/p&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;p&gt;Initiation of antiretroviral therapy (ART) is recommended as soon as possible after diagnosis of HIV. Barriers to care should be addressed, including ensuring access to ART and adherence support. Integrase strand transfer inhibitor–containing regimens remain the mainstay of initial therapy. For people who have achieved viral suppression with a daily oral regimen, long-acting injectable therapy with cabotegravir plus rilpivirine given as infrequently as every 2 months is now an option. Weight gain and metabolic complications have been linked to certain antiretroviral medications; novel strategies to ameliorate these complications are needed. Management of comorbidities throughout the life span is increasingly important, because people with HIV are living longer and confronting the health challenges of aging. In addition, management of substance use disorder in people with HIV requires an evidence-based, integrated approach. Options for preexposure prophylaxis include oral medications (tenofovir disoproxil fumarate or tenofovir alafenamide plus emtricitabine) and, for the first time, a long-acting injectable agent, cabotegravir. Recent global health emergencies, like the SARS-CoV-2 pandemic and monkeypox virus outbreak, continue to have a major effect on people with HIV and the delivery of services. To address these and other challenges, an equity-based approach is essential.&lt;/p&gt;&lt;h3&gt;Conclusions and Relevance&lt;/h3&gt;&lt;p&gt;Advances in treatment and prevention of HIV continue to improve outcomes, but challenges and opportunities remain.&lt;/p&gt;" /><meta name="citation_journal_title" content="JAMA" /><meta name="citation_journal_abbrev" content="JAMA" /><meta name="citation_volume" content="329" /><meta name="citation_issue" content="1" /><meta name="citation_publication_date" content="2023/01/03" /><meta name="citation_issn" content="0098-7484" /><meta name="citation_publisher" content="American Medical Association" /><meta name="citation_reference" content="citation_title=Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA Panel.; citation_author=Saag  MS; citation_author=Gandhi  RT; citation_author=Hoy  JF;  citation_journal_title=JAMA;  citation_year=2020;  citation_volume=324;  citation_issue=16;  citation_pages=1651-1669; " /><meta name="citation_reference" content="citation_title=The periodic health examination.; citation_author=Canadian Task Force on the Periodic Health Examination;  citation_journal_title=Can Med Assoc J;  citation_year=1979;  citation_volume=121;  citation_issue=9;  citation_pages=1193-1254; " /><meta name="citation_reference" content="citation_title=Initiating antiretroviral treatment for newly diagnosed HIV patients in sexual health clinics greatly improves timeliness of viral suppression.; citation_author=Pathela  P; citation_author=Jamison  K; citation_author=Braunstein  SL;  citation_journal_title=AIDS;  citation_year=2021;  citation_volume=35;  citation_issue=11;  citation_pages=1805-1812; " /><meta name="citation_reference" content="citation_title=Evidence regarding rapid initiation of antiretroviral therapy in patients living with HIV.; citation_author=Michienzi  SM; citation_author=Barrios  M; citation_author=Badowski  ME;  citation_journal_title=Curr Infect Dis Rep;  citation_year=2021;  citation_volume=23;  citation_issue=5;  citation_pages=7" /><meta name="citation_reference" content="citation_title=Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in a rapid-initiation model of care for human immunodeficiency virus type 1 infection: primary analysis of the DIAMOND study.; citation_author=Huhn  GD; citation_author=Crofoot  G; citation_author=Ramgopal  M;  citation_journal_title=Clin Infect Dis;  citation_year=2020;  citation_volume=71;  citation_issue=12;  citation_pages=3110-3117; " /><meta name="citation_reference" content="citation_title=Early HIV treatment and survival over six years of observation in the ANRS 12249 treatment as prevention trial.; citation_author=Baisley  K; citation_author=Orne-Gliemann  J; citation_author=Larmarange  J;  citation_journal_title=HIV Med;  citation_year=2022;  citation_volume=23;  citation_issue=8;  citation_pages=922-928; " /><meta name="citation_reference" content="citation_title=The impact of the housing status on clinical outcomes and health care utilization among individuals living with HIV.; citation_author=Stanic  A; citation_author=Rybin  D; citation_author=Cannata  F;  citation_journal_title=AIDS Care;  citation_year=2021;  citation_volume=33;  citation_issue=1;  citation_pages=1-9; " /><meta name="citation_reference" content="citation_title=Exploring individual-level barriers to HIV medication adherence among men who have sex with men in the HIV Prevention Trials Network (HPTN 065) study.; citation_author=Maragh-Bass  AC; citation_author=Gamble  T; citation_author=El-Sadr  WM; citation_author=Hanscom  B; citation_author=Tolley  EE;  citation_journal_title=AIDS Care;  citation_year=2021;  citation_volume=33;  citation_issue=11;  citation_pages=1404-1413; " /><meta name="citation_reference" content="citation_title=Strategies to improve HIV care outcomes for people with HIV who are out of care.; citation_author=Higa  DH; citation_author=Crepaz  N; citation_author=Mullins  MM;  citation_journal_title=AIDS;  citation_year=2022;  citation_volume=36;  citation_issue=6;  citation_pages=853-862; " /><meta name="citation_reference" content="citation_author=National Academies of Sciences Engineering and Medicine; citation_publisher=National Academies Press, ;  citation_title=Opportunities to Improve Opioid Use Disorder and Infectious Disease Services;  citation_year=2020; " /><meta name="citation_reference" content="citation_title=Rapid antiretroviral therapy among individuals with acute and early HIV.; citation_author=Martin  TCS; citation_author=Abrams  M; citation_author=Anderson  C; citation_author=Little  SJ;  citation_journal_title=Clin Infect Dis;  citation_year=2021;  citation_volume=73;  citation_issue=1;  citation_pages=130-133; " /><meta name="citation_reference" content="citation_title=Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, phase 3 trial.; citation_author=Chéret  A; citation_author=Bauer  R; citation_author=Meiffrédy  V;  citation_journal_title=J Antimicrob Chemother;  citation_year=2022;  citation_volume=77;  citation_issue=9;  citation_pages=2506-2515; " /><meta name="citation_reference" content="citation_title=Antiretroviral initiation at ≥800 CD4+ cells/mm3 associated with lower human immunodeficiency virus reservoir size.; citation_author=Rasmussen  TA; citation_author=Ahuja  SK; citation_author=Kuwanda  L;  citation_journal_title=Clin Infect Dis;  citation_year=2022;  citation_volume=75;  citation_issue=10;  citation_pages=1781-1791; " /><meta name="citation_reference" content="citation_title=Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.; citation_author=Hunt  PW; citation_author=Brenchley  J; citation_author=Sinclair  E;  citation_journal_title=J Infect Dis;  citation_year=2008;  citation_volume=197;  citation_pages=126-133; " /><meta name="citation_reference" content="citation_title=Antiretroviral therapy reduces T-cell activation and immune exhaustion markers in human immunodeficiency virus controllers.; citation_author=AIDS Clinical Trials Group Study A5308 Team; citation_author=Li  JZ; citation_author=Segal  FP; citation_author=Bosch  RJ;  citation_journal_title=Clin Infect Dis;  citation_year=2020;  citation_volume=70;  citation_issue=8;  citation_pages=1636-1642; " /><meta name="citation_reference" content="citation_title=Antiretroviral therapy for HIV controllers: reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort.; citation_author=ANRS CO21 Study Group; citation_author=Plaçais  L; citation_author=Boufassa  F; citation_author=Lécuroux  C;  citation_journal_title=EClinicalMedicine;  citation_year=2021;  citation_volume=37; " /><meta name="citation_reference" content="citation_title=Rapid ART start in early HIV infection: time to viral load suppression and retention in care in a London cohort.; citation_author=Dean Street Collaborative Group; citation_author=Girometti  N; citation_author=Lander  F; citation_author=McOwan  A; citation_author=Nwokolo  N; citation_author=Boffito  M; citation_author=Whitlock  G;  citation_journal_title=HIV Med;  citation_year=2020;  citation_volume=21;  citation_issue=9;  citation_pages=613-615; " /><meta name="citation_reference" content="citation_title=Recent abacavir use and incident cardiovascular disease in contemporary treated people living with HIV.; citation_author=RESPOND Study Group; citation_author=Jaschinski  N; citation_author=Greenberg  L; citation_author=Neesgaard  B;  citation_journal_title=AIDS;  citation_year=2022; " /><meta name="citation_reference" content="citation_title=First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable HIV viremia in an urban HIV clinic.; citation_author=Christopoulos  KA; citation_author=Grochowski  J; citation_author=Mayorga-Munoz  F;  citation_journal_title=Clin Infect Dis;  citation_year=2022; " /><meta name="citation_reference" content="citation_title=Cabotegravir for HIV prevention in cisgender men and transgender women.; citation_author=HPTN 083 Study Team; citation_author=Landovitz  RJ; citation_author=Donnell  D; citation_author=Clement  ME;  citation_journal_title=N Engl J Med;  citation_year=2021;  citation_volume=385;  citation_issue=7;  citation_pages=595-608; " /><meta name="citation_reference" content="citation_title=Characterization of human immunodeficiency virus (HIV) infections in women who received injectable cabotegravir or tenofovir disoproxil fumarate/emtricitabine for HIV prevention: HPTN 084.; citation_author=Eshleman  SH; citation_author=Fogel  JM; citation_author=Piwowar-Manning  E;  citation_journal_title=J Infect Dis;  citation_year=2022;  citation_volume=225;  citation_issue=10;  citation_pages=1741-1749; " /><meta name="citation_reference" content="citation_title=Updated efficacy, safety, and case studies in HPTN 083: CAB-LA vs TDF/FTC for PrEP [Abstract 96] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections.; citation_author=Landovitz  R; citation_author=Donnell  D; citation_author=Tran  H;  citation_journal_title=Top Antiv Med;  citation_year=2022;  citation_volume=30;  citation_pages=37" /><meta name="citation_reference" content="Department of Health and Human Services. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. ClinicalInfo. Updated March 17, 2022. Accessed November 9, 2022. https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new-guidelines?view=full " /><meta name="citation_reference" content="citation_author=Zash  R; citation_author=Holmes  LB; citation_author=Diseko  M;  citation_year=2022; " /><meta name="citation_reference" content="citation_title=Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.; citation_author=IMPAACT 2010/VESTED Study Team and Investigators; citation_author=Lockman  S; citation_author=Brummel  SS; citation_author=Ziemba  L;  citation_journal_title=Lancet;  citation_year=2021;  citation_volume=397;  citation_issue=10281;  citation_pages=1276-1292; " /><meta name="citation_reference" content="citation_title=Growth of infants with perinatal exposure to maternal DTG vs EFV and TDF vs TAF [Abstract 30] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections.; citation_author=Stranix-Chibanda  L; citation_author=Ziemba  L; citation_author=Brummer  S;  citation_journal_title=Top Antiv Med;  citation_year=2022;  citation_volume=30;  citation_pages=10-11; " /><meta name="citation_reference" content="citation_title=Dolutegravir in pregnancy as compared with current HIV regimens in the United States.; citation_author=Pediatric HIV/AIDS Cohort Study; citation_author=Patel  K; citation_author=Huo  Y; citation_author=Jao  J;  citation_journal_title=N Engl J Med;  citation_year=2022;  citation_volume=387;  citation_issue=9;  citation_pages=799-809; " /><meta name="citation_reference" content="citation_title=What is the optimum time to start antiretroviral therapy in people with HIV and tuberculosis coinfection? a systematic review and meta-analysis.; citation_author=Burke  RM; citation_author=Rickman  HM; citation_author=Singh  V;  citation_journal_title=J Int AIDS Soc;  citation_year=2021;  citation_volume=24;  citation_issue=7; " /><meta name="citation_reference" content="citation_author=Ingle  SM; citation_author=Miro  JM; citation_author=Furrer  H;  citation_year=2015; " /><meta name="citation_reference" content="National Institutes of Health, Centers for Disease Control and Prevention, and HIV Medicine Association of the Infectious Disease Society of America. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Updated September 28, 2022. Accessed November 9, 2022. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections  https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection " /><meta name="citation_reference" content="citation_title=Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial.; citation_author=International Study of Patients With HIV on Rifampicin ING Study Group; citation_author=Dooley  KE; citation_author=Kaplan  R; citation_author=Mwelase  N;  citation_journal_title=Clin Infect Dis;  citation_year=2020;  citation_volume=70;  citation_issue=4;  citation_pages=549-556; " /><meta name="citation_reference" content="citation_title=Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.; citation_author=ANRS 12300 Reflate TB2 Study Group; citation_author=De Castro  N; citation_author=Marcy  O; citation_author=Chazallon  C;  citation_journal_title=Lancet Infect Dis;  citation_year=2021;  citation_volume=21;  citation_issue=6;  citation_pages=813-822; " /><meta name="citation_reference" content="citation_title=Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.; citation_author=HPTN 052-ACTG Study Team; citation_author=Grinsztejn  B; citation_author=Hosseinipour  MC; citation_author=Ribaudo  HJ;  citation_journal_title=Lancet Infect Dis;  citation_year=2014;  citation_volume=14;  citation_issue=4;  citation_pages=281-290; " /><meta name="citation_reference" content="citation_author=Marcy  O; citation_author=De Castro  N; citation_author=Chazallon  C;  citation_year=2020; " /><meta name="citation_reference" content="citation_title=Efficacy and safety of switching to dolutegravir/lamivudine (DTG/3TC) versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with HIV-1: results through week 144 from the phase 3, non-inferiority TANGO randomized trial.; citation_author=Osiyemi  O; citation_author=De Wit  S; citation_author=Ajana  F;  citation_journal_title=Clin Infect Dis;  citation_year=2022;  citation_volume=75;  citation_issue=6;  citation_pages=975-986; " /><meta name="citation_reference" content="citation_title=Efficacy and safety of switching to the 2-drug regimen dolutegravir/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with HIV-1: week 48 results from the phase 3, non-inferiority SALSA randomized trial.; citation_author=Llibre  JM; citation_author=Brites  C; citation_author=Cheng  CY;  citation_journal_title=Clin Infect Dis;  citation_year=2022; " /><meta name="citation_reference" content="citation_title=Brief report: durable suppression and low rate of virologic failure 3 years after switch to dolutegravir + rilpivirine 2-drug regimen: 148-week results from the SWORD-1 and SWORD-2 randomized clinical trials.; citation_author=van Wyk  J; citation_author=Orkin  C; citation_author=Rubio  R;  citation_journal_title=J Acquir Immune Defic Syndr;  citation_year=2020;  citation_volume=85;  citation_issue=3;  citation_pages=325-330; " /><meta name="citation_reference" content="citation_title=Clinical outcomes of 2-drug regimens vs 3-drug regimens in antiretroviral treatment-experienced people living with human immunodeficiency virus.; citation_author=RESPOND (International Cohort Consortium of Infectious Diseases) Study Group; citation_author=Greenberg  L; citation_author=Ryom  L; citation_author=Neesgaard  B;  citation_journal_title=Clin Infect Dis;  citation_year=2021;  citation_volume=73;  citation_issue=7;  citation_pages=e2323-e2333; " /><meta name="citation_reference" content="citation_title=Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study.; citation_author=van Wyk  J; citation_author=Ajana  F; citation_author=Bisshop  F;  citation_journal_title=Clin Infect Dis;  citation_year=2020;  citation_volume=71;  citation_issue=8;  citation_pages=1920-1929; " /><meta name="citation_reference" content="citation_title=Archived resistance and response to &lt;40 c/mL &amp; TND–DTG/3TC FDC at week 48 in SALSA [Abstract 481] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections.; citation_author=Underwood  M; citation_author=Osiyemi  O; citation_author=Rubio  R;  citation_journal_title=Top Antiv Med;  citation_year=2022;  citation_volume=30;  citation_pages=184" /><meta name="citation_reference" content="citation_author=Marks  K; citation_author=Kang  M; citation_author=Umbleja  T;  citation_year=2022; " /><meta name="citation_reference" content="citation_title=A randomized trial of switching treatment-experienced adults from PI/r to DTG [Abstract 136] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections.; citation_author=Ombajo  LA; citation_author=Penner  J; citation_author=Nkuranga  J;  citation_journal_title=Top Antiv Med;  citation_year=2022;  citation_volume=30;  citation_pages=52" /><meta name="citation_reference" content="citation_title=Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus.; citation_author=GS-US-380–4030 Investigators; citation_author=Sax  PE; citation_author=Rockstroh  JK; citation_author=Luetkemeyer  AF;  citation_journal_title=Clin Infect Dis;  citation_year=2021;  citation_volume=73;  citation_issue=2;  citation_pages=e485-e493; " /><meta name="citation_reference" content="citation_title=Switching to bictegravir/emtricitabine/tenofovir alafenamide in Black Americans with HIV-1: a randomized phase 3b, multicenter, open-label study.; citation_author=BRAAVE2020 Investigators; citation_author=Hagins  D; citation_author=Kumar  P; citation_author=Saag  M;  citation_journal_title=J Acquir Immune Defic Syndr;  citation_year=2021;  citation_volume=88;  citation_issue=1;  citation_pages=86-95; " /><meta name="citation_reference" content="citation_title=High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.; citation_author=Sax  PE; citation_author=Andreatta  K; citation_author=Molina  JM;  citation_journal_title=AIDS;  citation_year=2022;  citation_volume=36;  citation_issue=11;  citation_pages=1511-1520; " /><meta name="citation_reference" content="citation_title=Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.; citation_author=Aboud  M; citation_author=Kaplan  R; citation_author=Lombaard  J;  citation_journal_title=Lancet Infect Dis;  citation_year=2019;  citation_volume=19;  citation_issue=3;  citation_pages=253-264; " /><meta name="citation_reference" content="citation_title=Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.; citation_author=NADIA Trial Team; citation_author=Paton  NI; citation_author=Musaazi  J; citation_author=Kityo  C;  citation_journal_title=Lancet HIV;  citation_year=2022;  citation_volume=9;  citation_issue=6;  citation_pages=e381-e393; " /><meta name="citation_reference" content="citation_title=Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials.; citation_author=Rizzardini  G; citation_author=Overton  ET; citation_author=Orkin  C;  citation_journal_title=J Acquir Immune Defic Syndr;  citation_year=2020;  citation_volume=85;  citation_issue=4;  citation_pages=498-506; " /><meta name="citation_reference" content="citation_title=Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.; citation_author=Overton  ET; citation_author=Richmond  G; citation_author=Rizzardini  G;  citation_journal_title=Lancet;  citation_year=2021;  citation_volume=396;  citation_issue=10267;  citation_pages=1994-2005; " /><meta name="citation_reference" content="citation_title=Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48 weeks.; citation_author=Murray  M; citation_author=Antela  A; citation_author=Mills  A;  citation_journal_title=AIDS Behav;  citation_year=2020;  citation_volume=24;  citation_issue=12;  citation_pages=3533-3544; " /><meta name="citation_reference" content="citation_title=Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.; citation_author=Orkin  C; citation_author=Bernal Morell  E; citation_author=Tan  DHS;  citation_journal_title=Lancet HIV;  citation_year=2021;  citation_volume=8;  citation_issue=11;  citation_pages=e668-e678; " /><meta name="citation_reference" content="citation_title=Clinical outcomes following the use of archived proviral HIV-1 DNA genotype to guide antiretroviral therapy adjustment.; citation_author=Ellis  KE; citation_author=Nawas  GT; citation_author=Chan  C;  citation_journal_title=Open Forum Infect Dis;  citation_year=2019;  citation_volume=7;  citation_issue=1; " /><meta name="citation_reference" content="citation_title=Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study.; citation_author=VIKING-3 Study Group; citation_author=Castagna  A; citation_author=Maggiolo  F; citation_author=Penco  G;  citation_journal_title=J Infect Dis;  citation_year=2014;  citation_volume=210;  citation_issue=3;  citation_pages=354-362; " /><meta name="citation_reference" content="Fostemsavir [prescribing information]. ViiV Healthcare; 2020. " /><meta name="citation_reference" content="citation_title=Prevalence of human immunodeficiency virus-1 integrase strand transfer inhibitor resistance in British Columbia, Canada between 2009 and 2016: a longitudinal analysis.; citation_author=Kamelian  K; citation_author=Lepik  KJ; citation_author=Chau  W;  citation_journal_title=Open Forum Infect Dis;  citation_year=2019;  citation_volume=6;  citation_issue=3; " /><meta name="citation_reference" content="citation_title=Should we be testing for baseline integrase resistance in patients newly diagnosed with human immunodeficiency virus?; citation_author=Koullias  Y; citation_author=Sax  PE; citation_author=Fields  NF; citation_author=Walensky  RP; citation_author=Hyle  EP;  citation_journal_title=Clin Infect Dis;  citation_year=2017;  citation_volume=65;  citation_issue=8;  citation_pages=1274-1281; " /><meta name="citation_reference" content="citation_title=The potential impact of initiating antiretroviral therapy with integrase inhibitors on HIV transmission risk in British Columbia, Canada.; citation_author=Zhu  J; citation_author=Rozada  I; citation_author=David  J;  citation_journal_title=EClinicalMedicine;  citation_year=2019;  citation_volume=13;  citation_pages=101-111; " /><meta name="citation_reference" content="citation_title=Mathematical modeling of HIV-1 transmission risk from condomless anal intercourse in HIV-infected MSM by the type of initial ART.; citation_author=Berenguer  J; citation_author=Parrondo  J; citation_author=Landovitz  RJ;  citation_journal_title=PLoS One;  citation_year=2019;  citation_volume=14;  citation_issue=7; " /><meta name="citation_reference" content="citation_title=Prevalence of genotypic baseline risk factors for cabotegravir   + rilpivirine failure among ARV-naive patients.; citation_author=Charpentier  C; citation_author=Storto  A; citation_author=Soulié  C;  citation_journal_title=J Antimicrob Chemother;  citation_year=2021;  citation_volume=76;  citation_issue=11;  citation_pages=2983-2987; " /><meta name="citation_reference" content="citation_title=Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity.; citation_author=Sise  ME; citation_author=Hirsch  JS; citation_author=Canetta  PA; citation_author=Herlitz  L; citation_author=Mohan  S;  citation_journal_title=AIDS;  citation_year=2015;  citation_volume=29;  citation_issue=8;  citation_pages=941-946; " /><meta name="citation_reference" content="citation_title=Simultaneous measurement of urinary albumin and total protein may facilitate decision-making in HIV-infected patients with proteinuria.; citation_author=Samarawickrama  A; citation_author=Cai  M; citation_author=Smith  ER;  citation_journal_title=HIV Med;  citation_year=2012;  citation_volume=13;  citation_issue=9;  citation_pages=526-532; " /><meta name="citation_reference" content="citation_title=Changes in renal function with long-term exposure to antiretroviral therapy in HIV-infected adults in Asia.; citation_author=Joshi  K; citation_author=Boettiger  D; citation_author=Kerr  S;  citation_journal_title=Pharmacoepidemiol Drug Saf;  citation_year=2018;  citation_volume=27;  citation_issue=11;  citation_pages=1209-1216; " /><meta name="citation_reference" content="citation_title=Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting.; citation_author=Kaboré  NF; citation_author=Poda  A; citation_author=Zoungrana  J;  citation_journal_title=BMC Nephrol;  citation_year=2019;  citation_volume=20;  citation_issue=1;  citation_pages=155" /><meta name="citation_reference" content="citation_title=HIV infection, tenofovir, and urine α1-microglobulin: a cross-sectional analysis in the Multicenter AIDS Cohort Study.; citation_author=Jotwani  V; citation_author=Scherzer  R; citation_author=Estrella  MM;  citation_journal_title=Am J Kidney Dis;  citation_year=2016;  citation_volume=68;  citation_issue=4;  citation_pages=571-581; " /><meta name="citation_reference" content="citation_title=Primary care guidance for persons with human immunodeficiency virus: 2020 update by the HIV Medicine Association of the Infectious Diseases Society of America.; citation_author=Thompson  MA; citation_author=Horberg  MA; citation_author=Agwu  AL;  citation_journal_title=Clin Infect Dis;  citation_year=2021;  citation_volume=73;  citation_issue=11;  citation_pages=e3572-e3605; " /><meta name="citation_reference" content="citation_title=Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials.; citation_author=Sax  PE; citation_author=Erlandson  KM; citation_author=Lake  JE;  citation_journal_title=Clin Infect Dis;  citation_year=2020;  citation_volume=71;  citation_issue=6;  citation_pages=1379-1389; " /><meta name="citation_reference" content="citation_title=Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: a cohort study.; citation_author=Swiss HIV Cohort Study; citation_author=Surial  B; citation_author=Mugglin  C; citation_author=Calmy  A;  citation_journal_title=Ann Intern Med;  citation_year=2021;  citation_volume=174;  citation_issue=6;  citation_pages=758-767; " /><meta name="citation_reference" content="citation_title=Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.; citation_author=DISCOVER Study Team; citation_author=Ogbuagu  O; citation_author=Ruane  PJ; citation_author=Podzamczer  D;  citation_journal_title=Lancet HIV;  citation_year=2021;  citation_volume=8;  citation_issue=7;  citation_pages=e397-e407; " /><meta name="citation_reference" content="citation_title=Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.; citation_author=North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD); citation_author=Bourgi  K; citation_author=Jenkins  CA; citation_author=Rebeiro  PF;  citation_journal_title=J Int AIDS Soc;  citation_year=2020;  citation_volume=23;  citation_issue=4; " /><meta name="citation_reference" content="citation_title=Weight gain before and after switch from TDF to TAF in a U.S. cohort study.; citation_author=Mallon  PW; citation_author=Brunet  L; citation_author=Hsu  RK;  citation_journal_title=J Int AIDS Soc;  citation_year=2021;  citation_volume=24;  citation_issue=4; " /><meta name="citation_reference" content="citation_title=Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.; citation_author=Venter  WDF; citation_author=Sokhela  S; citation_author=Simmons  B;  citation_journal_title=Lancet HIV;  citation_year=2020;  citation_volume=7;  citation_issue=10;  citation_pages=e666-e676; " /><meta name="citation_reference" content="citation_title=Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART).; citation_author=Bischoff  J; citation_author=Gu  W; citation_author=Schwarze-Zander  C;  citation_journal_title=EClinicalMedicine;  citation_year=2021;  citation_volume=40; " /><meta name="citation_reference" content="citation_title=The integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in human/simian adipose tissue and human adipocytes.; citation_author=Gorwood  J; citation_author=Bourgeois  C; citation_author=Pourcher  V;  citation_journal_title=Clin Infect Dis;  citation_year=2020;  citation_volume=71;  citation_issue=10;  citation_pages=e549-e560; " /><meta name="citation_reference" content="citation_title=Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV.; citation_author=NEAT022 Study Group; citation_author=González-Cordón  A; citation_author=Assoumou  L; citation_author=Moyle  G;  citation_journal_title=J Antimicrob Chemother;  citation_year=2021;  citation_volume=76;  citation_issue=9;  citation_pages=2380-2393; " /><meta name="citation_reference" content="citation_title=Efavirenz pharmacogenetics and weight gain following switch to integrase inhibitor-containing regimens.; citation_author=Leonard  MA; citation_author=Cindi  Z; citation_author=Bradford  Y;  citation_journal_title=Clin Infect Dis;  citation_year=2021;  citation_volume=73;  citation_issue=7;  citation_pages=e2153-e2163; " /><meta name="citation_reference" content="citation_title=Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.; citation_author=Plum  PE; citation_author=Maes  N; citation_author=Sauvage  AS;  citation_journal_title=BMC Infect Dis;  citation_year=2021;  citation_volume=21;  citation_issue=1;  citation_pages=910" /><meta name="citation_reference" content="citation_title=Trends in myocardial infarction risk by HIV status in 2 US healthcare systems [Abstract 39] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections.; citation_author=Silverberg  MJ; citation_author=Lyass  A; citation_author=Hurley  L;  citation_journal_title=Top Antiv Med;  citation_year=2022;  citation_volume=30;  citation_pages=15" /><meta name="citation_reference" content="citation_title=Bictegravir-based antiretroviral therapy-associated accelerated hyperglycemia and diabetes mellitus.; citation_author=Nolan  NS; citation_author=Adamson  S; citation_author=Reeds  D; citation_author=O’Halloran  JA;  citation_journal_title=Open Forum Infect Dis;  citation_year=2021;  citation_volume=8;  citation_issue=5; " /><meta name="citation_reference" content="citation_title=Integrase strand transfer inhibitors are associated with incident diabetes mellitus in people with HIV.; citation_author=O’Halloran  JA; citation_author=Sahrmann  J; citation_author=Parra-Rodriguez  L;  citation_journal_title=Clin Infect Dis;  citation_year=2022; " /><meta name="citation_reference" content="citation_title=Metabolic changes associated with the use of integrase strand transfer inhibitors among virally controlled women.; citation_author=Summers  NA; citation_author=Lahiri  CD; citation_author=Angert  CD;  citation_journal_title=J Acquir Immune Defic Syndr;  citation_year=2020;  citation_volume=85;  citation_issue=3;  citation_pages=355-362; " /><meta name="citation_reference" content="citation_title=Risk of incident diabetes mellitus, weight gain, and their relationships with integrase inhibitor-based initial antiretroviral therapy among persons with human immunodeficiency virus in the United States and Canada.; citation_author=Rebeiro  PF; citation_author=Jenkins  CA; citation_author=Bian  A;  citation_journal_title=Clin Infect Dis;  citation_year=2021;  citation_volume=73;  citation_issue=7;  citation_pages=e2234-e2242; " /><meta name="citation_reference" content="citation_title=Effect of changes in body mass index on the risk of cardiovascular disease and diabetes mellitus in HIV-positive individuals: results from the D:A:D study.; citation_author=D:A:D Study Group; citation_author=Petoumenos  K; citation_author=Kuwanda  L; citation_author=Ryom  L;  citation_journal_title=J Acquir Immune Defic Syndr;  citation_year=2021;  citation_volume=86;  citation_issue=5;  citation_pages=579-586; " /><meta name="citation_reference" content="citation_title=Week-48 metabolic health after switch to DTG/3TC vs CAR by baseline regimen: SALSA [Abstract 603] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections.; citation_author=Hagins  D; citation_author=Mussini  C; citation_author=Zhang  F;  citation_journal_title=Top Antiv Med;  citation_year=2022;  citation_volume=30;  citation_pages=236" /><meta name="citation_reference" content="citation_title=Once-weekly semaglutide in adults with overweight or obesity.; citation_author=STEP 1 Study Group; citation_author=Wilding  JPH; citation_author=Batterham  RL; citation_author=Calanna  S;  citation_journal_title=N Engl J Med;  citation_year=2021;  citation_volume=384;  citation_issue=11;  citation_pages=989-1002; " /><meta name="citation_reference" content="Semaglutide’s efficacy in achieving weight loss for those with HIV (SWIFT) [NCT04174755]. ClinicalTrials.gov. Accessed November 9, 2022. https://clinicaltrials.gov/ct2/show/NCT04174755 " /><meta name="citation_reference" content="citation_title=Delayed presentation of HIV among older individuals: a growing problem.; citation_author=Justice  AC; citation_author=Goetz  MB; citation_author=Stewart  CN;  citation_journal_title=Lancet HIV;  citation_year=2022;  citation_volume=9;  citation_issue=4;  citation_pages=e269-e280; " /><meta name="citation_reference" content="citation_title=Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004-18: a cohort study.; citation_author=North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD); citation_author=Lee  JS; citation_author=Humes  E; citation_author=Hogan  BC;  citation_journal_title=Lancet HIV;  citation_year=2022;  citation_volume=9;  citation_pages=S2" /><meta name="citation_reference" content="citation_title=Immunological and virological response to initial antiretroviral therapy among older people living with HIV in the Canadian Observational Cohort (CANOC).; citation_author=Canadian Observational Cohort (CANOC) Collaboration; citation_author=Zhabokritsky  A; citation_author=Szadkowski  L; citation_author=Burchell  AN;  citation_journal_title=HIV Med;  citation_year=2021;  citation_volume=22;  citation_issue=8;  citation_pages=759-769; " /><meta name="citation_reference" content="citation_title=Antiretroviral therapy in older people with HIV.; citation_author=Richterman  A; citation_author=Sax  PE;  citation_journal_title=Curr Opin HIV AIDS;  citation_year=2020;  citation_volume=15;  citation_issue=2;  citation_pages=118-125; " /><meta name="citation_reference" content="citation_title=Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.; citation_author=Swiss HIV Cohort Study; citation_author=Courlet  P; citation_author=Stader  F; citation_author=Guidi  M;  citation_journal_title=AIDS;  citation_year=2020;  citation_volume=34;  citation_issue=1;  citation_pages=103-108; " /><meta name="citation_reference" content="citation_title=Polypharmacy in older adults with HIV infection: effects on the brain.; citation_author=Smith  L; citation_author=Letendre  S; citation_author=Erlandson  KM; citation_author=Ma  Q; citation_author=Ellis  RJ; citation_author=Farhadian  SF;  citation_journal_title=J Am Geriatr Soc;  citation_year=2022;  citation_volume=70;  citation_issue=3;  citation_pages=924-927; " /><meta name="citation_reference" content="citation_title=Deprescribing of non-antiretroviral therapy in HIV-infected patients.; citation_author=Gesida and SEFH; citation_author=Blanco  JR; citation_author=Morillo  R; citation_author=Abril  V;  citation_journal_title=Eur J Clin Pharmacol;  citation_year=2020;  citation_volume=76;  citation_issue=3;  citation_pages=305-318; " /><meta name="citation_reference" content="citation_title=Potentially inappropriate medications in older adults living with HIV.; citation_author=López-Centeno  B; citation_author=Badenes-Olmedo  C; citation_author=Mataix-Sanjuan  A;  citation_journal_title=HIV Med;  citation_year=2020;  citation_volume=21;  citation_issue=8;  citation_pages=541-546; " /><meta name="citation_reference" content="citation_title=A call to action: the role of antiretroviral stewardship in inpatient practice, a joint policy paper of the Infectious Diseases Society of America, HIV Medicine Association, and American Academy of HIV Medicine.; citation_author=Koren  DE; citation_author=Scarsi  KK; citation_author=Farmer  EK;  citation_journal_title=Clin Infect Dis;  citation_year=2020;  citation_volume=70;  citation_issue=11;  citation_pages=2241-2246; " /><meta name="citation_reference" content="citation_title=Geriatric conditions and healthcare utilisation in older adults living with HIV.; citation_author=Greene  M; citation_author=Shi  Y; citation_author=Boscardin  J; citation_author=Sudore  R; citation_author=Gandhi  M; citation_author=Covinsky  K;  citation_journal_title=Age Ageing;  citation_year=2022;  citation_volume=51;  citation_issue=5; " /><meta name="citation_reference" content="citation_title=The impact of frailty on all-cause mortality in patients with HIV infection: a systematic review and meta-analysis.; citation_author=Liu  S; citation_author=Yan  Q; citation_author=Jiang  Y;  citation_journal_title=AIDS Res Hum Retroviruses;  citation_year=2022;  citation_volume=38;  citation_issue=9;  citation_pages=692-699; " /><meta name="citation_reference" content="citation_title=Higher comorbidity burden predicts worsening neurocognitive trajectories in people with human immunodeficiency virus.; citation_author=Ellis  RJ; citation_author=Paolillo  E; citation_author=Saloner  R; citation_author=Heaton  RK;  citation_journal_title=Clin Infect Dis;  citation_year=2022;  citation_volume=74;  citation_issue=8;  citation_pages=1323-1328; " /><meta name="citation_reference" content="citation_title=Abnormal cognitive aging in people with HIV: evidence from data integration between two countries’ cohort studies.; citation_author=Aung  HL; citation_author=Gates  TM; citation_author=Mao  L; citation_author=Brew  BJ; citation_author=Rourke  SB; citation_author=Cysique  LA;  citation_journal_title=AIDS;  citation_year=2022;  citation_volume=36;  citation_issue=8;  citation_pages=1171-1179; " /><meta name="citation_reference" content="citation_title=ACTG A5324: a randomized trial of ART intensification for cognitive impairment in PWH [Abstract 133] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections.; citation_author=Letendre  SL; citation_author=Roa  J; citation_author=Chen  H;  citation_journal_title=Top Antiv Med;  citation_year=2022;  citation_volume=30;  citation_pages=50-51; " /><meta name="citation_reference" content="citation_title=The shifting age distribution of people with HIV using antiretroviral therapy in the United States.; citation_author=Althoff  KN; citation_author=Stewart  CN; citation_author=Humes  E;  citation_journal_title=AIDS;  citation_year=2022;  citation_volume=36;  citation_issue=3;  citation_pages=459-471; " /><meta name="citation_reference" content="citation_title=Strengths and challenges of various models of geriatric consultation for older adults living with human immunodeficiency virus.; citation_author=Davis  AJ; citation_author=Greene  M; citation_author=Siegler  E;  citation_journal_title=Clin Infect Dis;  citation_year=2022;  citation_volume=74;  citation_issue=6;  citation_pages=1101-1106; " /><meta name="citation_reference" content="citation_title=How health systems can adapt to a population ageing with HIV and comorbid disease.; citation_author=Kiplagat  J; citation_author=Tran  DN; citation_author=Barber  T;  citation_journal_title=Lancet HIV;  citation_year=2022;  citation_volume=9;  citation_issue=4;  citation_pages=e281-e292; " /><meta name="citation_reference" content="citation_title=Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV.; citation_author=Lazarus  JV; citation_author=Safreed-Harmon  K; citation_author=Kamarulzaman  A;  citation_journal_title=Nat Commun;  citation_year=2021;  citation_volume=12;  citation_issue=1;  citation_pages=4450" /><meta name="citation_reference" content="Syphilis. Centers for Disease Control and Prevention. Updated March 24, 2022. Accessed November 9, 2022. https://www.cdc.gov/std/treatment-guidelines/syphilis.htm " /><meta name="citation_reference" content="US Public Health Service. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States–2021 Update: A Clinical Practice Guideline. Centers for Disease Control and Prevention. Published 2021. Accessed July 28, 2022. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf " /><meta name="citation_reference" content="citation_title=Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.; citation_author=Shieh  E; citation_author=Marzinke  MA; citation_author=Fuchs  EJ;  citation_journal_title=J Int AIDS Soc;  citation_year=2019;  citation_volume=22;  citation_issue=11; " /><meta name="citation_reference" content="citation_title=Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy.; citation_author=Yager  JL; citation_author=Anderson  PL;  citation_journal_title=Expert Opin Drug Metab Toxicol;  citation_year=2020;  citation_volume=16;  citation_issue=6;  citation_pages=463-474; " /><meta name="citation_reference" content="citation_title=Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.; citation_author=HPTN 084 Study Group; citation_author=Delany-Moretlwe  S; citation_author=Hughes  JP; citation_author=Bock  P;  citation_journal_title=Lancet;  citation_year=2022;  citation_volume=399;  citation_issue=10337;  citation_pages=1779-1789; " /><meta name="citation_reference" content="citation_title=Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.; citation_author=Landovitz  RJ; citation_author=Li  S; citation_author=Eron  JJ;  citation_journal_title=Lancet HIV;  citation_year=2020;  citation_volume=7;  citation_issue=7;  citation_pages=e472-e481; " /><meta name="citation_reference" content="citation_title=CA-LA PrEP: early detection of HIV infection may reduce InSTI resistance risk [Abstract LB95] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections.; citation_author=Eshleman  S; citation_author=Fogel  JM; citation_author=Halvas  EK;  citation_journal_title=Top Antiv Med;  citation_year=2022;  citation_volume=30;  citation_pages=36-37; " /><meta name="citation_reference" content="National Clinician Consultation Center website. Accessed November 9, 2022. https://aidsetc.org/aetc-program/national-clinician-consulation-center " /><meta name="citation_reference" content="citation_title=Patterns and clinical consequences of discontinuing HIV preexposure prophylaxis during primary care.; citation_author=Krakower  D; citation_author=Maloney  KM; citation_author=Powell  VE;  citation_journal_title=J Int AIDS Soc;  citation_year=2019;  citation_volume=22;  citation_issue=2; " /><meta name="citation_reference" content="citation_title=Barriers to preexposure prophylaxis use among individuals with recently acquired HIV infection in Northern California.; citation_author=Marcus  JL; citation_author=Hurley  LB; citation_author=Dentoni-Lasofsky  D;  citation_journal_title=AIDS Care;  citation_year=2019;  citation_volume=31;  citation_issue=5;  citation_pages=536-544; " /><meta name="citation_reference" content="citation_title=Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.; citation_author=DRIVE-FORWARD Study Group; citation_author=Molina  JM; citation_author=Squires  K; citation_author=Sax  PE;  citation_journal_title=Lancet HIV;  citation_year=2018;  citation_volume=5;  citation_issue=5;  citation_pages=e211-e220; " /><meta name="citation_reference" content="citation_author=Luetkemeyer  A; citation_author=Dombroski  J; citation_author=Cohen  S;  citation_year=2022; " /><meta name="citation_reference" content="citation_title=Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam.; citation_author=Wagman  JA; citation_author=Wynn  A; citation_author=Matsuzaki  M;  citation_journal_title=AIDS;  citation_year=2020;  citation_volume=34;  citation_issue=15;  citation_pages=2285-2294; " /><meta name="citation_reference" content="citation_title=Drug treatment as HIV prevention among women and girls who inject drugs from a global perspective: progress, gaps, and future directions.; citation_author=Springer  SA; citation_author=Larney  S; citation_author=Alam-Mehrjerdi  Z; citation_author=Altice  FL; citation_author=Metzger  D; citation_author=Shoptaw  S;  citation_journal_title=J Acquir Immune Defic Syndr;  citation_year=2015;  citation_volume=69;  citation_pages=S155-S161; " /><meta name="citation_reference" content="citation_title=Associations between methamphetamine use and lack of viral suppression among a cohort of HIV-positive persons who inject drugs in Hai Phong, Vietnam.; citation_author=DRIVE Study Team; citation_author=Feelemyer  J; citation_author=Arasteh  K; citation_author=Huong  DT;  citation_journal_title=AIDS;  citation_year=2020;  citation_volume=34;  citation_issue=13;  citation_pages=1875-1882; " /><meta name="citation_reference" content="citation_title=Changes in days of unhealthy alcohol use and antiretroviral therapy adherence, HIV RNA levels, and condomless sex: a secondary analysis of clinical trial data.; citation_author=Satre  DD; citation_author=Sarovar  V; citation_author=Leyden  W;  citation_journal_title=AIDS Behav;  citation_year=2020;  citation_volume=24;  citation_issue=6;  citation_pages=1784-1792; " /><meta name="citation_reference" content="citation_title=Integrating responses to the opioid use disorder and infectious disease epidemics: a report from the National Academies of Sciences, Engineering, and Medicine.; citation_author=Springer  SA; citation_author=Merluzzi  AP; citation_author=Del Rio  C;  citation_journal_title=JAMA;  citation_year=2020;  citation_volume=324;  citation_issue=1;  citation_pages=37-38; " /><meta name="citation_reference" content="citation_title=Federal and state action needed to end the infectious complications of illicit drug use in the United States: IDSA and HIVMA’s advocacy agenda.; citation_author=Springer  SA; citation_author=Barocas  JA; citation_author=Wurcel  A;  citation_journal_title=J Infect Dis;  citation_year=2020;  citation_volume=222;  citation_pages=S230-S238; " /><meta name="citation_reference" content="citation_title=Impact of abstinence and of reducing illicit drug use without abstinence on human immunodeficiency virus viral load.; citation_author=Nance  RM; citation_author=Trejo  MEP; citation_author=Whitney  BM;  citation_journal_title=Clin Infect Dis;  citation_year=2020;  citation_volume=70;  citation_issue=5;  citation_pages=867-874; " /><meta name="citation_reference" content="citation_title=Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis.; citation_author=Hoffman  KA; citation_author=Baker  R; citation_author=Fanucchi  LC;  citation_journal_title=Addict Sci Clin Pract;  citation_year=2021;  citation_volume=16;  citation_issue=1;  citation_pages=67" /><meta name="citation_reference" content="citation_title=HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial.; citation_author=Korthuis  PT; citation_author=Cook  RR; citation_author=Lum  PJ;  citation_journal_title=Addiction;  citation_year=2022;  citation_volume=117;  citation_issue=7;  citation_pages=1961-1971; " /><meta name="citation_reference" content="citation_title=Assessing the temporality between transitions onto opioid agonist therapy and engagement with antiretroviral therapy in a cohort of HIV-positive people who use opioids daily.; citation_author=Mitra  S; citation_author=Grant  C; citation_author=Nolan  S; citation_author=Mohd Salleh  NA; citation_author=Milloy  MJ; citation_author=Richardson  L;  citation_journal_title=AIDS Behav;  citation_year=2022;  citation_volume=26;  citation_issue=6;  citation_pages=1933-1942; " /><meta name="citation_reference" content="citation_title=Associations between alcohol use and HIV care cascade outcomes among adults undergoing population-based HIV testing in East Africa.; citation_author=Puryear  SB; citation_author=Balzer  LB; citation_author=Ayieko  J;  citation_journal_title=AIDS;  citation_year=2020;  citation_volume=34;  citation_issue=3;  citation_pages=405-413; " /><meta name="citation_reference" content="citation_title=A systematic review and meta-analysis of studies evaluating the effect of medication treatment for opioid use disorder on infectious disease outcomes.; citation_author=McNamara  KF; citation_author=Biondi  BE; citation_author=Hernández-Ramírez  RU; citation_author=Taweh  N; citation_author=Grimshaw  AA; citation_author=Springer  SA;  citation_journal_title=Open Forum Infect Dis;  citation_year=2021;  citation_volume=8;  citation_issue=8; " /><meta name="citation_reference" content="citation_title=Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners.; citation_author=Springer  SA; citation_author=Qiu  J; citation_author=Saber-Tehrani  AS; citation_author=Altice  FL;  citation_journal_title=PLoS One;  citation_year=2012;  citation_volume=7;  citation_issue=5; " /><meta name="citation_reference" content="citation_title=Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV with opioid use disorders transitioning to the community: results of a double-blind, placebo-controlled randomized trial.; citation_author=Springer  SA; citation_author=Di Paola  A; citation_author=Azar  MM;  citation_journal_title=J Acquir Immune Defic Syndr;  citation_year=2018;  citation_volume=78;  citation_issue=1;  citation_pages=43-53; " /><meta name="citation_reference" content="citation_title=Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV and alcohol use disorders transitioning to the community: results from a double-blind, placebo-controlled trial.; citation_author=Springer  SA; citation_author=Di Paola  A; citation_author=Barbour  R; citation_author=Azar  MM; citation_author=Altice  FL;  citation_journal_title=J Acquir Immune Defic Syndr;  citation_year=2018;  citation_volume=79;  citation_issue=1;  citation_pages=92-100; " /><meta name="citation_reference" content="citation_title=Medications for treatment of opioid use disorder among persons living with HIV.; citation_author=Fanucchi  L; citation_author=Springer  SA; citation_author=Korthuis  PT;  citation_journal_title=Curr HIV/AIDS Rep;  citation_year=2019;  citation_volume=16;  citation_issue=1;  citation_pages=1-6; " /><meta name="citation_reference" content="citation_title=Beyond antibiotics: a practical guide for the infectious disease physician to treat opioid use disorder in the setting of associated infectious diseases.; citation_author=Seval  N; citation_author=Eaton  E; citation_author=Springer  SA;  citation_journal_title=Open Forum Infect Dis;  citation_year=2019;  citation_volume=7;  citation_issue=1; " /><meta name="citation_reference" content="citation_title=Incentives for viral suppression in people living with HIV: a randomized clinical trial.; citation_author=Silverman  K; citation_author=Holtyn  AF; citation_author=Rodewald  AM;  citation_journal_title=AIDS Behav;  citation_year=2019;  citation_volume=23;  citation_issue=9;  citation_pages=2337-2346; " /><meta name="citation_reference" content="citation_title=Contingency management for treatment of substance use disorders: a meta-analysis.; citation_author=Prendergast  M; citation_author=Podus  D; citation_author=Finney  J; citation_author=Greenwell  L; citation_author=Roll  J;  citation_journal_title=Addiction;  citation_year=2006;  citation_volume=101;  citation_issue=11;  citation_pages=1546-1560; " /><meta name="citation_reference" content="citation_title=Contingency management to reduce methamphetamine use and sexual risk among men who have sex with men: a randomized controlled trial.; citation_author=Menza  TW; citation_author=Jameson  DR; citation_author=Hughes  JP; citation_author=Colfax  GN; citation_author=Shoptaw  S; citation_author=Golden  MR;  citation_journal_title=BMC Public Health;  citation_year=2010;  citation_volume=10;  citation_pages=774" /><meta name="citation_reference" content="citation_title=Contingency management facilitates the use of postexposure prophylaxis among stimulant-using men who have sex with men.; citation_author=Landovitz  RJ; citation_author=Fletcher  JB; citation_author=Shoptaw  S; citation_author=Reback  CJ;  citation_journal_title=Open Forum Infect Dis;  citation_year=2015;  citation_volume=2;  citation_issue=1; " /><meta name="citation_reference" content="citation_title=The pre-exposure prophylaxis (PrEP) care cascade in people who inject drugs: a systematic review.; citation_author=Mistler  CB; citation_author=Copenhaver  MM; citation_author=Shrestha  R;  citation_journal_title=AIDS Behav;  citation_year=2021;  citation_volume=25;  citation_issue=5;  citation_pages=1490-1506; " /><meta name="citation_reference" content="citation_title=HIV pre-exposure prophylaxis and buprenorphine at a drug detoxification center during the opioid epidemic: opportunities and challenges.; citation_author=Assoumou  SA; citation_author=Paniagua  SM; citation_author=Gonzalez  P;  citation_journal_title=AIDS Behav;  citation_year=2021;  citation_volume=25;  citation_issue=8;  citation_pages=2591-2598; " /><meta name="citation_reference" content="citation_title=Pre-exposure prophylaxis (PrEP) indication and uptake among people receiving buprenorphine for the treatment of opioid use disorder.; citation_author=Beck  L; citation_author=Parlier-Ahmad  AB; citation_author=Martin  CE;  citation_journal_title=J Subst Abuse Treat;  citation_year=2022;  citation_volume=132; " /><meta name="citation_reference" content="citation_title=Awareness of and willingness to use pre-exposure prophylaxis (PrEP) among people who inject drugs and men who have sex with men in India: results from a multi-city cross-sectional survey.; citation_author=Belludi  A; citation_author=McFall  AM; citation_author=Solomon  SS;  citation_journal_title=PLoS One;  citation_year=2021;  citation_volume=16;  citation_issue=2; " /><meta name="citation_reference" content="citation_title=Multiple injections per injection episode: high-risk injection practice among people who injected pills during the 2015 HIV outbreak in Indiana.; citation_author=Broz  D; citation_author=Zibbell  J; citation_author=Foote  C;  citation_journal_title=Int J Drug Policy;  citation_year=2018;  citation_volume=52;  citation_pages=97-101; " /><meta name="citation_reference" content="citation_title=Safer in care: a pandemic-tested model of integrated HIV/OUD care.; citation_author=Eaton  EF; citation_author=Tamhane  A; citation_author=Turner  W; citation_author=Raper  JL; citation_author=Saag  MS; citation_author=Cropsey  KL;  citation_journal_title=Drug Alcohol Depend;  citation_year=2022;  citation_volume=231; " /><meta name="citation_reference" content="citation_title=Linking criminal justice-involved individuals to HIV, hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: progress, gaps, and future directions.; citation_author=Taweh  N; citation_author=Schlossberg  E; citation_author=Frank  C;  citation_journal_title=Int J Drug Policy;  citation_year=2021;  citation_volume=96; " /><meta name="citation_reference" content="citation_title=Impact of the COVID-19 pandemic on the UNAIDS six 95% HIV control targets.; citation_author=Jiang  T; citation_author=Liu  C; citation_author=Zhang  J; citation_author=Huang  X; citation_author=Xu  J;  citation_journal_title=Front Med (Lausanne);  citation_year=2022;  citation_volume=9; " /><meta name="citation_reference" content="citation_title=Persistent disparities in COVID-19-associated impacts on HIV prevention and care among a global sample of sexual and gender minority individuals.; citation_author=Santos  GM; citation_author=Hong  C; citation_author=Wilson  N;  citation_journal_title=Glob Public Health;  citation_year=2022;  citation_volume=17;  citation_issue=6;  citation_pages=827-842; " /><meta name="citation_reference" content="citation_title=Transient reductions in human immunodeficiency virus (HIV) clinic attendance and food security during the coronavirus disease 2019 (COVID-19) pandemic for people living with HIV in 4 African countries.; citation_author=AFRICOS Study Group; citation_author=Dear  N; citation_author=Duff  E; citation_author=Esber  A;  citation_journal_title=Clin Infect Dis;  citation_year=2021;  citation_volume=73;  citation_issue=10;  citation_pages=1901-1905; " /><meta name="citation_reference" content="citation_title=Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models.; citation_author=HIV Modelling Consortium; citation_author=Jewell  BL; citation_author=Mudimu  E; citation_author=Stover  J;  citation_journal_title=Lancet HIV;  citation_year=2020;  citation_volume=7;  citation_issue=9;  citation_pages=e629-e640; " /><meta name="citation_reference" content="citation_title=Overview of SARS-CoV-2 infection in adults living with HIV.; citation_author=COVID-19 in HIV Investigators; citation_author=Ambrosioni  J; citation_author=Blanco  JL; citation_author=Reyes-Urueña  JM;  citation_journal_title=Lancet HIV;  citation_year=2021;  citation_volume=8;  citation_issue=5;  citation_pages=e294-e305; " /><meta name="citation_reference" content="citation_title=The interplay between HIV and COVID-19: summary of the data and responses to date.; citation_author=Brown  LB; citation_author=Spinelli  MA; citation_author=Gandhi  M;  citation_journal_title=Curr Opin HIV AIDS;  citation_year=2021;  citation_volume=16;  citation_issue=1;  citation_pages=63-73; " /><meta name="citation_reference" content="citation_title=SARS-CoV-2 testing and positivity among persons with and without HIV in 6 US cohorts.; citation_author=CIVET Collaboration of the NA-ACCORD of IeDEA; citation_author=Park  LS; citation_author=McGinnis  KA; citation_author=Gordon  KS;  citation_journal_title=J Acquir Immune Defic Syndr;  citation_year=2022;  citation_volume=90;  citation_issue=3;  citation_pages=249-255; " /><meta name="citation_reference" content="citation_title=Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence.; citation_author=Treskova-Schwarzbach  M; citation_author=Haas  L; citation_author=Reda  S;  citation_journal_title=BMC Med;  citation_year=2021;  citation_volume=19;  citation_issue=1;  citation_pages=212" /><meta name="citation_reference" content="citation_title=Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study.; citation_author=PISCIS Study Group; citation_author=Nomah  DK; citation_author=Reyes-Urueña  J; citation_author=Díaz  Y;  citation_journal_title=Lancet HIV;  citation_year=2021;  citation_volume=8;  citation_issue=11;  citation_pages=e701-e710; " /><meta name="citation_reference" content="citation_title=Factors associated with severity of COVID-19 disease in a multicenter cohort of people with HIV in the United States, March-December 2020.; citation_author=CFAR Network of Integrated Clinical Systems; citation_author=Shapiro  AE; citation_author=Bender Ignacio  RA; citation_author=Whitney  BM;  citation_journal_title=J Acquir Immune Defic Syndr;  citation_year=2022;  citation_volume=90;  citation_issue=4;  citation_pages=369-376; " /><meta name="citation_reference" content="citation_title=Coronavirus disease 2019 (COVID-19) infection among people with human immunodeficiency virus in New York City: a population-level analysis of linked surveillance data.; citation_author=Braunstein  SL; citation_author=Lazar  R; citation_author=Wahnich  A; citation_author=Daskalakis  DC; citation_author=Blackstock  OJ;  citation_journal_title=Clin Infect Dis;  citation_year=2021;  citation_volume=72;  citation_issue=12;  citation_pages=e1021-e1029; " /><meta name="citation_reference" content="citation_title=Characteristics, comorbidities, and outcomes in a multicenter registry of patients with human immunodeficiency virus and coronavirus disease 2019.; citation_author=Dandachi  D; citation_author=Geiger  G; citation_author=Montgomery  MW;  citation_journal_title=Clin Infect Dis;  citation_year=2021;  citation_volume=73;  citation_issue=7;  citation_pages=e1964-e1972; " /><meta name="citation_reference" content="citation_title=The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with human immunodeficiency virus (HIV).; citation_author=Woldemeskel  BA; citation_author=Karaba  AH; citation_author=Garliss  CC;  citation_journal_title=Clin Infect Dis;  citation_year=2022;  citation_volume=74;  citation_issue=7;  citation_pages=1268-1270; " /><meta name="citation_reference" content="citation_title=Safety and Immunogenicity of SARS-CoV-2 vaccines in people with HIV.; citation_author=González de Aledo  M; citation_author=Cañizares  A; citation_author=Vázquez-Rodríguez  P;  citation_journal_title=AIDS;  citation_year=2022;  citation_volume=36;  citation_issue=5;  citation_pages=691-695; " /><meta name="citation_reference" content="citation_title=Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.; citation_author=Lee  ARYB; citation_author=Wong  SY; citation_author=Chai  LYA;  citation_journal_title=BMJ;  citation_year=2022;  citation_volume=376; " /><meta name="citation_reference" content="citation_title=Impaired antibody response to COVID-19 vaccination in advanced HIV infection.; citation_author=Hassold  N; citation_author=Brichler  S; citation_author=Ouedraogo  E;  citation_journal_title=AIDS;  citation_year=2022;  citation_volume=36;  citation_issue=4;  citation_pages=F1-F5; " /><meta name="citation_reference" content="citation_title=High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV—but HIV viremia matters?; citation_author=COVAXID Study Group; citation_author=Xu  X; citation_author=Vesterbacka  J; citation_author=Aleman  S; citation_author=Nowak  P;  citation_journal_title=AIDS;  citation_year=2022;  citation_volume=36;  citation_issue=3;  citation_pages=479-481; " /><meta name="citation_reference" content="citation_title=Prospective evaluation of coronavirus disease 2019 (COVID-19) vaccine responses across a broad spectrum of immunocompromising conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS) study.; citation_author=Haidar  G; citation_author=Agha  M; citation_author=Bilderback  A;  citation_journal_title=Clin Infect Dis;  citation_year=2022;  citation_volume=75;  citation_issue=1;  citation_pages=e630-e644; " /><meta name="citation_reference" content="citation_title=Covid-19 vaccine immunogenicity in people living with HIV-1.; citation_author=Nault  L; citation_author=Marchitto  L; citation_author=Goyette  G;  citation_journal_title=Vaccine;  citation_year=2022;  citation_volume=40;  citation_issue=26;  citation_pages=3633-3637; " /><meta name="citation_reference" content="citation_title=Characterization of serum and mucosal SARS-CoV-2-antibodies in HIV-1-infected subjects after BNT162b2 mRNA vaccination or SARS-CoV-2 infection.; citation_author=Schmidt  KG; citation_author=Harrer  EG; citation_author=Tascilar  K;  citation_journal_title=Viruses;  citation_year=2022;  citation_volume=14;  citation_issue=3;  citation_pages=651" /><meta name="citation_reference" content="citation_title=Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial.; citation_author=2019nCoV-501 Study Group; citation_author=Madhi  SA; citation_author=Moodley  D; citation_author=Hanley  S;  citation_journal_title=Lancet HIV;  citation_year=2022;  citation_volume=9;  citation_issue=5;  citation_pages=e309-e322; " /><meta name="citation_reference" content="citation_title=Analysis of postvaccination breakthrough COVID-19 infections among adults with HIV in the United States.; citation_author=Corona-Infectious-Virus Epidemiology Team (CIVETs) of the NA-ACCORD of IeDEA; citation_author=Coburn  SB; citation_author=Humes  E; citation_author=Lang  R;  citation_journal_title=JAMA Netw Open;  citation_year=2022;  citation_volume=5;  citation_issue=6; " /><meta name="citation_reference" content="Guidance for COVID-19 and People with HIV. Guidelines Working Groups of the NIH Office of AIDS Research Advisory Council and US Department of Health and Human Services (HHS). Updated February 22, 2022. Accessed July 28, 2022. https://clinicalinfo.hiv.gov/en/guidelines/guidance-covid-19-and-people-hiv/whats-new-covid-19-and-hiv-guidance " /><meta name="citation_reference" content="National Institutes of Health. COVID-19 treatment guidelines. Accessed November 9, 2022. https://www.covid19treatmentguidelines.nih.gov/ " /><meta name="citation_reference" content="citation_title=Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19.; citation_author=Bhimraj  A; citation_author=Morgan  RL; citation_author=Shumaker  AH;  citation_journal_title=Clin Infect Dis;  citation_year=2020; " /><meta name="citation_reference" content="citation_title=Factors associated with severe COVID-19 and post-acute COVID-19 syndrome in a cohort of people living with HIV on antiretroviral treatment and with undetectable HIV RNA.; citation_author=Mazzitelli  M; citation_author=Trunfio  M; citation_author=Sasset  L;  citation_journal_title=Viruses;  citation_year=2022;  citation_volume=14;  citation_issue=3;  citation_pages=493" /><meta name="citation_reference" content="citation_title=Detection of monkeypox virus in anorectal swabs from asymptomatic men who have sex with men in a sexually transmitted infection screening program in Paris, France.; citation_author=Ferré  VM; citation_author=Bachelard  A; citation_author=Zaidi  M;  citation_journal_title=Ann Intern Med;  citation_year=2022;  citation_volume=175;  citation_issue=10;  citation_pages=1491-1492; " /><meta name="citation_reference" content="citation_title=Interferon inhibition for lupus with anifrolumab: critical appraisal of the evidence leading to FDA approval.; citation_author=Loncharich  MF; citation_author=Anderson  CW;  citation_journal_title=ACR Open Rheumatol;  citation_year=2022;  citation_volume=4;  citation_issue=6;  citation_pages=486-491; " /><meta name="citation_reference" content="citation_title=Monkeypox virus infection in humans across 16 countries—April-June 2022.; citation_author=SHARE-net Clinical Group; citation_author=Thornhill  JP; citation_author=Barkati  S; citation_author=Walmsley  S;  citation_journal_title=N Engl J Med;  citation_year=2022;  citation_volume=387;  citation_issue=8;  citation_pages=679-691; " /><meta name="citation_reference" content="Health Alert Network (HAN). Severe manifestations of monkeypox among people who are immunocompromised due to HIV or other conditions. Published September 29, 2022. Accessed November 1, 2022. https://emergency.cdc.gov/han/2022/han00475.asp " /><meta name="citation_reference" content="Clinical Info HIV. Guidelines for the use of antretroviral agents in adults and adolescents with HIV. Updated September 1, 2022. Accessed November 9, 2022. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/overview?view=full " /><meta name="citation_reference" content="UNAIDS. 2021 UNAIDS Global AIDS Update: Confronting Inequalities—Lessons for Pandemic Responses From 40 Years of AIDS. Published July 14, 2021. Accessed November 9, 2022. https://www.unaids.org/en/resources/documents/2021/2021-global-aids-update " /><meta name="citation_reference" content="citation_title=Epidemiology of HIV in the USA: epidemic burden, inequities, contexts, and responses.; citation_author=Sullivan  PS; citation_author=Satcher Johnson  A; citation_author=Pembleton  ES;  citation_journal_title=Lancet;  citation_year=2021;  citation_volume=397;  citation_issue=10279;  citation_pages=1095-1106; " /><meta name="citation_reference" content="citation_title=HIV testing before and during the COVID-19 pandemic—United States, 2019-2020.; citation_author=DiNenno  EA; citation_author=Delaney  KP; citation_author=Pitasi  MA;  citation_journal_title=MMWR Morb Mortal Wkly Rep;  citation_year=2022;  citation_volume=71;  citation_issue=25;  citation_pages=820-824; " /><meta name="citation_reference" content="Centers for Disease Control and Prevention (CDC). Diagnoses of HIV infection in the United States and dependent areas 2020. Accessed November 9, 2022. https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-33/index.html " /><meta name="citation_reference" content="citation_title=Association between social vulnerability and rates of HIV diagnoses among black adults, by selected characteristics and region of residence—United States, 2018.; citation_author=Dailey  AF; citation_author=Gant  Z; citation_author=Hu  X; citation_author=Johnson Lyons  S; citation_author=Okello  A; citation_author=Satcher Johnson  A;  citation_journal_title=MMWR Morb Mortal Wkly Rep;  citation_year=2022;  citation_volume=71;  citation_issue=5;  citation_pages=167-170; " /><meta name="citation_reference" content="HIV/AIDS Surveillance in Europe 2021: 2020 data. European Centre for Disease Prevention and Control. Published 2021. Accessed November 9, 2022. https://www.ecdc.europa.eu/sites/default/files/documents/2021-Annual_HIV_Report_0.pdf " /><meta name="citation_reference" content="citation_title=Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study.; citation_author=Schaefer  R; citation_author=Schmidt  HA; citation_author=Ravasi  G;  citation_journal_title=Lancet HIV;  citation_year=2021;  citation_volume=8;  citation_issue=8;  citation_pages=e502-e510; " /><meta name="citation_reference" content="citation_title=Could disparities in PrEP uptake limit the public health benefit?; citation_author=Keen  P; citation_author=Bavinton  BR;  citation_journal_title=Lancet Public Health;  citation_year=2020;  citation_volume=5;  citation_issue=9;  citation_pages=e467-e468; " /><meta name="citation_reference" content="citation_title=The potential impact of long-acting cabotegravir for HIV prevention in South Africa: a mathematical modeling study.; citation_author=Smith  JA; citation_author=Garnett  GP; citation_author=Hallett  TB;  citation_journal_title=J Infect Dis;  citation_year=2021;  citation_volume=224;  citation_issue=7;  citation_pages=1179-1186; " /><meta name="citation_reference" content="Political Declaration on HIV and AIDS: Ending Inequalities and Getting on Track to End AIDS by 2030. UNAIDS. Published June 9, 2021. Accessed July 28, 2022. https://www.unaids.org/sites/default/files/media_asset/2021_political-declaration-on-hiv-and-aids_en.pdf " /><meta name="citation_fulltext_world_readable" content="" /><meta name="citation_pdf_url" content="https://jamanetwork.com/journals/jama/articlepdf/2799240/jama_gandhi_2022_sc_220007_1671563383.14209.pdf" />

    
        <title>Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society–USA Panel | JAMA | JAMA Network</title>

    <meta name="description" content="This guideline from the International Antiviral (formerly AIDS) Society–USA updates practice recommendations for managing HIV infection, including when to">


    <link rel="canonical" href="https://jamanetwork.com/journals/jama/fullarticle/2799240" />









    
    <script src="//cdn.jamanetwork.com/UI/app/dist/head.min.js?v=638488852268208351"></script>
     
     <script src="https://r451.jamanetwork.com/script.js"></script>
        <div class="widget-WidgetLoader widget-instance-AMA_AdTag_HeaderScript">
        
    <meta class="SCM-SharedWidgets-AsyncHeaderAdLoader" data-url="/AMA/AdTag/AMA_AdTag_HeaderScript" data-params="{&quot;parameters&quot;:{&quot;siteName&quot;:&quot;jama&quot;,&quot;siteId&quot;:3,&quot;journalId&quot;:67,&quot;adDisplay&quot;:0,&quot;adSection&quot;:&quot;scholarly&quot;,&quot;adPosition&quot;:&quot;&quot;,&quot;fromGoogle&quot;:false},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}">
 
    </div>
</head>

<body data-sitename="jama" class="pg_article " data-thm="jama">
    
    <script>
        
        var App = App || {};
        App.suppressAds = App.suppressAds || !!document.getElementsByClassName('suppress-ads').length;
        App.suppressGtm = App.suppressGtm || !!document.getElementsByClassName('suppress-gtm').length;
    </script>

    

        <div id="ad-interstitial" class="ad-interstitial">
            <script>
      googletag.cmd.push(function() {
        if (App.suppressAds) { return; }
        App.Ads.slots[13] = googletag.defineOutOfPageSlot(App.Ads.adPath + '/scholarly', 'ad-interstitial')
          .setTargeting('pos', ['interstitial'])
          .addService(googletag.pubads());
        googletag.display('ad-interstitial');
        googletag.pubads().refresh([App.Ads.slots[13]], {changeCorrelator: false});
      });
            </script>
        </div>




    
    <a class="accessible js-skip-to-navigation" href="#skip-to-navigation">[Skip to Navigation]</a>

    <!-- Google Tag Manager --><noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-WNKSNP" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-WNKSNP');</script><!-- End Google Tag Manager -->

    
    
    <span class="hide tagmanagervalue" data-attribute="productName" data-value="JAMA" data-type="string"></span>
    <form method="post" action="./2799240" id="webform" class="m0">
<input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="qDBkf1MH06RIIJm85CneyuOybCD0578e4+EgdZt690NWJjaKIS0BVB4W7xBIChGO8fpk3DtqaxviF/35juCh8UTQlhY=" />

<input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="2173C2F0" />
<input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="fmzRqHmjvD7ey/+w+pe+Zl3hb08aGYl4e1/O26RDx7S0lAmqR6Yvhd53dvLAzOsFYd8EYBZPYFFSUCKpJ4Og9J0pUTI3v75TXWZ+sP3jKnZl4/v5D8jioMN6+7/XRAwsrXgX836DVjJkHvs3p9wDl0v4RHj8fdF2jGaTQ44yzilqQOa6ViRlqm0U8mlUcCFgPRxCuI/Gmmx7xAfnno3nFBhUrSbilSnauGTi7O2aoR+MyBraXUs4HwEaXVTQ3Yy9g/ma+c1bxDvpVgY2dlL5O9dN/D3j1GCTrQccCAPhxCfM/3SdkqA6vOB/xWjg4zS1voszLmtT8J8RStQIdbs3ar6RwMU4EVZk1Ive8M3gCJY4m0lEGWCIeY/5Ond+S/c2hHYj1et72VNcQfKN/mGYkBXgkoICLZLnkwzcb7vHi5JWSCIALmV1S60DJDX/qHYWKgarTY9u5DcQKffe2tT6vii1uVOcsRv0kM2lBdPWRRnwBUER6tttHbYok2DJc61Lu93G/EIBRsowEPfhXtdOf4MZJPDGdp7j5092YICD/0w2sjBDmlW9DALWJQRJjDcmQlU3LWswG6B4POEAZUfm6UER7YQAgya5/56cusUP4nPdRGJCSjzSSm2WkwYXTzFZ3XwoKav7q5+fBSjiUUDF/eEwaS8=" />
        
        <input id="hdnSiteID" type="hidden" value="3" />
        <input id="hdnDomain" type="hidden" value=".jamanetwork.com" />

        
        

        
        

    <section class="master-header">
        


<script type='text/javascript'>
    var App = App || {};
    App.LoginUserInfo = {
        isInstLoggedIn: [0],
        currentSessionId: 'fw33kfdkx23mxteiz21gfdb5'
    };
</script>



<input name="ctl00$ctl00$BodyContent$Header$hfGlobalSearchSiteURL" type="hidden" id="hfGlobalSearchSiteURL" value="https://jamanetwork.com/" />

<input name="ctl00$ctl00$BodyContent$Header$hfAppIsPaidUser" type="hidden" id="hfAppIsPaidUser" value="false" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppIsMember" type="hidden" id="hfAppIsMember" value="false" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppSubscribedTo" type="hidden" id="hfAppSubscribedTo" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppIsIndividual" type="hidden" id="hfAppIsIndividual" value="false" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppHasAccess" type="hidden" id="hfAppHasAccess" value="false" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppIsReferredFromGoogle" type="hidden" id="hfAppIsReferredFromGoogle" value="False" />
<input name="ctl00$ctl00$BodyContent$Header$hfSolrAutoSuggestMinimumCharactersLength" type="hidden" id="hfSolrAutoSuggestMinimumCharactersLength" value="2" />
<input name="ctl00$ctl00$BodyContent$Header$hfSolrJournalName" type="hidden" id="hfSolrJournalName" value="JAMA" />
<input name="ctl00$ctl00$BodyContent$Header$hfSolrJournalID" type="hidden" id="hfSolrJournalID" value="J67" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppIsLucy" type="hidden" id="hfAppIsLucy" value="false" />


<div class="header-wrap">
    <header class="header">
            <div class="widget-GdprCookieBanner widget-instance-GdprCookieBanner">
        <div class="gdpr-cookie-wrapper js-gdpr-banner">
	<div class="gdpr-cookie-body">
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our <a href="https://jamanetwork.com/pages/privacy-policy#cookies">Cookie Policy</a>&nbsp;<span class="pipe">|</span>&nbsp;<a href="javascript:;" class="js-gdpr-cookie-acceptLink at-acceptgdpr">Continue</a>	</div>
            <input id="hdnDomain" type="hidden" value=".jamanetwork.com" />

    <input id="hdnDomainGdpr" type="hidden" value=".jamanetwork.com" />
    <input id="hdnClientIdGdpr" type="hidden" value="3" />

</div> 
    </div>

        <div class="network-bar">
            <a class="jama-network" href="/" title="JAMA Network Home">
                <img alt="JAMA Network Home" class="title-image" width="443" height="52" src="//cdn.jamanetwork.com/UI/app/svg/Jama_Network_Logo.svg">
            </a>
            
        </div>

        <a class="nav-toggler" href="#nav">
            <div class="nav-toggler-indicator">
                <span class="indicator-stroke"></span>
                <span class="indicator-stroke"></span>
                <span class="indicator-stroke"></span>
                <span class="indicator-stroke"></span>
            </div>
            <div class="nav-toggler-site">
                <span id="BodyContent_Header_siteFullNamenav" class="nav-toggler-microsite"><span class='network'>JAMA</span></span>
            </div>
        </a>
        <nav id="nav" class="nav hide" >
            <div class="nav-journal-level sb-nav-journal-level">
                <a href="https://jamanetwork.com/journals/jama" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_0" class="home">Home</a><a href="https://jamanetwork.com/journals/jama/newonline" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_1" class="new-online">New Online</a><a href="https://jamanetwork.com/journals/jama/currentissue" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_2" class="current-issue">Current Issue</a><a href="https://jamanetwork.com/journals/jama/pages/for-authors" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_3" class="for-authors">For Authors</a>
            </div>
            <div class="nav-journals">
                    <div class="widget-SelfServeContent widget-instance-HamburgerPublicationMenu">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="HamburgerPublicationMenu" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    .nav-journals {margin-bottom: 1em;}
    .nav-heading {color: #B9B9B9;border-bottom: 1px solid #242424;border-top: 1px solid #242424;font-size: 1.15em;font-weight: 400;margin: 0;padding: .7em .75em;text-transform: uppercase;}
    a.no-bullet:before {content:none !important;}
    .nav-heading {font-size: 1.15em;margin-bottom:0;padding-left: 38px;}
    .nav-journals a.theme-jama {background-color: #242424;border-bottom: 1px solid #fff;border-top: 1px solid #fff;color: #fff;font-size: 1.15em;margin-bottom: 8px;padding: 11px 0 9px 37px;}
    .nav-journals a.theme-jama::before {background: unset;content: "\e91b";display: none;font-family: ama_icons !important;font-size: 1.25em;line-height: 1;}
    .nav-journals a.theme-jama-network-open {border-bottom:0;}
    .nav .widget-instance-HamburgerPublicationMenu a {padding-left: 36px;}
    .fake-ribbon {border-left: 8px solid #BE1E32;}
    .fake-ribbon a:before {content:none;}
    .nav .widget-instance-HamburgerPublicationMenu .fake-ribbon a {padding-left:30px;}
</style>
<h2 class="nav-heading">Journals</h2>
<a href="/journals/jama" class="theme-jama">JAMA</a>
<a href="/journals/jamanetworkopen" class="theme-jama-network-open">JAMA Network Open</a>
<a href="/journals/jamacardiology" class="theme-jama-cardiology">JAMA Cardiology</a>
<a href="/journals/jamadermatology" class="theme-jama-dermatology">JAMA Dermatology</a>
<a href="/journals/jama-health-forum" class="theme-jama-health-forum">JAMA Health Forum</a>
<a href="/journals/jamainternalmedicine" class="theme-jama-internal-medicine">JAMA Internal Medicine</a>
<a href="/journals/jamaneurology" class="theme-jama-neurology">JAMA Neurology</a>
<a href="/journals/jamaoncology" class="theme-jama-oncology">JAMA Oncology</a>
<a href="/journals/jamaophthalmology" class="theme-jama-ophthalmology">JAMA Ophthalmology </a>
<a href="/journals/jamaotolaryngology" class="theme-jama-otolaryngology-head-neck-surgery">JAMA Otolaryngology–Head &amp; Neck Surgery</a>
<a href="/journals/jamapediatrics" class="theme-jama-pediatrics">JAMA Pediatrics</a>
<a href="/journals/jamapsychiatry" class="theme-jama-psychiatry">JAMA Psychiatry</a>
<a href="/journals/jamasurgery" class="theme-jama-surgery">JAMA Surgery</a>
<a href="/journals/archneurpsyc" class="theme-archives-of-neurology-psychiatry-1919-1959-">Archives of Neurology &amp; Psychiatry (1919-1959)</a>
<h2 class="nav-heading">Podcasts</h2>
<a href="/journals/jama/pages/jama-clinical-reviews">Clinical Reviews</a>
<a href="/journals/jama/pages/jama-editors-summary">Editors' Summary</a>
<a href="/journals/jama/pages/jama-medical-news">Medical News</a>
<a href="/journals/jama/pages/jama-author-interviews">Author Interviews</a>
<a href="/pages/audio" class="no-bullet">More</a>


</div>

 
    </div>
    
            </div>
            <div class="nav-network-other">
                <a href="https://edhub.ama-assn.org/jn-learning" id="BodyContent_Header_rptOtherResources_aItemResourceList_0" class="is-b link-jn-learning-cme" target="_blank">JN Learning / CME</a><a href="https://store.jamanetwork.com/index.aspx?productcode=64" id="BodyContent_Header_rptOtherResources_aItemResourceList_1" class="is-b link-subscribe" target="_blank">Subscribe</a><a href="https://careers.jamanetwork.com/" id="BodyContent_Header_rptOtherResources_aItemResourceList_2" class="is-b link-jobs" target="_blank">Jobs</a><a href="https://jamanetwork.com/pages/resources-for-librarians" id="BodyContent_Header_rptOtherResources_aItemResourceList_3" class="is-b link-institutions-librarians">Institutions / Librarians</a><a href="https://jamanetwork.com/pages/reprints-and-permissions" id="BodyContent_Header_rptOtherResources_aItemResourceList_4" class="is-b link-reprints-permissions" rel="nofollow">Reprints &amp; Permissions</a>
            </div>
            <div class="white text-xxs">
                <div class="p05 ml4 mr3 mb1 mt10 flex hamburger-menu-legal">
                    <a href="/pages/conditions-of-use" class="p0" rel="nofollow">Terms of Use</a>
                    <span class="pl1 pr1">| </span>
                    <a href="/pages/privacy-policy" class="p0" rel="nofollow">Privacy Policy</a>
                    <span class="pl1 pr1">| </span>
                    <a href="/pages/accessibility-statement" class="p0" rel="nofollow">Accessibility Statement</a>
                </div>
                <div class="ta-c">
                    <span class="pb1">2024 American Medical Association. All Rights Reserved</span>
                </div>
            </div>
        </nav>

        

        
        <a class="toolbar-search-trigger is-b" data-mobile-tog-target=".site-search"></a>

        
        <div id="site-search" role="search" class="site-search">
            <div class="site-search-bar">
                
                <div role="search">
                    <select name="ctl00$ctl00$BodyContent$Header$ddlForSearch" id="BodyContent_Header_ddlForSearch" Name="dropDownList" class="cs-select cs-skin-border" title="Search Site Selector" role="options" aria-labelledby="searchLabel">
	<option value="J*">Search All</option>
	<option value="3">JAMA</option>
	<option value="214">JAMA Network Open</option>
	<option value="192">JAMA Cardiology</option>
	<option value="12">JAMA Dermatology</option>
	<option value="261">JAMA Forum Archive</option>
	<option value="193">JAMA Health Forum</option>
	<option value="15">JAMA Internal Medicine</option>
	<option value="16">JAMA Neurology</option>
	<option value="159">JAMA Oncology</option>
	<option value="17">JAMA Ophthalmology</option>
	<option value="18">JAMA Otolaryngology–Head &amp; Neck Surgery</option>
	<option value="19">JAMA Pediatrics</option>
	<option value="14">JAMA Psychiatry</option>
	<option value="20">JAMA Surgery</option>
	<option value="23">Archives of Neurology &amp; Psychiatry</option>

</select>
                </div>
                
                <div class="search-input-container">
                    <input type="search" name="textbox" autocomplete="off" role="textbox" id="search-term" aria-labelledby="searchLabel" class="search-term at-microsite-search-term" placeholder="Enter Search Term" maxlength="255" title="Enter Search Term">
                  
                    <ul id="umbrellaSiteAutoCompleteResults" class="term-list hidden"></ul>
                    
                    <label style="display:none" for="umbrellaSiteSearchInputHint" id="searchLabel">Input Search Term</label>
                      <input class="searchTerm search-input" name="textbox" role="textbox" type="text" id="umbrellaSiteSearchInputHint" aria-labelledby="searchLabel" title="Input Search Term" autocomplete="off">
                </div>
                <!-- /.search-input-container -->
                
                <a name="button" role="button" class="search-button is-b" alt="search button" href="javascript:;"></a>
            </div>
        </div>
        
        <div id="BodyContent_Header_GlobalSignIn_auth" class="auth">
            <a class="auth--trigger is-b is-a" href="javascript:;">
                <span id="BodyContent_Header_GlobalSignIn_spnUserFullName" class="user-full-name">Sign In</span>
            </a>

            <div class="auth--dropdown js-signIn-dropdown">
                
                <div class="auth--option auth--ind">
                    
                    <div id="BodyContent_Header_GlobalSignIn_divUserFullName" class="auth--ind-user"></div>                    
                    
                    <div id="BodyContent_Header_GlobalSignIn_divIndSignIn" class="auth--ind-auth">
                        <div class="auth--title">Individual Sign In</div>
                        <a href="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f2799240" id="BodyContent_Header_GlobalSignIn_oauthSignInLink" rel="nofollow" class="auth--ind-sign-in">Sign in</a><a href="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f2799240" id="BodyContent_Header_GlobalSignIn_oauthSignUpLink" rel="nofollow" class="auth--ind-create">Create an Account</a>
                    </div>
                </div>

                
                <div id="BodyContent_Header_GlobalSignIn_divInstSignIn" class="auth--option auth--inst">

                    
                    
                    <div class="auth--inst-auth">
                        <div class="auth--title">Access through your institution</div>
                        <a href="/signinshibboleth?returnUrl=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f2799240" id="BodyContent_Header_GlobalSignIn_institutionSignIn" rel="nofollow" class="auth--shib">Sign In</a>
                    </div>
                    </div>
 
                                               
                <div id="BodyContent_Header_GlobalSignIn_divPurchaseOptions" class="auth--option auth--purchase">
                    <div class="auth--title">Purchase Options:</div>
                    
                    <a id="BodyContent_Header_GlobalSignIn_lnkSubscribeJournal" class="auth--subscribe" rel="nofollow" href="https://store.jamanetwork.com/index.aspx?productcode=64">Subscribe to the JAMA journal</a>
                </div>

                
                

                
            </div>
        </div>




    </header>
</div>


<div class="editors-choice-header">
</div>

<div id="BodyContent_Header_divAds" class="header-ad-wrap sb-background-primary-dark">
        <div class="leader-ad desktop-only">
            
                <div class="widget-WidgetLoader widget-instance-AMA_AdTag_LeaderboardAd">
        
    <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_LeaderboardAd" data-params="{&quot;parameters&quot;:{&quot;siteName&quot;:&quot;jama&quot;,&quot;siteId&quot;:3,&quot;journalId&quot;:67,&quot;adDisplay&quot;:1,&quot;adSection&quot;:&quot;scholarly&quot;,&quot;adPosition&quot;:&quot;atf&quot;,&quot;fromGoogle&quot;:false},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}"></div>
 
    </div>

        </div>
    </div>

<!-- /.header-ad-wrap -->


    </section>


    <section class="master-main">
        
    <div class="social-share hide" data-share-journal="JAMA_current" data-share-title="Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults"></div>

        <div class="widget-UserContentAccessWrite widget-instance-AMA_LocalStorage_Article">
        <div class="SCM-SharedWidgets-LocalStorage-UserContentAccessWrite" data-values='{"id":"2799240","type":"Article","date":"5/5/2024 8:56:34 AM"}'></div>
 
    </div>
    <div class="widget-ArticleToggleView widget-instance-AMA_ArticleToggleView">
        
    <div class="widget-ArticleFullView widget-instance-AMA_ArticleFullView">
        
<script>
    (function () {
        var bodyElem = document.querySelector('body');
        var className = 'split-screen';

        if (bodyElem.classList) {
            bodyElem.classList.add(className);
        } else {
            el.className += ' ' + className;
        }
    })();
</script>


<div id="resources-panel" class="resources-panel">
                <span class="hide tagmanagervalue" data-attribute="template" data-value="splitscreen" data-type="string"></span>


    <div class="tab-nav">
        <a class="tab-nav-trigger tab-nav-full-text tablet-down" href="#full-text-tab">
            <i class="icon-full_text"><span class="sr-t">full text icon</span></i>
            <div class="tab-nav-tab-name">Full Text</div>
        </a>
        <a class="tab-nav-trigger tab-nav-contents target-tab-active" href="#contents-tab">
            <i class="icon-contents"><span class="sr-t">contents icon</span></i>
            <div class="tab-nav-tab-name">Contents</div>
        </a>
        <a class="tab-nav-trigger tab-nav-figure-table" href="#figure-table-tab">
            <i class="icon-figures"><span class="sr-t">figure icon</span></i>
            <div class="tab-nav-tab-name">Figures / <br> Tables</div>
        </a>
        <a class="tab-nav-trigger tab-nav-multimedia" href="#multimedia-tab">
            <i class="icon-multimedia"><span class="sr-t">multimedia icon</span></i>
            <div class="tab-nav-tab-name">Multimedia</div>
        </a>
        <a class="tab-nav-trigger tab-nav-supplemental" href="#supplemental-tab">
            <i class="icon-attach"><span class="sr-t">attach icon</span></i>
            <div class="tab-nav-tab-name">Supplemental <br> Content</div>
        </a>
        <a class="tab-nav-trigger tab-nav-references" href="#references-tab">
            <i class="icon-references"><span class="sr-t">references icon</span></i>
            <div class="tab-nav-tab-name">References</div>
        </a>
        <a class="tab-nav-trigger tab-nav-related" href="#related-tab">
            <i class="icon-related"><span class="sr-t">related icon</span></i>
            <div class="tab-nav-tab-name">Related</div>
        </a>
        <a class="tab-nav-trigger tab-nav-comments" href="#comments-tab">
            <i class="icon-user-comments"><span class="sr-t">comments icon</span></i>
            <div class="tab-nav-tab-name">Comments</div>
        </a>
    </div>



    <div class="resource-tabs">
        <div id="contents-tab" class="resource-tab js-resource-tab contents-tab tab-active">
            <div class="contents-tab-contents">
            <a id="pdf-link" class="toolbar-tool toolbar-pdf al-link pdfaccess" data-article-id="2799240" data-article-url="/journals/jama/articlepdf/2799240/jama_gandhi_2022_sc_220007_1671563383.14209.pdf" data-ajax-url="/Content/CheckPdfAccess"><span class="toolbar-pdf-text"><span class="toolbar-link-text-extra">Download </span><span class="toolbar-link-text">PDF</span></span>
            </a>
    <div class="widget-ArticleJumpLinks widget-instance-AMA_ArticleJumpLinks_Widget">
            <a href="#top" class="section-jump-link contents-tab-jump-link top-of-article" data-tab-toggle=".tab-nav-full-text">Top of Article</a>
    <ul class="section-jump-links bullet ml2 pl1">
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#248771203" data-tab-toggle=".tab-nav-full-text">Abstract</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#248771208" data-tab-toggle=".tab-nav-full-text">Introduction</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#248771213" data-tab-toggle=".tab-nav-full-text">Methods</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#248771221" data-tab-toggle=".tab-nav-full-text">Initiation of ART</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#248771226" data-tab-toggle=".tab-nav-full-text">Initial ART Regimens for Individuals With HIV</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#248771245" data-tab-toggle=".tab-nav-full-text">When and How to Switch ART Regimens</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#248771265" data-tab-toggle=".tab-nav-full-text">Laboratory Monitoring in Individuals With Established HIV at HIV Diagnosis and Starting ART</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#248771276" data-tab-toggle=".tab-nav-full-text">Weight Gain and Metabolic Complications With ART</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#248771283" data-tab-toggle=".tab-nav-full-text">HIV and Aging</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#248771290" data-tab-toggle=".tab-nav-full-text">Prevention of HIV Infection</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#248771313" data-tab-toggle=".tab-nav-full-text">Postexposure Prophylaxis for HIV and Bacterial STIs</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#248771316" data-tab-toggle=".tab-nav-full-text">Substance Use in Persons at Risk for and With HIV</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#248771338" data-tab-toggle=".tab-nav-full-text">Conclusions</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#248771340" data-tab-toggle=".tab-nav-full-text">Article Information</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#248771341" data-tab-toggle=".tab-nav-full-text">References</a></li>
    </ul>
 
    </div>
    <div class="widget-SelfServeContent widget-instance-AMA_Contents_Tab_SelfServe">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="v2_article_content_tab" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="bc_right_rail_article_promo"><!-- Content Goes Here --></div>


</div>

 
    </div>

            </div>
            <div class="contents-tab-ad">
                <div id="split-screen-contab"></div>
            </div>
        </div>

        
        <div id="figure-table-tab" class="resource-tab js-resource-tab figure-table-tab need-jobs-ad">
    <div class="widget-ArticleFiguresAndTables widget-instance-AMA_Article_Tables_Tab">
        <div class="figure-table-wrapper thm-bd-top"><div class="table-label">Table 1.  Strength of Recommendation and Quality of Evidence Rating Scale<sup>a</sup></div><a class="figure-table-anchor" id="jsc220007t1"> </a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="jsc220007t1" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/jsc220007t1_1671563383.33715.png?Expires=1717902761&amp;Signature=vOpkK1yQxL3wxrqffhAPRLH5Q1cBMBiC7ESAUbAWESP-6eU3tPubr6B4jKO~FZIqhIy57HcfzdORZrXPZqupybb9XuqQks7el3Rogr2Na98W7YPXEocZ6cU4xIqKUdH0DO~ZUNvk-IY~1auNo5cOE-itW-bVpjdyNAlktXYmi~t0CEaB7AhVUIsjFHe1GzOPkmVB3N2UasrWXNrn-XEUvrmwlImahIVUfL875HjfkOmngsryOIJzQC6mboYXFi5vG7ENgpoS7~GOocwDxGiajMSZHd2Mr2FX6IaNiJsCyNB~f9hiVWnq8MH~EYjNdpyj9oQYf32t8E6XOo0FKRERtA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="jsc220007t1" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/jsc220007t1_1671563383.33715.png?Expires=1717902761&Signature=vOpkK1yQxL3wxrqffhAPRLH5Q1cBMBiC7ESAUbAWESP-6eU3tPubr6B4jKO~FZIqhIy57HcfzdORZrXPZqupybb9XuqQks7el3Rogr2Na98W7YPXEocZ6cU4xIqKUdH0DO~ZUNvk-IY~1auNo5cOE-itW-bVpjdyNAlktXYmi~t0CEaB7AhVUIsjFHe1GzOPkmVB3N2UasrWXNrn-XEUvrmwlImahIVUfL875HjfkOmngsryOIJzQC6mboYXFi5vG7ENgpoS7~GOocwDxGiajMSZHd2Mr2FX6IaNiJsCyNB~f9hiVWnq8MH~EYjNdpyj9oQYf32t8E6XOo0FKRERtA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=248771220&ar=2799240&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/jsc220007t1_1671563383.33715.png?Expires=1717902761&amp;Signature=vOpkK1yQxL3wxrqffhAPRLH5Q1cBMBiC7ESAUbAWESP-6eU3tPubr6B4jKO~FZIqhIy57HcfzdORZrXPZqupybb9XuqQks7el3Rogr2Na98W7YPXEocZ6cU4xIqKUdH0DO~ZUNvk-IY~1auNo5cOE-itW-bVpjdyNAlktXYmi~t0CEaB7AhVUIsjFHe1GzOPkmVB3N2UasrWXNrn-XEUvrmwlImahIVUfL875HjfkOmngsryOIJzQC6mboYXFi5vG7ENgpoS7~GOocwDxGiajMSZHd2Mr2FX6IaNiJsCyNB~f9hiVWnq8MH~EYjNdpyj9oQYf32t8E6XOo0FKRERtA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="jsc220007t1" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/m_jsc220007t1_1671563383.33715.png?Expires=1717902761&amp;Signature=JeoSVq~dHmpk9gCNJgu9wvQQRwFWZ-mZ1CyLhxrP1LsisIfsdGifPja0NcxfaGSoQ8txZ9BUfQ5llXeep8YRmQBx8i8mMfv2I6HQXKu4Y6cl6XNUCxfhh0hSd0e3QvSf7ehPZIrmT0imyJEamxhttOPNOKP~G4~eYYocRHIyK3VYVlvQQGPxtL4k82JTN8KMJlO6GAIewTVSve9YhDroINFcA8XDGaML1yC5IzcMewGLItRlMp8jbM~yitsY88RyeNYd2CuNUKMBRrjBuMYvjgYvN5AV7UtrlHCmq5Xwvv98wDfDAnlPeKmQjnPRaz7gOzwXjIywiMJEpmYGHH~sqQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Strength of Recommendation and Quality of Evidence Rating Scalea" class="content-img lazy" path-from-xml="jsc220007t1" /></a></div></div><div class="table-caption"></div></div><div class="figure-table-wrapper thm-bd-top"><div class="table-label">Table 2.  Other Recommended Initial Antiretroviral Therapy (ART) Regimens</div><a class="figure-table-anchor" id="jsc220007t2"> </a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="jsc220007t2" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/jsc220007t2_1671563383.42957.png?Expires=1717902761&amp;Signature=KVyK2cG0fWU5AQC5EmWlkrs47uGYB5w7jubGka74VLqSRQdGekG339ZteEi6NOu86iAVlEgV~nTbGADRI73Qp9mfCYrss4A4u65loKnnHSs69ASVL7OiNSvB229mXro-hhyQ5QzQArcLipKPj3s2eMMvUTMerxT1l1X~oNpA~kC1cE~Q4EqcptWRm~D9iOOuraYw6UAozCx0vztblgCpv~ccG03TDxIW5IkXbD0QLdJEUWJQckYfrkEa2L7k87kZ2DkIRXltmdq2dMApLHENAu07TWKeiM9OmdKsf9UhxNgysgdFTA3W3HXa8aF4glcwFpBJp-V2A~OurvBAcvUsNQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="jsc220007t2" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/jsc220007t2_1671563383.42957.png?Expires=1717902761&Signature=KVyK2cG0fWU5AQC5EmWlkrs47uGYB5w7jubGka74VLqSRQdGekG339ZteEi6NOu86iAVlEgV~nTbGADRI73Qp9mfCYrss4A4u65loKnnHSs69ASVL7OiNSvB229mXro-hhyQ5QzQArcLipKPj3s2eMMvUTMerxT1l1X~oNpA~kC1cE~Q4EqcptWRm~D9iOOuraYw6UAozCx0vztblgCpv~ccG03TDxIW5IkXbD0QLdJEUWJQckYfrkEa2L7k87kZ2DkIRXltmdq2dMApLHENAu07TWKeiM9OmdKsf9UhxNgysgdFTA3W3HXa8aF4glcwFpBJp-V2A~OurvBAcvUsNQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=248771244&ar=2799240&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/jsc220007t2_1671563383.42957.png?Expires=1717902761&amp;Signature=KVyK2cG0fWU5AQC5EmWlkrs47uGYB5w7jubGka74VLqSRQdGekG339ZteEi6NOu86iAVlEgV~nTbGADRI73Qp9mfCYrss4A4u65loKnnHSs69ASVL7OiNSvB229mXro-hhyQ5QzQArcLipKPj3s2eMMvUTMerxT1l1X~oNpA~kC1cE~Q4EqcptWRm~D9iOOuraYw6UAozCx0vztblgCpv~ccG03TDxIW5IkXbD0QLdJEUWJQckYfrkEa2L7k87kZ2DkIRXltmdq2dMApLHENAu07TWKeiM9OmdKsf9UhxNgysgdFTA3W3HXa8aF4glcwFpBJp-V2A~OurvBAcvUsNQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="jsc220007t2" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/m_jsc220007t2_1671563383.42957.png?Expires=1717902761&amp;Signature=lsGb1~81DTOSExvHXbNq2dzW8CBwKVE2hI7peSDlKMCjfM5wtkESK0nFqFymGJFoedgFTYZupNCayhtPCsQbtKQkGqFz15anmxXQ~X6XvBlqfITX-mMew1soHQMUWbM4elySlO3jHvKkdyJaP2374kWmGzM94Pgf3p1w6d~BwW7RjHLOs24DWFqfu9qcslNGVRF2tulxEXSFgPy-97I32Xnng104II60nkr0Mj1~ya5XMKlSEvPL95r8DDgVI2~5RtXPUZAjjkugWh7rbb9X2zj9EeDM6s2KSZWKnWmoYSRTERmBnpbxx-bqggEJsJ4CjoEenWdqb1I1RcyxymOtHg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Other Recommended Initial Antiretroviral Therapy (ART) Regimens" class="content-img lazy" path-from-xml="jsc220007t2" /></a></div></div><div class="table-caption"></div></div><div class="figure-table-wrapper thm-bd-top"><div class="table-label">Table 3.  Recommendations for Laboratory Monitoring for Persons With HIV</div><a class="figure-table-anchor" id="jsc220007t3"> </a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="jsc220007t3" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/jsc220007t3_1671563383.50744.png?Expires=1717902761&amp;Signature=x8WRpg5Ia~EkoxHbRzsyjPp9qTEDr-S~87L~ONg1DcGpH3QVCIUj8sZpOjusTDCKyZozfyIwIa5aMAwUknZYJ-WlcaKrp4ALgj0VBs5Wm4dqlsEQLKRIgTjo3PX7yuwYSnQFhPwSPIpXf8l3StdKEDBOQEU7A~Juy~bWyElU16NBjwvlYEd9HGJLrYqpFUgUrZENxiUhaVk0sdZmZhuBdPnJzjn6mt4G5Dk1S4xJRe5EeOLSfPORHOJBL7BgIjpZHIn87Vfjsj2MbBPdkYUMS9FWwZHXSK9iMBykd-THg0bj5GZ5LmgSRVexeS03OJO3Rzzsakyswpl5Y~RhuQ7~QA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="jsc220007t3" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/jsc220007t3_1671563383.50744.png?Expires=1717902761&Signature=x8WRpg5Ia~EkoxHbRzsyjPp9qTEDr-S~87L~ONg1DcGpH3QVCIUj8sZpOjusTDCKyZozfyIwIa5aMAwUknZYJ-WlcaKrp4ALgj0VBs5Wm4dqlsEQLKRIgTjo3PX7yuwYSnQFhPwSPIpXf8l3StdKEDBOQEU7A~Juy~bWyElU16NBjwvlYEd9HGJLrYqpFUgUrZENxiUhaVk0sdZmZhuBdPnJzjn6mt4G5Dk1S4xJRe5EeOLSfPORHOJBL7BgIjpZHIn87Vfjsj2MbBPdkYUMS9FWwZHXSK9iMBykd-THg0bj5GZ5LmgSRVexeS03OJO3Rzzsakyswpl5Y~RhuQ7~QA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=248771267&ar=2799240&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/jsc220007t3_1671563383.50744.png?Expires=1717902761&amp;Signature=x8WRpg5Ia~EkoxHbRzsyjPp9qTEDr-S~87L~ONg1DcGpH3QVCIUj8sZpOjusTDCKyZozfyIwIa5aMAwUknZYJ-WlcaKrp4ALgj0VBs5Wm4dqlsEQLKRIgTjo3PX7yuwYSnQFhPwSPIpXf8l3StdKEDBOQEU7A~Juy~bWyElU16NBjwvlYEd9HGJLrYqpFUgUrZENxiUhaVk0sdZmZhuBdPnJzjn6mt4G5Dk1S4xJRe5EeOLSfPORHOJBL7BgIjpZHIn87Vfjsj2MbBPdkYUMS9FWwZHXSK9iMBykd-THg0bj5GZ5LmgSRVexeS03OJO3Rzzsakyswpl5Y~RhuQ7~QA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="jsc220007t3" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/m_jsc220007t3_1671563383.50744.png?Expires=1717902761&amp;Signature=xx4U6RrQxzm5FXkqcSO2JgyIRAf4sQ0vqYzK~zMsQZRTTGdgKk~1cQWRtz0qvnc-mqUm~lp-rMiN4EKxn8nkWobYhHeMbQntN1HkCn0GCJLhHRzbcAGxoJuLBcEgaMlImFwREzWoFNOB0H~pIixotDOhl5iE0Toxh2ZBHVZnPmvUnblNhM05RyqSiDb5DOK7TR4XNu-FHrdlekCtA~jHSRi-uf~t06YHa~TpQRnnvTM3p-d7JfR6ewk00Uc3IR57r7Fr3r-D-szuCbqxadtFp-lrdjq-WQVvZVJauySMyX0AsGIZVtPP3XL8RKqXDgvYTHYHzQkrrlAHTfj2KwTswQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Recommendations for Laboratory Monitoring for Persons With HIV" class="content-img lazy" path-from-xml="jsc220007t3" /></a></div></div><div class="table-caption"></div></div><div class="figure-table-wrapper thm-bd-top"><div class="table-label">Table 4.  Recommendations for Biomedical HIV Prevention by Population and Transmission Risk Behavior<sup>a</sup></div><a class="figure-table-anchor" id="jsc220007t4"> </a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="jsc220007t4" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/jsc220007t4_1671563383.59186.png?Expires=1717902761&amp;Signature=d~NjlQt0m0y5lxBfu1QiwsBeQ92wKcH0K6DAWRP~lX0QZbjlhDF7QSPeNTFwz2jlblCl-R0Xvi2aVddZcSepUp5vB6nZk9gnUX2gY3f8EAhjZ8Q0yAZ3Jbpl946cu7pVo6B0yd7r~NjhGXiA9isZk~G6QPQVA2C806xANGqsS40v~tsKGqlXgMbUXrKpSkufndhl3Avix9iySlTspNW0bDc65OdhyZMGbrQBz3jQnE8ulioxKVBx8dMMSlckvjQk3Xy5Qjzncm0ZYB~Qvjy3mZIZfmXE1fEMHiJ7pOLIfdstrsKrCD4NowIgCwUBxg89yqwor4nuMm0ebDFA3RWCNg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="jsc220007t4" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/jsc220007t4_1671563383.59186.png?Expires=1717902761&Signature=d~NjlQt0m0y5lxBfu1QiwsBeQ92wKcH0K6DAWRP~lX0QZbjlhDF7QSPeNTFwz2jlblCl-R0Xvi2aVddZcSepUp5vB6nZk9gnUX2gY3f8EAhjZ8Q0yAZ3Jbpl946cu7pVo6B0yd7r~NjhGXiA9isZk~G6QPQVA2C806xANGqsS40v~tsKGqlXgMbUXrKpSkufndhl3Avix9iySlTspNW0bDc65OdhyZMGbrQBz3jQnE8ulioxKVBx8dMMSlckvjQk3Xy5Qjzncm0ZYB~Qvjy3mZIZfmXE1fEMHiJ7pOLIfdstrsKrCD4NowIgCwUBxg89yqwor4nuMm0ebDFA3RWCNg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=248771292&ar=2799240&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/jsc220007t4_1671563383.59186.png?Expires=1717902761&amp;Signature=d~NjlQt0m0y5lxBfu1QiwsBeQ92wKcH0K6DAWRP~lX0QZbjlhDF7QSPeNTFwz2jlblCl-R0Xvi2aVddZcSepUp5vB6nZk9gnUX2gY3f8EAhjZ8Q0yAZ3Jbpl946cu7pVo6B0yd7r~NjhGXiA9isZk~G6QPQVA2C806xANGqsS40v~tsKGqlXgMbUXrKpSkufndhl3Avix9iySlTspNW0bDc65OdhyZMGbrQBz3jQnE8ulioxKVBx8dMMSlckvjQk3Xy5Qjzncm0ZYB~Qvjy3mZIZfmXE1fEMHiJ7pOLIfdstrsKrCD4NowIgCwUBxg89yqwor4nuMm0ebDFA3RWCNg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="jsc220007t4" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/m_jsc220007t4_1671563383.59186.png?Expires=1717902761&amp;Signature=MQW9mhpwvA11s7THRCXTYYjOsweWeZ0oSU~h4crEPZ86MAiCc5aOtcXlXZaoWikah27HnI0EosPA5ZfrdOonoN3GckL4e2oj63OS9rSgF7uFz5PL7gK1QhSVq5UnfoS4K-GdVqGBQXH5TEmTFBrv21Thm5py-s2JpXQym5jYNlvtH1bCpW54XaiqzCmuXhH7HQTMQtUF2ivvRNciFdoizDcDUKvrG60slhXemtuHp7JnQYy9tq8xYdmwX8YyElbIPE017SjqEC23pCahqw~yny3IbpXI62qH3eQv3awSD1qVIvsDPeAPAJMFwg2SUvObUA1GFgTyjbE06Sgh0V9F6g__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Recommendations for Biomedical HIV Prevention by Population and Transmission Risk Behaviora" class="content-img lazy" path-from-xml="jsc220007t4" /></a></div></div><div class="table-caption"></div></div> 
    </div>

        </div>

        
        <div id="multimedia-tab" class="resource-tab js-resource-tab multimedia-tab need-jobs-ad">
    <div class="widget-MultimediaInfo widget-instance-AMAv2MultimediaContent">
        

        <div class="multimedia-item audio ">
                    <div class="audio-group-duration">
            Audio (22:19)
        </div>
        <div><a class="audio-title" href="https://jamanetwork.com/learning/audio-player/18741120" target="_blank" aria-label="Linked Multimedia Button"><div class="multimedia-title">Advances in Treatment and Prevention of HIV</div></a></div>
        <a class="audio-anchor"></a>
    <div class="widget-AudioPlayer widget-instance-AMA_MultimediaInfo_PlatformAudioPlayer_MultimediaInfo">
            <div class="audio-element-wrapper js-audio-element-wrapper">
                            <a class="audio-anchor" id="101001jama202221884"></a>
        <div id="audio-player-wrapper" class="js-audio-player-wrapper audio-player-wrapper">
            <audio class="js-audio-player" id="audio-player" type="audio/mp3" preload="none" src=https://traffic.libsyn.com/secure/jamaclinicalreviews/advances_in_treatment_and_prevention_of_hiv.mp3></audio>
            <div class="display-elements">
                <div class="audio-controls">
                    <a id="backward" class="js-btn-backward audio-back" href="javascript:;" aria-label="Back Button">
                        <img src="//cdn.jamanetwork.com/UI/app/svg/multimedia/Backward_15.svg" alt="Backward 15" />
                    </a>
                    <a id="play-pause" class="js-play-pause audio-play" href="javascript:;" aria-label="Play Button">
                        <img src="//cdn.jamanetwork.com/UI/app/svg/multimedia/Play.svg" alt="Play" />
                    </a>
                    <a id="play-pause" class="js-play-pause audio-pause" href="javascript:;" aria-label="Pause Button">
                        <img src="//cdn.jamanetwork.com/UI/app/svg/multimedia/Pause.svg" alt="Pause" />
                    </a>
                    <a id="forward" class="js-btn-forward audio-forward" href="javascript:;" aria-label="Fast Forward Button">
                        <img src="//cdn.jamanetwork.com/UI/app/svg/multimedia/Forward_15.svg" alt="Forward 15" />
                    </a>
                </div>
                <div class="js-progressBar-clickable progressBar-clickable">
                    <div class="js-progressBar progressBar">
                        <div class="js-loading-animation">
                            <div class="loading-blade thm-bg-col sb-pc"></div>
                            <div class="loading-blade thm-bg-col sb-pc"></div>
                            <div class="loading-blade thm-bg-col sb-pc"></div>
                            <div class="loading-blade thm-bg-col sb-pc"></div>
                            <div class="loading-blade thm-bg-col sb-pc"></div>
                            <div class="loading-blade thm-bg-col sb-pc"></div>
                            <div class="loading-blade thm-bg-col sb-pc"></div>
                            <div class="loading-blade thm-bg-col sb-pc"></div>
                        </div>
                        <div class="js-timeBar timeBar thm-bg-col sb-background-pc" tabindex="0" aria-label="Progress Bar"></div>
                    </div>
                </div>
                <div class="audio-speed">
                    <a id="speed-1x" class="js-btn-speed" play-speed=1 href="javascript:;" aria-label="Speed Control Button">1x</a>
                </div>
                <div class="audio-time">
                    <span id="time" class="js-time js-timeAudioCurrent">0:00</span>
                    <span> / </span>
                    <span class="js-initialTime">0:00</span>
                    <span class="js-duration hide"></span>
                </div>
            </div>
        </div>
            <div class="linked-content-urls-wrapper">
                            <span><a class="thm-col sb-pc linked-content" target="_blank" href="https://jamanetwork.com/journals/jama/pages/jama-clinical-reviews" aria-label="Subscribe To Podcast Button">Subscribe to Podcast</a></span>

            </div>
        
    </div>
 
    </div>

        </div>

            <span class="hide tagmanagervalue" data-attribute="arrRelatedAudio" data-value="10.1001/jama.2022.21884" data-type="array"></span>





 
    </div>

        </div>

        
        <div id="supplemental-tab" class="resource-tab js-resource-tab supplemental-tab need-jobs-ad">
    <div class="widget-ArticleDataSupplements widget-instance-AMA_Data_Supplements_Tab">
            <div class="supplement">
        <a id="note-JSC220007-1" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/939060/jsc220007supp1_prod_1671563383.14709.pdf?Expires=1717902761&amp;Signature=27CjA2IjEZB9rjL6EMVqUBGxpvZJbp18gMgBJzhw0rxOKybHhNzKXSK8b3qPCoWKd79~Q5zB2JelvuC52l1rqkPuCi8EPOe9F24dzrqTnyTz2EMtLDX0k09ecRjnhhaEkX4R~Pbhe6Dv7KKc6jzpaVXROPPWOEy7t05sOhi7YDhjxZNtvXF6wFkdQy3RVjnUxMXv5AECKSGaQ-7YIEfrA1hG7bCW8eu0nzWYXbAeWz9IgX-MZc4XkGmy3204A~5f4ZWToy-mgAJ7V9J6k7wuedZD8LnMH~VZPd0lYean7DhOSTNOaeiRv7UipTr4yBRvUcsKUP7r6MPnuCOQNsCavw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" class="supplement-link supplement-download stats-supplement-download" rel=&quot;nofollow&quot;>
            <div class="pdf supplement-type"></div>
                <div class="supplement-title"><span class="title-label">Supplement.</span><p class="para">eMethods. Recommendations Development Process</p><p class="para">eBox 1. Volunteer IAS-USA Scientific Leadership Board, September 2022</p><p class="para">eBox 2. IAS-USA Antiretroviral Therapy Recommendations Panel</p><p class="para">eBox 3. Working Sections of the IAS-USA Antiretroviral Therapy Recommendations Panel</p><p class="para">eTable 1. Summary of Evidence Collection</p><p class="para">eTable 2. Search Terms Used and Results of EMBASE and PubMed Literature Searches</p><p class="para">eTable 3. Information Requested From Antiretroviral Drug Manufacturers</p><p class="para">eTable 4. Screening Tools for Substance Use Disorders</p><p class="para">eTable 4a. Example of Use of NIDA Quick Screen for OUD Then Reflex NIDA ASSIST and the RODS</p><p class="para">eTable 5. FDA-approved Medication Treatments of Opioid Use Disorder</p><p class="para">eTable6. Medication Treatments for Alcohol Use Disorder</p><p class="para">eFigure 1. Schematic of How to Initiate Buprenorphine in a Person With OUD</p></div>
        </a>        
    </div>

 
    </div>

        </div>

        
        <div id="references-tab" class="resource-tab js-resource-tab references-tab need-jobs-ad">
            <div class="references-wrap">
    <div class="widget-SectionDisplay widget-instance-AMA_References_Tab">
        
<div class="references"><div class="reference"><a class="reference-number" id="jsc220007r1">1.</a><div class="reference-content">Saag
         MS﻿, Gandhi
         RT﻿, Hoy
         JF﻿, 
     et al.  Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA Panel. ﻿ <i xmlns:helper="urn:XsltStringHelper"> JAMA</i>. 2020;324(16):1651-1669. doi:<a href="http://jamanetwork.com/article.aspx?doi=10.1001/jama.2020.17025">10.1001/jama.2020.17025</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Antiretroviral%20drugs%20for%20treatment%20and%20prevention%20of%20HIV%20infection%20in%20adults%3A%202020%20recommendations%20of%20the%20International%20Antiviral%20Society-USA%20Panel.&amp;author=MS%20Saag&amp;author=RT%20Gandhi&amp;author=JF%20Hoy&amp;publication_year=2020&amp;journal=JAMA&amp;volume=324&amp;pages=1651-1669" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1001/jama.2020.17025" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1001/jama.2020.17025" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r2">2.</a><div class="reference-content">Canadian Task Force on the Periodic Health Examination.  The periodic health examination. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Can Med Assoc J</i>. 1979;121(9):1193-1254.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/115569" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20periodic%20health%20examination.&amp;publication_year=1979&amp;journal=Can%20Med%20Assoc%20J&amp;volume=121&amp;pages=1193-1254" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r3">3.</a><div class="reference-content">Pathela
         P﻿, Jamison
         K﻿, Braunstein
         SL﻿, 
     et al.  Initiating antiretroviral treatment for newly diagnosed HIV patients in sexual health clinics greatly improves timeliness of viral suppression. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2021;35(11):1805-1812. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000002937">10.1097/QAD.0000000000002937</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Initiating%20antiretroviral%20treatment%20for%20newly%20diagnosed%20HIV%20patients%20in%20sexual%20health%20clinics%20greatly%20improves%20timeliness%20of%20viral%20suppression.&amp;author=P%20Pathela&amp;author=K%20Jamison&amp;author=SL%20Braunstein&amp;publication_year=2021&amp;journal=AIDS&amp;volume=35&amp;pages=1805-1812" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000002937" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000002937" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r4">4.</a><div class="reference-content">Michienzi
         SM﻿, Barrios
         M﻿, Badowski
         ME﻿.  Evidence regarding rapid initiation of antiretroviral therapy in patients living with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Curr Infect Dis Rep</i>. 2021;23(5):7. doi:<a href="http://dx.doi.org/10.1007/s11908-021-00750-5">10.1007/s11908-021-00750-5</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Evidence%20regarding%20rapid%20initiation%20of%20antiretroviral%20therapy%20in%20patients%20living%20with%20HIV.&amp;author=SM%20Michienzi&amp;author=M%20Barrios&amp;author=ME%20Badowski&amp;publication_year=2021&amp;journal=Curr%20Infect%20Dis%20Rep&amp;volume=23&amp;pages=7" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1007/s11908-021-00750-5" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1007/s11908-021-00750-5" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r5">5.</a><div class="reference-content">Huhn
         GD﻿, Crofoot
         G﻿, Ramgopal
         M﻿, 
     et al.  Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in a rapid-initiation model of care for human immunodeficiency virus type 1 infection: primary analysis of the DIAMOND study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2020;71(12):3110-3117. doi:<a href="http://dx.doi.org/10.1093/cid/ciz1213">10.1093/cid/ciz1213</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Darunavir%2Fcobicistat%2Femtricitabine%2Ftenofovir%20alafenamide%20in%20a%20rapid-initiation%20model%20of%20care%20for%20human%20immunodeficiency%20virus%20type%201%20infection%3A%20primary%20analysis%20of%20the%20DIAMOND%20study.&amp;author=GD%20Huhn&amp;author=G%20Crofoot&amp;author=M%20Ramgopal&amp;publication_year=2020&amp;journal=Clin%20Infect%20Dis&amp;volume=71&amp;pages=3110-3117" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciz1213" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciz1213" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r6">6.</a><div class="reference-content">Baisley
         K﻿, Orne-Gliemann
         J﻿, Larmarange
         J﻿, 
     et al.  Early HIV treatment and survival over six years of observation in the ANRS 12249 treatment as prevention trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> HIV Med</i>. 2022;23(8):922-928. doi:<a href="http://dx.doi.org/10.1111/hiv.13263">10.1111/hiv.13263</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Early%20HIV%20treatment%20and%20survival%20over%20six%20years%20of%20observation%20in%20the%20ANRS%2012249%20treatment%20as%20prevention%20trial.&amp;author=K%20Baisley&amp;author=J%20Orne-Gliemann&amp;author=J%20Larmarange&amp;publication_year=2022&amp;journal=HIV%20Med&amp;volume=23&amp;pages=922-928" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1111/hiv.v23.8" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1111/hiv.v23.8" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r7">7.</a><div class="reference-content">Stanic
         A﻿, Rybin
         D﻿, Cannata
         F﻿, 
     et al.  The impact of the housing status on clinical outcomes and health care utilization among individuals living with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS Care</i>. 2021;33(1):1-9. doi:<a href="http://dx.doi.org/10.1080/09540121.2019.1695728">10.1080/09540121.2019.1695728</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20impact%20of%20the%20housing%20status%20on%20clinical%20outcomes%20and%20health%20care%20utilization%20among%20individuals%20living%20with%20HIV.&amp;author=A%20Stanic&amp;author=D%20Rybin&amp;author=F%20Cannata&amp;publication_year=2021&amp;journal=AIDS%20Care&amp;volume=33&amp;pages=1-9" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1080/09540121.2019.1695728" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1080/09540121.2019.1695728" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r8">8.</a><div class="reference-content">Maragh-Bass
         AC﻿, Gamble
         T﻿, El-Sadr
         WM﻿, Hanscom
         B﻿, Tolley
         EE﻿.  Exploring individual-level barriers to HIV medication adherence among men who have sex with men in the HIV Prevention Trials Network (HPTN 065) study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS Care</i>. 2021;33(11):1404-1413. doi:<a href="http://dx.doi.org/10.1080/09540121.2020.1828799">10.1080/09540121.2020.1828799</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Exploring%20individual-level%20barriers%20to%20HIV%20medication%20adherence%20among%20men%20who%20have%20sex%20with%20men%20in%20the%20HIV%20Prevention%20Trials%20Network%20%28HPTN%20065%29%20study.&amp;author=AC%20Maragh-Bass&amp;author=T%20Gamble&amp;author=WM%20El-Sadr&amp;author=B%20Hanscom&amp;author=EE%20Tolley&amp;publication_year=2021&amp;journal=AIDS%20Care&amp;volume=33&amp;pages=1404-1413" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1080/09540121.2020.1828799" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1080/09540121.2020.1828799" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r9">9.</a><div class="reference-content">Higa
         DH﻿, Crepaz
         N﻿, Mullins
         MM﻿, 
     et al.  Strategies to improve HIV care outcomes for people with HIV who are out of care. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2022;36(6):853-862. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000003172">10.1097/QAD.0000000000003172</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Strategies%20to%20improve%20HIV%20care%20outcomes%20for%20people%20with%20HIV%20who%20are%20out%20of%20care.&amp;author=DH%20Higa&amp;author=N%20Crepaz&amp;author=MM%20Mullins&amp;publication_year=2022&amp;journal=AIDS&amp;volume=36&amp;pages=853-862" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000003172" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000003172" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r10">10.</a><div class="reference-content">National Academies of Sciences Engineering and Medicine. <i xmlns:helper="urn:XsltStringHelper"> Opportunities to Improve Opioid Use Disorder and Infectious Disease Services</i>.  National Academies Press; 2020.</div></div><div class="reference"><a class="reference-number" id="jsc220007r11">11.</a><div class="reference-content">Martin
         TCS﻿, Abrams
         M﻿, Anderson
         C﻿, Little
         SJ﻿.  Rapid antiretroviral therapy among individuals with acute and early HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2021;73(1):130-133. doi:<a href="http://dx.doi.org/10.1093/cid/ciaa1174">10.1093/cid/ciaa1174</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Rapid%20antiretroviral%20therapy%20among%20individuals%20with%20acute%20and%20early%20HIV.&amp;author=TCS%20Martin&amp;author=M%20Abrams&amp;author=C%20Anderson&amp;author=SJ%20Little&amp;publication_year=2021&amp;journal=Clin%20Infect%20Dis&amp;volume=73&amp;pages=130-133" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciaa1174" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciaa1174" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r12">12.</a><div class="reference-content">Chéret
         A﻿, Bauer
         R﻿, Meiffrédy
         V﻿, 
     et al.  Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, phase 3 trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Antimicrob Chemother</i>. 2022;77(9):2506-2515. doi:<a href="http://dx.doi.org/10.1093/jac/dkac207">10.1093/jac/dkac207</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Once-daily%20dolutegravir%20versus%20darunavir%20plus%20cobicistat%20in%20adults%20at%20the%20time%20of%20primary%20HIV-1%20infection%3A%20the%20OPTIPRIM2-ANRS%20169%20randomized%2C%20open-label%2C%20phase%203%20trial.&amp;author=A%20Chéret&amp;author=R%20Bauer&amp;author=V%20Meiffrédy&amp;publication_year=2022&amp;journal=J%20Antimicrob%20Chemother&amp;volume=77&amp;pages=2506-2515" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/jac/dkac207" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/jac/dkac207" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r13">13.</a><div class="reference-content">Rasmussen
         TA﻿, Ahuja
         SK﻿, Kuwanda
         L﻿, 
     et al.  Antiretroviral initiation at ≥800 CD4+ cells/mm3 associated with lower human immunodeficiency virus reservoir size. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2022;75(10):1781-1791. doi:<a href="http://dx.doi.org/10.1093/cid/ciac249">10.1093/cid/ciac249</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Antiretroviral%20initiation%20at%20%E2%89%A5800%20CD4%2B%20cells%2Fmm3%20associated%20with%20lower%20human%20immunodeficiency%20virus%20reservoir%20size.&amp;author=TA%20Rasmussen&amp;author=SK%20Ahuja&amp;author=L%20Kuwanda&amp;publication_year=2022&amp;journal=Clin%20Infect%20Dis&amp;volume=75&amp;pages=1781-1791" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciac249" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciac249" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r14">14.</a><div class="reference-content">Hunt
         PW﻿, Brenchley
         J﻿, Sinclair
         E﻿, 
     et al.  Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Infect Dis</i>. 2008;197:126-133. doi:<a href="http://dx.doi.org/10.1086/524143">10.1086/524143</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Relationship%20between%20T%20cell%20activation%20and%20CD4%2B%20T%20cell%20count%20in%20HIV-seropositive%20individuals%20with%20undetectable%20plasma%20HIV%20RNA%20levels%20in%20the%20absence%20of%20therapy.&amp;author=PW%20Hunt&amp;author=J%20Brenchley&amp;author=E%20Sinclair&amp;publication_year=2008&amp;journal=J%20Infect%20Dis&amp;volume=197&amp;pages=126-133" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1086/529001" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1086/529001" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r15">15.</a><div class="reference-content">Li
         JZ﻿, Segal
         FP﻿, Bosch
         RJ﻿, 
     et al; AIDS Clinical Trials Group Study A5308 Team.  Antiretroviral therapy reduces T-cell activation and immune exhaustion markers in human immunodeficiency virus controllers. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2020;70(8):1636-1642. doi:<a href="http://dx.doi.org/10.1093/cid/ciz442">10.1093/cid/ciz442</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31131858" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Antiretroviral%20therapy%20reduces%20T-cell%20activation%20and%20immune%20exhaustion%20markers%20in%20human%20immunodeficiency%20virus%20controllers.&amp;author=JZ%20Li&amp;author=FP%20Segal&amp;author=RJ%20Bosch&amp;publication_year=2020&amp;journal=Clin%20Infect%20Dis&amp;volume=70&amp;pages=1636-1642" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciz442" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciz442" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r16">16.</a><div class="reference-content">Plaçais
         L﻿, Boufassa
         F﻿, Lécuroux
         C﻿, 
     et al; ANRS CO21 Study Group.  Antiretroviral therapy for HIV controllers: reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort. ﻿ <i xmlns:helper="urn:XsltStringHelper"> EClinicalMedicine</i>. 2021;37:100963. doi:<a href="http://dx.doi.org/10.1016/j.eclinm.2021.100963">10.1016/j.eclinm.2021.100963</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34195579" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Antiretroviral%20therapy%20for%20HIV%20controllers%3A%20reasons%20for%20initiation%20and%20outcomes%20in%20the%20French%20ANRS-CO21%20CODEX%20cohort.&amp;author=L%20Plaçais&amp;author=F%20Boufassa&amp;author=C%20Lécuroux&amp;publication_year=2021&amp;journal=EClinicalMedicine&amp;volume=37&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.eclinm.2021.100963" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.eclinm.2021.100963" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r17">17.</a><div class="reference-content">Girometti
         N﻿, Lander
         F﻿, McOwan
         A﻿, Nwokolo
         N﻿, Boffito
         M﻿, Whitlock
         G﻿; Dean Street Collaborative Group.  Rapid ART start in early HIV infection: time to viral load suppression and retention in care in a London cohort. ﻿ <i xmlns:helper="urn:XsltStringHelper"> HIV Med</i>. 2020;21(9):613-615. doi:<a href="http://dx.doi.org/10.1111/hiv.12900">10.1111/hiv.12900</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32869951" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Rapid%20ART%20start%20in%20early%20HIV%20infection%3A%20time%20to%20viral%20load%20suppression%20and%20retention%20in%20care%20in%20a%20London%20cohort.&amp;author=N%20Girometti&amp;author=F%20Lander&amp;author=A%20McOwan&amp;author=N%20Nwokolo&amp;author=M%20Boffito&amp;author=G%20Whitlock&amp;publication_year=2020&amp;journal=HIV%20Med&amp;volume=21&amp;pages=613-615" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1111/hiv.v21.9" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1111/hiv.v21.9" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r18">18.</a><div class="reference-content">Jaschinski
         N﻿, Greenberg
         L﻿, Neesgaard
         B﻿, 
     et al; RESPOND Study Group.  Recent abacavir use and incident cardiovascular disease in contemporary treated people living with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. Published online August 24, 2022. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000003373">10.1097/QAD.0000000000003373</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/36001525" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Recent%20abacavir%20use%20and%20incident%20cardiovascular%20disease%20in%20contemporary%20treated%20people%20living%20with%20HIV.&amp;author=N%20Jaschinski&amp;author=L%20Greenberg&amp;author=B%20Neesgaard&amp;publication_year=2022&amp;journal=AIDS&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000003373" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000003373" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r19">19.</a><div class="reference-content">Christopoulos
         KA﻿, Grochowski
         J﻿, Mayorga-Munoz
         F﻿, 
     et al.  First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable HIV viremia in an urban HIV clinic. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. Published online August 1, 2022. doi:<a href="http://dx.doi.org/10.1093/cid/ciac631">10.1093/cid/ciac631</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35913500" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=First%20demonstration%20project%20of%20long-acting%20injectable%20antiretroviral%20therapy%20for%20persons%20with%20and%20without%20detectable%20HIV%20viremia%20in%20an%20urban%20HIV%20clinic.&amp;author=KA%20Christopoulos&amp;author=J%20Grochowski&amp;author=F%20Mayorga-Munoz&amp;publication_year=2022&amp;journal=Clin%20Infect%20Dis&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciac631" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciac631" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r20">20.</a><div class="reference-content">Landovitz
         RJ﻿, Donnell
         D﻿, Clement
         ME﻿, 
     et al; HPTN 083 Study Team.  Cabotegravir for HIV prevention in cisgender men and transgender women. ﻿ <i xmlns:helper="urn:XsltStringHelper"> N Engl J Med</i>. 2021;385(7):595-608. doi:<a href="http://dx.doi.org/10.1056/NEJMoa2101016">10.1056/NEJMoa2101016</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34379922" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cabotegravir%20for%20HIV%20prevention%20in%20cisgender%20men%20and%20transgender%20women.&amp;author=RJ%20Landovitz&amp;author=D%20Donnell&amp;author=ME%20Clement&amp;publication_year=2021&amp;journal=N%20Engl%20J%20Med&amp;volume=385&amp;pages=595-608" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMoa2101016" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMoa2101016" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r21">21.</a><div class="reference-content">Eshleman
         SH﻿, Fogel
         JM﻿, Piwowar-Manning
         E﻿, 
     et al.  Characterization of human immunodeficiency virus (HIV) infections in women who received injectable cabotegravir or tenofovir disoproxil fumarate/emtricitabine for HIV prevention: HPTN 084. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Infect Dis</i>. 2022;225(10):1741-1749. doi:<a href="http://dx.doi.org/10.1093/infdis/jiab576">10.1093/infdis/jiab576</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35301540" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Characterization%20of%20human%20immunodeficiency%20virus%20%28HIV%29%20infections%20in%20women%20who%20received%20injectable%20cabotegravir%20or%20tenofovir%20disoproxil%20fumarate%2Femtricitabine%20for%20HIV%20prevention%3A%20HPTN%20084.&amp;author=SH%20Eshleman&amp;author=JM%20Fogel&amp;author=E%20Piwowar-Manning&amp;publication_year=2022&amp;journal=J%20Infect%20Dis&amp;volume=225&amp;pages=1741-1749" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/infdis/jiab576" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/infdis/jiab576" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r22">22.</a><div class="reference-content">Landovitz
         R﻿, Donnell
         D﻿, Tran
         H﻿, 
     et al.  Updated efficacy, safety, and case studies in HPTN 083: CAB-LA vs TDF/FTC for PrEP [Abstract 96] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Top Antiv Med</i>. 2022;30(1 suppl):37.<a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Updated%20efficacy%2C%20safety%2C%20and%20case%20studies%20in%20HPTN%20083%3A%20CAB-LA%20vs%20TDF%2FFTC%20for%20PrEP%20%5BAbstract%2096%5D%20in%20special%20issue%3A%20Abstracts%20From%20the%202022%20Conference%20on%20Retroviruses%20and%20Opportunistic%20Infections.&amp;author=R%20Landovitz&amp;author=D%20Donnell&amp;author=H%20Tran&amp;publication_year=2022&amp;journal=Top%20Antiv%20Med&amp;volume=30&amp;pages=37" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r23">23.</a><div class="reference-content">Department of Health and Human Services. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. ClinicalInfo. Updated March 17, 2022. Accessed November 9, 2022. <a href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new-guidelines?view=full">https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new-guidelines?view=full</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r24">24.</a><div class="reference-content">Zash
         R﻿, Holmes
         LB﻿, Diseko
         M﻿, 
     et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana. Poster presented at: 11th IAS Conference on HIV Science; July 18-21, 2022.</div></div><div class="reference"><a class="reference-number" id="jsc220007r25">25.</a><div class="reference-content">Lockman
         S﻿, Brummel
         SS﻿, Ziemba
         L﻿, 
     et al; IMPAACT 2010/VESTED Study Team and Investigators.  Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet</i>. 2021;397(10281):1276-1292. doi:<a href="http://dx.doi.org/10.1016/S0140-6736(21)00314-7">10.1016/S0140-6736(21)00314-7</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33812487" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Efficacy%20and%20safety%20of%20dolutegravir%20with%20emtricitabine%20and%20tenofovir%20alafenamide%20fumarate%20or%20tenofovir%20disoproxil%20fumarate%2C%20and%20efavirenz%2C%20emtricitabine%2C%20and%20tenofovir%20disoproxil%20fumarate%20HIV%20antiretroviral%20therapy%20regimens%20started%20in%20pregnancy%20%28IMPAACT%202010%2FVESTED%29%3A%20a%20multicentre%2C%20open-label%2C%20randomised%2C%20controlled%2C%20phase%203%20trial.&amp;author=S%20Lockman&amp;author=SS%20Brummel&amp;author=L%20Ziemba&amp;publication_year=2021&amp;journal=Lancet&amp;volume=397&amp;pages=1276-1292" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S0140-6736(21)00314-7" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S0140-6736(21)00314-7" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r26">26.</a><div class="reference-content">Stranix-Chibanda
         L﻿, Ziemba
         L﻿, Brummer
         S﻿, 
     et al.  Growth of infants with perinatal exposure to maternal DTG vs EFV and TDF vs TAF [Abstract 30] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Top Antiv Med</i>. 2022;30(1 suppl):10-11.<a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Growth%20of%20infants%20with%20perinatal%20exposure%20to%20maternal%20DTG%20vs%20EFV%20and%20TDF%20vs%20TAF%20%5BAbstract%2030%5D%20in%20special%20issue%3A%20Abstracts%20From%20the%202022%20Conference%20on%20Retroviruses%20and%20Opportunistic%20Infections.&amp;author=L%20Stranix-Chibanda&amp;author=L%20Ziemba&amp;author=S%20Brummer&amp;publication_year=2022&amp;journal=Top%20Antiv%20Med&amp;volume=30&amp;pages=10-11" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r27">27.</a><div class="reference-content">Patel
         K﻿, Huo
         Y﻿, Jao
         J﻿, 
     et al; Pediatric HIV/AIDS Cohort Study; Swiss Mother and Child HIV Cohort Study.  Dolutegravir in pregnancy as compared with current HIV regimens in the United States. ﻿ <i xmlns:helper="urn:XsltStringHelper"> N Engl J Med</i>. 2022;387(9):799-809. doi:<a href="http://dx.doi.org/10.1056/NEJMoa2200600">10.1056/NEJMoa2200600</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/36053505" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Dolutegravir%20in%20pregnancy%20as%20compared%20with%20current%20HIV%20regimens%20in%20the%20United%20States.&amp;author=K%20Patel&amp;author=Y%20Huo&amp;author=J%20Jao&amp;publication_year=2022&amp;journal=N%20Engl%20J%20Med&amp;volume=387&amp;pages=799-809" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMoa2200600" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMoa2200600" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r28">28.</a><div class="reference-content">Burke
         RM﻿, Rickman
         HM﻿, Singh
         V﻿, 
     et al.  What is the optimum time to start antiretroviral therapy in people with HIV and tuberculosis coinfection? a systematic review and meta-analysis. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Int AIDS Soc</i>. 2021;24(7):e25772. doi:<a href="http://dx.doi.org/10.1002/jia2.25772">10.1002/jia2.25772</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34289243" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=What%20is%20the%20optimum%20time%20to%20start%20antiretroviral%20therapy%20in%20people%20with%20HIV%20and%20tuberculosis%20coinfection%3F%20a%20systematic%20review%20and%20meta-analysis.&amp;author=RM%20Burke&amp;author=HM%20Rickman&amp;author=V%20Singh&amp;publication_year=2021&amp;journal=J%20Int%20AIDS%20Soc&amp;volume=24&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1002/jia2.v24.7" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1002/jia2.v24.7" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r29">29.</a><div class="reference-content">Ingle
         SM﻿, Miro
         JM﻿, Furrer
         H﻿, 
     et al. Impact of ART on mortality in cryptococcal meningitis patients: high-income settings. Poster presented at: 22nd Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, Washington.</div></div><div class="reference"><a class="reference-number" id="jsc220007r30">30.</a><div class="reference-content">National Institutes of Health, Centers for Disease Control and Prevention, and HIV Medicine Association of the Infectious Disease Society of America. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Updated September 28, 2022. Accessed November 9, 2022. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections</a>﻿ <a href="https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection">https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r31">31.</a><div class="reference-content">Dooley
         KE﻿, Kaplan
         R﻿, Mwelase
         N﻿, 
     et al; International Study of Patients With HIV on Rifampicin ING Study Group.  Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2020;70(4):549-556.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/30918967" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Dolutegravir-based%20antiretroviral%20therapy%20for%20patients%20coinfected%20with%20tuberculosis%20and%20human%20immunodeficiency%20virus%3A%20a%20multicenter%2C%20noncomparative%2C%20open-label%2C%20randomized%20trial.&amp;author=KE%20Dooley&amp;author=R%20Kaplan&amp;author=N%20Mwelase&amp;publication_year=2020&amp;journal=Clin%20Infect%20Dis&amp;volume=70&amp;pages=549-556" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r32">32.</a><div class="reference-content">De Castro
         N﻿, Marcy
         O﻿, Chazallon
         C﻿, 
     et al; ANRS 12300 Reflate TB2 Study Group.  Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet Infect Dis</i>. 2021;21(6):813-822. doi:<a href="http://dx.doi.org/10.1016/S1473-3099(20)30869-0">10.1016/S1473-3099(20)30869-0</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33667406" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Standard%20dose%20raltegravir%20or%20efavirenz-based%20antiretroviral%20treatment%20for%20patients%20co-infected%20with%20HIV%20and%20tuberculosis%20%28ANRS%2012%20300%20Reflate%20TB%202%29%3A%20an%20open-label%2C%20non-inferiority%2C%20randomised%2C%20phase%203%20trial.&amp;author=N%20De Castro&amp;author=O%20Marcy&amp;author=C%20Chazallon&amp;publication_year=2021&amp;journal=Lancet%20Infect%20Dis&amp;volume=21&amp;pages=813-822" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S1473-3099(20)30869-0" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S1473-3099(20)30869-0" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r33">33.</a><div class="reference-content">Grinsztejn
         B﻿, Hosseinipour
         MC﻿, Ribaudo
         HJ﻿, 
     et al; HPTN 052-ACTG Study Team.  Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet Infect Dis</i>. 2014;14(4):281-290. doi:<a href="http://dx.doi.org/10.1016/S1473-3099(13)70692-3">10.1016/S1473-3099(13)70692-3</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/24602844" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20early%20versus%20delayed%20initiation%20of%20antiretroviral%20treatment%20on%20clinical%20outcomes%20of%20HIV-1%20infection%3A%20results%20from%20the%20phase%203%20HPTN%20052%20randomised%20controlled%20trial.&amp;author=B%20Grinsztejn&amp;author=MC%20Hosseinipour&amp;author=HJ%20Ribaudo&amp;publication_year=2014&amp;journal=Lancet%20Infect%20Dis&amp;volume=14&amp;pages=281-290" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S1473-3099(13)70692-3" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S1473-3099(13)70692-3" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r34">34.</a><div class="reference-content">Marcy
         O﻿, De Castro
         N﻿, Chazallon
         C﻿, 
     et al. Adherence and factors associated with virologic success in HIV-1 infected adults witH tuberculosis receiving raltegravir or efavirenz in the ANRS 12300 Reflate TB2 trial. Poster presented at: International AIDS Conference; 2020.</div></div><div class="reference"><a class="reference-number" id="jsc220007r35">35.</a><div class="reference-content">Osiyemi
         O﻿, De Wit
         S﻿, Ajana
         F﻿, 
     et al.  Efficacy and safety of switching to dolutegravir/lamivudine (DTG/3TC) versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with HIV-1: results through week 144 from the phase 3, non-inferiority TANGO randomized trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2022;75(6):975-986. doi:<a href="http://dx.doi.org/10.1093/cid/ciac036">10.1093/cid/ciac036</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Efficacy%20and%20safety%20of%20switching%20to%20dolutegravir%2Flamivudine%20%28DTG%2F3TC%29%20versus%20continuing%20a%20tenofovir%20alafenamide-based%203-%20or%204-drug%20regimen%20for%20maintenance%20of%20virologic%20suppression%20in%20adults%20living%20with%20HIV-1%3A%20results%20through%20week%20144%20from%20the%20phase%203%2C%20non-inferiority%20TANGO%20randomized%20trial.&amp;author=O%20Osiyemi&amp;author=S%20De Wit&amp;author=F%20Ajana&amp;publication_year=2022&amp;journal=Clin%20Infect%20Dis&amp;volume=75&amp;pages=975-986" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciac036" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciac036" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r36">36.</a><div class="reference-content">Llibre
         JM﻿, Brites
         C﻿, Cheng
         CY﻿, 
     et al.  Efficacy and safety of switching to the 2-drug regimen dolutegravir/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with HIV-1: week 48 results from the phase 3, non-inferiority SALSA randomized trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. Published online March 2, 2022. doi:<a href="http://dx.doi.org/10.1093/cid/ciac130">10.1093/cid/ciac130</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35235656" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Efficacy%20and%20safety%20of%20switching%20to%20the%202-drug%20regimen%20dolutegravir%2Flamivudine%20versus%20continuing%20a%203-%20or%204-drug%20regimen%20for%20maintaining%20virologic%20suppression%20in%20adults%20living%20with%20HIV-1%3A%20week%2048%20results%20from%20the%20phase%203%2C%20non-inferiority%20SALSA%20randomized%20trial.&amp;author=JM%20Llibre&amp;author=C%20Brites&amp;author=CY%20Cheng&amp;publication_year=2022&amp;journal=Clin%20Infect%20Dis&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciac130" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciac130" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r37">37.</a><div class="reference-content">van Wyk
         J﻿, Orkin
         C﻿, Rubio
         R﻿, 
     et al.  Brief report: durable suppression and low rate of virologic failure 3 years after switch to dolutegravir + rilpivirine 2-drug regimen: 148-week results from the SWORD-1 and SWORD-2 randomized clinical trials. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Acquir Immune Defic Syndr</i>. 2020;85(3):325-330. doi:<a href="http://dx.doi.org/10.1097/QAI.0000000000002449">10.1097/QAI.0000000000002449</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32675772" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Brief%20report%3A%20durable%20suppression%20and%20low%20rate%20of%20virologic%20failure%203%20years%20after%20switch%20to%20dolutegravir%20%2B%20rilpivirine%202-drug%20regimen%3A%20148-week%20results%20from%20the%20SWORD-1%20and%20SWORD-2%20randomized%20clinical%20trials.&amp;author=J%20van Wyk&amp;author=C%20Orkin&amp;author=R%20Rubio&amp;publication_year=2020&amp;journal=J%20Acquir%20Immune%20Defic%20Syndr&amp;volume=85&amp;pages=325-330" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAI.0000000000002449" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAI.0000000000002449" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r38">38.</a><div class="reference-content">Greenberg
         L﻿, Ryom
         L﻿, Neesgaard
         B﻿, 
     et al; RESPOND (International Cohort Consortium of Infectious Diseases) Study Group.  Clinical outcomes of 2-drug regimens vs 3-drug regimens in antiretroviral treatment-experienced people living with human immunodeficiency virus. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2021;73(7):e2323-e2333. doi:<a href="http://dx.doi.org/10.1093/cid/ciaa1878">10.1093/cid/ciaa1878</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33354721" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Clinical%20outcomes%20of%202-drug%20regimens%20vs%203-drug%20regimens%20in%20antiretroviral%20treatment-experienced%20people%20living%20with%20human%20immunodeficiency%20virus.&amp;author=L%20Greenberg&amp;author=L%20Ryom&amp;author=B%20Neesgaard&amp;publication_year=2021&amp;journal=Clin%20Infect%20Dis&amp;volume=73&amp;pages=e2323-e2333" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciaa1878" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciaa1878" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r39">39.</a><div class="reference-content">van Wyk
         J﻿, Ajana
         F﻿, Bisshop
         F﻿, 
     et al.  Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2020;71(8):1920-1929. doi:<a href="http://dx.doi.org/10.1093/cid/ciz1243">10.1093/cid/ciz1243</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31905383" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Efficacy%20and%20safety%20of%20switching%20to%20dolutegravir%2Flamivudine%20fixed-dose%202-drug%20regimen%20vs%20continuing%20a%20tenofovir%20alafenamide-based%203-%20or%204-drug%20regimen%20for%20maintenance%20of%20virologic%20suppression%20in%20adults%20living%20with%20human%20immunodeficiency%20virus%20type%201%3A%20phase%203%2C%20randomized%2C%20noninferiority%20TANGO%20study.&amp;author=J%20van Wyk&amp;author=F%20Ajana&amp;author=F%20Bisshop&amp;publication_year=2020&amp;journal=Clin%20Infect%20Dis&amp;volume=71&amp;pages=1920-1929" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciz1243" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciz1243" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r40">40.</a><div class="reference-content">Underwood
         M﻿, Osiyemi
         O﻿, Rubio
         R﻿, 
     et al.  Archived resistance and response to &lt;40 c/mL &amp; TND–DTG/3TC FDC at week 48 in SALSA [Abstract 481] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Top Antiv Med</i>. 2022;30(1 suppl):184.<a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Archived%20resistance%20and%20response%20to%20%3C40%20c%2FmL%20%26%20TND%E2%80%93DTG%2F3TC%20FDC%20at%20week%2048%20in%20SALSA%20%5BAbstract%20481%5D%20in%20special%20issue%3A%20Abstracts%20From%20the%202022%20Conference%20on%20Retroviruses%20and%20Opportunistic%20Infections.&amp;author=M%20Underwood&amp;author=O%20Osiyemi&amp;author=R%20Rubio&amp;publication_year=2022&amp;journal=Top%20Antiv%20Med&amp;volume=30&amp;pages=184" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r41">41.</a><div class="reference-content">Marks
         K﻿, Kang
         M﻿, Umbleja
         T﻿, 
     et al. High HBsAb seroprotection achieved 4 weeks after 3 doses of HepB-CpG vaccine in people living with HIV (PLWH) without Prior HBV vaccination (ACTG A5379 Group B Preliminary Results). Poster presented at: ID Week; October 11-15, 2022; Washington, DC.</div></div><div class="reference"><a class="reference-number" id="jsc220007r42">42.</a><div class="reference-content">Ombajo
         LA﻿, Penner
         J﻿, Nkuranga
         J﻿, 
     et al.  A randomized trial of switching treatment-experienced adults from PI/r to DTG [Abstract 136] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Top Antiv Med</i>. 2022;30(1 suppl):52.<a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20randomized%20trial%20of%20switching%20treatment-experienced%20adults%20from%20PI%2Fr%20to%20DTG%20%5BAbstract%20136%5D%20in%20special%20issue%3A%20Abstracts%20From%20the%202022%20Conference%20on%20Retroviruses%20and%20Opportunistic%20Infections.&amp;author=LA%20Ombajo&amp;author=J%20Penner&amp;author=J%20Nkuranga&amp;publication_year=2022&amp;journal=Top%20Antiv%20Med&amp;volume=30&amp;pages=52" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r43">43.</a><div class="reference-content">Sax
         PE﻿, Rockstroh
         JK﻿, Luetkemeyer
         AF﻿, 
     et al; GS-US-380–4030 Investigators.  Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2021;73(2):e485-e493. doi:<a href="http://dx.doi.org/10.1093/cid/ciaa988">10.1093/cid/ciaa988</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32668455" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Switching%20to%20bictegravir%2C%20emtricitabine%2C%20and%20tenofovir%20alafenamide%20in%20virologically%20suppressed%20adults%20with%20human%20immunodeficiency%20virus.&amp;author=PE%20Sax&amp;author=JK%20Rockstroh&amp;author=AF%20Luetkemeyer&amp;publication_year=2021&amp;journal=Clin%20Infect%20Dis&amp;volume=73&amp;pages=e485-e493" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciaa988" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciaa988" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r44">44.</a><div class="reference-content">Hagins
         D﻿, Kumar
         P﻿, Saag
         M﻿, 
     et al; BRAAVE2020 Investigators.  Switching to bictegravir/emtricitabine/tenofovir alafenamide in Black Americans with HIV-1: a randomized phase 3b, multicenter, open-label study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Acquir Immune Defic Syndr</i>. 2021;88(1):86-95. doi:<a href="http://dx.doi.org/10.1097/QAI.0000000000002731">10.1097/QAI.0000000000002731</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34397746" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Switching%20to%20bictegravir%2Femtricitabine%2Ftenofovir%20alafenamide%20in%20Black%20Americans%20with%20HIV-1%3A%20a%20randomized%20phase%203b%2C%20multicenter%2C%20open-label%20study.&amp;author=D%20Hagins&amp;author=P%20Kumar&amp;author=M%20Saag&amp;publication_year=2021&amp;journal=J%20Acquir%20Immune%20Defic%20Syndr&amp;volume=88&amp;pages=86-95" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAI.0000000000002731" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAI.0000000000002731" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r45">45.</a><div class="reference-content">Sax
         PE﻿, Andreatta
         K﻿, Molina
         JM﻿, 
     et al.  High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2022;36(11):1511-1520. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000003244">10.1097/QAD.0000000000003244</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35466963" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=High%20efficacy%20of%20switching%20to%20bictegravir%2Femtricitabine%2Ftenofovir%20alafenamide%20in%20people%20with%20suppressed%20HIV%20and%20preexisting%20M184V%2FI.&amp;author=PE%20Sax&amp;author=K%20Andreatta&amp;author=JM%20Molina&amp;publication_year=2022&amp;journal=AIDS&amp;volume=36&amp;pages=1511-1520" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000003244" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000003244" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r46">46.</a><div class="reference-content">Aboud
         M﻿, Kaplan
         R﻿, Lombaard
         J﻿, 
     et al.  Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet Infect Dis</i>. 2019;19(3):253-264. doi:<a href="http://dx.doi.org/10.1016/S1473-3099(19)30036-2">10.1016/S1473-3099(19)30036-2</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/30732940" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Dolutegravir%20versus%20ritonavir-boosted%20lopinavir%20both%20with%20dual%20nucleoside%20reverse%20transcriptase%20inhibitor%20therapy%20in%20adults%20with%20HIV-1%20infection%20in%20whom%20first-line%20therapy%20has%20failed%20%28DAWNING%29%3A%20an%20open-label%2C%20non-inferiority%2C%20phase%203b%20trial.&amp;author=M%20Aboud&amp;author=R%20Kaplan&amp;author=J%20Lombaard&amp;publication_year=2019&amp;journal=Lancet%20Infect%20Dis&amp;volume=19&amp;pages=253-264" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S1473-3099(19)30036-2" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S1473-3099(19)30036-2" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r47">47.</a><div class="reference-content">Paton
         NI﻿, Musaazi
         J﻿, Kityo
         C﻿, 
     et al; NADIA Trial Team.  Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2022;9(6):e381-e393. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(22)00092-3">10.1016/S2352-3018(22)00092-3</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35460601" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Efficacy%20and%20safety%20of%20dolutegravir%20or%20darunavir%20in%20combination%20with%20lamivudine%20plus%20either%20zidovudine%20or%20tenofovir%20for%20second-line%20treatment%20of%20HIV%20infection%20%28NADIA%29%3A%20week%2096%20results%20from%20a%20prospective%2C%20multicentre%2C%20open-label%2C%20factorial%2C%20randomised%2C%20non-inferiority%20trial.&amp;author=NI%20Paton&amp;author=J%20Musaazi&amp;author=C%20Kityo&amp;publication_year=2022&amp;journal=Lancet%20HIV&amp;volume=9&amp;pages=e381-e393" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(22)00092-3" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(22)00092-3" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r48">48.</a><div class="reference-content">Rizzardini
         G﻿, Overton
         ET﻿, Orkin
         C﻿, 
     et al.  Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Acquir Immune Defic Syndr</i>. 2020;85(4):498-506. doi:<a href="http://dx.doi.org/10.1097/QAI.0000000000002466">10.1097/QAI.0000000000002466</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33136751" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Long-acting%20injectable%20cabotegravir%20%2B%20rilpivirine%20for%20HIV%20maintenance%20therapy%3A%20week%2048%20pooled%20analysis%20of%20phase%203%20ATLAS%20and%20FLAIR%20trials.&amp;author=G%20Rizzardini&amp;author=ET%20Overton&amp;author=C%20Orkin&amp;publication_year=2020&amp;journal=J%20Acquir%20Immune%20Defic%20Syndr&amp;volume=85&amp;pages=498-506" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAI.0000000000002466" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAI.0000000000002466" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r49">49.</a><div class="reference-content">Overton
         ET﻿, Richmond
         G﻿, Rizzardini
         G﻿, 
     et al.  Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet</i>. 2021;396(10267):1994-2005. doi:<a href="http://dx.doi.org/10.1016/S0140-6736(20)32666-0">10.1016/S0140-6736(20)32666-0</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33308425" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Long-acting%20cabotegravir%20and%20rilpivirine%20dosed%20every%202%20months%20in%20adults%20with%20HIV-1%20infection%20%28ATLAS-2M%29%2C%2048-week%20results%3A%20a%20randomised%2C%20multicentre%2C%20open-label%2C%20phase%203b%2C%20non-inferiority%20study.&amp;author=ET%20Overton&amp;author=G%20Richmond&amp;author=G%20Rizzardini&amp;publication_year=2021&amp;journal=Lancet&amp;volume=396&amp;pages=1994-2005" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S0140-6736(20)32666-0" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S0140-6736(20)32666-0" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r50">50.</a><div class="reference-content">Murray
         M﻿, Antela
         A﻿, Mills
         A﻿, 
     et al.  Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48 weeks. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS Behav</i>. 2020;24(12):3533-3544. doi:<a href="http://dx.doi.org/10.1007/s10461-020-02929-8">10.1007/s10461-020-02929-8</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32447500" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Patient-reported%20outcomes%20in%20ATLAS%20and%20FLAIR%20participants%20on%20long-acting%20regimens%20of%20cabotegravir%20and%20rilpivirine%20over%2048%20weeks.&amp;author=M%20Murray&amp;author=A%20Antela&amp;author=A%20Mills&amp;publication_year=2020&amp;journal=AIDS%20Behav&amp;volume=24&amp;pages=3533-3544" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1007/s10461-020-02929-8" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1007/s10461-020-02929-8" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r51">51.</a><div class="reference-content">Orkin
         C﻿, Bernal Morell
         E﻿, Tan
         DHS﻿, 
     et al.  Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2021;8(11):e668-e678. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(21)00184-3">10.1016/S2352-3018(21)00184-3</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34656207" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Initiation%20of%20long-acting%20cabotegravir%20plus%20rilpivirine%20as%20direct-to-injection%20or%20with%20an%20oral%20lead-in%20in%20adults%20with%20HIV-1%20infection%3A%20week%20124%20results%20of%20the%20open-label%20phase%203%20FLAIR%20study.&amp;author=C%20Orkin&amp;author=E%20Bernal Morell&amp;author=DHS%20Tan&amp;publication_year=2021&amp;journal=Lancet%20HIV&amp;volume=8&amp;pages=e668-e678" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(21)00184-3" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(21)00184-3" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r52">52.</a><div class="reference-content">Ellis
         KE﻿, Nawas
         GT﻿, Chan
         C﻿, 
     et al.  Clinical outcomes following the use of archived proviral HIV-1 DNA genotype to guide antiretroviral therapy adjustment. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Open Forum Infect Dis</i>. 2019;7(1):ofz533. doi:<a href="http://dx.doi.org/10.1093/ofid/ofz533">10.1093/ofid/ofz533</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31915714" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Clinical%20outcomes%20following%20the%20use%20of%20archived%20proviral%20HIV-1%20DNA%20genotype%20to%20guide%20antiretroviral%20therapy%20adjustment.&amp;author=KE%20Ellis&amp;author=GT%20Nawas&amp;author=C%20Chan&amp;publication_year=2019&amp;journal=Open%20Forum%20Infect%20Dis&amp;volume=7&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/ofid/ofz533" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/ofid/ofz533" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r53">53.</a><div class="reference-content">Castagna
         A﻿, Maggiolo
         F﻿, Penco
         G﻿, 
     et al; VIKING-3 Study Group.  Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Infect Dis</i>. 2014;210(3):354-362. doi:<a href="http://dx.doi.org/10.1093/infdis/jiu051">10.1093/infdis/jiu051</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/24446523" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Dolutegravir%20in%20antiretroviral-experienced%20patients%20with%20raltegravir-%20and%2For%20elvitegravir-resistant%20HIV-1%3A%2024-week%20results%20of%20the%20phase%20III%20VIKING-3%20study.&amp;author=A%20Castagna&amp;author=F%20Maggiolo&amp;author=G%20Penco&amp;publication_year=2014&amp;journal=J%20Infect%20Dis&amp;volume=210&amp;pages=354-362" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/infdis/jiu051" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/infdis/jiu051" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r54">54.</a><div class="reference-content">Fostemsavir [prescribing information]. ViiV Healthcare; 2020.</div></div><div class="reference"><a class="reference-number" id="jsc220007r55">55.</a><div class="reference-content">Kamelian
         K﻿, Lepik
         KJ﻿, Chau
         W﻿, 
     et al.  Prevalence of human immunodeficiency virus-1 integrase strand transfer inhibitor resistance in British Columbia, Canada between 2009 and 2016: a longitudinal analysis. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Open Forum Infect Dis</i>. 2019;6(3):ofz060. doi:<a href="http://dx.doi.org/10.1093/ofid/ofz060">10.1093/ofid/ofz060</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/30895202" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Prevalence%20of%20human%20immunodeficiency%20virus-1%20integrase%20strand%20transfer%20inhibitor%20resistance%20in%20British%20Columbia%2C%20Canada%20between%202009%20and%202016%3A%20a%20longitudinal%20analysis.&amp;author=K%20Kamelian&amp;author=KJ%20Lepik&amp;author=W%20Chau&amp;publication_year=2019&amp;journal=Open%20Forum%20Infect%20Dis&amp;volume=6&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/ofid/ofz060" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/ofid/ofz060" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r56">56.</a><div class="reference-content">Koullias
         Y﻿, Sax
         PE﻿, Fields
         NF﻿, Walensky
         RP﻿, Hyle
         EP﻿.  Should we be testing for baseline integrase resistance in patients newly diagnosed with human immunodeficiency virus? ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2017;65(8):1274-1281. doi:<a href="http://dx.doi.org/10.1093/cid/cix542">10.1093/cid/cix542</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/28605418" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Should%20we%20be%20testing%20for%20baseline%20integrase%20resistance%20in%20patients%20newly%20diagnosed%20with%20human%20immunodeficiency%20virus%3F&amp;author=Y%20Koullias&amp;author=PE%20Sax&amp;author=NF%20Fields&amp;author=RP%20Walensky&amp;author=EP%20Hyle&amp;publication_year=2017&amp;journal=Clin%20Infect%20Dis&amp;volume=65&amp;pages=1274-1281" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/cix542" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/cix542" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r57">57.</a><div class="reference-content">Zhu
         J﻿, Rozada
         I﻿, David
         J﻿, 
     et al.  The potential impact of initiating antiretroviral therapy with integrase inhibitors on HIV transmission risk in British Columbia, Canada. ﻿ <i xmlns:helper="urn:XsltStringHelper"> EClinicalMedicine</i>. 2019;13:101-111. doi:<a href="http://dx.doi.org/10.1016/j.eclinm.2019.07.001">10.1016/j.eclinm.2019.07.001</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31517267" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20potential%20impact%20of%20initiating%20antiretroviral%20therapy%20with%20integrase%20inhibitors%20on%20HIV%20transmission%20risk%20in%20British%20Columbia%2C%20Canada.&amp;author=J%20Zhu&amp;author=I%20Rozada&amp;author=J%20David&amp;publication_year=2019&amp;journal=EClinicalMedicine&amp;volume=13&amp;pages=101-111" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.eclinm.2019.07.001" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.eclinm.2019.07.001" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r58">58.</a><div class="reference-content">Berenguer
         J﻿, Parrondo
         J﻿, Landovitz
         RJ﻿.  Mathematical modeling of HIV-1 transmission risk from condomless anal intercourse in HIV-infected MSM by the type of initial ART. ﻿ <i xmlns:helper="urn:XsltStringHelper"> PLoS One</i>. 2019;14(7):e0219802. doi:<a href="http://dx.doi.org/10.1371/journal.pone.0219802">10.1371/journal.pone.0219802</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31323075" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Mathematical%20modeling%20of%20HIV-1%20transmission%20risk%20from%20condomless%20anal%20intercourse%20in%20HIV-infected%20MSM%20by%20the%20type%20of%20initial%20ART.&amp;author=J%20Berenguer&amp;author=J%20Parrondo&amp;author=RJ%20Landovitz&amp;publication_year=2019&amp;journal=PLoS%20One&amp;volume=14&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1371/journal.pone.0219802" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1371/journal.pone.0219802" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r59">59.</a><div class="reference-content">Charpentier
         C﻿, Storto
         A﻿, Soulié
         C﻿, 
     et al.  Prevalence of genotypic baseline risk factors for cabotegravir   + rilpivirine failure among ARV-naive patients. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Antimicrob Chemother</i>. 2021;76(11):2983-2987. doi:<a href="http://dx.doi.org/10.1093/jac/dkab161">10.1093/jac/dkab161</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34015097" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Prevalence%20of%20genotypic%20baseline%20risk%20factors%20for%20cabotegravir%E2%80%89%E2%80%8A%E2%80%89%2B%E2%80%8Arilpivirine%20failure%20among%20ARV-naive%20patients.&amp;author=C%20Charpentier&amp;author=A%20Storto&amp;author=C%20Soulié&amp;publication_year=2021&amp;journal=J%20Antimicrob%20Chemother&amp;volume=76&amp;pages=2983-2987" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/jac/dkab161" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/jac/dkab161" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r60">60.</a><div class="reference-content">Sise
         ME﻿, Hirsch
         JS﻿, Canetta
         PA﻿, Herlitz
         L﻿, Mohan
         S﻿.  Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2015;29(8):941-946. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000000628">10.1097/QAD.0000000000000628</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/25784440" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Nonalbumin%20proteinuria%20predominates%20in%20biopsy-proven%20tenofovir%20nephrotoxicity.&amp;author=ME%20Sise&amp;author=JS%20Hirsch&amp;author=PA%20Canetta&amp;author=L%20Herlitz&amp;author=S%20Mohan&amp;publication_year=2015&amp;journal=AIDS&amp;volume=29&amp;pages=941-946" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000000628" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000000628" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r61">61.</a><div class="reference-content">Samarawickrama
         A﻿, Cai
         M﻿, Smith
         ER﻿, 
     et al.  Simultaneous measurement of urinary albumin and total protein may facilitate decision-making in HIV-infected patients with proteinuria. ﻿ <i xmlns:helper="urn:XsltStringHelper"> HIV Med</i>. 2012;13(9):526-532. doi:<a href="http://dx.doi.org/10.1111/j.1468-1293.2012.01003.x">10.1111/j.1468-1293.2012.01003.x</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/22413854" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Simultaneous%20measurement%20of%20urinary%20albumin%20and%20total%20protein%20may%20facilitate%20decision-making%20in%20HIV-infected%20patients%20with%20proteinuria.&amp;author=A%20Samarawickrama&amp;author=M%20Cai&amp;author=ER%20Smith&amp;publication_year=2012&amp;journal=HIV%20Med&amp;volume=13&amp;pages=526-532" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1111/j.1468-1293.2012.01003.x" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1111/j.1468-1293.2012.01003.x" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r62">62.</a><div class="reference-content">Joshi
         K﻿, Boettiger
         D﻿, Kerr
         S﻿, 
     et al.  Changes in renal function with long-term exposure to antiretroviral therapy in HIV-infected adults in Asia. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Pharmacoepidemiol Drug Saf</i>. 2018;27(11):1209-1216. doi:<a href="http://dx.doi.org/10.1002/pds.4657">10.1002/pds.4657</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/30246898" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Changes%20in%20renal%20function%20with%20long-term%20exposure%20to%20antiretroviral%20therapy%20in%20HIV-infected%20adults%20in%20Asia.&amp;author=K%20Joshi&amp;author=D%20Boettiger&amp;author=S%20Kerr&amp;publication_year=2018&amp;journal=Pharmacoepidemiol%20Drug%20Saf&amp;volume=27&amp;pages=1209-1216" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1002/pds.4657" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1002/pds.4657" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r63">63.</a><div class="reference-content">Kaboré
         NF﻿, Poda
         A﻿, Zoungrana
         J﻿, 
     et al.  Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting. ﻿ <i xmlns:helper="urn:XsltStringHelper"> BMC Nephrol</i>. 2019;20(1):155. doi:<a href="http://dx.doi.org/10.1186/s12882-019-1335-9">10.1186/s12882-019-1335-9</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31064340" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Chronic%20kidney%20disease%20and%20HIV%20in%20the%20era%20of%20antiretroviral%20treatment%3A%20findings%20from%20a%2010-year%20cohort%20study%20in%20a%20west%20African%20setting.&amp;author=NF%20Kaboré&amp;author=A%20Poda&amp;author=J%20Zoungrana&amp;publication_year=2019&amp;journal=BMC%20Nephrol&amp;volume=20&amp;pages=155" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1186/s12882-019-1335-9" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1186/s12882-019-1335-9" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r64">64.</a><div class="reference-content">Jotwani
         V﻿, Scherzer
         R﻿, Estrella
         MM﻿, 
     et al.  HIV infection, tenofovir, and urine α1-microglobulin: a cross-sectional analysis in the Multicenter AIDS Cohort Study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Am J Kidney Dis</i>. 2016;68(4):571-581. doi:<a href="http://dx.doi.org/10.1053/j.ajkd.2016.03.430">10.1053/j.ajkd.2016.03.430</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/27287300" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=HIV%20infection%2C%20tenofovir%2C%20and%20urine%20%CE%B11-microglobulin%3A%20a%20cross-sectional%20analysis%20in%20the%20Multicenter%20AIDS%20Cohort%20Study.&amp;author=V%20Jotwani&amp;author=R%20Scherzer&amp;author=MM%20Estrella&amp;publication_year=2016&amp;journal=Am%20J%20Kidney%20Dis&amp;volume=68&amp;pages=571-581" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1053/j.ajkd.2016.03.430" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1053/j.ajkd.2016.03.430" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r65">65.</a><div class="reference-content">Thompson
         MA﻿, Horberg
         MA﻿, Agwu
         AL﻿, 
     et al.  Primary care guidance for persons with human immunodeficiency virus: 2020 update by the HIV Medicine Association of the Infectious Diseases Society of America. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2021;73(11):e3572-e3605. doi:<a href="http://dx.doi.org/10.1093/cid/ciaa1391">10.1093/cid/ciaa1391</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33225349" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Primary%20care%20guidance%20for%20persons%20with%20human%20immunodeficiency%20virus%3A%202020%20update%20by%20the%20HIV%20Medicine%20Association%20of%20the%20Infectious%20Diseases%20Society%20of%20America.&amp;author=MA%20Thompson&amp;author=MA%20Horberg&amp;author=AL%20Agwu&amp;publication_year=2021&amp;journal=Clin%20Infect%20Dis&amp;volume=73&amp;pages=e3572-e3605" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciaa1391" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciaa1391" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r66">66.</a><div class="reference-content">Sax
         PE﻿, Erlandson
         KM﻿, Lake
         JE﻿, 
     et al.  Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2020;71(6):1379-1389. doi:<a href="http://dx.doi.org/10.1093/cid/ciz999">10.1093/cid/ciz999</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31606734" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Weight%20gain%20following%20initiation%20of%20antiretroviral%20therapy%3A%20risk%20factors%20in%20randomized%20comparative%20clinical%20trials.&amp;author=PE%20Sax&amp;author=KM%20Erlandson&amp;author=JE%20Lake&amp;publication_year=2020&amp;journal=Clin%20Infect%20Dis&amp;volume=71&amp;pages=1379-1389" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciz999" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciz999" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r67">67.</a><div class="reference-content">Surial
         B﻿, Mugglin
         C﻿, Calmy
         A﻿, 
     et al; Swiss HIV Cohort Study.  Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: a cohort study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Ann Intern Med</i>. 2021;174(6):758-767. doi:<a href="http://dx.doi.org/10.7326/M20-4853">10.7326/M20-4853</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33721521" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Weight%20and%20metabolic%20changes%20after%20switching%20from%20tenofovir%20disoproxil%20fumarate%20to%20tenofovir%20alafenamide%20in%20people%20living%20with%20HIV%3A%20a%20cohort%20study.&amp;author=B%20Surial&amp;author=C%20Mugglin&amp;author=A%20Calmy&amp;publication_year=2021&amp;journal=Ann%20Intern%20Med&amp;volume=174&amp;pages=758-767" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.7326/M20-4853" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.7326/M20-4853" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r68">68.</a><div class="reference-content">Ogbuagu
         O﻿, Ruane
         PJ﻿, Podzamczer
         D﻿, 
     et al; DISCOVER Study Team.  Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2021;8(7):e397-e407. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(21)00071-0">10.1016/S2352-3018(21)00071-0</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34197772" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Long-term%20safety%20and%20efficacy%20of%20emtricitabine%20and%20tenofovir%20alafenamide%20vs%20emtricitabine%20and%20tenofovir%20disoproxil%20fumarate%20for%20HIV-1%20pre-exposure%20prophylaxis%3A%20week%2096%20results%20from%20a%20randomised%2C%20double-blind%2C%20placebo-controlled%2C%20phase%203%20trial.&amp;author=O%20Ogbuagu&amp;author=PJ%20Ruane&amp;author=D%20Podzamczer&amp;publication_year=2021&amp;journal=Lancet%20HIV&amp;volume=8&amp;pages=e397-e407" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(21)00071-0" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(21)00071-0" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r69">69.</a><div class="reference-content">Bourgi
         K﻿, Jenkins
         CA﻿, Rebeiro
         PF﻿, 
     et al; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).  Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Int AIDS Soc</i>. 2020;23(4):e25484. doi:<a href="http://dx.doi.org/10.1002/jia2.25484">10.1002/jia2.25484</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32294337" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Weight%20gain%20among%20treatment-na%C3%AFve%20persons%20with%20HIV%20starting%20integrase%20inhibitors%20compared%20to%20non-nucleoside%20reverse%20transcriptase%20inhibitors%20or%20protease%20inhibitors%20in%20a%20large%20observational%20cohort%20in%20the%20United%20States%20and%20Canada.&amp;author=K%20Bourgi&amp;author=CA%20Jenkins&amp;author=PF%20Rebeiro&amp;publication_year=2020&amp;journal=J%20Int%20AIDS%20Soc&amp;volume=23&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1002/jia2.v23.4" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1002/jia2.v23.4" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r70">70.</a><div class="reference-content">Mallon
         PW﻿, Brunet
         L﻿, Hsu
         RK﻿, 
     et al.  Weight gain before and after switch from TDF to TAF in a U.S. cohort study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Int AIDS Soc</i>. 2021;24(4):e25702. doi:<a href="http://dx.doi.org/10.1002/jia2.25702">10.1002/jia2.25702</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33838004" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Weight%20gain%20before%20and%20after%20switch%20from%20TDF%20to%20TAF%20in%20a%20U.S.%20cohort%20study.&amp;author=PW%20Mallon&amp;author=L%20Brunet&amp;author=RK%20Hsu&amp;publication_year=2021&amp;journal=J%20Int%20AIDS%20Soc&amp;volume=24&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1002/jia2.v24.4" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1002/jia2.v24.4" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r71">71.</a><div class="reference-content">Venter
         WDF﻿, Sokhela
         S﻿, Simmons
         B﻿, 
     et al.  Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2020;7(10):e666-e676. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(20)30241-1">10.1016/S2352-3018(20)30241-1</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33010240" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Dolutegravir%20with%20emtricitabine%20and%20tenofovir%20alafenamide%20or%20tenofovir%20disoproxil%20fumarate%20versus%20efavirenz%2C%20emtricitabine%2C%20and%20tenofovir%20disoproxil%20fumarate%20for%20initial%20treatment%20of%20HIV-1%20infection%20%28ADVANCE%29%3A%20week%2096%20results%20from%20a%20randomised%2C%20phase%203%2C%20non-inferiority%20trial.&amp;author=WDF%20Venter&amp;author=S%20Sokhela&amp;author=B%20Simmons&amp;publication_year=2020&amp;journal=Lancet%20HIV&amp;volume=7&amp;pages=e666-e676" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(20)30241-1" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(20)30241-1" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r72">72.</a><div class="reference-content">Bischoff
         J﻿, Gu
         W﻿, Schwarze-Zander
         C﻿, 
     et al.  Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART). ﻿ <i xmlns:helper="urn:XsltStringHelper"> EClinicalMedicine</i>. 2021;40:101116. doi:<a href="http://dx.doi.org/10.1016/j.eclinm.2021.101116">10.1016/j.eclinm.2021.101116</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34522873" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Stratifying%20the%20risk%20of%20NAFLD%20in%20patients%20with%20HIV%20under%20combination%20antiretroviral%20therapy%20%28cART%29.&amp;author=J%20Bischoff&amp;author=W%20Gu&amp;author=C%20Schwarze-Zander&amp;publication_year=2021&amp;journal=EClinicalMedicine&amp;volume=40&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.eclinm.2021.101116" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.eclinm.2021.101116" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r73">73.</a><div class="reference-content">Gorwood
         J﻿, Bourgeois
         C﻿, Pourcher
         V﻿, 
     et al.  The integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in human/simian adipose tissue and human adipocytes. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2020;71(10):e549-e560. doi:<a href="http://dx.doi.org/10.1093/cid/ciaa259">10.1093/cid/ciaa259</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32166319" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20integrase%20inhibitors%20dolutegravir%20and%20raltegravir%20exert%20proadipogenic%20and%20profibrotic%20effects%20and%20induce%20insulin%20resistance%20in%20human%2Fsimian%20adipose%20tissue%20and%20human%20adipocytes.&amp;author=J%20Gorwood&amp;author=C%20Bourgeois&amp;author=V%20Pourcher&amp;publication_year=2020&amp;journal=Clin%20Infect%20Dis&amp;volume=71&amp;pages=e549-e560" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciaa259" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciaa259" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r74">74.</a><div class="reference-content">González-Cordón
         A﻿, Assoumou
         L﻿, Moyle
         G﻿, 
     et al; NEAT022 Study Group.  Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Antimicrob Chemother</i>. 2021;76(9):2380-2393. doi:<a href="http://dx.doi.org/10.1093/jac/dkab158">10.1093/jac/dkab158</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34120186" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Switching%20from%20boosted%20PIs%20to%20dolutegravir%20decreases%20soluble%20CD14%20and%20adiponectin%20in%20high%20cardiovascular%20risk%20people%20living%20with%20HIV.&amp;author=A%20González-Cordón&amp;author=L%20Assoumou&amp;author=G%20Moyle&amp;publication_year=2021&amp;journal=J%20Antimicrob%20Chemother&amp;volume=76&amp;pages=2380-2393" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/jac/dkab158" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/jac/dkab158" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r75">75.</a><div class="reference-content">Leonard
         MA﻿, Cindi
         Z﻿, Bradford
         Y﻿, 
     et al.  Efavirenz pharmacogenetics and weight gain following switch to integrase inhibitor-containing regimens. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2021;73(7):e2153-e2163. doi:<a href="http://dx.doi.org/10.1093/cid/ciaa1219">10.1093/cid/ciaa1219</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32829410" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Efavirenz%20pharmacogenetics%20and%20weight%20gain%20following%20switch%20to%20integrase%20inhibitor-containing%20regimens.&amp;author=MA%20Leonard&amp;author=Z%20Cindi&amp;author=Y%20Bradford&amp;publication_year=2021&amp;journal=Clin%20Infect%20Dis&amp;volume=73&amp;pages=e2153-e2163" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciaa1219" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciaa1219" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r76">76.</a><div class="reference-content">Plum
         PE﻿, Maes
         N﻿, Sauvage
         AS﻿, 
     et al.  Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> BMC Infect Dis</i>. 2021;21(1):910. doi:<a href="http://dx.doi.org/10.1186/s12879-021-06479-9">10.1186/s12879-021-06479-9</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34488664" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Impact%20of%20switch%20from%20tenofovir%20disoproxil%20fumarate-based%20regimens%20to%20tenofovir%20alafenamide-based%20regimens%20on%20lipid%20profile%2C%20weight%20gain%20and%20cardiovascular%20risk%20score%20in%20people%20living%20with%20HIV.&amp;author=PE%20Plum&amp;author=N%20Maes&amp;author=AS%20Sauvage&amp;publication_year=2021&amp;journal=BMC%20Infect%20Dis&amp;volume=21&amp;pages=910" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1186/s12879-021-06479-9" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1186/s12879-021-06479-9" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r77">77.</a><div class="reference-content">Silverberg
         MJ﻿, Lyass
         A﻿, Hurley
         L﻿, 
     et al.  Trends in myocardial infarction risk by HIV status in 2 US healthcare systems [Abstract 39] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Top Antiv Med</i>. 2022;30(1 suppl):15.<a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Trends%20in%20myocardial%20infarction%20risk%20by%20HIV%20status%20in%202%20US%20healthcare%20systems%20%5BAbstract%2039%5D%20in%20special%20issue%3A%20Abstracts%20From%20the%202022%20Conference%20on%20Retroviruses%20and%20Opportunistic%20Infections.&amp;author=MJ%20Silverberg&amp;author=A%20Lyass&amp;author=L%20Hurley&amp;publication_year=2022&amp;journal=Top%20Antiv%20Med&amp;volume=30&amp;pages=15" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r78">78.</a><div class="reference-content">Nolan
         NS﻿, Adamson
         S﻿, Reeds
         D﻿, O’Halloran
         JA﻿.  Bictegravir-based antiretroviral therapy-associated accelerated hyperglycemia and diabetes mellitus. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Open Forum Infect Dis</i>. 2021;8(5):ofab077. doi:<a href="http://dx.doi.org/10.1093/ofid/ofab077">10.1093/ofid/ofab077</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33981777" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Bictegravir-based%20antiretroviral%20therapy-associated%20accelerated%20hyperglycemia%20and%20diabetes%20mellitus.&amp;author=NS%20Nolan&amp;author=S%20Adamson&amp;author=D%20Reeds&amp;author=JA%20O’Halloran&amp;publication_year=2021&amp;journal=Open%20Forum%20Infect%20Dis&amp;volume=8&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/ofid/ofab077" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/ofid/ofab077" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r79">79.</a><div class="reference-content">O’Halloran
         JA﻿, Sahrmann
         J﻿, Parra-Rodriguez
         L﻿, 
     et al.  Integrase strand transfer inhibitors are associated with incident diabetes mellitus in people with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. Published online May 6, 2022. doi:<a href="http://dx.doi.org/10.1093/cid/ciac355">10.1093/cid/ciac355</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35521785" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Integrase%20strand%20transfer%20inhibitors%20are%20associated%20with%20incident%20diabetes%20mellitus%20in%20people%20with%20HIV.&amp;author=JA%20O’Halloran&amp;author=J%20Sahrmann&amp;author=L%20Parra-Rodriguez&amp;publication_year=2022&amp;journal=Clin%20Infect%20Dis&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciac355" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciac355" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r80">80.</a><div class="reference-content">Summers
         NA﻿, Lahiri
         CD﻿, Angert
         CD﻿, 
     et al.  Metabolic changes associated with the use of integrase strand transfer inhibitors among virally controlled women. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Acquir Immune Defic Syndr</i>. 2020;85(3):355-362. doi:<a href="http://dx.doi.org/10.1097/QAI.0000000000002447">10.1097/QAI.0000000000002447</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33060420" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Metabolic%20changes%20associated%20with%20the%20use%20of%20integrase%20strand%20transfer%20inhibitors%20among%20virally%20controlled%20women.&amp;author=NA%20Summers&amp;author=CD%20Lahiri&amp;author=CD%20Angert&amp;publication_year=2020&amp;journal=J%20Acquir%20Immune%20Defic%20Syndr&amp;volume=85&amp;pages=355-362" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAI.0000000000002447" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAI.0000000000002447" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r81">81.</a><div class="reference-content">Rebeiro
         PF﻿, Jenkins
         CA﻿, Bian
         A﻿, 
     et al.  Risk of incident diabetes mellitus, weight gain, and their relationships with integrase inhibitor-based initial antiretroviral therapy among persons with human immunodeficiency virus in the United States and Canada. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2021;73(7):e2234-e2242. doi:<a href="http://dx.doi.org/10.1093/cid/ciaa1403">10.1093/cid/ciaa1403</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32936919" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Risk%20of%20incident%20diabetes%20mellitus%2C%20weight%20gain%2C%20and%20their%20relationships%20with%20integrase%20inhibitor-based%20initial%20antiretroviral%20therapy%20among%20persons%20with%20human%20immunodeficiency%20virus%20in%20the%20United%20States%20and%20Canada.&amp;author=PF%20Rebeiro&amp;author=CA%20Jenkins&amp;author=A%20Bian&amp;publication_year=2021&amp;journal=Clin%20Infect%20Dis&amp;volume=73&amp;pages=e2234-e2242" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciaa1403" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciaa1403" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r82">82.</a><div class="reference-content">Petoumenos
         K﻿, Kuwanda
         L﻿, Ryom
         L﻿, 
     et al; D:A:D Study Group.  Effect of changes in body mass index on the risk of cardiovascular disease and diabetes mellitus in HIV-positive individuals: results from the D:A:D study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Acquir Immune Defic Syndr</i>. 2021;86(5):579-586. doi:<a href="http://dx.doi.org/10.1097/QAI.0000000000002603">10.1097/QAI.0000000000002603</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33351531" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effect%20of%20changes%20in%20body%20mass%20index%20on%20the%20risk%20of%20cardiovascular%20disease%20and%20diabetes%20mellitus%20in%20HIV-positive%20individuals%3A%20results%20from%20the%20D%3AA%3AD%20study.&amp;author=K%20Petoumenos&amp;author=L%20Kuwanda&amp;author=L%20Ryom&amp;publication_year=2021&amp;journal=J%20Acquir%20Immune%20Defic%20Syndr&amp;volume=86&amp;pages=579-586" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAI.0000000000002603" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAI.0000000000002603" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r83">83.</a><div class="reference-content">Hagins
         D﻿, Mussini
         C﻿, Zhang
         F﻿, 
     et al.  Week-48 metabolic health after switch to DTG/3TC vs CAR by baseline regimen: SALSA [Abstract 603] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Top Antiv Med</i>. 2022;30(1 suppl):236.<a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Week-48%20metabolic%20health%20after%20switch%20to%20DTG%2F3TC%20vs%20CAR%20by%20baseline%20regimen%3A%20SALSA%20%5BAbstract%20603%5D%20in%20special%20issue%3A%20Abstracts%20From%20the%202022%20Conference%20on%20Retroviruses%20and%20Opportunistic%20Infections.&amp;author=D%20Hagins&amp;author=C%20Mussini&amp;author=F%20Zhang&amp;publication_year=2022&amp;journal=Top%20Antiv%20Med&amp;volume=30&amp;pages=236" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r84">84.</a><div class="reference-content">Wilding
         JPH﻿, Batterham
         RL﻿, Calanna
         S﻿, 
     et al; STEP 1 Study Group.  Once-weekly semaglutide in adults with overweight or obesity. ﻿ <i xmlns:helper="urn:XsltStringHelper"> N Engl J Med</i>. 2021;384(11):989-1002. doi:<a href="http://dx.doi.org/10.1056/NEJMoa2032183">10.1056/NEJMoa2032183</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33567185" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Once-weekly%20semaglutide%20in%20adults%20with%20overweight%20or%20obesity.&amp;author=JPH%20Wilding&amp;author=RL%20Batterham&amp;author=S%20Calanna&amp;publication_year=2021&amp;journal=N%20Engl%20J%20Med&amp;volume=384&amp;pages=989-1002" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMoa2032183" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMoa2032183" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r85">85.</a><div class="reference-content">Semaglutide’s efficacy in achieving weight loss for those with HIV (SWIFT) [NCT04174755]. ClinicalTrials.gov. Accessed November 9, 2022. <a href="https://clinicaltrials.gov/ct2/show/NCT04174755">https://clinicaltrials.gov/ct2/show/NCT04174755</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r86">86.</a><div class="reference-content">Justice
         AC﻿, Goetz
         MB﻿, Stewart
         CN﻿, 
     et al.  Delayed presentation of HIV among older individuals: a growing problem. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2022;9(4):e269-e280. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(22)00003-0">10.1016/S2352-3018(22)00003-0</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35218732" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Delayed%20presentation%20of%20HIV%20among%20older%20individuals%3A%20a%20growing%20problem.&amp;author=AC%20Justice&amp;author=MB%20Goetz&amp;author=CN%20Stewart&amp;publication_year=2022&amp;journal=Lancet%20HIV&amp;volume=9&amp;pages=e269-e280" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(22)00003-0" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(22)00003-0" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r87">87.</a><div class="reference-content">Lee
         JS﻿, Humes
         E﻿, Hogan
         BC﻿, 
     et al; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).  Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004-18: a cohort study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2022;9(suppl 1):S2. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(22)00067-4">10.1016/S2352-3018(22)00067-4</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35304844" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Observed%20CD4%20counts%20at%20entry%20into%20HIV%20care%20and%20at%20antiretroviral%20therapy%20prescription%20by%20age%20in%20the%20USA%2C%202004-18%3A%20a%20cohort%20study.&amp;author=JS%20Lee&amp;author=E%20Humes&amp;author=BC%20Hogan&amp;publication_year=2022&amp;journal=Lancet%20HIV&amp;volume=9&amp;pages=S2" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(22)00067-4" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(22)00067-4" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r88">88.</a><div class="reference-content">Zhabokritsky
         A﻿, Szadkowski
         L﻿, Burchell
         AN﻿, 
     et al; Canadian Observational Cohort (CANOC) Collaboration.  Immunological and virological response to initial antiretroviral therapy among older people living with HIV in the Canadian Observational Cohort (CANOC). ﻿ <i xmlns:helper="urn:XsltStringHelper"> HIV Med</i>. 2021;22(8):759-769. doi:<a href="http://dx.doi.org/10.1111/hiv.13125">10.1111/hiv.13125</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34075683" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Immunological%20and%20virological%20response%20to%20initial%20antiretroviral%20therapy%20among%20older%20people%20living%20with%20HIV%20in%20the%20Canadian%20Observational%20Cohort%20%28CANOC%29.&amp;author=A%20Zhabokritsky&amp;author=L%20Szadkowski&amp;author=AN%20Burchell&amp;publication_year=2021&amp;journal=HIV%20Med&amp;volume=22&amp;pages=759-769" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1111/hiv.v22.8" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1111/hiv.v22.8" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r89">89.</a><div class="reference-content">Richterman
         A﻿, Sax
         PE﻿.  Antiretroviral therapy in older people with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Curr Opin HIV AIDS</i>. 2020;15(2):118-125. doi:<a href="http://dx.doi.org/10.1097/COH.0000000000000614">10.1097/COH.0000000000000614</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31990705" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Antiretroviral%20therapy%20in%20older%20people%20with%20HIV.&amp;author=A%20Richterman&amp;author=PE%20Sax&amp;publication_year=2020&amp;journal=Curr%20Opin%20HIV%20AIDS&amp;volume=15&amp;pages=118-125" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/COH.0000000000000614" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/COH.0000000000000614" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r90">90.</a><div class="reference-content">Courlet
         P﻿, Stader
         F﻿, Guidi
         M﻿, 
     et al; Swiss HIV Cohort Study.  Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2020;34(1):103-108. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000002372">10.1097/QAD.0000000000002372</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31490233" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Pharmacokinetic%20profiles%20of%20boosted%20darunavir%2C%20dolutegravir%20and%20lamivudine%20in%20aging%20people%20living%20with%20HIV.&amp;author=P%20Courlet&amp;author=F%20Stader&amp;author=M%20Guidi&amp;publication_year=2020&amp;journal=AIDS&amp;volume=34&amp;pages=103-108" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000002372" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000002372" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r91">91.</a><div class="reference-content">Smith
         L﻿, Letendre
         S﻿, Erlandson
         KM﻿, Ma
         Q﻿, Ellis
         RJ﻿, Farhadian
         SF﻿.  Polypharmacy in older adults with HIV infection: effects on the brain. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Am Geriatr Soc</i>. 2022;70(3):924-927. doi:<a href="http://dx.doi.org/10.1111/jgs.17569">10.1111/jgs.17569</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34855982" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Polypharmacy%20in%20older%20adults%20with%20HIV%20infection%3A%20effects%20on%20the%20brain.&amp;author=L%20Smith&amp;author=S%20Letendre&amp;author=KM%20Erlandson&amp;author=Q%20Ma&amp;author=RJ%20Ellis&amp;author=SF%20Farhadian&amp;publication_year=2022&amp;journal=J%20Am%20Geriatr%20Soc&amp;volume=70&amp;pages=924-927" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1111/jgs.v70.3" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1111/jgs.v70.3" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r92">92.</a><div class="reference-content">Blanco
         JR﻿, Morillo
         R﻿, Abril
         V﻿, 
     et al; Gesida and SEFH.  Deprescribing of non-antiretroviral therapy in HIV-infected patients. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Eur J Clin Pharmacol</i>. 2020;76(3):305-318. doi:<a href="http://dx.doi.org/10.1007/s00228-019-02785-z">10.1007/s00228-019-02785-z</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31865412" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Deprescribing%20of%20non-antiretroviral%20therapy%20in%20HIV-infected%20patients.&amp;author=JR%20Blanco&amp;author=R%20Morillo&amp;author=V%20Abril&amp;publication_year=2020&amp;journal=Eur%20J%20Clin%20Pharmacol&amp;volume=76&amp;pages=305-318" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1007/s00228-019-02785-z" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1007/s00228-019-02785-z" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r93">93.</a><div class="reference-content">López-Centeno
         B﻿, Badenes-Olmedo
         C﻿, Mataix-Sanjuan
         A﻿, 
     et al.  Potentially inappropriate medications in older adults living with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> HIV Med</i>. 2020;21(8):541-546. doi:<a href="http://dx.doi.org/10.1111/hiv.12883">10.1111/hiv.12883</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32516849" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Potentially%20inappropriate%20medications%20in%20older%20adults%20living%20with%20HIV.&amp;author=B%20López-Centeno&amp;author=C%20Badenes-Olmedo&amp;author=A%20Mataix-Sanjuan&amp;publication_year=2020&amp;journal=HIV%20Med&amp;volume=21&amp;pages=541-546" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1111/hiv.v21.8" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1111/hiv.v21.8" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r94">94.</a><div class="reference-content">Koren
         DE﻿, Scarsi
         KK﻿, Farmer
         EK﻿, 
     et al.  A call to action: the role of antiretroviral stewardship in inpatient practice, a joint policy paper of the Infectious Diseases Society of America, HIV Medicine Association, and American Academy of HIV Medicine. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2020;70(11):2241-2246. doi:<a href="http://dx.doi.org/10.1093/cid/ciz792">10.1093/cid/ciz792</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32445480" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20call%20to%20action%3A%20the%20role%20of%20antiretroviral%20stewardship%20in%20inpatient%20practice%2C%20a%20joint%20policy%20paper%20of%20the%20Infectious%20Diseases%20Society%20of%20America%2C%20HIV%20Medicine%20Association%2C%20and%20American%20Academy%20of%20HIV%20Medicine.&amp;author=DE%20Koren&amp;author=KK%20Scarsi&amp;author=EK%20Farmer&amp;publication_year=2020&amp;journal=Clin%20Infect%20Dis&amp;volume=70&amp;pages=2241-2246" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciz792" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciz792" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r95">95.</a><div class="reference-content">Greene
         M﻿, Shi
         Y﻿, Boscardin
         J﻿, Sudore
         R﻿, Gandhi
         M﻿, Covinsky
         K﻿.  Geriatric conditions and healthcare utilisation in older adults living with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Age Ageing</i>. 2022;51(5):afac093. doi:<a href="http://dx.doi.org/10.1093/ageing/afac093">10.1093/ageing/afac093</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35511728" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Geriatric%20conditions%20and%20healthcare%20utilisation%20in%20older%20adults%20living%20with%20HIV.&amp;author=M%20Greene&amp;author=Y%20Shi&amp;author=J%20Boscardin&amp;author=R%20Sudore&amp;author=M%20Gandhi&amp;author=K%20Covinsky&amp;publication_year=2022&amp;journal=Age%20Ageing&amp;volume=51&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/ageing/afac093" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/ageing/afac093" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r96">96.</a><div class="reference-content">Liu
         S﻿, Yan
         Q﻿, Jiang
         Y﻿, 
     et al.  The impact of frailty on all-cause mortality in patients with HIV infection: a systematic review and meta-analysis. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS Res Hum Retroviruses</i>. 2022;38(9):692-699. doi:<a href="http://dx.doi.org/10.1089/aid.2021.0155">10.1089/aid.2021.0155</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35658605" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20impact%20of%20frailty%20on%20all-cause%20mortality%20in%20patients%20with%20HIV%20infection%3A%20a%20systematic%20review%20and%20meta-analysis.&amp;author=S%20Liu&amp;author=Q%20Yan&amp;author=Y%20Jiang&amp;publication_year=2022&amp;journal=AIDS%20Res%20Hum%20Retroviruses&amp;volume=38&amp;pages=692-699" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1089/aid.2021.0155" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1089/aid.2021.0155" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r97">97.</a><div class="reference-content">Ellis
         RJ﻿, Paolillo
         E﻿, Saloner
         R﻿, Heaton
         RK﻿.  Higher comorbidity burden predicts worsening neurocognitive trajectories in people with human immunodeficiency virus. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2022;74(8):1323-1328. doi:<a href="http://dx.doi.org/10.1093/cid/ciab655">10.1093/cid/ciab655</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34329400" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Higher%20comorbidity%20burden%20predicts%20worsening%20neurocognitive%20trajectories%20in%20people%20with%20human%20immunodeficiency%20virus.&amp;author=RJ%20Ellis&amp;author=E%20Paolillo&amp;author=R%20Saloner&amp;author=RK%20Heaton&amp;publication_year=2022&amp;journal=Clin%20Infect%20Dis&amp;volume=74&amp;pages=1323-1328" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciab655" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciab655" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r98">98.</a><div class="reference-content">Aung
         HL﻿, Gates
         TM﻿, Mao
         L﻿, Brew
         BJ﻿, Rourke
         SB﻿, Cysique
         LA﻿.  Abnormal cognitive aging in people with HIV: evidence from data integration between two countries’ cohort studies. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2022;36(8):1171-1179. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000003230">10.1097/QAD.0000000000003230</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35471252" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Abnormal%20cognitive%20aging%20in%20people%20with%20HIV%3A%20evidence%20from%20data%20integration%20between%20two%20countries%E2%80%99%20cohort%20studies.&amp;author=HL%20Aung&amp;author=TM%20Gates&amp;author=L%20Mao&amp;author=BJ%20Brew&amp;author=SB%20Rourke&amp;author=LA%20Cysique&amp;publication_year=2022&amp;journal=AIDS&amp;volume=36&amp;pages=1171-1179" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000003230" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000003230" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r99">99.</a><div class="reference-content">Letendre
         SL﻿, Roa
         J﻿, Chen
         H﻿, 
     et al.  ACTG A5324: a randomized trial of ART intensification for cognitive impairment in PWH [Abstract 133] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Top Antiv Med</i>. 2022;30(1 suppl):50-51.<a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=ACTG%20A5324%3A%20a%20randomized%20trial%20of%20ART%20intensification%20for%20cognitive%20impairment%20in%20PWH%20%5BAbstract%20133%5D%20in%20special%20issue%3A%20Abstracts%20From%20the%202022%20Conference%20on%20Retroviruses%20and%20Opportunistic%20Infections.&amp;author=SL%20Letendre&amp;author=J%20Roa&amp;author=H%20Chen&amp;publication_year=2022&amp;journal=Top%20Antiv%20Med&amp;volume=30&amp;pages=50-51" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r100">100.</a><div class="reference-content">Althoff
         KN﻿, Stewart
         CN﻿, Humes
         E﻿, 
     et al.  The shifting age distribution of people with HIV using antiretroviral therapy in the United States. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2022;36(3):459-471. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000003128">10.1097/QAD.0000000000003128</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34750289" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20shifting%20age%20distribution%20of%20people%20with%20HIV%20using%20antiretroviral%20therapy%20in%20the%20United%20States.&amp;author=KN%20Althoff&amp;author=CN%20Stewart&amp;author=E%20Humes&amp;publication_year=2022&amp;journal=AIDS&amp;volume=36&amp;pages=459-471" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000003128" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000003128" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r101">101.</a><div class="reference-content">Davis
         AJ﻿, Greene
         M﻿, Siegler
         E﻿, 
     et al.  Strengths and challenges of various models of geriatric consultation for older adults living with human immunodeficiency virus. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2022;74(6):1101-1106. doi:<a href="http://dx.doi.org/10.1093/cid/ciab682">10.1093/cid/ciab682</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34358303" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Strengths%20and%20challenges%20of%20various%20models%20of%20geriatric%20consultation%20for%20older%20adults%20living%20with%20human%20immunodeficiency%20virus.&amp;author=AJ%20Davis&amp;author=M%20Greene&amp;author=E%20Siegler&amp;publication_year=2022&amp;journal=Clin%20Infect%20Dis&amp;volume=74&amp;pages=1101-1106" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciab682" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciab682" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r102">102.</a><div class="reference-content">Kiplagat
         J﻿, Tran
         DN﻿, Barber
         T﻿, 
     et al.  How health systems can adapt to a population ageing with HIV and comorbid disease. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2022;9(4):e281-e292. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(22)00009-1">10.1016/S2352-3018(22)00009-1</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35218734" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=How%20health%20systems%20can%20adapt%20to%20a%20population%20ageing%20with%20HIV%20and%20comorbid%20disease.&amp;author=J%20Kiplagat&amp;author=DN%20Tran&amp;author=T%20Barber&amp;publication_year=2022&amp;journal=Lancet%20HIV&amp;volume=9&amp;pages=e281-e292" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(22)00009-1" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(22)00009-1" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r103">103.</a><div class="reference-content">Lazarus
         JV﻿, Safreed-Harmon
         K﻿, Kamarulzaman
         A﻿, 
     et al.  Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Nat Commun</i>. 2021;12(1):4450. doi:<a href="http://dx.doi.org/10.1038/s41467-021-24673-w">10.1038/s41467-021-24673-w</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34272399" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Consensus%20statement%20on%20the%20role%20of%20health%20systems%20in%20advancing%20the%20long-term%20well-being%20of%20people%20living%20with%20HIV.&amp;author=JV%20Lazarus&amp;author=K%20Safreed-Harmon&amp;author=A%20Kamarulzaman&amp;publication_year=2021&amp;journal=Nat%20Commun&amp;volume=12&amp;pages=4450" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1038/s41467-021-24673-w" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1038/s41467-021-24673-w" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r104">104.</a><div class="reference-content">Syphilis. Centers for Disease Control and Prevention. Updated March 24, 2022. Accessed November 9, 2022. <a href="https://www.cdc.gov/std/treatment-guidelines/syphilis.htm">https://www.cdc.gov/std/treatment-guidelines/syphilis.htm</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r105">105.</a><div class="reference-content">US Public Health Service. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States–2021 Update: A Clinical Practice Guideline. Centers for Disease Control and Prevention. Published 2021. Accessed July 28, 2022. <a href="https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf">https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r106">106.</a><div class="reference-content">Shieh
         E﻿, Marzinke
         MA﻿, Fuchs
         EJ﻿, 
     et al.  Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Int AIDS Soc</i>. 2019;22(11):e25405. doi:<a href="http://dx.doi.org/10.1002/jia2.25405">10.1002/jia2.25405</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31692269" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Transgender%20women%20on%20oral%20HIV%20pre-exposure%20prophylaxis%20have%20significantly%20lower%20tenofovir%20and%20emtricitabine%20concentrations%20when%20also%20taking%20oestrogen%20when%20compared%20to%20cisgender%20men.&amp;author=E%20Shieh&amp;author=MA%20Marzinke&amp;author=EJ%20Fuchs&amp;publication_year=2019&amp;journal=J%20Int%20AIDS%20Soc&amp;volume=22&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1002/jia2.v22.11" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1002/jia2.v22.11" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r107">107.</a><div class="reference-content">Yager
         JL﻿, Anderson
         PL﻿.  Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Expert Opin Drug Metab Toxicol</i>. 2020;16(6):463-474. doi:<a href="http://dx.doi.org/10.1080/17425255.2020.1752662">10.1080/17425255.2020.1752662</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32250177" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Pharmacology%20and%20drug%20interactions%20with%20HIV%20PrEP%20in%20transgender%20persons%20receiving%20gender%20affirming%20hormone%20therapy.&amp;author=JL%20Yager&amp;author=PL%20Anderson&amp;publication_year=2020&amp;journal=Expert%20Opin%20Drug%20Metab%20Toxicol&amp;volume=16&amp;pages=463-474" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1080/17425255.2020.1752662" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1080/17425255.2020.1752662" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r108">108.</a><div class="reference-content">Delany-Moretlwe
         S﻿, Hughes
         JP﻿, Bock
         P﻿, 
     et al; HPTN 084 Study Group.  Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet</i>. 2022;399(10337):1779-1789. doi:<a href="http://dx.doi.org/10.1016/S0140-6736(22)00538-4">10.1016/S0140-6736(22)00538-4</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35378077" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cabotegravir%20for%20the%20prevention%20of%20HIV-1%20in%20women%3A%20results%20from%20HPTN%20084%2C%20a%20phase%203%2C%20randomised%20clinical%20trial.&amp;author=S%20Delany-Moretlwe&amp;author=JP%20Hughes&amp;author=P%20Bock&amp;publication_year=2022&amp;journal=Lancet&amp;volume=399&amp;pages=1779-1789" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S0140-6736(22)00538-4" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S0140-6736(22)00538-4" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r109">109.</a><div class="reference-content">Landovitz
         RJ﻿, Li
         S﻿, Eron
         JJ
         Jr﻿, 
     et al.  Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2020;7(7):e472-e481. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(20)30106-5">10.1016/S2352-3018(20)30106-5</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32497491" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Tail-phase%20safety%2C%20tolerability%2C%20and%20pharmacokinetics%20of%20long-acting%20injectable%20cabotegravir%20in%20HIV-uninfected%20adults%3A%20a%20secondary%20analysis%20of%20the%20HPTN%20077%20trial.&amp;author=RJ%20Landovitz&amp;author=S%20Li&amp;author=JJ%20Eron&amp;publication_year=2020&amp;journal=Lancet%20HIV&amp;volume=7&amp;pages=e472-e481" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(20)30106-5" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(20)30106-5" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r110">110.</a><div class="reference-content">Eshleman
         S﻿, Fogel
         JM﻿, Halvas
         EK﻿, 
     et al.  CA-LA PrEP: early detection of HIV infection may reduce InSTI resistance risk [Abstract LB95] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Top Antiv Med</i>. 2022;30(1 suppl):36-37.<a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=CA-LA%20PrEP%3A%20early%20detection%20of%20HIV%20infection%20may%20reduce%20InSTI%20resistance%20risk%20%5BAbstract%20LB95%5D%20in%20special%20issue%3A%20Abstracts%20From%20the%202022%20Conference%20on%20Retroviruses%20and%20Opportunistic%20Infections.&amp;author=S%20Eshleman&amp;author=JM%20Fogel&amp;author=EK%20Halvas&amp;publication_year=2022&amp;journal=Top%20Antiv%20Med&amp;volume=30&amp;pages=36-37" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r111">111.</a><div class="reference-content">National Clinician Consultation Center website. Accessed November 9, 2022. <a href="https://aidsetc.org/aetc-program/national-clinician-consulation-center">https://aidsetc.org/aetc-program/national-clinician-consulation-center</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r112">112.</a><div class="reference-content">Krakower
         D﻿, Maloney
         KM﻿, Powell
         VE﻿, 
     et al.  Patterns and clinical consequences of discontinuing HIV preexposure prophylaxis during primary care. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Int AIDS Soc</i>. 2019;22(2):e25250. doi:<a href="http://dx.doi.org/10.1002/jia2.25250">10.1002/jia2.25250</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/30768762" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Patterns%20and%20clinical%20consequences%20of%20discontinuing%20HIV%20preexposure%20prophylaxis%20during%20primary%20care.&amp;author=D%20Krakower&amp;author=KM%20Maloney&amp;author=VE%20Powell&amp;publication_year=2019&amp;journal=J%20Int%20AIDS%20Soc&amp;volume=22&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1002/jia2.2019.22.issue-2" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1002/jia2.2019.22.issue-2" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r113">113.</a><div class="reference-content">Marcus
         JL﻿, Hurley
         LB﻿, Dentoni-Lasofsky
         D﻿, 
     et al.  Barriers to preexposure prophylaxis use among individuals with recently acquired HIV infection in Northern California. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS Care</i>. 2019;31(5):536-544. doi:<a href="http://dx.doi.org/10.1080/09540121.2018.1533238">10.1080/09540121.2018.1533238</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/30304942" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Barriers%20to%20preexposure%20prophylaxis%20use%20among%20individuals%20with%20recently%20acquired%20HIV%20infection%20in%20Northern%20California.&amp;author=JL%20Marcus&amp;author=LB%20Hurley&amp;author=D%20Dentoni-Lasofsky&amp;publication_year=2019&amp;journal=AIDS%20Care&amp;volume=31&amp;pages=536-544" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1080/09540121.2018.1533238" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1080/09540121.2018.1533238" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r114">114.</a><div class="reference-content">Molina
         JM﻿, Squires
         K﻿, Sax
         PE﻿, 
     et al; DRIVE-FORWARD Study Group.  Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2018;5(5):e211-e220. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(18)30021-3">10.1016/S2352-3018(18)30021-3</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/29592840" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Doravirine%20versus%20ritonavir-boosted%20darunavir%20in%20antiretroviral-naive%20adults%20with%20HIV-1%20%28DRIVE-FORWARD%29%3A%2048-week%20results%20of%20a%20randomised%2C%20double-blind%2C%20phase%203%2C%20non-inferiority%20trial.&amp;author=JM%20Molina&amp;author=K%20Squires&amp;author=PE%20Sax&amp;publication_year=2018&amp;journal=Lancet%20HIV&amp;volume=5&amp;pages=e211-e220" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(18)30021-3" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(18)30021-3" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r115">115.</a><div class="reference-content">Luetkemeyer
         A﻿, Dombroski
         J﻿, Cohen
         S﻿. Doxycycline post-exposure prophylaxis for STI prevention among MSM and transgender women on HIV PrEP or living with HIV: high efficacy to reduce incident STIs in a randomised trial [Abstract OALBX0103]. Poster presented at: 24th International AIDS Conference; 2022; Montreal, Quebec, Canada.</div></div><div class="reference"><a class="reference-number" id="jsc220007r116">116.</a><div class="reference-content">Wagman
         JA﻿, Wynn
         A﻿, Matsuzaki
         M﻿, 
     et al.  Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2020;34(15):2285-2294. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000002716">10.1097/QAD.0000000000002716</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33048870" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Hazardous%20alcohol%20use%2C%20antiretroviral%20therapy%20receipt%2C%20and%20viral%20suppression%20in%20people%20living%20with%20HIV%20who%20inject%20drugs%20in%20the%20United%20States%2C%20India%2C%20Russia%2C%20and%20Vietnam.&amp;author=JA%20Wagman&amp;author=A%20Wynn&amp;author=M%20Matsuzaki&amp;publication_year=2020&amp;journal=AIDS&amp;volume=34&amp;pages=2285-2294" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000002716" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000002716" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r117">117.</a><div class="reference-content">Springer
         SA﻿, Larney
         S﻿, Alam-Mehrjerdi
         Z﻿, Altice
         FL﻿, Metzger
         D﻿, Shoptaw
         S﻿.  Drug treatment as HIV prevention among women and girls who inject drugs from a global perspective: progress, gaps, and future directions. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Acquir Immune Defic Syndr</i>. 2015;69(suppl 2):S155-S161. doi:<a href="http://dx.doi.org/10.1097/QAI.0000000000000637">10.1097/QAI.0000000000000637</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/25978482" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Drug%20treatment%20as%20HIV%20prevention%20among%20women%20and%20girls%20who%20inject%20drugs%20from%20a%20global%20perspective%3A%20progress%2C%20gaps%2C%20and%20future%20directions.&amp;author=SA%20Springer&amp;author=S%20Larney&amp;author=Z%20Alam-Mehrjerdi&amp;author=FL%20Altice&amp;author=D%20Metzger&amp;author=S%20Shoptaw&amp;publication_year=2015&amp;journal=J%20Acquir%20Immune%20Defic%20Syndr&amp;volume=69&amp;pages=S155-S161" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAI.0000000000000637" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAI.0000000000000637" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r118">118.</a><div class="reference-content">Feelemyer
         J﻿, Arasteh
         K﻿, Huong
         DT﻿, 
     et al; DRIVE Study Team.  Associations between methamphetamine use and lack of viral suppression among a cohort of HIV-positive persons who inject drugs in Hai Phong, Vietnam. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2020;34(13):1875-1882. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000002680">10.1097/QAD.0000000000002680</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32910061" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Associations%20between%20methamphetamine%20use%20and%20lack%20of%20viral%20suppression%20among%20a%20cohort%20of%20HIV-positive%20persons%20who%20inject%20drugs%20in%20Hai%20Phong%2C%20Vietnam.&amp;author=J%20Feelemyer&amp;author=K%20Arasteh&amp;author=DT%20Huong&amp;publication_year=2020&amp;journal=AIDS&amp;volume=34&amp;pages=1875-1882" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000002680" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000002680" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r119">119.</a><div class="reference-content">Satre
         DD﻿, Sarovar
         V﻿, Leyden
         W﻿, 
     et al.  Changes in days of unhealthy alcohol use and antiretroviral therapy adherence, HIV RNA levels, and condomless sex: a secondary analysis of clinical trial data. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS Behav</i>. 2020;24(6):1784-1792. doi:<a href="http://dx.doi.org/10.1007/s10461-019-02742-y">10.1007/s10461-019-02742-y</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31773444" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Changes%20in%20days%20of%20unhealthy%20alcohol%20use%20and%20antiretroviral%20therapy%20adherence%2C%20HIV%20RNA%20levels%2C%20and%20condomless%20sex%3A%20a%20secondary%20analysis%20of%20clinical%20trial%20data.&amp;author=DD%20Satre&amp;author=V%20Sarovar&amp;author=W%20Leyden&amp;publication_year=2020&amp;journal=AIDS%20Behav&amp;volume=24&amp;pages=1784-1792" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1007/s10461-019-02742-y" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1007/s10461-019-02742-y" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r120">120.</a><div class="reference-content">Springer
         SA﻿, Merluzzi
         AP﻿, Del Rio
         C﻿.  Integrating responses to the opioid use disorder and infectious disease epidemics: a report from the National Academies of Sciences, Engineering, and Medicine. ﻿ <i xmlns:helper="urn:XsltStringHelper"> JAMA</i>. 2020;324(1):37-38. doi:<a href="http://jamanetwork.com/article.aspx?doi=10.1001/jama.2020.2559">10.1001/jama.2020.2559</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32159771" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Integrating%20responses%20to%20the%20opioid%20use%20disorder%20and%20infectious%20disease%20epidemics%3A%20a%20report%20from%20the%20National%20Academies%20of%20Sciences%2C%20Engineering%2C%20and%20Medicine.&amp;author=SA%20Springer&amp;author=AP%20Merluzzi&amp;author=C%20Del Rio&amp;publication_year=2020&amp;journal=JAMA&amp;volume=324&amp;pages=37-38" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1001/jama.2020.2559" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1001/jama.2020.2559" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r121">121.</a><div class="reference-content">Springer
         SA﻿, Barocas
         JA﻿, Wurcel
         A﻿, 
     et al.  Federal and state action needed to end the infectious complications of illicit drug use in the United States: IDSA and HIVMA’s advocacy agenda. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Infect Dis</i>. 2020;222(suppl 5):S230-S238. doi:<a href="http://dx.doi.org/10.1093/infdis/jiz673">10.1093/infdis/jiz673</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32877568" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Federal%20and%20state%20action%20needed%20to%20end%20the%20infectious%20complications%20of%20illicit%20drug%20use%20in%20the%20United%20States%3A%20IDSA%20and%20HIVMA%E2%80%99s%20advocacy%20agenda.&amp;author=SA%20Springer&amp;author=JA%20Barocas&amp;author=A%20Wurcel&amp;publication_year=2020&amp;journal=J%20Infect%20Dis&amp;volume=222&amp;pages=S230-S238" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/infdis/jiz673" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/infdis/jiz673" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r122">122.</a><div class="reference-content">Nance
         RM﻿, Trejo
         MEP﻿, Whitney
         BM﻿, 
     et al.  Impact of abstinence and of reducing illicit drug use without abstinence on human immunodeficiency virus viral load. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2020;70(5):867-874. doi:<a href="http://dx.doi.org/10.1093/cid/ciz299">10.1093/cid/ciz299</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/30994900" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Impact%20of%20abstinence%20and%20of%20reducing%20illicit%20drug%20use%20without%20abstinence%20on%20human%20immunodeficiency%20virus%20viral%20load.&amp;author=RM%20Nance&amp;author=MEP%20Trejo&amp;author=BM%20Whitney&amp;publication_year=2020&amp;journal=Clin%20Infect%20Dis&amp;volume=70&amp;pages=867-874" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciz299" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciz299" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r123">123.</a><div class="reference-content">Hoffman
         KA﻿, Baker
         R﻿, Fanucchi
         LC﻿, 
     et al.  Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Addict Sci Clin Pract</i>. 2021;16(1):67. doi:<a href="http://dx.doi.org/10.1186/s13722-021-00277-z">10.1186/s13722-021-00277-z</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34758887" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Perspectives%20on%20extended-release%20naltrexone%20induction%20among%20patients%20living%20with%20HIV%20and%20opioid%20use%20disorder%3A%20a%20qualitative%20analysis.&amp;author=KA%20Hoffman&amp;author=R%20Baker&amp;author=LC%20Fanucchi&amp;publication_year=2021&amp;journal=Addict%20Sci%20Clin%20Pract&amp;volume=16&amp;pages=67" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1186/s13722-021-00277-z" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1186/s13722-021-00277-z" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r124">124.</a><div class="reference-content">Korthuis
         PT﻿, Cook
         RR﻿, Lum
         PJ﻿, 
     et al.  HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Addiction</i>. 2022;117(7):1961-1971. doi:<a href="http://dx.doi.org/10.1111/add.15836">10.1111/add.15836</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35129242" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=HIV%20clinic-based%20extended-release%20naltrexone%20versus%20treatment%20as%20usual%20for%20people%20with%20HIV%20and%20opioid%20use%20disorder%3A%20a%20non-blinded%2C%20randomized%20non-inferiority%20trial.&amp;author=PT%20Korthuis&amp;author=RR%20Cook&amp;author=PJ%20Lum&amp;publication_year=2022&amp;journal=Addiction&amp;volume=117&amp;pages=1961-1971" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1111/add.v117.7" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1111/add.v117.7" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r125">125.</a><div class="reference-content">Mitra
         S﻿, Grant
         C﻿, Nolan
         S﻿, Mohd Salleh
         NA﻿, Milloy
         MJ﻿, Richardson
         L﻿.  Assessing the temporality between transitions onto opioid agonist therapy and engagement with antiretroviral therapy in a cohort of HIV-positive people who use opioids daily. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS Behav</i>. 2022;26(6):1933-1942. doi:<a href="http://dx.doi.org/10.1007/s10461-021-03543-y">10.1007/s10461-021-03543-y</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34977956" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Assessing%20the%20temporality%20between%20transitions%20onto%20opioid%20agonist%20therapy%20and%20engagement%20with%20antiretroviral%20therapy%20in%20a%20cohort%20of%20HIV-positive%20people%20who%20use%20opioids%20daily.&amp;author=S%20Mitra&amp;author=C%20Grant&amp;author=S%20Nolan&amp;author=NA%20Mohd Salleh&amp;author=MJ%20Milloy&amp;author=L%20Richardson&amp;publication_year=2022&amp;journal=AIDS%20Behav&amp;volume=26&amp;pages=1933-1942" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1007/s10461-021-03543-y" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1007/s10461-021-03543-y" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r126">126.</a><div class="reference-content">Puryear
         SB﻿, Balzer
         LB﻿, Ayieko
         J﻿, 
     et al.  Associations between alcohol use and HIV care cascade outcomes among adults undergoing population-based HIV testing in East Africa. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2020;34(3):405-413. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000002427">10.1097/QAD.0000000000002427</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31725431" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Associations%20between%20alcohol%20use%20and%20HIV%20care%20cascade%20outcomes%20among%20adults%20undergoing%20population-based%20HIV%20testing%20in%20East%20Africa.&amp;author=SB%20Puryear&amp;author=LB%20Balzer&amp;author=J%20Ayieko&amp;publication_year=2020&amp;journal=AIDS&amp;volume=34&amp;pages=405-413" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000002427" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000002427" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r127">127.</a><div class="reference-content">McNamara
         KF﻿, Biondi
         BE﻿, Hernández-Ramírez
         RU﻿, Taweh
         N﻿, Grimshaw
         AA﻿, Springer
         SA﻿.  A systematic review and meta-analysis of studies evaluating the effect of medication treatment for opioid use disorder on infectious disease outcomes. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Open Forum Infect Dis</i>. 2021;8(8):ofab289. doi:<a href="http://dx.doi.org/10.1093/ofid/ofab289">10.1093/ofid/ofab289</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34430670" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20systematic%20review%20and%20meta-analysis%20of%20studies%20evaluating%20the%20effect%20of%20medication%20treatment%20for%20opioid%20use%20disorder%20on%20infectious%20disease%20outcomes.&amp;author=KF%20McNamara&amp;author=BE%20Biondi&amp;author=RU%20Hernández-Ramírez&amp;author=N%20Taweh&amp;author=AA%20Grimshaw&amp;author=SA%20Springer&amp;publication_year=2021&amp;journal=Open%20Forum%20Infect%20Dis&amp;volume=8&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/ofid/ofab289" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/ofid/ofab289" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r128">128.</a><div class="reference-content">Springer
         SA﻿, Qiu
         J﻿, Saber-Tehrani
         AS﻿, Altice
         FL﻿.  Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. ﻿ <i xmlns:helper="urn:XsltStringHelper"> PLoS One</i>. 2012;7(5):e38335. doi:<a href="http://dx.doi.org/10.1371/journal.pone.0038335">10.1371/journal.pone.0038335</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/22719814" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Retention%20on%20buprenorphine%20is%20associated%20with%20high%20levels%20of%20maximal%20viral%20suppression%20among%20HIV-infected%20opioid%20dependent%20released%20prisoners.&amp;author=SA%20Springer&amp;author=J%20Qiu&amp;author=AS%20Saber-Tehrani&amp;author=FL%20Altice&amp;publication_year=2012&amp;journal=PLoS%20One&amp;volume=7&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1371/journal.pone.0038335" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1371/journal.pone.0038335" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r129">129.</a><div class="reference-content">Springer
         SA﻿, Di Paola
         A﻿, Azar
         MM﻿, 
     et al.  Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV with opioid use disorders transitioning to the community: results of a double-blind, placebo-controlled randomized trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Acquir Immune Defic Syndr</i>. 2018;78(1):43-53. doi:<a href="http://dx.doi.org/10.1097/QAI.0000000000001634">10.1097/QAI.0000000000001634</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/29373393" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Extended-release%20naltrexone%20improves%20viral%20suppression%20among%20incarcerated%20persons%20living%20with%20HIV%20with%20opioid%20use%20disorders%20transitioning%20to%20the%20community%3A%20results%20of%20a%20double-blind%2C%20placebo-controlled%20randomized%20trial.&amp;author=SA%20Springer&amp;author=A%20Di Paola&amp;author=MM%20Azar&amp;publication_year=2018&amp;journal=J%20Acquir%20Immune%20Defic%20Syndr&amp;volume=78&amp;pages=43-53" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAI.0000000000001634" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAI.0000000000001634" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r130">130.</a><div class="reference-content">Springer
         SA﻿, Di Paola
         A﻿, Barbour
         R﻿, Azar
         MM﻿, Altice
         FL﻿.  Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV and alcohol use disorders transitioning to the community: results from a double-blind, placebo-controlled trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Acquir Immune Defic Syndr</i>. 2018;79(1):92-100. doi:<a href="http://dx.doi.org/10.1097/QAI.0000000000001759">10.1097/QAI.0000000000001759</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/29781884" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Extended-release%20naltrexone%20improves%20viral%20suppression%20among%20incarcerated%20persons%20living%20with%20HIV%20and%20alcohol%20use%20disorders%20transitioning%20to%20the%20community%3A%20results%20from%20a%20double-blind%2C%20placebo-controlled%20trial.&amp;author=SA%20Springer&amp;author=A%20Di Paola&amp;author=R%20Barbour&amp;author=MM%20Azar&amp;author=FL%20Altice&amp;publication_year=2018&amp;journal=J%20Acquir%20Immune%20Defic%20Syndr&amp;volume=79&amp;pages=92-100" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAI.0000000000001759" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAI.0000000000001759" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r131">131.</a><div class="reference-content">Fanucchi
         L﻿, Springer
         SA﻿, Korthuis
         PT﻿.  Medications for treatment of opioid use disorder among persons living with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Curr HIV/AIDS Rep</i>. 2019;16(1):1-6. doi:<a href="http://dx.doi.org/10.1007/s11904-019-00436-7">10.1007/s11904-019-00436-7</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/30684117" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Medications%20for%20treatment%20of%20opioid%20use%20disorder%20among%20persons%20living%20with%20HIV.&amp;author=L%20Fanucchi&amp;author=SA%20Springer&amp;author=PT%20Korthuis&amp;publication_year=2019&amp;journal=Curr%20HIV%2FAIDS%20Rep&amp;volume=16&amp;pages=1-6" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1007/s11904-019-00436-7" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1007/s11904-019-00436-7" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r132">132.</a><div class="reference-content">Seval
         N﻿, Eaton
         E﻿, Springer
         SA﻿.  Beyond antibiotics: a practical guide for the infectious disease physician to treat opioid use disorder in the setting of associated infectious diseases. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Open Forum Infect Dis</i>. 2019;7(1):ofz539. doi:<a href="http://dx.doi.org/10.1093/ofid/ofz539">10.1093/ofid/ofz539</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31993454" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Beyond%20antibiotics%3A%20a%20practical%20guide%20for%20the%20infectious%20disease%20physician%20to%20treat%20opioid%20use%20disorder%20in%20the%20setting%20of%20associated%20infectious%20diseases.&amp;author=N%20Seval&amp;author=E%20Eaton&amp;author=SA%20Springer&amp;publication_year=2019&amp;journal=Open%20Forum%20Infect%20Dis&amp;volume=7&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/ofid/ofz539" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/ofid/ofz539" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r133">133.</a><div class="reference-content">Silverman
         K﻿, Holtyn
         AF﻿, Rodewald
         AM﻿, 
     et al.  Incentives for viral suppression in people living with HIV: a randomized clinical trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS Behav</i>. 2019;23(9):2337-2346. doi:<a href="http://dx.doi.org/10.1007/s10461-019-02592-8">10.1007/s10461-019-02592-8</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31297681" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Incentives%20for%20viral%20suppression%20in%20people%20living%20with%20HIV%3A%20a%20randomized%20clinical%20trial.&amp;author=K%20Silverman&amp;author=AF%20Holtyn&amp;author=AM%20Rodewald&amp;publication_year=2019&amp;journal=AIDS%20Behav&amp;volume=23&amp;pages=2337-2346" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1007/s10461-019-02592-8" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1007/s10461-019-02592-8" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r134">134.</a><div class="reference-content">Prendergast
         M﻿, Podus
         D﻿, Finney
         J﻿, Greenwell
         L﻿, Roll
         J﻿.  Contingency management for treatment of substance use disorders: a meta-analysis. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Addiction</i>. 2006;101(11):1546-1560. doi:<a href="http://dx.doi.org/10.1111/j.1360-0443.2006.01581.x">10.1111/j.1360-0443.2006.01581.x</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/17034434" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Contingency%20management%20for%20treatment%20of%20substance%20use%20disorders%3A%20a%20meta-analysis.&amp;author=M%20Prendergast&amp;author=D%20Podus&amp;author=J%20Finney&amp;author=L%20Greenwell&amp;author=J%20Roll&amp;publication_year=2006&amp;journal=Addiction&amp;volume=101&amp;pages=1546-1560" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1111/add.2006.101.issue-11" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1111/add.2006.101.issue-11" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r135">135.</a><div class="reference-content">Menza
         TW﻿, Jameson
         DR﻿, Hughes
         JP﻿, Colfax
         GN﻿, Shoptaw
         S﻿, Golden
         MR﻿.  Contingency management to reduce methamphetamine use and sexual risk among men who have sex with men: a randomized controlled trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> BMC Public Health</i>. 2010;10:774. doi:<a href="http://dx.doi.org/10.1186/1471-2458-10-774">10.1186/1471-2458-10-774</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/21172026" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Contingency%20management%20to%20reduce%20methamphetamine%20use%20and%20sexual%20risk%20among%20men%20who%20have%20sex%20with%20men%3A%20a%20randomized%20controlled%20trial.&amp;author=TW%20Menza&amp;author=DR%20Jameson&amp;author=JP%20Hughes&amp;author=GN%20Colfax&amp;author=S%20Shoptaw&amp;author=MR%20Golden&amp;publication_year=2010&amp;journal=BMC%20Public%20Health&amp;volume=10&amp;pages=774" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1186/1471-2458-10-774" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1186/1471-2458-10-774" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r136">136.</a><div class="reference-content">Landovitz
         RJ﻿, Fletcher
         JB﻿, Shoptaw
         S﻿, Reback
         CJ﻿.  Contingency management facilitates the use of postexposure prophylaxis among stimulant-using men who have sex with men. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Open Forum Infect Dis</i>. 2015;2(1):ofu114. doi:<a href="http://dx.doi.org/10.1093/ofid/ofu114">10.1093/ofid/ofu114</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/25884003" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Contingency%20management%20facilitates%20the%20use%20of%20postexposure%20prophylaxis%20among%20stimulant-using%20men%20who%20have%20sex%20with%20men.&amp;author=RJ%20Landovitz&amp;author=JB%20Fletcher&amp;author=S%20Shoptaw&amp;author=CJ%20Reback&amp;publication_year=2015&amp;journal=Open%20Forum%20Infect%20Dis&amp;volume=2&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/ofid/ofu114" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/ofid/ofu114" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r137">137.</a><div class="reference-content">Mistler
         CB﻿, Copenhaver
         MM﻿, Shrestha
         R﻿.  The pre-exposure prophylaxis (PrEP) care cascade in people who inject drugs: a systematic review. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS Behav</i>. 2021;25(5):1490-1506. doi:<a href="http://dx.doi.org/10.1007/s10461-020-02988-x">10.1007/s10461-020-02988-x</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32749627" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20pre-exposure%20prophylaxis%20%28PrEP%29%20care%20cascade%20in%20people%20who%20inject%20drugs%3A%20a%20systematic%20review.&amp;author=CB%20Mistler&amp;author=MM%20Copenhaver&amp;author=R%20Shrestha&amp;publication_year=2021&amp;journal=AIDS%20Behav&amp;volume=25&amp;pages=1490-1506" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1007/s10461-020-02988-x" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1007/s10461-020-02988-x" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r138">138.</a><div class="reference-content">Assoumou
         SA﻿, Paniagua
         SM﻿, Gonzalez
         P﻿, 
     et al.  HIV pre-exposure prophylaxis and buprenorphine at a drug detoxification center during the opioid epidemic: opportunities and challenges. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS Behav</i>. 2021;25(8):2591-2598. doi:<a href="http://dx.doi.org/10.1007/s10461-021-03220-0">10.1007/s10461-021-03220-0</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33751315" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=HIV%20pre-exposure%20prophylaxis%20and%20buprenorphine%20at%20a%20drug%20detoxification%20center%20during%20the%20opioid%20epidemic%3A%20opportunities%20and%20challenges.&amp;author=SA%20Assoumou&amp;author=SM%20Paniagua&amp;author=P%20Gonzalez&amp;publication_year=2021&amp;journal=AIDS%20Behav&amp;volume=25&amp;pages=2591-2598" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1007/s10461-021-03220-0" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1007/s10461-021-03220-0" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r139">139.</a><div class="reference-content">Beck
         L﻿, Parlier-Ahmad
         AB﻿, Martin
         CE﻿.  Pre-exposure prophylaxis (PrEP) indication and uptake among people receiving buprenorphine for the treatment of opioid use disorder. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Subst Abuse Treat</i>. 2022;132:108506. doi:<a href="http://dx.doi.org/10.1016/j.jsat.2021.108506">10.1016/j.jsat.2021.108506</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34098202" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Pre-exposure%20prophylaxis%20%28PrEP%29%20indication%20and%20uptake%20among%20people%20receiving%20buprenorphine%20for%20the%20treatment%20of%20opioid%20use%20disorder.&amp;author=L%20Beck&amp;author=AB%20Parlier-Ahmad&amp;author=CE%20Martin&amp;publication_year=2022&amp;journal=J%20Subst%20Abuse%20Treat&amp;volume=132&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.jsat.2021.108506" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.jsat.2021.108506" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r140">140.</a><div class="reference-content">Belludi
         A﻿, McFall
         AM﻿, Solomon
         SS﻿, 
     et al.  Awareness of and willingness to use pre-exposure prophylaxis (PrEP) among people who inject drugs and men who have sex with men in India: results from a multi-city cross-sectional survey. ﻿ <i xmlns:helper="urn:XsltStringHelper"> PLoS One</i>. 2021;16(2):e0247352. doi:<a href="http://dx.doi.org/10.1371/journal.pone.0247352">10.1371/journal.pone.0247352</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33630909" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Awareness%20of%20and%20willingness%20to%20use%20pre-exposure%20prophylaxis%20%28PrEP%29%20among%20people%20who%20inject%20drugs%20and%20men%20who%20have%20sex%20with%20men%20in%20India%3A%20results%20from%20a%20multi-city%20cross-sectional%20survey.&amp;author=A%20Belludi&amp;author=AM%20McFall&amp;author=SS%20Solomon&amp;publication_year=2021&amp;journal=PLoS%20One&amp;volume=16&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1371/journal.pone.0247352" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1371/journal.pone.0247352" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r141">141.</a><div class="reference-content">Broz
         D﻿, Zibbell
         J﻿, Foote
         C﻿, 
     et al.  Multiple injections per injection episode: high-risk injection practice among people who injected pills during the 2015 HIV outbreak in Indiana. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Int J Drug Policy</i>. 2018;52:97-101. doi:<a href="http://dx.doi.org/10.1016/j.drugpo.2017.12.003">10.1016/j.drugpo.2017.12.003</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/29278838" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Multiple%20injections%20per%20injection%20episode%3A%20high-risk%20injection%20practice%20among%20people%20who%20injected%20pills%20during%20the%202015%20HIV%20outbreak%20in%20Indiana.&amp;author=D%20Broz&amp;author=J%20Zibbell&amp;author=C%20Foote&amp;publication_year=2018&amp;journal=Int%20J%20Drug%20Policy&amp;volume=52&amp;pages=97-101" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.drugpo.2017.12.003" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.drugpo.2017.12.003" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r142">142.</a><div class="reference-content">Eaton
         EF﻿, Tamhane
         A﻿, Turner
         W﻿, Raper
         JL﻿, Saag
         MS﻿, Cropsey
         KL﻿.  Safer in care: a pandemic-tested model of integrated HIV/OUD care. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Drug Alcohol Depend</i>. 2022;231:109241. doi:<a href="http://dx.doi.org/10.1016/j.drugalcdep.2021.109241">10.1016/j.drugalcdep.2021.109241</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35007957" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Safer%20in%20care%3A%20a%20pandemic-tested%20model%20of%20integrated%20HIV%2FOUD%20care.&amp;author=EF%20Eaton&amp;author=A%20Tamhane&amp;author=W%20Turner&amp;author=JL%20Raper&amp;author=MS%20Saag&amp;author=KL%20Cropsey&amp;publication_year=2022&amp;journal=Drug%20Alcohol%20Depend&amp;volume=231&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.drugalcdep.2021.109241" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.drugalcdep.2021.109241" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r143">143.</a><div class="reference-content">Taweh
         N﻿, Schlossberg
         E﻿, Frank
         C﻿, 
     et al.  Linking criminal justice-involved individuals to HIV, hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: progress, gaps, and future directions. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Int J Drug Policy</i>. 2021;96:103283. doi:<a href="http://dx.doi.org/10.1016/j.drugpo.2021.103283">10.1016/j.drugpo.2021.103283</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34020864" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Linking%20criminal%20justice-involved%20individuals%20to%20HIV%2C%20hepatitis%20C%2C%20and%20opioid%20use%20disorder%20prevention%20and%20treatment%20services%20upon%20release%20to%20the%20community%3A%20progress%2C%20gaps%2C%20and%20future%20directions.&amp;author=N%20Taweh&amp;author=E%20Schlossberg&amp;author=C%20Frank&amp;publication_year=2021&amp;journal=Int%20J%20Drug%20Policy&amp;volume=96&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.drugpo.2021.103283" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.drugpo.2021.103283" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r144">144.</a><div class="reference-content">Jiang
         T﻿, Liu
         C﻿, Zhang
         J﻿, Huang
         X﻿, Xu
         J﻿.  Impact of the COVID-19 pandemic on the UNAIDS six 95% HIV control targets. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Front Med (Lausanne)</i>. 2022;9:818054. doi:<a href="http://dx.doi.org/10.3389/fmed.2022.818054">10.3389/fmed.2022.818054</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35252256" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Impact%20of%20the%20COVID-19%20pandemic%20on%20the%20UNAIDS%20six%2095%25%20HIV%20control%20targets.&amp;author=T%20Jiang&amp;author=C%20Liu&amp;author=J%20Zhang&amp;author=X%20Huang&amp;author=J%20Xu&amp;publication_year=2022&amp;journal=Front%20Med%20%28Lausanne%29&amp;volume=9&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.3389/fmed.2022.818054" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.3389/fmed.2022.818054" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r145">145.</a><div class="reference-content">Santos
         GM﻿, Hong
         C﻿, Wilson
         N﻿, 
     et al.  Persistent disparities in COVID-19-associated impacts on HIV prevention and care among a global sample of sexual and gender minority individuals. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Glob Public Health</i>. 2022;17(6):827-842. doi:<a href="http://dx.doi.org/10.1080/17441692.2022.2063362">10.1080/17441692.2022.2063362</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35435149" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Persistent%20disparities%20in%20COVID-19-associated%20impacts%20on%20HIV%20prevention%20and%20care%20among%20a%20global%20sample%20of%20sexual%20and%20gender%20minority%20individuals.&amp;author=GM%20Santos&amp;author=C%20Hong&amp;author=N%20Wilson&amp;publication_year=2022&amp;journal=Glob%20Public%20Health&amp;volume=17&amp;pages=827-842" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1080/17441692.2022.2063362" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1080/17441692.2022.2063362" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r146">146.</a><div class="reference-content">Dear
         N﻿, Duff
         E﻿, Esber
         A﻿, 
     et al; AFRICOS Study Group.  Transient reductions in human immunodeficiency virus (HIV) clinic attendance and food security during the coronavirus disease 2019 (COVID-19) pandemic for people living with HIV in 4 African countries. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2021;73(10):1901-1905. doi:<a href="http://dx.doi.org/10.1093/cid/ciab379">10.1093/cid/ciab379</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33906235" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Transient%20reductions%20in%20human%20immunodeficiency%20virus%20%28HIV%29%20clinic%20attendance%20and%20food%20security%20during%20the%20coronavirus%20disease%202019%20%28COVID-19%29%20pandemic%20for%20people%20living%20with%20HIV%20in%204%20African%20countries.&amp;author=N%20Dear&amp;author=E%20Duff&amp;author=A%20Esber&amp;publication_year=2021&amp;journal=Clin%20Infect%20Dis&amp;volume=73&amp;pages=1901-1905" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciab379" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciab379" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r147">147.</a><div class="reference-content">Jewell
         BL﻿, Mudimu
         E﻿, Stover
         J﻿, 
     et al; HIV Modelling Consortium.  Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2020;7(9):e629-e640. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(20)30211-3">10.1016/S2352-3018(20)30211-3</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32771089" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Potential%20effects%20of%20disruption%20to%20HIV%20programmes%20in%20sub-Saharan%20Africa%20caused%20by%20COVID-19%3A%20results%20from%20multiple%20mathematical%20models.&amp;author=BL%20Jewell&amp;author=E%20Mudimu&amp;author=J%20Stover&amp;publication_year=2020&amp;journal=Lancet%20HIV&amp;volume=7&amp;pages=e629-e640" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(20)30211-3" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(20)30211-3" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r148">148.</a><div class="reference-content">Ambrosioni
         J﻿, Blanco
         JL﻿, Reyes-Urueña
         JM﻿, 
     et al; COVID-19 in HIV Investigators.  Overview of SARS-CoV-2 infection in adults living with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2021;8(5):e294-e305. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(21)00070-9">10.1016/S2352-3018(21)00070-9</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33915101" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Overview%20of%20SARS-CoV-2%20infection%20in%20adults%20living%20with%20HIV.&amp;author=J%20Ambrosioni&amp;author=JL%20Blanco&amp;author=JM%20Reyes-Urueña&amp;publication_year=2021&amp;journal=Lancet%20HIV&amp;volume=8&amp;pages=e294-e305" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(21)00070-9" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(21)00070-9" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r149">149.</a><div class="reference-content">Brown
         LB﻿, Spinelli
         MA﻿, Gandhi
         M﻿.  The interplay between HIV and COVID-19: summary of the data and responses to date. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Curr Opin HIV AIDS</i>. 2021;16(1):63-73. doi:<a href="http://dx.doi.org/10.1097/COH.0000000000000659">10.1097/COH.0000000000000659</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33186229" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20interplay%20between%20HIV%20and%20COVID-19%3A%20summary%20of%20the%20data%20and%20responses%20to%20date.&amp;author=LB%20Brown&amp;author=MA%20Spinelli&amp;author=M%20Gandhi&amp;publication_year=2021&amp;journal=Curr%20Opin%20HIV%20AIDS&amp;volume=16&amp;pages=63-73" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/COH.0000000000000659" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/COH.0000000000000659" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r150">150.</a><div class="reference-content">Park
         LS﻿, McGinnis
         KA﻿, Gordon
         KS﻿, 
     et al; CIVET Collaboration of the NA-ACCORD of IeDEA.  SARS-CoV-2 testing and positivity among persons with and without HIV in 6 US cohorts. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Acquir Immune Defic Syndr</i>. 2022;90(3):249-255. doi:<a href="http://dx.doi.org/10.1097/QAI.0000000000002943">10.1097/QAI.0000000000002943</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35195574" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=SARS-CoV-2%20testing%20and%20positivity%20among%20persons%20with%20and%20without%20HIV%20in%206%20US%20cohorts.&amp;author=LS%20Park&amp;author=KA%20McGinnis&amp;author=KS%20Gordon&amp;publication_year=2022&amp;journal=J%20Acquir%20Immune%20Defic%20Syndr&amp;volume=90&amp;pages=249-255" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAI.0000000000002943" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAI.0000000000002943" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r151">151.</a><div class="reference-content">Treskova-Schwarzbach
         M﻿, Haas
         L﻿, Reda
         S﻿, 
     et al.  Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence. ﻿ <i xmlns:helper="urn:XsltStringHelper"> BMC Med</i>. 2021;19(1):212. doi:<a href="http://dx.doi.org/10.1186/s12916-021-02058-6">10.1186/s12916-021-02058-6</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34446016" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Pre-existing%20health%20conditions%20and%20severe%20COVID-19%20outcomes%3A%20an%20umbrella%20review%20approach%20and%20meta-analysis%20of%20global%20evidence.&amp;author=M%20Treskova-Schwarzbach&amp;author=L%20Haas&amp;author=S%20Reda&amp;publication_year=2021&amp;journal=BMC%20Med&amp;volume=19&amp;pages=212" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1186/s12916-021-02058-6" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1186/s12916-021-02058-6" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r152">152.</a><div class="reference-content">Nomah
         DK﻿, Reyes-Urueña
         J﻿, Díaz
         Y﻿, 
     et al; PISCIS Study Group.  Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2021;8(11):e701-e710. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(21)00240-X">10.1016/S2352-3018(21)00240-X</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34655549" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Sociodemographic%2C%20clinical%2C%20and%20immunological%20factors%20associated%20with%20SARS-CoV-2%20diagnosis%20and%20severe%20COVID-19%20outcomes%20in%20people%20living%20with%20HIV%3A%20a%20retrospective%20cohort%20study.&amp;author=DK%20Nomah&amp;author=J%20Reyes-Urueña&amp;author=Y%20Díaz&amp;publication_year=2021&amp;journal=Lancet%20HIV&amp;volume=8&amp;pages=e701-e710" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(21)00240-X" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(21)00240-X" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r153">153.</a><div class="reference-content">Shapiro
         AE﻿, Bender Ignacio
         RA﻿, Whitney
         BM﻿, 
     et al; CFAR Network of Integrated Clinical Systems.  Factors associated with severity of COVID-19 disease in a multicenter cohort of people with HIV in the United States, March-December 2020. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Acquir Immune Defic Syndr</i>. 2022;90(4):369-376. doi:<a href="http://dx.doi.org/10.1097/QAI.0000000000002989">10.1097/QAI.0000000000002989</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35364600" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Factors%20associated%20with%20severity%20of%20COVID-19%20disease%20in%20a%20multicenter%20cohort%20of%20people%20with%20HIV%20in%20the%20United%20States%2C%20March-December%202020.&amp;author=AE%20Shapiro&amp;author=RA%20Bender Ignacio&amp;author=BM%20Whitney&amp;publication_year=2022&amp;journal=J%20Acquir%20Immune%20Defic%20Syndr&amp;volume=90&amp;pages=369-376" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAI.0000000000002989" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAI.0000000000002989" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r154">154.</a><div class="reference-content">Braunstein
         SL﻿, Lazar
         R﻿, Wahnich
         A﻿, Daskalakis
         DC﻿, Blackstock
         OJ﻿.  Coronavirus disease 2019 (COVID-19) infection among people with human immunodeficiency virus in New York City: a population-level analysis of linked surveillance data. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2021;72(12):e1021-e1029. doi:<a href="http://dx.doi.org/10.1093/cid/ciaa1793">10.1093/cid/ciaa1793</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33252620" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Coronavirus%20disease%202019%20%28COVID-19%29%20infection%20among%20people%20with%20human%20immunodeficiency%20virus%20in%20New%20York%20City%3A%20a%20population-level%20analysis%20of%20linked%20surveillance%20data.&amp;author=SL%20Braunstein&amp;author=R%20Lazar&amp;author=A%20Wahnich&amp;author=DC%20Daskalakis&amp;author=OJ%20Blackstock&amp;publication_year=2021&amp;journal=Clin%20Infect%20Dis&amp;volume=72&amp;pages=e1021-e1029" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciaa1793" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciaa1793" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r155">155.</a><div class="reference-content">Dandachi
         D﻿, Geiger
         G﻿, Montgomery
         MW﻿, 
     et al.  Characteristics, comorbidities, and outcomes in a multicenter registry of patients with human immunodeficiency virus and coronavirus disease 2019. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2021;73(7):e1964-e1972. doi:<a href="http://dx.doi.org/10.1093/cid/ciaa1339">10.1093/cid/ciaa1339</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32905581" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Characteristics%2C%20comorbidities%2C%20and%20outcomes%20in%20a%20multicenter%20registry%20of%20patients%20with%20human%20immunodeficiency%20virus%20and%20coronavirus%20disease%202019.&amp;author=D%20Dandachi&amp;author=G%20Geiger&amp;author=MW%20Montgomery&amp;publication_year=2021&amp;journal=Clin%20Infect%20Dis&amp;volume=73&amp;pages=e1964-e1972" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciaa1339" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciaa1339" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r156">156.</a><div class="reference-content">Woldemeskel
         BA﻿, Karaba
         AH﻿, Garliss
         CC﻿, 
     et al.  The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with human immunodeficiency virus (HIV). ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2022;74(7):1268-1270. doi:<a href="http://dx.doi.org/10.1093/cid/ciab648">10.1093/cid/ciab648</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34293114" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20BNT162b2%20mRNA%20vaccine%20elicits%20robust%20humoral%20and%20cellular%20immune%20responses%20in%20people%20living%20with%20human%20immunodeficiency%20virus%20%28HIV%29.&amp;author=BA%20Woldemeskel&amp;author=AH%20Karaba&amp;author=CC%20Garliss&amp;publication_year=2022&amp;journal=Clin%20Infect%20Dis&amp;volume=74&amp;pages=1268-1270" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciab648" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciab648" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r157">157.</a><div class="reference-content">González de Aledo
         M﻿, Cañizares
         A﻿, Vázquez-Rodríguez
         P﻿, 
     et al.  Safety and Immunogenicity of SARS-CoV-2 vaccines in people with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2022;36(5):691-695. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000003161">10.1097/QAD.0000000000003161</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34999608" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Safety%20and%20Immunogenicity%20of%20SARS-CoV-2%20vaccines%20in%20people%20with%20HIV.&amp;author=M%20González de Aledo&amp;author=A%20Cañizares&amp;author=P%20Vázquez-Rodríguez&amp;publication_year=2022&amp;journal=AIDS&amp;volume=36&amp;pages=691-695" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000003161" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000003161" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r158">158.</a><div class="reference-content">Lee
         ARYB﻿, Wong
         SY﻿, Chai
         LYA﻿, 
     et al.  Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. ﻿ <i xmlns:helper="urn:XsltStringHelper"> BMJ</i>. 2022;376:e068632. doi:<a href="http://dx.doi.org/10.1136/bmj-2021-068632">10.1136/bmj-2021-068632</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35236664" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Efficacy%20of%20covid-19%20vaccines%20in%20immunocompromised%20patients%3A%20systematic%20review%20and%20meta-analysis.&amp;author=ARYB%20Lee&amp;author=SY%20Wong&amp;author=LYA%20Chai&amp;publication_year=2022&amp;journal=BMJ&amp;volume=376&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1136/bmj-2021-068632" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1136/bmj-2021-068632" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r159">159.</a><div class="reference-content">Hassold
         N﻿, Brichler
         S﻿, Ouedraogo
         E﻿, 
     et al.  Impaired antibody response to COVID-19 vaccination in advanced HIV infection. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2022;36(4):F1-F5. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000003166">10.1097/QAD.0000000000003166</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35013085" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Impaired%20antibody%20response%20to%20COVID-19%20vaccination%20in%20advanced%20HIV%20infection.&amp;author=N%20Hassold&amp;author=S%20Brichler&amp;author=E%20Ouedraogo&amp;publication_year=2022&amp;journal=AIDS&amp;volume=36&amp;pages=F1-F5" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000003166" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000003166" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r160">160.</a><div class="reference-content">Xu
         X﻿, Vesterbacka
         J﻿, Aleman
         S﻿, Nowak
         P﻿; COVAXID Study Group.  High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV—but HIV viremia matters? ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2022;36(3):479-481. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000003135">10.1097/QAD.0000000000003135</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35084386" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=High%20seroconversion%20rate%20after%20vaccination%20with%20mRNA%20BNT162b2%20vaccine%20against%20SARS-CoV-2%20among%20people%20with%20HIV%E2%80%94but%20HIV%20viremia%20matters%3F&amp;author=X%20Xu&amp;author=J%20Vesterbacka&amp;author=S%20Aleman&amp;author=P%20Nowak&amp;publication_year=2022&amp;journal=AIDS&amp;volume=36&amp;pages=479-481" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000003135" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000003135" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r161">161.</a><div class="reference-content">Haidar
         G﻿, Agha
         M﻿, Bilderback
         A﻿, 
     et al.  Prospective evaluation of coronavirus disease 2019 (COVID-19) vaccine responses across a broad spectrum of immunocompromising conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS) study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2022;75(1):e630-e644. doi:<a href="http://dx.doi.org/10.1093/cid/ciac103">10.1093/cid/ciac103</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35179197" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Prospective%20evaluation%20of%20coronavirus%20disease%202019%20%28COVID-19%29%20vaccine%20responses%20across%20a%20broad%20spectrum%20of%20immunocompromising%20conditions%3A%20the%20COVID-19%20Vaccination%20in%20the%20Immunocompromised%20Study%20%28COVICS%29%20study.&amp;author=G%20Haidar&amp;author=M%20Agha&amp;author=A%20Bilderback&amp;publication_year=2022&amp;journal=Clin%20Infect%20Dis&amp;volume=75&amp;pages=e630-e644" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciac103" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciac103" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r162">162.</a><div class="reference-content">Nault
         L﻿, Marchitto
         L﻿, Goyette
         G﻿, 
     et al.  Covid-19 vaccine immunogenicity in people living with HIV-1. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Vaccine</i>. 2022;40(26):3633-3637. doi:<a href="http://dx.doi.org/10.1016/j.vaccine.2022.04.090">10.1016/j.vaccine.2022.04.090</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35568588" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Covid-19%20vaccine%20immunogenicity%20in%20people%20living%20with%20HIV-1.&amp;author=L%20Nault&amp;author=L%20Marchitto&amp;author=G%20Goyette&amp;publication_year=2022&amp;journal=Vaccine&amp;volume=40&amp;pages=3633-3637" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.vaccine.2022.04.090" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.vaccine.2022.04.090" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r163">163.</a><div class="reference-content">Schmidt
         KG﻿, Harrer
         EG﻿, Tascilar
         K﻿, 
     et al.  Characterization of serum and mucosal SARS-CoV-2-antibodies in HIV-1-infected subjects after BNT162b2 mRNA vaccination or SARS-CoV-2 infection. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Viruses</i>. 2022;14(3):651. doi:<a href="http://dx.doi.org/10.3390/v14030651">10.3390/v14030651</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35337058" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Characterization%20of%20serum%20and%20mucosal%20SARS-CoV-2-antibodies%20in%20HIV-1-infected%20subjects%20after%20BNT162b2%20mRNA%20vaccination%20or%20SARS-CoV-2%20infection.&amp;author=KG%20Schmidt&amp;author=EG%20Harrer&amp;author=K%20Tascilar&amp;publication_year=2022&amp;journal=Viruses&amp;volume=14&amp;pages=651" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.3390/v14030651" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.3390/v14030651" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r164">164.</a><div class="reference-content">Madhi
         SA﻿, Moodley
         D﻿, Hanley
         S﻿, 
     et al; 2019nCoV-501 Study Group.  Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2022;9(5):e309-e322. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(22)00041-8">10.1016/S2352-3018(22)00041-8</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35489376" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Immunogenicity%20and%20safety%20of%20a%20SARS-CoV-2%20recombinant%20spike%20protein%20nanoparticle%20vaccine%20in%20people%20living%20with%20and%20without%20HIV-1%20infection%3A%20a%20randomised%2C%20controlled%2C%20phase%202A%2F2B%20trial.&amp;author=SA%20Madhi&amp;author=D%20Moodley&amp;author=S%20Hanley&amp;publication_year=2022&amp;journal=Lancet%20HIV&amp;volume=9&amp;pages=e309-e322" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(22)00041-8" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(22)00041-8" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r165">165.</a><div class="reference-content">Coburn
         SB﻿, Humes
         E﻿, Lang
         R﻿, 
     et al; Corona-Infectious-Virus Epidemiology Team (CIVETs) of the NA-ACCORD of IeDEA.  Analysis of postvaccination breakthrough COVID-19 infections among adults with HIV in the United States. ﻿ <i xmlns:helper="urn:XsltStringHelper"> JAMA Netw Open</i>. 2022;5(6):e2215934. doi:<a href="http://jamanetwork.com/article.aspx?doi=10.1001/jamanetworkopen.2022.15934">10.1001/jamanetworkopen.2022.15934</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35671054" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Analysis%20of%20postvaccination%20breakthrough%20COVID-19%20infections%20among%20adults%20with%20HIV%20in%20the%20United%20States.&amp;author=SB%20Coburn&amp;author=E%20Humes&amp;author=R%20Lang&amp;publication_year=2022&amp;journal=JAMA%20Netw%20Open&amp;volume=5&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1001/jamanetworkopen.2022.15934" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1001/jamanetworkopen.2022.15934" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r166">166.</a><div class="reference-content">Guidance for COVID-19 and People with HIV. Guidelines Working Groups of the NIH Office of AIDS Research Advisory Council and US Department of Health and Human Services (HHS). Updated February 22, 2022. Accessed July 28, 2022. <a href="https://clinicalinfo.hiv.gov/en/guidelines/guidance-covid-19-and-people-hiv/whats-new-covid-19-and-hiv-guidance">https://clinicalinfo.hiv.gov/en/guidelines/guidance-covid-19-and-people-hiv/whats-new-covid-19-and-hiv-guidance</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r167">167.</a><div class="reference-content">National Institutes of Health. COVID-19 treatment guidelines. Accessed November 9, 2022. <a href="https://www.covid19treatmentguidelines.nih.gov/">https://www.covid19treatmentguidelines.nih.gov/</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r168">168.</a><div class="reference-content">Bhimraj
         A﻿, Morgan
         RL﻿, Shumaker
         AH﻿, 
     et al.  Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. Published online April 27, 2020. <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32338708" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Infectious%20Diseases%20Society%20of%20America%20guidelines%20on%20the%20treatment%20and%20management%20of%20patients%20with%20COVID-19.&amp;author=A%20Bhimraj&amp;author=RL%20Morgan&amp;author=AH%20Shumaker&amp;publication_year=2020&amp;journal=Clin%20Infect%20Dis&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r169">169.</a><div class="reference-content">Mazzitelli
         M﻿, Trunfio
         M﻿, Sasset
         L﻿, 
     et al.  Factors associated with severe COVID-19 and post-acute COVID-19 syndrome in a cohort of people living with HIV on antiretroviral treatment and with undetectable HIV RNA. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Viruses</i>. 2022;14(3):493. doi:<a href="http://dx.doi.org/10.3390/v14030493">10.3390/v14030493</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35336900" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Factors%20associated%20with%20severe%20COVID-19%20and%20post-acute%20COVID-19%20syndrome%20in%20a%20cohort%20of%20people%20living%20with%20HIV%20on%20antiretroviral%20treatment%20and%20with%20undetectable%20HIV%20RNA.&amp;author=M%20Mazzitelli&amp;author=M%20Trunfio&amp;author=L%20Sasset&amp;publication_year=2022&amp;journal=Viruses&amp;volume=14&amp;pages=493" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.3390/v14030493" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.3390/v14030493" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r170">170.</a><div class="reference-content">Ferré
         VM﻿, Bachelard
         A﻿, Zaidi
         M﻿, 
     et al.  Detection of monkeypox virus in anorectal swabs from asymptomatic men who have sex with men in a sexually transmitted infection screening program in Paris, France. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Ann Intern Med</i>. 2022;175(10):1491-1492. doi:<a href="http://dx.doi.org/10.7326/M22-2183">10.7326/M22-2183</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35969863" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Detection%20of%20monkeypox%20virus%20in%20anorectal%20swabs%20from%20asymptomatic%20men%20who%20have%20sex%20with%20men%20in%20a%20sexually%20transmitted%20infection%20screening%20program%20in%20Paris%2C%20France.&amp;author=VM%20Ferré&amp;author=A%20Bachelard&amp;author=M%20Zaidi&amp;publication_year=2022&amp;journal=Ann%20Intern%20Med&amp;volume=175&amp;pages=1491-1492" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.7326/M22-2183" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.7326/M22-2183" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r171">171.</a><div class="reference-content">Loncharich
         MF﻿, Anderson
         CW﻿.  Interferon inhibition for lupus with anifrolumab: critical appraisal of the evidence leading to FDA approval. ﻿ <i xmlns:helper="urn:XsltStringHelper"> ACR Open Rheumatol</i>. 2022;4(6):486-491. doi:<a href="http://dx.doi.org/10.1002/acr2.11414">10.1002/acr2.11414</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35157371" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Interferon%20inhibition%20for%20lupus%20with%20anifrolumab%3A%20critical%20appraisal%20of%20the%20evidence%20leading%20to%20FDA%20approval.&amp;author=MF%20Loncharich&amp;author=CW%20Anderson&amp;publication_year=2022&amp;journal=ACR%20Open%20Rheumatol&amp;volume=4&amp;pages=486-491" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1002/acr2.v4.6" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1002/acr2.v4.6" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r172">172.</a><div class="reference-content">Thornhill
         JP﻿, Barkati
         S﻿, Walmsley
         S﻿, 
     et al; SHARE-net Clinical Group.  Monkeypox virus infection in humans across 16 countries—April-June 2022. ﻿ <i xmlns:helper="urn:XsltStringHelper"> N Engl J Med</i>. 2022;387(8):679-691. doi:<a href="http://dx.doi.org/10.1056/NEJMoa2207323">10.1056/NEJMoa2207323</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35866746" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Monkeypox%20virus%20infection%20in%20humans%20across%2016%20countries%E2%80%94April-June%202022.&amp;author=JP%20Thornhill&amp;author=S%20Barkati&amp;author=S%20Walmsley&amp;publication_year=2022&amp;journal=N%20Engl%20J%20Med&amp;volume=387&amp;pages=679-691" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMoa2207323" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMoa2207323" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r173">173.</a><div class="reference-content">Health Alert Network (HAN). Severe manifestations of monkeypox among people who are immunocompromised due to HIV or other conditions. Published September 29, 2022. Accessed November 1, 2022. <a href="https://emergency.cdc.gov/han/2022/han00475.asp">https://emergency.cdc.gov/han/2022/han00475.asp</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r174">174.</a><div class="reference-content">Clinical Info HIV. Guidelines for the use of antretroviral agents in adults and adolescents with HIV. Updated September 1, 2022. Accessed November 9, 2022. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/overview?view=full">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/overview?view=full</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r175">175.</a><div class="reference-content">UNAIDS. 2021 UNAIDS Global AIDS Update: Confronting Inequalities—Lessons for Pandemic Responses From 40 Years of AIDS. Published July 14, 2021. Accessed November 9, 2022. <a href="https://www.unaids.org/en/resources/documents/2021/2021-global-aids-update">https://www.unaids.org/en/resources/documents/2021/2021-global-aids-update</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r176">176.</a><div class="reference-content">Sullivan
         PS﻿, Satcher Johnson
         A﻿, Pembleton
         ES﻿, 
     et al.  Epidemiology of HIV in the USA: epidemic burden, inequities, contexts, and responses. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet</i>. 2021;397(10279):1095-1106. doi:<a href="http://dx.doi.org/10.1016/S0140-6736(21)00395-0">10.1016/S0140-6736(21)00395-0</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33617774" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Epidemiology%20of%20HIV%20in%20the%20USA%3A%20epidemic%20burden%2C%20inequities%2C%20contexts%2C%20and%20responses.&amp;author=PS%20Sullivan&amp;author=A%20Satcher Johnson&amp;author=ES%20Pembleton&amp;publication_year=2021&amp;journal=Lancet&amp;volume=397&amp;pages=1095-1106" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S0140-6736(21)00395-0" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S0140-6736(21)00395-0" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r177">177.</a><div class="reference-content">DiNenno
         EA﻿, Delaney
         KP﻿, Pitasi
         MA﻿, 
     et al.  HIV testing before and during the COVID-19 pandemic—United States, 2019-2020. ﻿ <i xmlns:helper="urn:XsltStringHelper"> MMWR Morb Mortal Wkly Rep</i>. 2022;71(25):820-824. doi:<a href="http://dx.doi.org/10.15585/mmwr.mm7125a2">10.15585/mmwr.mm7125a2</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35737573" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=HIV%20testing%20before%20and%20during%20the%20COVID-19%20pandemic%E2%80%94United%20States%2C%202019-2020.&amp;author=EA%20DiNenno&amp;author=KP%20Delaney&amp;author=MA%20Pitasi&amp;publication_year=2022&amp;journal=MMWR%20Morb%20Mortal%20Wkly%20Rep&amp;volume=71&amp;pages=820-824" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.15585/mmwr.mm7125a2" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.15585/mmwr.mm7125a2" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r178">178.</a><div class="reference-content">Centers for Disease Control and Prevention (CDC).  Diagnoses of HIV infection in the United States and dependent areas 2020.  Accessed November 9, 2022. <a href="https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-33/index.html">https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-33/index.html</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r179">179.</a><div class="reference-content">Dailey
         AF﻿, Gant
         Z﻿, Hu
         X﻿, Johnson Lyons
         S﻿, Okello
         A﻿, Satcher Johnson
         A﻿.  Association between social vulnerability and rates of HIV diagnoses among black adults, by selected characteristics and region of residence—United States, 2018. ﻿ <i xmlns:helper="urn:XsltStringHelper"> MMWR Morb Mortal Wkly Rep</i>. 2022;71(5):167-170. doi:<a href="http://dx.doi.org/10.15585/mmwr.mm7105a2">10.15585/mmwr.mm7105a2</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35113849" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Association%20between%20social%20vulnerability%20and%20rates%20of%20HIV%20diagnoses%20among%20black%20adults%2C%20by%20selected%20characteristics%20and%20region%20of%20residence%E2%80%94United%20States%2C%202018.&amp;author=AF%20Dailey&amp;author=Z%20Gant&amp;author=X%20Hu&amp;author=S%20Johnson Lyons&amp;author=A%20Okello&amp;author=A%20Satcher Johnson&amp;publication_year=2022&amp;journal=MMWR%20Morb%20Mortal%20Wkly%20Rep&amp;volume=71&amp;pages=167-170" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.15585/mmwr.mm7105a2" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.15585/mmwr.mm7105a2" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r180">180.</a><div class="reference-content">HIV/AIDS Surveillance in Europe 2021: 2020 data. European Centre for Disease Prevention and Control. Published 2021. Accessed November 9, 2022. <a href="https://www.ecdc.europa.eu/sites/default/files/documents/2021-Annual_HIV_Report_0.pdf">https://www.ecdc.europa.eu/sites/default/files/documents/2021-Annual_HIV_Report_0.pdf</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r181">181.</a><div class="reference-content">Schaefer
         R﻿, Schmidt
         HA﻿, Ravasi
         G﻿, 
     et al.  Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2021;8(8):e502-e510. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(21)00127-2">10.1016/S2352-3018(21)00127-2</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34265283" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Adoption%20of%20guidelines%20on%20and%20use%20of%20oral%20pre-exposure%20prophylaxis%3A%20a%20global%20summary%20and%20forecasting%20study.&amp;author=R%20Schaefer&amp;author=HA%20Schmidt&amp;author=G%20Ravasi&amp;publication_year=2021&amp;journal=Lancet%20HIV&amp;volume=8&amp;pages=e502-e510" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(21)00127-2" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(21)00127-2" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r182">182.</a><div class="reference-content">Keen
         P﻿, Bavinton
         BR﻿.  Could disparities in PrEP uptake limit the public health benefit? ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet Public Health</i>. 2020;5(9):e467-e468. doi:<a href="http://dx.doi.org/10.1016/S2468-2667(20)30183-3">10.1016/S2468-2667(20)30183-3</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32888440" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Could%20disparities%20in%20PrEP%20uptake%20limit%20the%20public%20health%20benefit%3F&amp;author=P%20Keen&amp;author=BR%20Bavinton&amp;publication_year=2020&amp;journal=Lancet%20Public%20Health&amp;volume=5&amp;pages=e467-e468" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2468-2667(20)30183-3" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2468-2667(20)30183-3" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r183">183.</a><div class="reference-content">Smith
         JA﻿, Garnett
         GP﻿, Hallett
         TB﻿.  The potential impact of long-acting cabotegravir for HIV prevention in South Africa: a mathematical modeling study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Infect Dis</i>. 2021;224(7):1179-1186. doi:<a href="http://dx.doi.org/10.1093/infdis/jiaa296">10.1093/infdis/jiaa296</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32492704" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20potential%20impact%20of%20long-acting%20cabotegravir%20for%20HIV%20prevention%20in%20South%20Africa%3A%20a%20mathematical%20modeling%20study.&amp;author=JA%20Smith&amp;author=GP%20Garnett&amp;author=TB%20Hallett&amp;publication_year=2021&amp;journal=J%20Infect%20Dis&amp;volume=224&amp;pages=1179-1186" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/infdis/jiaa296" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/infdis/jiaa296" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r184">184.</a><div class="reference-content">Political Declaration on HIV and AIDS: Ending Inequalities and Getting on Track to End AIDS by 2030. UNAIDS. Published June 9, 2021. Accessed July 28, 2022. <a href="https://www.unaids.org/sites/default/files/media_asset/2021_political-declaration-on-hiv-and-aids_en.pdf">https://www.unaids.org/sites/default/files/media_asset/2021_political-declaration-on-hiv-and-aids_en.pdf</a></div></div></div> 
    </div>

            </div>
        </div>

        
        <div id="related-tab" class="resource-tab js-resource-tab related-tab need-jobs-ad">
    <div class="widget-ArticleLinks widget-instance-AMA_See_Also_Related_Content">
        
    <ul class="article-links related-content">

            <li class="article-link related-article odd">
                <a href="https://jamanetwork.com/journals/jama/fullarticle/2688574" class="td-n">
                        <div class="related-article-title">Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults</div>
                                            <div class="related-journal-name">JAMA</div>
                    <div class="related-article-type">Special Communication</div>
                    <div class="related-article-date">July 24, 2018</div>
                    <div class="related-article-excerpt">This statement from the International Antiviral Society–USA updates recommendations for the use of antiretroviral drugs to treat adults with established HIV infection and to prevent HIV infection among persons at risk.</div>
                    <div class="related-article-authors">Michael S. Saag, MD; Constance A. Benson, MD; Rajesh T. Gandhi, MD; Jennifer F. Hoy, MBBS; Raphael J. Landovitz, MD; Michael J. Mugavero, MD, MHSc; Paul E. Sax, MD; Davey M. Smith, MD; Melanie A. Thompson, MD; Susan P. Buchbinder, MD; Carlos del Rio, MD; Joseph J. Eron Jr, MD; Gerd Fätkenheuer, MD; Huldrych F. Günthard, MD; Jean-Michel Molina, MD; Donna M. Jacobsen, BS; Paul A. Volberding, MD</div>
                </a>
            </li>
            <li class="article-link related-article even">
                <a href="https://jamanetwork.com/journals/jama/fullarticle/2771873" class="td-n">
                        <div class="related-article-title">Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults</div>
                                            <div class="related-journal-name">JAMA</div>
                    <div class="related-article-type">Special Communication</div>
                    <div class="related-article-date">October 27, 2020</div>
                    <div class="related-article-excerpt">This guideline from the International Antiviral (formerly AIDS) Society–USA updates practice recommendations for managing HIV infection including when to initiate antiviral therapy, how to monitor patients’ response, when to change antiviral regimens, and use of preexposure prophylaxis (PrEP) to prevent infection in those at risk.</div>
                    <div class="related-article-authors">Michael S. Saag, MD; Rajesh T. Gandhi, MD; Jennifer F. Hoy, MBBS; Raphael J. Landovitz, MD; Melanie A. Thompson, MD; Paul E. Sax, MD; Davey M. Smith, MD; Constance A. Benson, MD; Susan P. Buchbinder, MD; Carlos del Rio, MD; Joseph J. Eron Jr, MD; Gerd Fätkenheuer, MD; Huldrych F. Günthard, MD; Jean-Michel Molina, MD; Donna M. Jacobsen, BS; Paul A. Volberding, MD</div>
                </a>
            </li>
            <li class="article-link related-article odd">
                <a href="https://jamanetwork.com/journals/jama/fullarticle/2799239" class="td-n">
                        <div class="related-article-title">Ending the HIV Epidemic</div>
                                            <div class="related-journal-name">JAMA</div>
                    <div class="related-article-type">Viewpoint</div>
                    <div class="related-article-date">December 13, 2022</div>
                    <div class="related-article-excerpt">This Viewpoint identifies several barriers to ending the HIV epidemic and urges increasing expertise in HIV medicine in underserved areas like the South challenging legislation designed to keep students ignorant.</div>
                    <div class="related-article-authors">Marwan Haddad, MD, MPH; Anna K. Person, MD; Hansel E. Tookes, MD, MPH</div>
                </a>
            </li>
            <li class="article-link related-article even">
                <a href="https://jamanetwork.com/journals/jama/fullarticle/2800024" class="td-n">
                        <div class="related-article-title">Prescription of Antiretroviral Therapy Among People With HIV by Race and Ethnicity</div>
                                            <div class="related-journal-name">JAMA</div>
                    <div class="related-article-type">Original Investigation</div>
                    <div class="related-article-date">January 3, 2023</div>
                    <div class="related-article-excerpt">This retrospective observational study of adults entering HIV care between 2007 and 2019 compares differences in the prescription of integrase inhibitor–containing antiretroviral therapy by patient race and ethnicity.</div>
                    <div class="related-article-authors">Lauren C. Zalla, PhD; Stephen R. Cole, PhD; Joseph J. Eron, MD; Adaora A. Adimora, MD, MPH; Anissa I. Vines, MS, PhD; Keri N. Althoff, MPH, PhD; Michael J. Silverberg, PhD, MPH; Michael A. Horberg, MD, MAS; Vincent C. Marconi, MD; Sally B. Coburn, PhD, MPH; Raynell Lang, MD, MS; Emily C. Williams, PhD, MPH; M. John Gill, MBChB; Kelly A. Gebo, MD, MPH; Marina Klein, MD, MS; Timothy R. Sterling, MD; Peter F. Rebeiro, PhD, MHS; Angel M. Mayor, MD, MS; Richard D. Moore, MD; Jessie K. Edwards, PhD</div>
                </a>
            </li>
            <li class="article-link related-article odd">
                <a href="https://jamanetwork.com/journals/jama/fullarticle/2803584" class="td-n">
                        <div class="related-article-title">Antiretroviral Treatment of HIV/AIDS During Pregnancy</div>
                                            <div class="related-journal-name">JAMA</div>
                    <div class="related-article-type">JAMA Insights</div>
                    <div class="related-article-date">April 18, 2023</div>
                    <div class="related-article-excerpt">This Insights in the Women’s Health series describes the availability, timing, and risks of antiretroviral therapy (ART) in pregnant individuals who have HIV infection.</div>
                    <div class="related-article-authors">Ahizechukwu C. Eke, MD, PhD, MPH; Shahin Lockman, MD; Lynne M. Mofenson, MD</div>
                </a>
            </li>
            <li class="article-link related-article even">
                <a href="https://jamanetwork.com/journals/jama/fullarticle/2812672" class="td-n">
                        <div class="related-article-title">Fourth-Generation HIV Testing</div>
                                            <div class="related-journal-name">JAMA</div>
                    <div class="related-article-type">JAMA Diagnostic Test Interpretation</div>
                    <div class="related-article-date">December 19, 2023</div>
                    <div class="related-article-excerpt">A 72-year-old man presented to the emergency department with fevers, night sweats, and rash 3 days after condomless vaginal intercourse. Results of a fourth-generation HIV test were positive and HIV-1-/2 antibody differentiation testing was negative. How would you interpret these results?</div>
                    <div class="related-article-authors">Michael R. Rose, MD, MPH; Natasha M. Chida, MD, MSPH; Joyce L. Jones, MD, MS</div>
                </a>
            </li>
            <li class="article-link related-article odd">
                <a href="https://jamanetwork.com/journals/jama/fullarticle/2812670" class="td-n">
                        <div class="related-article-title">Pride</div>
                                            <div class="related-journal-name">JAMA</div>
                    <div class="related-article-type">A Piece of My Mind</div>
                    <div class="related-article-date">December 26, 2023</div>
                    <div class="related-article-excerpt">In this narrative medicine essay, an internal medicine physician, invited to speak at an International AIDS Society plenary session about his HIV work, endures a cool response from his parents upon sharing his HIV status but is met with a standing ovation and cheered by his chosen family and friends after the speech.</div>
                    <div class="related-article-authors">David Malebranche, MD, MPH</div>
                </a>
            </li>
            <li class="article-link related-article even">
                <a href="https://jamanetwork.com/journals/jama/fullarticle/2816037" class="td-n">
                        <div class="related-article-title">Updated HIV Treatment Recommendation on Use of Cabotegravir and Rilpivirine</div>
                                            <div class="related-journal-name">JAMA</div>
                    <div class="related-article-type">Comment & Response</div>
                    <div class="related-article-date">March 26, 2024</div>
                    <div class="related-article-excerpt"></div>
                    <div class="related-article-authors">Paul E. Sax, MD; Melanie A. Thompson, MD; Michael S. Saag, MD; IAS-USA Treatment Guidelines Panel</div>
                </a>
            </li>
    </ul>
 
    </div>
    <div class="widget-EditorsChoice widget-instance-AMA_EditorsChoice_Links">
        
 
    </div>
    <div class="widget-RelatedTopics widget-instance-AMA_Related_Topics">
        
 
    </div>
                <div class="ymal--footer">
    <div class="widget-WidgetLoader widget-instance-AMA_PersonalizedContent_SplitScreenView_Footer">
        <div class="SCM-SharedWidgets-AsyncWidgetLoader" data-url="/Personalization/PersonalizedContent/AMA_PersonalizedContent_SplitScreenView_Footer" data-params="{&quot;parameters&quot;:{&quot;resourceIdToExclude&quot;:2799240,&quot;resourceTypeToExclude&quot;:3},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}"></div>
 
    </div>

                </div>
                <hr />
                <div class="manage-interest">
                    <h4><a href="#" class="manage-interests-link-no-access thm-col-sec">Select Your Interests</a></h4>
    <div class="widget-ManageCollectionInterests widget-instance-ManageCollectionInterests_SplitScreen">
        <div class="manage-interests-modal reveal-modal small modal" data-reveal>
<div class="manage-interests--header">
    <div class="widget-SelfServeContent widget-instance-AMA_ManageInterests_Header">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="AllSitesManageInterestsHeader" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style>
    h4 {
    font-size: 20px !important;
    }
</style>
<h4>Select Your Interests</h4>
<p>Customize your JAMA Network experience by selecting one or more topics from the list below.</p>


</div>

 
    </div>

</div><div class="manage-interests--categories">
    <ul class="category-list">
            <li><span class="category-list-item " data-categoryid="46425">Academic Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5489">Acid Base, Electrolytes, Fluids</span></li>
            <li><span class="category-list-item " data-categoryid="5504">Allergy and Clinical Immunology</span></li>
            <li><span class="category-list-item " data-categoryid="46447">American Indian or Alaska Natives</span></li>
            <li><span class="category-list-item " data-categoryid="5510">Anesthesiology</span></li>
            <li><span class="category-list-item " data-categoryid="42143">Anticoagulation</span></li>
            <li><span class="category-list-item " data-categoryid="6261">Art and Images in Psychiatry</span></li>
            <li><span class="category-list-item " data-categoryid="44024">Artificial Intelligence</span></li>
            <li><span class="category-list-item " data-categoryid="42097">Assisted Reproduction</span></li>
            <li><span class="category-list-item " data-categoryid="42099">Bleeding and Transfusion</span></li>
            <li><span class="category-list-item " data-categoryid="5548">Cardiology</span></li>
            <li><span class="category-list-item " data-categoryid="44036">Caring for the Critically Ill Patient</span></li>
            <li><span class="category-list-item " data-categoryid="6255">Challenges in Clinical Electrocardiography</span></li>
            <li><span class="category-list-item " data-categoryid="46435">Climate and Health</span></li>
            <li><span class="category-list-item " data-categoryid="46448">Climate Change</span></li>
            <li><span class="category-list-item " data-categoryid="44038">Clinical Challenge</span></li>
            <li><span class="category-list-item " data-categoryid="5589">Clinical Decision Support</span></li>
            <li><span class="category-list-item " data-categoryid="44039">Clinical Implications of Basic Neuroscience</span></li>
            <li><span class="category-list-item " data-categoryid="5614">Clinical Pharmacy and Pharmacology</span></li>
            <li><span class="category-list-item " data-categoryid="5575">Complementary and Alternative Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="44040">Consensus Statements</span></li>
            <li><span class="category-list-item " data-categoryid="46099">Coronavirus (COVID-19)</span></li>
            <li><span class="category-list-item " data-categoryid="5584">Critical Care Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="46325">Cultural Competency</span></li>
            <li><span class="category-list-item " data-categoryid="44019">Dental Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5598">Dermatology</span></li>
            <li><span class="category-list-item " data-categoryid="44011">Diabetes and Endocrinology</span></li>
            <li><span class="category-list-item " data-categoryid="46320">Diagnostic Test Interpretation</span></li>
            <li><span class="category-list-item " data-categoryid="42054">Drug Development</span></li>
            <li><span class="category-list-item " data-categoryid="5620">Electronic Health Records</span></li>
            <li><span class="category-list-item " data-categoryid="5621">Emergency Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5819">End of Life, Hospice, Palliative Care</span></li>
            <li><span class="category-list-item " data-categoryid="42107">Environmental Health</span></li>
            <li><span class="category-list-item " data-categoryid="46387">Equity, Diversity, and Inclusion</span></li>
            <li><span class="category-list-item " data-categoryid="42108">Ethics</span></li>
            <li><span class="category-list-item " data-categoryid="5644">Facial Plastic Surgery</span></li>
            <li><span class="category-list-item " data-categoryid="44012">Gastroenterology and Hepatology</span></li>
            <li><span class="category-list-item " data-categoryid="5664">Genetics and Genomics</span></li>
            <li><span class="category-list-item " data-categoryid="44041">Genomics and Precision Health</span></li>
            <li><span class="category-list-item " data-categoryid="5668">Geriatrics</span></li>
            <li><span class="category-list-item " data-categoryid="5670">Global Health</span></li>
            <li><span class="category-list-item " data-categoryid="46427">Guide to Statistics and Methods</span></li>
            <li><span class="category-list-item " data-categoryid="5672">Guidelines</span></li>
            <li><span class="category-list-item " data-categoryid="5674">Hair Disorders</span></li>
            <li><span class="category-list-item " data-categoryid="42113">Health Care Delivery Models</span></li>
            <li><span class="category-list-item " data-categoryid="42114">Health Care Economics, Insurance, Payment</span></li>
            <li><span class="category-list-item " data-categoryid="42116">Health Care Quality</span></li>
            <li><span class="category-list-item " data-categoryid="5680">Health Care Reform</span></li>
            <li><span class="category-list-item " data-categoryid="5830">Health Care Safety</span></li>
            <li><span class="category-list-item " data-categoryid="5682">Health Care Workforce</span></li>
            <li><span class="category-list-item " data-categoryid="5679">Health Disparities</span></li>
            <li><span class="category-list-item " data-categoryid="46328">Health Inequities</span></li>
            <li><span class="category-list-item " data-categoryid="44020">Health Policy</span></li>
            <li><span class="category-list-item " data-categoryid="46451">Health Systems Science</span></li>
            <li><span class="category-list-item " data-categoryid="5688">Hematology</span></li>
            <li><span class="category-list-item " data-categoryid="5692">History of Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5514">Humanities</span></li>
            <li><span class="category-list-item " data-categoryid="5697">Hypertension</span></li>
            <li><span class="category-list-item " data-categoryid="44043">Images in Neurology</span></li>
            <li><span class="category-list-item " data-categoryid="45887">Implementation Science</span></li>
            <li><span class="category-list-item " data-categoryid="5702">Infectious Diseases</span></li>
            <li><span class="category-list-item " data-categoryid="44044">Innovations in Health Care Delivery</span></li>
            <li><span class="category-list-item " data-categoryid="44070">JAMA Infographic</span></li>
            <li><span class="category-list-item " data-categoryid="5716">Law and Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="45308">Leading Change</span></li>
            <li><span class="category-list-item " data-categoryid="44045">Less is More</span></li>
            <li><span class="category-list-item " data-categoryid="46327">LGBTQIA Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5720">Lifestyle Behaviors</span></li>
            <li><span class="category-list-item " data-categoryid="45311">Medical Coding</span></li>
            <li><span class="category-list-item " data-categoryid="5738">Medical Devices and Equipment</span></li>
            <li><span class="category-list-item " data-categoryid="44023">Medical Education</span></li>
            <li><span class="category-list-item " data-categoryid="5739">Medical Education and Training</span></li>
            <li><span class="category-list-item " data-categoryid="5713">Medical Journals and Publishing</span></li>
            <li><span class="category-list-item " data-categoryid="5746">Melanoma</span></li>
            <li><span class="category-list-item " data-categoryid="44025">Mobile Health and Telemedicine</span></li>
            <li><span class="category-list-item " data-categoryid="5766">Narrative Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5769">Nephrology</span></li>
            <li><span class="category-list-item " data-categoryid="5777">Neurology</span></li>
            <li><span class="category-list-item " data-categoryid="44052">Neuroscience and Psychiatry</span></li>
            <li><span class="category-list-item " data-categoryid="44053">Notable Notes</span></li>
            <li><span class="category-list-item " data-categoryid="5787">Nursing</span></li>
            <li><span class="category-list-item " data-categoryid="5788">Nutrition</span></li>
            <li><span class="category-list-item " data-categoryid="44027">Nutrition, Obesity, Exercise</span></li>
            <li><span class="category-list-item " data-categoryid="5791">Obesity</span></li>
            <li><span class="category-list-item " data-categoryid="44013">Obstetrics and Gynecology</span></li>
            <li><span class="category-list-item " data-categoryid="5796">Occupational Health</span></li>
            <li><span class="category-list-item " data-categoryid="5801">Oncology</span></li>
            <li><span class="category-list-item " data-categoryid="5804">Ophthalmology</span></li>
            <li><span class="category-list-item " data-categoryid="5808">Orthopedics</span></li>
            <li><span class="category-list-item " data-categoryid="5811">Otolaryngology</span></li>
            <li><span class="category-list-item " data-categoryid="44028">Pain Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="46446">Palliative Care</span></li>
            <li><span class="category-list-item " data-categoryid="44029">Pathology and Laboratory Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="45306">Patient Care</span></li>
            <li><span class="category-list-item " data-categoryid="6258">Patient Information</span></li>
            <li><span class="category-list-item " data-categoryid="5843">Pediatrics</span></li>
            <li><span class="category-list-item " data-categoryid="44060">Performance Improvement</span></li>
            <li><span class="category-list-item " data-categoryid="45315">Performance Measures</span></li>
            <li><span class="category-list-item " data-categoryid="42050">Perioperative Care and Consultation</span></li>
            <li><span class="category-list-item " data-categoryid="42125">Pharmacoeconomics</span></li>
            <li><span class="category-list-item " data-categoryid="42126">Pharmacoepidemiology</span></li>
            <li><span class="category-list-item " data-categoryid="5851">Pharmacogenetics</span></li>
            <li><span class="category-list-item " data-categoryid="44030">Pharmacy and Clinical Pharmacology</span></li>
            <li><span class="category-list-item " data-categoryid="5856">Physical Medicine and Rehabilitation</span></li>
            <li><span class="category-list-item " data-categoryid="42059">Physical Therapy</span></li>
            <li><span class="category-list-item " data-categoryid="45313">Physician Leadership</span></li>
            <li><span class="category-list-item " data-categoryid="44061">Poetry</span></li>
            <li><span class="category-list-item " data-categoryid="45316">Population Health</span></li>
            <li><span class="category-list-item " data-categoryid="46445">Primary Care</span></li>
            <li><span class="category-list-item " data-categoryid="45309">Professional Well-being</span></li>
            <li><span class="category-list-item " data-categoryid="44064">Professionalism</span></li>
            <li><span class="category-list-item " data-categoryid="5871">Psychiatry and Behavioral Health</span></li>
            <li><span class="category-list-item " data-categoryid="42128">Public Health</span></li>
            <li><span class="category-list-item " data-categoryid="5877">Pulmonary Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="42129">Radiology</span></li>
            <li><span class="category-list-item " data-categoryid="42058">Regulatory Agencies</span></li>
            <li><span class="category-list-item " data-categoryid="46443">Reproductive Health</span></li>
            <li><span class="category-list-item " data-categoryid="5916">Research, Methods, Statistics</span></li>
            <li><span class="category-list-item " data-categoryid="42142">Resuscitation</span></li>
            <li><span class="category-list-item " data-categoryid="5896">Rheumatology</span></li>
            <li><span class="category-list-item " data-categoryid="46326">Risk Management</span></li>
            <li><span class="category-list-item " data-categoryid="38802">Scientific Discovery and the Future of Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5833">Shared Decision Making and Communication</span></li>
            <li><span class="category-list-item " data-categoryid="5912">Sleep Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5915">Sports Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5533">Stem Cell Transplantation</span></li>
            <li><span class="category-list-item " data-categoryid="5921">Substance Use and Addiction Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5923">Surgery</span></li>
            <li><span class="category-list-item " data-categoryid="44065">Surgical Innovation</span></li>
            <li><span class="category-list-item " data-categoryid="44066">Surgical Pearls</span></li>
            <li><span class="category-list-item " data-categoryid="44067">Teachable Moment</span></li>
            <li><span class="category-list-item " data-categoryid="45310">Technology and Finance</span></li>
            <li><span class="category-list-item " data-categoryid="44034">The Art of JAMA</span></li>
            <li><span class="category-list-item " data-categoryid="44037">The Arts and Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="6257">The Rational Clinical Examination</span></li>
            <li><span class="category-list-item " data-categoryid="5936">Tobacco and e-Cigarettes</span></li>
            <li><span class="category-list-item " data-categoryid="5938">Toxicology</span></li>
            <li><span class="category-list-item " data-categoryid="46433">Translational Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="42136">Trauma and Injury</span></li>
            <li><span class="category-list-item " data-categoryid="5942">Treatment Adherence</span></li>
            <li><span class="category-list-item " data-categoryid="46323">Ultrasonography</span></li>
            <li><span class="category-list-item " data-categoryid="5947">Urology</span></li>
            <li><span class="category-list-item " data-categoryid="44069">Users&#39; Guide to the Medical Literature</span></li>
            <li><span class="category-list-item " data-categoryid="5950">Vaccination</span></li>
            <li><span class="category-list-item " data-categoryid="5955">Venous Thromboembolism</span></li>
            <li><span class="category-list-item " data-categoryid="45312">Veterans Health</span></li>
            <li><span class="category-list-item " data-categoryid="5957">Violence</span></li>
            <li><span class="category-list-item " data-categoryid="42139">Women&#39;s Health</span></li>
            <li><span class="category-list-item " data-categoryid="45307">Workflow and Process</span></li>
            <li><span class="category-list-item " data-categoryid="42140">Wound Care, Infection, Healing</span></li>
    </ul>
</div>

    
<div class="manage-interests--save-preferences">
    <div class="save-preferences-btn thm-bg ">
        <span class="save-preferences-btn-text fw-b">Save Preferences</span>
    </div>
</div>
<div class="manage-interests--privacy-terms"> <a class="manage-interests--privacy-terms-color" href="/pages/privacy-policy">Privacy Policy</a> | <a class="manage-interests--privacy-terms-color" href="/pages/terms-of-use">Terms of Use</a></div>

    
    <a class="close-reveal-modal icon-close"></a>
</div> 
    </div>

                </div>
                <h4 class="thm-col-sec" align="center">
                    Others Also Liked
                </h4>
                <div id="trendmd-suggestions"></div>

        </div>


        
        <div id="comments-tab" class="resource-tab js-resource-tab comments-tab js-comments-tab single-comment-view">



        </div>
    </div>
</div>

<a id="skip-to-navigation" href="#" tabindex="-1"></a>
<div id="content-panel" class="content-panel">
    <a id="top"></a>

    <div id="full-text-tab" class="resource-tab js-resource-tab full-text-tab">
    <div class="widget-ArticleLinks widget-instance-AMA_ErrataArticleLinks_FullText">
         
    </div>
    <div class="widget-ArticleLinks widget-instance-AMA_ArticleLinks_ToErrata_FullText">
        
 
    </div>
    <div class="widget-ArticleNavLinks widget-instance-AMA_ArticleNavLinks">
                <a class="toc-link btn" href="https://jamanetwork.com/journals/jama/issue/329/1">This Issue</a>
 
    </div>



            <div class="article-metrics-wrapper" id="divArticleLevelMetrics">
    <div class="widget-ArticleLevelMetrics widget-instance-AMA_ArticleMetrics">
        

    <div class="artmet-condensed-wrap clearfix">
        <div class="artmet-condensed-stats clearfix">
                <div class="artmet-item artmet-views">
                    <span class="artmet-text sb-sc">Views</span>
                    <span class="artmet-number sb-sc">211,892</span>
                </div>
                                <div class="artmet-item artmet-citations">
                            <a class="artmet-citations-link" href="https://www.webofscience.com/api/gateway?GWVersion=2&amp;SrcApp=silverchair&amp;SrcAuth=WosAPI&amp;KeyUT=WOS:000912844600001&amp;DestLinkType=FullRecord&amp;DestApp=WOS_CPL" target="_blank">
                                <span class="artmet-text">Citations</span>
                                <span class="artmet-number">124</span>
                            </a>
                    </div>
                                <div class="artmet-item artmet-altmetric">
    <div class="widget-AltmetricLink widget-instance-AMAv2_ArticleLevelMetrics_AltmetricLinkSummary">
            <!-- Altmetrics -->
    <div id="altmetricEmbedId" class='altmetric-embed' data-link-target="_blank" data-badge-type="text" data-hide-no-mentions="false" data-doi="10.1001/jama.2022.22246"
     
        
        ></div>
 
    </div>

                    </div>

        </div>

        <div class="artmet-modal-trigger-wrap">
            <a rel="nofollow" class="artmet-modal-trigger" data-article-id="2799240"><i class="icon-metrics"></i><span>View Metrics</span></a>
        </div>
    </div>

 
    </div>

            </div>
        <ul class="toolbar">
            <li class="toolbar-pdf-wrap toolbar-tool-wrap">
            <a id="pdf-link" class="toolbar-tool toolbar-pdf al-link pdfaccess" data-article-id="2799240" data-article-url="/journals/jama/articlepdf/2799240/jama_gandhi_2022_sc_220007_1671563383.14209.pdf" data-ajax-url="/Content/CheckPdfAccess"><span class="toolbar-pdf-text"><span class="toolbar-link-text-extra">Download </span><span class="toolbar-link-text">PDF</span></span>
            </a>

            </li>
            <li class="toolbar-share-wrap toolbar-tool-wrap">
                <div class="toolbar-tool">
                    <a class="st-custom-button addthis_button_twitter is-b toolbar-twitter toolbar-share"
                       data-network="twitter"
                       data-title=""
                       data-url=""
                       data-email-subject=""
                       rel="nofollow"
                       href="javascript:;">
                        <span class="share-text">X</span>
                    </a>
                    <a class="st-custom-button addthis_button_facebook is-b toolbar-facebook toolbar-share"
                       data-network="facebook"
                       data-title=""
                       data-url=""
                       data-email-subject=""
                       rel="nofollow"
                       href="javascript:;">
                        <span class="share-text">Facebook</span>
                    </a>
                    <a class="toolbar-share-more-link is-a" rel="nofollow"><span class="icon icon-carrot_down social-arrow"></span><span class="more-text-wrap">More</span></a>
                    <div class="toolbar-share-more">
                        <a class="st-custom-button addthis_button_linkedin is-b toolbar-linkedin toolbar-share"
                           data-network="linkedin"
                           data-title=""
                           data-url=""
                           data-email-subject=""
                           rel="nofollow"
                           href="javascript:;">
                            <span class="share-text">LinkedIn</span>
                        </a>
                    </div>
                </div>
            </li>
    <li class="toolbar-cme-wrap toolbar-tool-wrap">
                <a class="toolbar-tool toolbar-cme is-b jama-active-cme-button" rel="nofollow" href="https://edhub.ama-assn.org/jn-learning/module/2799240">CME &amp; MOC</a>

    </li>







            <li class="toolbar-citation-wrap toolbar-tool-wrap">
    <div class="widget-ToolboxGetCitation widget-instance-AMA_Get_Citation">
        
        <a class="toolbar-tool toolbar-citation is-b stats-citation" rel="nofollow" data-reveal-id="get-citation" data-reveal>
            <span class="toolbar-link-text">Cite</span>
            <span class="toolbar-link-text-extra">This</span>
        </a>
    <div id="get-citation" class="reveal-modal get-citation" data-reveal>
        <h3 class="get-citation-title">Citation</h3>
        <p class="get-citation-citation">Gandhi RT<span class='al-author-delim'>, </span>Bedimo R<span class='al-author-delim'>, </span>Hoy JF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults<span class="subtitle"><span class="colon-for-citation-subtitle">: </span>2022 Recommendations of the International Antiviral Society–USA Panel</span>. <em>JAMA.</em> 2023;329(1):63–84. doi:10.1001/jama.2022.22246</p>
        <h4 class="get-citation-download-heading">Manage citations:</h4>
        <div class="get-citation-types">
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2799240&amp;resourceType=3&amp;citationFormat=0">Ris (Zotero)</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2799240&amp;resourceType=3&amp;citationFormat=1">EndNote</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2799240&amp;resourceType=3&amp;citationFormat=2">BibTex</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2799240&amp;resourceType=3&amp;citationFormat=3">Medlars</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2799240&amp;resourceType=3&amp;citationFormat=0">ProCite</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2799240&amp;resourceType=3&amp;citationFormat=3">RefWorks</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2799240&amp;resourceType=3&amp;citationFormat=0">Reference Manager</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2799240&amp;resourceType=3&amp;citationFormat=0">Mendeley</a>
        </div>

        <p class="get-citation-copyright">&#169; 2024 </p>
        <a class="close-reveal-modal icon-close" rel="nofollow"></a>
    </div>


 
    </div>

            </li>
            <li class="toolbar-permissions-wrap toolbar-tool-wrap">
    <div class="widget-ToolboxPermissions widget-instance-AMA_Get_Permissions">
            <a href="http://s100.copyright.com/AppDispatchServlet?publisherName=AMA&amp;publication=0098-7484&amp;title=Antiretroviral+Drugs+for+Treatment+and+Prevention+of+HIV+Infection+in+Adults%3a+2022+Recommendations+of+the+International+Antiviral+Society%e2%80%93USA+Panel&amp;publicationDate=2023-01-03&amp;volumeNum=329&amp;issueNum=1&amp;author=Gandhi%2c+Rajesh+T.%3b+Bedimo%2c+Roger&amp;startPage=63&amp;endPage=84&amp;contentId=10.1001%2fjama.2022.22246&amp;oa=&amp;orderBeanReset=True" rel="nofollow" id="PermissionsLink" class="toolbar-tool toolbar-permissions is-b" target="_blank"><span class="toolbar-link-text">Permissions</span></a>
 
    </div>

            </li>
        </ul>

    <div class="widget-ArticleTopInfo widget-instance-AMA_ArticleTop_Info_Widget">
        

    <div class="meta-access-type free-access is-b"></div>


            <span class="hide tagmanagervalue" data-attribute="articleId" data-value="2799240" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="arrArticleAuthor" data-value="Rajesh%20T.%C2%A0Gandhi%2C%C2%A0MD,Roger%C2%A0Bedimo%2C%C2%A0MD,Jennifer%20F.%C2%A0Hoy%2C%C2%A0MBBS,Raphael%20J.%C2%A0Landovitz%2C%C2%A0MD,Davey%20M.%C2%A0Smith%2C%C2%A0MD,Ellen%20F.%C2%A0Eaton%2C%C2%A0MD,Clara%C2%A0Lehmann%2C%C2%A0MD,Sandra%20A.%C2%A0Springer%2C%C2%A0MD,Paul%20E.%C2%A0Sax%2C%C2%A0MD,Melanie%20A.%C2%A0Thompson%2C%C2%A0MD,Constance%20A.%C2%A0Benson%2C%C2%A0MD,Susan%20P.%C2%A0Buchbinder%2C%C2%A0MD,Carlos%C2%A0del%20Rio%2C%C2%A0MD,Joseph%20J.%C2%A0Eron%C2%A0Jr%2C%C2%A0MD,Huldrych%20F.%C2%A0G%C3%BCnthard%2C%C2%A0MD,Jean-Michel%C2%A0Molina%2C%C2%A0MD,Donna%20M.%C2%A0Jacobsen%2C%C2%A0BS,Michael%20S.%C2%A0Saag%2C%C2%A0MD" data-type="array"></span>
            <span class="hide tagmanagervalue" data-attribute="articleDOI" data-value="10.1001/jama.2022.22246" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="articleTitle" data-value="Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults&lt;span class=&quot;subtitle&quot;&gt;&lt;span class=&quot;colon-for-citation-subtitle&quot;&gt;: &lt;/span&gt;2022 Recommendations of the International Antiviral Society–USA Panel&lt;/span&gt;" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="type" data-value="Special Communication" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="issueVolume" data-value="329" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="issueNo" data-value="1" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="publishDate" data-value="January 3, 2023" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="category" data-value="Review" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="journalClub" data-value="No" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="contentStatus" data-value="Free" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="articlePubState" data-value="Final" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="contentMedium" data-value="Article" data-type="string"></span>


        <div class="meta-article-type-wrap">
            <div class="meta-article-type thm-col">Special Communication </div>
        </div>
        <div class="meta-date">December 1, 2022</div>
        <div class="meta-article-title-wrap">
            
            <h1 class="meta-article-title ">Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults<span class="subtitle"><span class="colon-for-citation-subtitle">: </span>2022 Recommendations of the International Antiviral Society–USA Panel</span></h1>

            
        </div>
            <div class="meta-authors">
                <span class="meta-authors--limited"><span class="wi-fullname brand-fg"><a href="/searchresults?author=Rajesh+T.+Gandhi&q=Rajesh+T.+Gandhi" rel=nofollow target="_blank">Rajesh T. Gandhi, MD<sup>1</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Roger+Bedimo&q=Roger+Bedimo" rel=nofollow target="_blank">Roger Bedimo, MD<sup>2</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Jennifer+F.+Hoy&q=Jennifer+F.+Hoy" rel=nofollow target="_blank">Jennifer F. Hoy, MBBS<sup>3</sup></a></span>; <a class="meta-authors--etal td-u stats-meta-authors--etal">et al</a></span>
                <span class="meta-authors--remaining"><span class="wi-fullname brand-fg"><a href="/searchresults?author=Raphael+J.+Landovitz&q=Raphael+J.+Landovitz" rel=nofollow target="_blank">Raphael J. Landovitz, MD<sup>4</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Davey+M.+Smith&q=Davey+M.+Smith" rel=nofollow target="_blank">Davey M. Smith, MD<sup>5</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Ellen+F.+Eaton&q=Ellen+F.+Eaton" rel=nofollow target="_blank">Ellen F. Eaton, MD<sup>6</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Clara+Lehmann&q=Clara+Lehmann" rel=nofollow target="_blank">Clara Lehmann, MD<sup>7</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Sandra+A.+Springer&q=Sandra+A.+Springer" rel=nofollow target="_blank">Sandra A. Springer, MD<sup>8,9</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Paul+E.+Sax&q=Paul+E.+Sax" rel=nofollow target="_blank">Paul E. Sax, MD<sup>10</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Melanie+A.+Thompson&q=Melanie+A.+Thompson" rel=nofollow target="_blank">Melanie A. Thompson, MD<sup>11</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Constance+A.+Benson&q=Constance+A.+Benson" rel=nofollow target="_blank">Constance A. Benson, MD<sup>5</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Susan+P.+Buchbinder&q=Susan+P.+Buchbinder" rel=nofollow target="_blank">Susan P. Buchbinder, MD<sup>12</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Carlos+del+Rio&q=Carlos+del+Rio" rel=nofollow target="_blank">Carlos del Rio, MD<sup>13</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Joseph+J.+Eron&q=Joseph+J.+Eron" rel=nofollow target="_blank">Joseph J. Eron Jr, MD<sup>14</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Huldrych+F.+G%c3%bcnthard&q=Huldrych+F.+G%c3%bcnthard" rel=nofollow target="_blank">Huldrych F. Günthard, MD<sup>15</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Jean-Michel+Molina&q=Jean-Michel+Molina" rel=nofollow target="_blank">Jean-Michel Molina, MD<sup>16</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Donna+M.+Jacobsen&q=Donna+M.+Jacobsen" rel=nofollow target="_blank">Donna M. Jacobsen, BS<sup>17</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Michael+S.+Saag&q=Michael+S.+Saag" rel=nofollow target="_blank">Michael S. Saag, MD<sup>6</sup></a></span></span>
            </div>
            <div class="meta-author">
                <a class="meta-author-title is-b stats-meta-author-toggle" data-tog-target=".meta-author-content">Author Affiliations</a>
                    <a class="meta-articleinfo-jumplink section-jump-link scroll-to stats-scroll-to-articleinfo" data-tab-toggle=".tab-nav-full-text" href="#248771340">Article Information</a>


                <div class="meta-author-content">
                        <ul class="meta-author-affiliations">
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>1</sup>Massachusetts General Hospital and Harvard Medical School, Boston</div>
                                </li>
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>2</sup>University of Texas Southwestern Medical Center, Dallas</div>
                                </li>
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>3</sup>The Alfred Hospital and Monash University, Melbourne, Australia</div>
                                </li>
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>4</sup>University of California Los Angeles</div>
                                </li>
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>5</sup>University of California San Diego School of Medicine</div>
                                </li>
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>6</sup>University of Alabama at Birmingham</div>
                                </li>
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>7</sup>University of Cologne and German Center for Infection Research (DZIF), Bonn-Cologne</div>
                                </li>
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>8</sup>Yale University School of Medicine, New Haven, Connecticut</div>
                                </li>
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>9</sup>The Veterans Administration Connecticut Healthcare System, West Haven</div>
                                </li>
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>10</sup>Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts</div>
                                </li>
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>11</sup>Thacker &amp; Thompson, Atlanta, Georgia</div>
                                </li>
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>12</sup>Department of Public Health, San Francisco, California</div>
                                </li>
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>13</sup>Emory University School of Medicine and Grady Health System, Atlanta, Georgia</div>
                                </li>
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>14</sup>The University of North Carolina School of Medicine at Chapel Hill</div>
                                </li>
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>15</sup>University Hospital Zurich and Institute of Medical Virology, University of Zurich, Zurich, Switzerland</div>
                                </li>
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>16</sup>University of Paris Cité, Saint-Louis and Lariboisière Hospitals, Assistance Publique Hopitaux de Paris, France</div>
                                </li>
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>17</sup>International Antiviral Society–USA, San Francisco, California</div>
                                </li>
                        </ul>



                </div>
            </div>
        <div class="meta-citation-wrap">
            <span class="meta-citation-journal-name">JAMA. </span><span class="meta-citation"> 2023;329(1):63-84. doi:10.1001/jama.2022.22246</span>
        </div>

 
    </div>
    <div class="widget-EditorsChoice widget-instance-AMA_EditorsChoice_Links">
        
 
    </div>
    <div class="widget-LinkedContentToolbar widget-instance-AMA_LinkedContentToolbar">
        
<div class="linked-content-toolbar">
    
    <div class="hidden js-search-open-multimedia-by-default" showContentByDefault="False"></div>
    <div class="linked-content-controls">
        <a class="linked-content-trigger td-n stats-graphical-abstract" href="#graphical-abstract-tab">
            <i class="icon-visual-abstract"><span class="sr-t">visual abstract icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Visual <div>Abstract</div></div>
        </a>
        <a class="linked-content-trigger td-n stats-editorial-comment" href="#editorial-comment-tab">
            <i class="icon-document"><span class="sr-t">editorial comment icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Editorial <div>Comment</div></div>
        </a>
        <a class="linked-content-trigger td-n stats-related-articles" href="#related-articles-tab">
            <i class="icon-related"><span class="sr-t">related articles icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Related <div>Articles</div></div>
        </a>
        <a class="linked-content-trigger td-n stats-author-interviews" href="#author-interviews-tab">
            <i class="icon-author_interview"><span class="sr-t">author interview icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Interviews</div>
        </a>
        <a class="linked-content-trigger td-n stats-more-multimedia" href="#more-multimedia-tab">
            <i class="icon-multimedia"><span class="sr-t">multimedia icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Multimedia</div>
        </a>
        <a class="linked-content-trigger td-n stats-listen-to-this-article" href="#listen-to-this-article-tab">
            <i class="icon-audio"><span class="sr-t">audio icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Listen to <div>this article</div></div>
        </a>
    </div>

    
<div class="linked-content-tabs">
    <div id="graphical-abstract-tab" class="linked-content-tab graphical-abstract-tab">
    <div class="widget-SectionDisplay widget-instance-AMA_GraphicalAbstract_Tab">
        
 
    </div>

    </div>

    
    <div id="editorial-comment-tab" class="linked-content-tab editorial-comment-tab">
    <div class="widget-ArticleLinks widget-instance-AMA_LinkedContentToolbar_EditorialComments">
        
 
    </div>

    </div>

    
    <div id="related-articles-tab" class="linked-content-tab related-article-tab">
    <div class="widget-ArticleLinks widget-instance-AMA_LinkedContentToolbar_RelatedArticle">
        
    <ul class="article-abstract-links related-abstract-content">
            <li class="article-link related-abstract-article">

                    <a class="related-article-title" href="https://jamanetwork.com/journals/jama/fullarticle/2688574">
                            <div class="related-article-type">Special Communication</div>
                        <div class="related-article-title sb-tc">Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults</div>
                    </a>
                    <div class="related-article-authors">Michael S. Saag, MD; Constance A. Benson, MD; Rajesh T. Gandhi, MD; Jennifer F. Hoy, MBBS; Raphael J. Landovitz, MD; Michael J. Mugavero, MD, MHSc; Paul E. Sax, MD; Davey M. Smith, MD; Melanie A. Thompson, MD; Susan P. Buchbinder, MD; Carlos del Rio, MD; Joseph J. Eron Jr, MD; Gerd Fätkenheuer, MD; Huldrych F. Günthard, MD; Jean-Michel Molina, MD; Donna M. Jacobsen, BS; Paul A. Volberding, MD</div>
                                    <div class="related-article-journal-name">JAMA</div>
            </li>
            <li class="article-link related-abstract-article">

                    <a class="related-article-title" href="https://jamanetwork.com/journals/jama/fullarticle/2771873">
                            <div class="related-article-type">Special Communication</div>
                        <div class="related-article-title sb-tc">Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults</div>
                    </a>
                    <div class="related-article-authors">Michael S. Saag, MD; Rajesh T. Gandhi, MD; Jennifer F. Hoy, MBBS; Raphael J. Landovitz, MD; Melanie A. Thompson, MD; Paul E. Sax, MD; Davey M. Smith, MD; Constance A. Benson, MD; Susan P. Buchbinder, MD; Carlos del Rio, MD; Joseph J. Eron Jr, MD; Gerd Fätkenheuer, MD; Huldrych F. Günthard, MD; Jean-Michel Molina, MD; Donna M. Jacobsen, BS; Paul A. Volberding, MD</div>
                                    <div class="related-article-journal-name">JAMA</div>
            </li>
            <li class="article-link related-abstract-article">

                    <a class="related-article-title" href="https://jamanetwork.com/journals/jama/fullarticle/2799239">
                            <div class="related-article-type">Viewpoint</div>
                        <div class="related-article-title sb-tc">Ending the HIV Epidemic</div>
                    </a>
                    <div class="related-article-authors">Marwan Haddad, MD, MPH; Anna K. Person, MD; Hansel E. Tookes, MD, MPH</div>
                                    <div class="related-article-journal-name">JAMA</div>
            </li>
            <li class="article-link related-abstract-article">

                    <a class="related-article-title" href="https://jamanetwork.com/journals/jama/fullarticle/2800024">
                            <div class="related-article-type">Original Investigation</div>
                        <div class="related-article-title sb-tc">Prescription of Antiretroviral Therapy Among People With HIV by Race and Ethnicity</div>
                    </a>
                    <div class="related-article-authors">Lauren C. Zalla, PhD; Stephen R. Cole, PhD; Joseph J. Eron, MD; Adaora A. Adimora, MD, MPH; Anissa I. Vines, MS, PhD; Keri N. Althoff, MPH, PhD; Michael J. Silverberg, PhD, MPH; Michael A. Horberg, MD, MAS; Vincent C. Marconi, MD; Sally B. Coburn, PhD, MPH; Raynell Lang, MD, MS; Emily C. Williams, PhD, MPH; M. John Gill, MBChB; Kelly A. Gebo, MD, MPH; Marina Klein, MD, MS; Timothy R. Sterling, MD; Peter F. Rebeiro, PhD, MHS; Angel M. Mayor, MD, MS; Richard D. Moore, MD; Jessie K. Edwards, PhD</div>
                                    <div class="related-article-journal-name">JAMA</div>
            </li>
            <li class="article-link related-abstract-article">

                    <a class="related-article-title" href="https://jamanetwork.com/journals/jama/fullarticle/2803584">
                            <div class="related-article-type">JAMA Insights</div>
                        <div class="related-article-title sb-tc">Antiretroviral Treatment of HIV/AIDS During Pregnancy</div>
                    </a>
                    <div class="related-article-authors">Ahizechukwu C. Eke, MD, PhD, MPH; Shahin Lockman, MD; Lynne M. Mofenson, MD</div>
                                    <div class="related-article-journal-name">JAMA</div>
            </li>
            <li class="article-link related-abstract-article">

                    <a class="related-article-title" href="https://jamanetwork.com/journals/jama/fullarticle/2812672">
                            <div class="related-article-type">JAMA Diagnostic Test Interpretation</div>
                        <div class="related-article-title sb-tc">Fourth-Generation HIV Testing</div>
                    </a>
                    <div class="related-article-authors">Michael R. Rose, MD, MPH; Natasha M. Chida, MD, MSPH; Joyce L. Jones, MD, MS</div>
                                    <div class="related-article-journal-name">JAMA</div>
            </li>
            <li class="article-link related-abstract-article">

                    <a class="related-article-title" href="https://jamanetwork.com/journals/jama/fullarticle/2812670">
                            <div class="related-article-type">A Piece of My Mind</div>
                        <div class="related-article-title sb-tc">Pride</div>
                    </a>
                    <div class="related-article-authors">David Malebranche, MD, MPH</div>
                                    <div class="related-article-journal-name">JAMA</div>
            </li>
            <li class="article-link related-abstract-article">

                    <a class="related-article-title" href="https://jamanetwork.com/journals/jama/fullarticle/2816037">
                            <div class="related-article-type">Comment & Response</div>
                        <div class="related-article-title sb-tc">Updated HIV Treatment Recommendation on Use of Cabotegravir and Rilpivirine</div>
                    </a>
                    <div class="related-article-authors">Paul E. Sax, MD; Melanie A. Thompson, MD; Michael S. Saag, MD; IAS-USA Treatment Guidelines Panel</div>
                                    <div class="related-article-journal-name">JAMA</div>
            </li>
    </ul>
 
    </div>
    <div class="widget-ArticleLinks widget-instance-AMA_LinkedContentToolbar_RelatedEditorsChoices">
        
 
    </div>

    </div>

    
    <div id="author-interviews-tab" class="linked-content-tab linked-author-interviews-tab">
    <div class="widget-AudioPlayer widget-instance-AMA_LinkedContentToolbar_PlatformAudioPlayer_AuthorInterviews">
                <div class="audio-border-top  thm-bg-col sb-background-pc"></div>
    <div class="audio-element-wrapper js-audio-element-wrapper">
            <div class="audio-group-duration">
                Audio  (22:19)
            </div>
                    <div><a class="audio-title" href="https://jamanetwork.com/learning/audio-player/18741120" target="_blank" aria-label="Linked Multimedia Button">Advances in Treatment and Prevention of HIV</a></div>
                <div id="audio-player-wrapper" class="js-audio-player-wrapper audio-player-wrapper">
            <audio class="js-audio-player" id="audio-player" type="audio/mp3" preload="none" src=https://traffic.libsyn.com/secure/jamaclinicalreviews/advances_in_treatment_and_prevention_of_hiv.mp3></audio>
            <div class="display-elements">
                <div class="audio-controls">
                    <a id="backward" class="js-btn-backward audio-back" href="javascript:;" aria-label="Back Button">
                        <img src="//cdn.jamanetwork.com/UI/app/svg/multimedia/Backward_15.svg" alt="Backward 15" />
                    </a>
                    <a id="play-pause" class="js-play-pause audio-play" href="javascript:;" aria-label="Play Button">
                        <img src="//cdn.jamanetwork.com/UI/app/svg/multimedia/Play.svg" alt="Play" />
                    </a>
                    <a id="play-pause" class="js-play-pause audio-pause" href="javascript:;" aria-label="Pause Button">
                        <img src="//cdn.jamanetwork.com/UI/app/svg/multimedia/Pause.svg" alt="Pause" />
                    </a>
                    <a id="forward" class="js-btn-forward audio-forward" href="javascript:;" aria-label="Fast Forward Button">
                        <img src="//cdn.jamanetwork.com/UI/app/svg/multimedia/Forward_15.svg" alt="Forward 15" />
                    </a>
                </div>
                <div class="js-progressBar-clickable progressBar-clickable">
                    <div class="js-progressBar progressBar">
                        <div class="js-loading-animation">
                            <div class="loading-blade thm-bg-col sb-pc"></div>
                            <div class="loading-blade thm-bg-col sb-pc"></div>
                            <div class="loading-blade thm-bg-col sb-pc"></div>
                            <div class="loading-blade thm-bg-col sb-pc"></div>
                            <div class="loading-blade thm-bg-col sb-pc"></div>
                            <div class="loading-blade thm-bg-col sb-pc"></div>
                            <div class="loading-blade thm-bg-col sb-pc"></div>
                            <div class="loading-blade thm-bg-col sb-pc"></div>
                        </div>
                        <div class="js-timeBar timeBar thm-bg-col sb-background-pc" tabindex="0" aria-label="Progress Bar"></div>
                    </div>
                </div>
                <div class="audio-speed">
                    <a id="speed-1x" class="js-btn-speed" play-speed=1 href="javascript:;" aria-label="Speed Control Button">1x</a>
                </div>
                <div class="audio-time">
                    <span id="time" class="js-time js-timeAudioCurrent">0:00</span>
                    <span> / </span>
                    <span class="js-initialTime">0:00</span>
                    <span class="js-duration hide"></span>
                </div>
            </div>
        </div>
            <div class="linked-content-urls-wrapper">
                            <span><a class="thm-col sb-pc linked-content" target="_blank" href="https://jamanetwork.com/journals/jama/pages/jama-clinical-reviews" aria-label="Subscribe To Podcast Button">Subscribe to Podcast</a></span>

            </div>
        
    </div>
 
    </div>
    <div class="widget-MultimediaInfo widget-instance-AMA_LinkedContentToolbar_AuthorInterviews">
        





 
    </div>

    </div>

    
    <div id="listen-to-this-article-tab" class="linked-content-tab linked-listen-to-this-article-tab">
    <div class="widget-AudioPlayer widget-instance-AMA_LinkedContentToolbar_PlatformAudioPlayer_ListenToThisArticle">
         
    </div>

    </div>

    
    <div id="more-multimedia-tab" class="linked-content-tab more-multimedia-tab">
    <div class="widget-MultimediaInfo widget-instance-AMA_LinkedContentToolbar_MoreMultimedia">
        





 
    </div>

    </div>
</div>
</div> 
    </div>

            <div class="widget-ArticleFulltext widget-instance-AMA_Article_FullText_Widget">
        <div class="article-full-text" data-userHasAccess="True">
    

            <a class="article-section-id-anchor" id="248771203"></a>
                        <div class="h3 cb section-type-abstract decorated-hed ">

                            <div class="heading-text thm-col sb-sc">
                                Abstract
                            </div>
                        </div>
<p><strong>Importance</strong> 
    <span>Recent advances in treatment and prevention of HIV warrant updated recommendations to guide optimal practice.</span></p><p><strong>Objective</strong> 
    <span>Based on a critical evaluation of new data, to provide clinicians with recommendations on use of antiretroviral drugs for the treatment and prevention of HIV, laboratory monitoring, care of people aging with HIV, substance use disorder and HIV, and new challenges in people with HIV, including COVID-19 and monkeypox virus infection.</span></p><p><strong>Evidence Review</strong> 
    <span>A panel of volunteer expert physician scientists were appointed to update the 2020 consensus recommendations. Relevant evidence in the literature (PubMed and Embase searches, which initially yielded 7891 unique citations, of which 834 were considered relevant) and studies presented at peer-reviewed scientific conferences between January 2020 and October 2022 were considered.</span></p><p><strong>Findings</strong> 
    <span>Initiation of antiretroviral therapy (ART) is recommended as soon as possible after diagnosis of HIV. Barriers to care should be addressed, including ensuring access to ART and adherence support. Integrase strand transfer inhibitor–containing regimens remain the mainstay of initial therapy. For people who have achieved viral suppression with a daily oral regimen, long-acting injectable therapy with cabotegravir plus rilpivirine given as infrequently as every 2 months is now an option. Weight gain and metabolic complications have been linked to certain antiretroviral medications; novel strategies to ameliorate these complications are needed. Management of comorbidities throughout the life span is increasingly important, because people with HIV are living longer and confronting the health challenges of aging. In addition, management of substance use disorder in people with HIV requires an evidence-based, integrated approach. Options for preexposure prophylaxis include oral medications (tenofovir disoproxil fumarate or tenofovir alafenamide plus emtricitabine) and, for the first time, a long-acting injectable agent, cabotegravir. Recent global health emergencies, like the SARS-CoV-2 pandemic and monkeypox virus outbreak, continue to have a major effect on people with HIV and the delivery of services. To address these and other challenges, an equity-based approach is essential.</span></p><p><strong>Conclusions and Relevance</strong> 
    <span>Advances in treatment and prevention of HIV continue to improve outcomes, but challenges and opportunities remain.</span></p>            <div class="movable-ad-target bta"> </div>
            <a class="article-section-id-anchor" id="248771208"></a>
                        <div class="h3 cb section-type-section  ">

                            <div class="heading-text thm-col sb-sc">
                                Introduction
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771209"></a>
<p class="para">Four decades after the initial cases of HIV were reported, strategies for treating and preventing HIV infection continue to advance. People with HIV should be treated as soon as possible after diagnosis. If they have an opportunistic infection, antiretroviral therapy (ART) should be started shortly after initiation of treatment of the infection. Initial ART options include daily oral therapy, usually with a combination containing an integrase strand transfer inhibitor (InSTI). For patients who have achieved viral suppression, a long-acting injectable regimen (cabotegravir and rilpivirine [RPV]), which can be dosed every 2 months, is an option.</p>            <a class="article-section-id-anchor" id="248771210"></a>
<p class="para">In addition to treatment improvements, there have been major advances in HIV prevention through preexposure prophylaxis (PrEP), including daily oral options and, for the first time, a long-acting injectable option, cabotegravir.</p>            <a class="article-section-id-anchor" id="248771211"></a>
<p class="para">As treatment and prevention of HIV improve, new challenges and opportunities arise. As people with HIV live longer, there are important considerations related to aging that require an integrated approach. Multidisciplinary and holistic care of people with substance use and substance use disorder is required to achieve optimal outcomes in treating and preventing HIV. Other infectious disease outbreaks, such as COVID-19 and now monkeypox virus infection, also present rapidly evolving challenges for clinicians and people with HIV. To effectively address these and other challenges, as well as to realize the opportunity to end the HIV epidemic, efforts must be redoubled, with equity being the guiding principle.</p>            <a class="article-section-id-anchor" id="248771212"></a>
<p class="para">This updated article provides current recommendations for treatment and prevention of HIV as well as an up-to-date discussion of important comorbidities and coinfections in people with HIV as they relate to the use of ART.</p>            <a class="article-section-id-anchor" id="248771213"></a>
                        <div class="h3 cb section-type-section  ">

                            <div class="heading-text thm-col sb-sc">
                                Methods
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771214"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Appointment of the Panel
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771215"></a>
<p class="para">A volunteer international panel of experts in HIV research and clinical care, and the panel leadership, was appointed by International Antiviral (formerly AIDS) Society–USA (IAS-USA). Members were screened for expertise, involvement in research and care, financial relationships, and ability to work toward consensus. New members were added since the panel’s last report to contribute additional expertise, particularly in substance use disorders and antiretroviral drugs. The panel convened in person and by conference calls from October 2021 to October 2022. Teams were appointed for each primary section, which evaluated relevant evidence and drafted recommendations for review by the full panel.</p>            <a class="article-section-id-anchor" id="248771216"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Identification of the Evidence
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771217"></a>
<p class="para">New evidence on antiretroviral drugs was identified in the published literature, major scientific conference presentations, or safety reports.<sup><a href="#jsc220007r1" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">1</a></sup> Literature searches were conducted by a panel member (C.d.R.) in PubMed and Embase for the period January 2020 to October 2022, and the panel monitored for new evidence thereafter. The 7891 unique citations were reviewed by a member (M.S.S.) who identified 834 possibly relevant publications. The substance use disorder team identified and reviewed additional evidence to develop this newly added section. Abstracts presented at scientific conferences between July 2020 and October 2022 were identified by panel members and teams. Additional relevant scientific publications or abstracts presented at peer-reviewed conferences were identified by the panel, and published and presented citations were obtained from drug manufacturers.</p>            <a class="article-section-id-anchor" id="248771218"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Process
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771219"></a>
<p class="para">The updated recommendations focus on adults with or at risk for HIV infection in settings in which most antiretroviral drugs are available. Each recommendation is rated for the strength of the recommendation and the quality of the supporting evidence (<a href="#jsc220007t1" class="table-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 1</a>). For recommendations that have not changed substantially or for which few new data have become available since 2020, the previous iterations of the recommendations provide background information and relevant evidence.<sup><a href="#jsc220007r1" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">1</a></sup> Key recommendations for each section are listed in a Box or Table. ART drug combinations that are co-formulated are noted with slashes (eg, drug A/drug B/drug C). Detailed tables and further details about the process, panel, evidence identification, and the IAS–USA and its policies are available in the <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-JSC220007-1">Supplement</a>.</p>            <a class="article-section-id-anchor" id="248771221"></a>
                        <div class="h3 cb section-type-section  ">

                            <div class="heading-text thm-col sb-sc">
                                Initiation of ART
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771222"></a>
<p class="para">Recommendations for when to start ART are reported in <a href="#jsc220007b1" class="section-jump-link contents-tab-jump-link scroll-to box-link" data-tab-toggle=".tab-nav-full-text">Box 1</a>. Initiating ART as soon as possible after an HIV diagnosis is a high priority to improve the health and life expectancy of people with HIV and to eliminate HIV transmission to sexual and injection drug use partners, as well as to infants.<sup><a href="#jsc220007r1" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">1</a></sup> Rapid ART initiation (within 7 days of diagnosis), including same-day initiation of ART on the day of diagnosis or the first clinic visit, improves the likelihood of persons linking to HIV care and the likelihood of and time to viral suppression.<sup><a href="#jsc220007r3" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">3</a></sup><sup>-<a href="#jsc220007r3" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">5</a></sup> In resource-limited settings, rapid ART initiation improved survival and longitudinal engagement in care.<sup><a href="#jsc220007r6" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">6</a></sup> In highly resourced settings, there are limited clinical and long-term outcomes from randomized clinical trials of rapid ART initiation. Based on the totality of evidence, ART initiation is recommended within 7 days of diagnosis, including on the day of diagnosis or the first clinic visit, if the patient is ready and there is no evidence of a co-occurring opportunistic infection that might affect the timing of initiation of treatment (evidence rating: AIII). Timing and choice of initial therapy in the presence of an acute opportunistic infection is discussed in the Initiating ART in the Setting of Active Opportunistic Infections and Cancer section below.</p>            <a class="article-section-id-anchor" id="248771223"></a>
<a id="jsc220007b1" name="jsc220007b1"><span style="display:none;">Box Section Ref ID</span></a><div class="box-section  clip-last-child thm-bg"><div class="label">Box 1. </div><h4 class="box-section--title">Key Recommendations for When to Start Antiretroviral Therapy (ART)</h4><ul class="bullet"><li><p class="para">Initiation of ART is recommended as soon as possible after diagnosis, ideally within 7 days, including on the same day as diagnosis or at the first clinic visit if the patient is ready and there is no suspicion for a concurrent opportunistic infection (evidence rating: AIII)</p></li><li><p class="para">Structural barriers that could delay receipt of ART (including same-day), and impede care engagement, continuous ART access, and ART adherence should be identified and addressed using evidence-informed strategies (evidence rating: AIIa)</p></li><li><p class="para">Initiation of ART at the time of diagnosis of acute HIV infection is recommended (evidence rating: AIIa)</p></li><li><p class="para">Initiation of ART is recommended within 2 weeks of initiation of treatment for most opportunistic infections</p><ul class="bullet"><li><p class="para">For persons with active tuberculosis without evidence of tuberculous meningitis, ART should be initiated within 2 weeks after initiation of tuberculosis treatment, especially for those with CD4 cell count less than 50/μL (evidence rating: AIa)</p></li><li><p class="para">For those with tuberculous meningitis, high-dose steroids should be initiated along with tuberculosis treatment and ART should be initiated within 2 weeks after starting tuberculosis treatment and steroids (evidence rating: BIa)</p></li><li><p class="para">For individuals with cryptococcal meningitis with access to close monitoring and supportive care for adverse events, ART should be initiated 2 to 4 weeks after starting antifungal therapy (evidence rating: BIIb); ART-naive individuals who have asymptomatic cryptococcal antigenemia and a negative lumbar puncture result with no evidence of cryptococcal meningitis should start ART immediately (evidence rating: BIII)</p></li><li><p class="para">Initiation of ART is recommended immediately in the setting of a new diagnosis of cancer with attention to drug-drug interactions (evidence rating: BIIa)</p></li></ul></li></ul></div>            <a class="article-section-id-anchor" id="248771224"></a>
<p class="para">The success of ART depends on addressing barriers to care and on reliable ART access and adherence support. Identification and elimination of barriers is especially crucial to the success of rapid ART initiation programs. Barriers often include lack of transportation, housing instability,<sup><a href="#jsc220007r7" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">7</a></sup> food insecurity, racism,<sup><a href="#jsc220007r8" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">8</a></sup> out-of-pocket drug costs, pharmacy availability, restrictive clinic hours, stigma, and discrimination. Barriers that impair care engagement and ART access and adherence should be identified and addressed using evidence-informed methods (evidence rating: AIIa). These include individual-level interventions such as case management and patient/peer navigation to initiate linkage to care and social services; transportation and accompaniment to visits; appointment reminders; and psychosocial support.<sup><a href="#jsc220007r9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup> Evidence-based structural interventions include “data to care” (using data systems to identify people who are out of care, to provide services), mobile clinics, telehealth, street medicine, use of visiting nurses, expanded clinic hours, pharmacy delivery, use of community health workers, and use of strategies to eliminate health care–related stigma and discrimination.<sup><a href="#jsc220007r10" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">10</a></sup></p>            <a class="article-section-id-anchor" id="248771225"></a>
<p class="para">The panel recommends initiating ART at the time of diagnosis for persons with acute HIV infection (evidence rating: AIIa). Immediate ART initiation leads to rapid viral suppression, thus decreasing the risk of transmission to others, and preserves immune responses.<sup><a href="#jsc220007r4" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">4</a></sup><sup>,<a href="#jsc220007r11" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">11</a></sup><sup>,<a href="#jsc220007r12" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">12</a></sup> Additionally, early ART initiation is associated with a lower viral reservoir.<sup><a href="#jsc220007r13" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">13</a></sup> People with HIV who have low or undetectable HIV RNA levels without taking ART (“elite controllers”) have elevated levels of inflammation that are reduced after ART is initiated.<sup><a href="#jsc220007r14" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">14</a></sup><sup>,<a href="#jsc220007r15" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">15</a></sup> In addition, even those who manifest low viral loads initially often do not maintain control over time.<sup><a href="#jsc220007r16" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">16</a></sup> Based on the theoretical benefits of reducing inflammation in people with HIV, treating elite controllers is reasonable.</p>            <a class="article-section-id-anchor" id="248771226"></a>
                        <div class="h3 cb section-type-section  ">

                            <div class="heading-text thm-col sb-sc">
                                Initial ART Regimens for Individuals With HIV
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771227"></a>
<p class="para">Recommended initial ART regimens for individuals with HIV are reported in <a href="#jsc220007b2" class="section-jump-link contents-tab-jump-link scroll-to box-link" data-tab-toggle=".tab-nav-full-text">Box 2</a>. Regimens containing the InSTIs bictegravir (BIC) or dolutegravir (DTG) are recommended as initial treatment for most individuals owing to their high efficacy, tolerability, safety, and high barrier to resistance; low pill burden; and low potential for drug-drug interactions (evidence rating: AIa). InSTI-based regimens also result in faster viral suppression than regimens containing a protease inhibitor (PI) (eg, boosted darunavir ) or nonnucleoside reverse transcriptase inhibitor (NNRTI).<sup><a href="#jsc220007r17" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">17</a></sup></p>            <a class="article-section-id-anchor" id="248771228"></a>
<a id="jsc220007b2" name="jsc220007b2"><span style="display:none;">Box Section Ref ID</span></a><div class="box-section  clip-last-child thm-bg"><div class="label">Box 2. </div><h4 class="box-section--title">Recommended Initial Antiretroviral Therapy (ART) Regimens</h4><h5 class="box-section--sub-title">Recommended for Most People With HIV</h5><ul class="bullet"><li><p class="para">The following are recommended (in alphabetical order) for most people with HIV:</p><ul class="bullet"><li><p class="para">BIC/TAF/FTC (evidence rating: AIa)</p></li><li><p class="para">Dolutegravir plus TXF/XTC (evidence rating: AIa)</p></li><li><p class="para">DTG/3TC (only if HIV RNA &lt;500 000 copies/mL and HBV coinfection not present). This regimen should not be used for rapid initiation when genotype, HIV RNA, and HBV serology results are not yet available (evidence rating: AIa)</p></li></ul></li><li><p class="para">Persons who acquired HIV while receiving preexposure prophylaxis with tenofovir alafenamide or tenofovir disoproxil fumarate with emtricitabine should have a blood sample for genotyping drawn prior to initiating therapy and a 3-drug regimen, preferably dolutegravir or bictegravir plus TXF/XTC, should be initiated if ART is to be started before genotype results are available (evidence rating: AIII)</p></li><li><p class="para">Persons who acquired HIV after exposure to cabotegravir for preexposure prophylaxis should have a blood sample for InSTI genotyping drawn prior to beginning therapy with an InSTI-based regimen (evidence rating: AIII)</p><ul class="bullet"><li><p class="para">If therapy is desired before genotype results are available or if InSTI-resistance is present, a boosted PI regimen containing darunavir and TXF/XTC should be used (evidence rating: AIII)</p></li></ul></li></ul><h5 class="box-section--sub-title">Recommended During Pregnancy</h5><ul class="bullet"><li><p class="para">TAF/XTC plus dolutegravir (evidence rating: AIa), withTDF/XTC plus dolutegravir a suitable alternative if tenofovir alafenamide is not available (evidence rating: AIa)</p></li><li><p class="para">The following drugs may be used if dolutegravir is not an option:</p><ul class="bullet"><li><p class="para">Raltegravir (400 mg twice daily) (evidence rating: AIIa)</p></li><li><p class="para">Atazanavir plus ritonavir (evidence rating: BIIa)</p></li><li><p class="para">Darunavir plus ritonavir (evidence rating: BIIa)</p></li><li><p class="para">Rilpivirine (evidence rating: BIIa)</p></li></ul></li></ul><h5 class="box-section--sub-title">Not Recommended to Initiate During Pregnancy Because of Inadequate Data to Support Use (Evidence Rating: AIII for All)</h5><ul class="bullet"><li><p class="para">Bictegravir</p></li><li><p class="para">Doravirine</p></li><li><p class="para">Cabotegravir</p></li><li><p class="para">DTG/3TC</p></li><li><p class="para">DTG/RPV</p></li></ul><p class="para">If patient is already taking, and stable while taking, bictegravir- or doravirine-containing regimens or the 2-drug regimens DTG/3TC or DTG/RPV and wishes to continue, counsel patient about uncertainties regarding safety during pregnancy and monitor HIV RNA more frequently</p><h5 class="box-section--sub-title">Should Not Be Used During Pregnancy Because of Inadequate Drug Levels</h5><ul class="bullet"><li><p class="para">Cobicistat-containing regimens (evidence rating: AIIb)</p></li></ul><h5 class="box-section--sub-title">Recommended During Tuberculosis Treatment (in Alphabetical Order by Anchor Drug)</h5><ul class="bullet"><li><p class="para">TXF/XTC is recommended with 1 of the following<sup>a</sup>:</p><ul class="bullet"><li><p class="para">Dolutegravir (50 mg twice daily) (evidence rating: BIa)</p></li><li><p class="para">Efavirenz (600 mg) (evidence rating: AIa)</p></li><li><p class="para">Raltegravir (800 mg twice daily) (evidence rating: BIa)</p></li></ul></li><li><p class="para">A ritonavir-boosted PI regimen with TXF/XTC may be used only if it is not possible to use any of the above regimens. In that case, rifabutin (150 mg) should be substituted for rifampin (evidence rating: BIII)</p></li><li><p class="para">Bictegravir, darunavir boosted with ritonavir or cobicistat, doravirine, EVG/COBI, long-acting cabotegravir plus rilpivirine, etravirine, and rilpivirine are not recommended with rifampin because of drug-drug interactions (evidence rating: AIIa)</p></li><li><p class="para">DTG/3TC is not recommended with rifampin because of drug-drug interactions and inadequate data (evidence rating: BIII)</p></li></ul><p class="para"><p class="para">Abbreviations: BIC, bictegravir; COBI, cobicistat; DTG, dolutegravir; EVG, elvitegravir; FTC, emtricitabine; HBV, hepatitis B virus; InSTI, integrase  strand transfer inhibitor; PI, protease inhibitor; RPV, rilpivirine; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; 3TC, lamivudine; TXF, tenofovir alafenamide or tenofovir disoproxil fumarate; XTC, emtricitabine or lamivudine.</p></p><p class="para"><p class="para"><sup>a</sup> There is a pharmacokinetic interaction between rifampin and tenofovir alafenamide; clinical data with coadministration are limited.</p></p></div>            <a class="article-section-id-anchor" id="248771229"></a>
<p class="para">Tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) (herein TXF)/emtricitabine (FTC) or lamivudine (3TC) (herein XTC) are recommended as nucleoside reverse transcriptase inhibitor (nRTI) components of initial ART regimens (when DTG/3TC is not used) (evidence rating: AIa). Abacavir is no longer recommended as initial therapy in most people with HIV owing to concerns about its association with cardiovascular disease,<sup><a href="#jsc220007r1" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">1</a></sup><sup>,<a href="#jsc220007r18" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">18</a></sup> the risk of abacavir hypersensitivity, the burden of HLA B*5701 testing, and no substantial advantage over DTG/3TC alone.</p>            <a class="article-section-id-anchor" id="248771230"></a>
<p class="para">DTG/3TC is the only 2-drug regimen currently recommended for initial therapy, but it should only be used when HIV RNA level is less than 500 000 copies/mL and neither hepatitis B coinfection nor lamivudine resistance is present (evidence rating: AIa). Accordingly, DTG/3TC should not be used for rapid ART initiation when these laboratory results are not yet available. Long-acting cabotegravir with rilpivirine is not recommended for initial ART, although its use has been explored in a small demonstration project (see Switches to Long-acting Cabotegravir and Rilpivirine section below).<sup><a href="#jsc220007r19" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">19</a></sup></p>            <a class="article-section-id-anchor" id="248771231"></a>
<p class="para">Although InSTIs and tenofovir alafenamide have been implicated in weight gain for some individuals and preliminary data raise concern about metabolic adverse effects with InSTIs, such concerns do not override the potential benefit of these drugs. Clinicians should provide resources and counsel patients regarding lifestyle changes that may ameliorate weight gain and other metabolic concerns (evidence rating: AIII) (see Weight Gain and Metabolic Complications With ART section below).</p>            <a class="article-section-id-anchor" id="248771232"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Initiation of ART in the Setting of PrEP Failure
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771233"></a>
<p class="para">InSTI resistance has been observed in people who acquire HIV in the setting of cabotegravir PrEP.<sup><a href="#jsc220007r20" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">20</a></sup><sup>,<a href="#jsc220007r21" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">21</a></sup> A pharmacokinetic study predicted that concentrations of cabotegravir may persist for up to 2.5 or 4 years in some persons assigned male or female at birth, respectively.<sup><a href="#jsc220007r22" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">22</a></sup> If HIV is acquired in the setting of prior cabotegravir PrEP, the results of an InSTI genotype test should be available before starting an InSTI-based regimen (evidence rating: AIII). If ART is to be started before resistance testing results are available, or such testing is not available (owing to resource constraints or inability to amplify with a low viral load), a boosted darunavir regimen with TXF/XTC should be started (evidence rating: AIII).</p>            <a class="article-section-id-anchor" id="248771234"></a>
<p class="para">In persons diagnosed with HIV while receiving TXF-based PrEP, resistance testing should be performed but initiation of ART need not be delayed while awaiting genotype results. A 3-drug regimen, preferably dolutegravir or bictegravir with TXF/XTC, is recommended until genotype results are available (evidence rating: AIII); in the rare but most extreme case of TXF/XTC-induced resistance associated with K65R and M184V mutations, TXF/XTC plus dolutegravir or bictegravir would still be expected to be active.</p>            <a class="article-section-id-anchor" id="248771235"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                ART and Pregnancy
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771236"></a>
<p class="para">All persons with HIV who are pregnant should be receiving ART for their own health and to prevent transmission of HIV to the fetus.<sup><a href="#jsc220007r1" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">1</a></sup> Those diagnosed with HIV during pregnancy should begin ART immediately with a recommended 3-drug regimen (evidence rating: AIa). Cobicistat should not be used during pregnancy owing to low drug levels that can impair efficacy (evidence rating: AIIb). At present, there are insufficient data to recommend initiation with bictegravir, doravirine, cabotegravir, and DTG/3TC during pregnancy (evidence rating: AIII). Although bictegravir, doravirine, DTG/3TC, or DTG/RPV should not be initiated during pregnancy, if patients are already stable with these regimens and choose to continue after being informed about the insufficient data, they should be followed up with more frequent HIV RNA monitoring (evidence rating: CIII).<sup><a href="#jsc220007r23" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">23</a></sup></p>            <a class="article-section-id-anchor" id="248771237"></a>
<p class="para">Although preliminary data from the Tsepamo study initially suggested an association between neural tube defects and dolutegravir exposure at the time of conception, updated results now show no statistically significant difference in the incidence of neural tube defects between regimens with and without dolutegravir when taken at the time of conception.<sup><a href="#jsc220007r24" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">24</a></sup> Dolutegravir, therefore, is a recommended agent for most people with HIV, including during pregnancy. The IMPAACT 2010 trial found dolutegravir regimens to be virologically superior to efavirenz (EFV)/TDF/FTC and demonstrated that dolutegravir plus TAF/FTC was associated with lower rates of adverse events and improved infant outcomes. Therefore, the recommended regimen for pregnancy is TAF/XTC plus dolutegravir (evidence rating: AIa), with TDF/XTC plus dolutegravir a suitable alternative if tenofovir alafenamide is not available (evidence rating: AIa). In the same study, efavirenz was associated with higher levels of infant growth stunting than dolutegravir.<sup><a href="#jsc220007r25" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">25</a></sup><sup>,<a href="#jsc220007r26" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">26</a></sup> An analysis from the Pediatric HIV/AIDS Cohort and the Swiss Mother and Child HIV Cohort also supports the use of dolutegravir in pregnancy, finding that rates of viral suppression with ritonavir-boosted atazanavir or raltegravir were lower than with dolutegravir.<sup><a href="#jsc220007r27" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">27</a></sup></p>            <a class="article-section-id-anchor" id="248771238"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Initiating ART in the Setting of Active Opportunistic Infections and Cancer
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771239"></a>
<p class="para">For persons with a concurrent opportunistic infection, initiation of ART within 2 weeks of initiation of treatment for the opportunistic infection is recommended, except where evidence supports delaying ART because of increased risk of morbidity or mortality from immune reconstitution inflammatory syndrome. With the availability of InSTIs and the use of adjunctive corticosteroid therapy, earlier recommendations for delaying <i>Mycobacterium tuberculosis</i> treatment have been reconsidered. For persons with active tuberculosis, ART should be initiated within 2 weeks after starting treatment for tuberculosis, particularly if the CD4 cell count is less than 50/μL (evidence rating: AIa). For those with tuberculous meningitis, high-dose steroids along with tuberculosis treatment is recommended, with ART initiation within 2 weeks thereafter (evidence rating: BIa).<sup><a href="#jsc220007r28" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">28</a></sup></p>            <a class="article-section-id-anchor" id="248771240"></a>
<p class="para">For persons with cryptococcal meningitis and with access to close monitoring and supportive care for adverse events, ART should be initiated 2 to 4 weeks after starting antifungal therapy (evidence rating: BIIb). The data supporting a delay in ART initiation for persons with cryptococcal meningitis were largely generated in resource-constrained settings where access to close monitoring and supportive care may not be as readily available and in persons who were not being treated with InSTI-based ART. A cohort study that did not show an increase in adverse outcomes with earlier initiation of ART<sup><a href="#jsc220007r29" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">29</a></sup> coupled with the availability of ART regimens with lower rates of adverse effects and drug interactions support earlier ART initiation. ART-naive individuals who have asymptomatic cryptococcal antigenemia and a negative lumbar puncture result should start ART immediately<sup><a href="#jsc220007r30" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">30</a></sup> (evidence rating: BIII), as should patients with cancer and untreated HIV (evidence rating: BIIa).</p>            <a class="article-section-id-anchor" id="248771241"></a>
<p class="para">Drug-drug interactions must be considered for all patients, but particularly for those with a diagnosis of HIV and tuberculosis. The only regimens that may be safely used with rifampin include dolutegravir (50 mg twice daily<sup><a href="#jsc220007r31" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">31</a></sup>) (evidence rating: BIa), efavirenz (600 mg once daily) (evidence rating: AIa), or raltegravir (800 mg twice daily) (evidence rating: BIa) (but not raltegravir [400 mg twice daily<sup><a href="#jsc220007r32" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">32</a></sup>] [evidence rating: AIa]), each given with TXF/XTC.<sup><a href="#jsc220007r31" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">31</a></sup><sup>-<a href="#jsc220007r31" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">33</a></sup> (There is a pharmacokinetic interaction between rifampin and tenofovir alafenamide; clinical data with coadministration are limited.) There are inadequate data to support use of DTG/3TC in this setting (evidence rating: BIII). Poorer adherence with twice-daily raltegravir contributed to increased virologic failure in 1 study, underscoring the need for adherence support when twice-daily regimens are used.<sup><a href="#jsc220007r34" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">34</a></sup> If none of these regimens can be used, ritonavir-boosted atazanavir or lopinavir with TXF/XTC may be used with rifabutin (150 mg daily).</p>            <a class="article-section-id-anchor" id="248771242"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Other Recommended Regimens
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771243"></a>
<p class="para">Other recommended regimens appear in <a href="#jsc220007t2" class="table-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 2</a>. Although InSTI-based regimens are recommended for most persons, there are special circumstances in which other regimens may be considered as initial ART. A boosted darunavir regimen may be used when InSTI or multidrug resistance is a consideration, including when there has been prior exposure to cabotegravir as PrEP (evidence rating: AIIb).</p>            <a class="article-section-id-anchor" id="248771245"></a>
                        <div class="h3 cb section-type-section  ">

                            <div class="heading-text thm-col sb-sc">
                                When and How to Switch ART Regimens
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771246"></a>
<p class="para">Regimen switches can be broadly categorized into those for patients with and for patients without viral suppression. Both indications for switching treatment require careful review of a patient’s ART regimen history, medication tolerability, concomitant medications, food requirements, reproductive plans, potential issues with insurance and coverage, and results from all prior resistance testing before switching (evidence rating: AIII).</p>            <a class="article-section-id-anchor" id="248771247"></a>
<p class="para">Regimen changes should also prompt more frequent clinical and laboratory follow-up until it is established that the regimen is well tolerated, not associated with toxicity, and is effective (evidence rating: AIII), with the first assessment of HIV RNA and safety laboratory assays at approximately 1 month after changing therapy. For patients who switched owing to virologic failure, the viral load test should be repeated monthly until suppression to undetectable is documented and then every 6 months thereafter (evidence rating: AIa).</p>            <a class="article-section-id-anchor" id="248771248"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Switching in the Setting of Viral Suppression
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771249"></a>
<p class="para">Persons with suppressed virus and no history of transmitted or acquired HIV drug resistance can generally switch therapy to any of the recommended initial regimens and maintain viral suppression. Recently, there has been increased interest in 2-drug strategies as a way of reducing drug exposure. Most data supporting this strategy come from prospective randomized trials of persons with no history of treatment failure switching to DTG/3TC<sup><a href="#jsc220007r35" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">35</a></sup><sup>,<a href="#jsc220007r36" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">36</a></sup> or DTG/RPV.<sup><a href="#jsc220007r37" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">37</a></sup> These studies demonstrated ongoing viral suppression comparable to continued 3-drug treatment, without evidence of loss of virologic control.<sup><a href="#jsc220007r38" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">38</a></sup> In addition, InSTI resistance was not observed in these studies, although NNRTI resistance occurred in 1% of participants receiving DTG/RPV. Furthermore, retrospective studies of baseline samples in the trials of <span style="font-variant:small-caps;">DTG/3TC</span> showed no adverse effect from archived resistance mutations, including M184V.<sup><a href="#jsc220007r39" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">39</a></sup><sup>,<a href="#jsc220007r40" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">40</a></sup> Thus, unless there is documented or suspected history of treatment failure, proviral resistance testing is not required prior to switching to 2-drug therapy, even if there is no available pretreatment resistance test result (evidence rating: BII).</p>            <a class="article-section-id-anchor" id="248771250"></a>
<p class="para">An important limitation of both 2-drug regimens is that they provide insufficient treatment for people with concomitant chronic hepatitis B who should, therefore, continue 3-drug regimens that include TXF/XTC. Furthermore, all people with HIV who lack immunity to hepatitis B should undergo immunization. Recent data show that hepatitis B CpG oligodeoxynucleotide vaccine (which is being investigated and compared with other vaccines in an ongoing clinical trial) is highly immunogenic in people with HIV who have high CD4 cell counts and suppressed virus while receiving ART.<sup><a href="#jsc220007r41" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">41</a></sup> Documenting a seropositive response to the vaccine is recommended prior to switching from a TXF-based 3-drug regimen to a 2-drug regimen that does not include TXF.</p>            <a class="article-section-id-anchor" id="248771251"></a>
<p class="para">Recent clinical trials in persons with viral suppression have demonstrated the safety of switching to dolutegravir plus 2 nRTIs or BIC/FTC/TAF, even in the setting of likely or proven nRTI resistance. In the 2SD study conducted in Kenya, participants receiving second-line regimens consisting of a boosted PI plus nRTIs were randomly assigned to continue their current treatment or switch to dolutegravir plus 2 nRTIs.<sup><a href="#jsc220007r42" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">42</a></sup> At 48 weeks, dolutegravir plus 2 nRTIs was noninferior to the continued therapy. Although no prior resistance assessments were performed in that trial, other studies of second-line boosted PI regimens in Africa have shown extensive nRTI resistance, including high rates of M184V and K65R mutations, and such resistance would be expected in the population enrolled in the 2SD trial.</p>            <a class="article-section-id-anchor" id="248771252"></a>
<p class="para">Similar results have been seen with switches to <span style="font-variant:small-caps;">BIC/FTC/TAF</span> in people with resistant virus.<sup><a href="#jsc220007r43" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">43</a></sup><sup>,<a href="#jsc220007r44" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">44</a></sup> Preexisting M184V/I mutations had no effect on efficacy in this setting.<sup><a href="#jsc220007r45" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">45</a></sup> In addition, prospective studies of people with treatment failure show high rates of viral suppression with dolutegravir plus 2 nRTIs,<sup><a href="#jsc220007r46" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">46</a></sup><sup>,<a href="#jsc220007r47" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">47</a></sup> implying that this regimen would maintain suppression regardless of nRTI resistance. By contrast, switches to first-generation InSTIs (raltegravir or elvitegravir) or NNRTIs from high resistance–barrier regimens containing a boosted PI are not recommended (evidence rating: AIa). The use of dolutegravir plus TXF/XTC or BIC/FTC/TAF in patients with current viral suppression and a documented history of M184V and K65R mutations is supported by the existing data from switch and failure studies. Situations where such regimens might be chosen include limited other treatment options, to avoid drug interactions or to maximize treatment simplicity to enhance adherence.</p>            <a class="article-section-id-anchor" id="248771253"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Switches to Long-acting Cabotegravir and Rilpivirine
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771254"></a>
<p class="para">In persons with no history of treatment failure and no known or suspected resistance to either drug, injectable cabotegravir and rilpivirine, given either every 1 or 2 months, was noninferior to continued oral ART.<sup><a href="#jsc220007r48" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">48</a></sup><sup>,<a href="#jsc220007r49" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">49</a></sup> Those interested in non-oral options for ART because of privacy, stigma, or convenience reasons will usually have greater satisfaction with cabotegravir and rilpivirine than continued oral ART.<sup><a href="#jsc220007r50" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">50</a></sup> One recent report described use of this regimen in 15 people with viremia not receiving oral ART.<sup><a href="#jsc220007r19" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">19</a></sup> Despite the short-term success of this approach in this study, cabotegravir plus rilpivirine is not recommended in the setting of viremia outside of a research setting and should be started only after viral suppression has been achieved with oral ART.</p>            <a class="article-section-id-anchor" id="248771255"></a>
<p class="para">Cabotegravir plus rilpivirine injections can be started after an oral lead-in to ensure tolerability or, alternatively, without an oral cabotegravir plus rilpivirine lead-in based on patient preference.<sup><a href="#jsc220007r51" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">51</a></sup> Since the regimen is administered by clinic staff, cabotegravir plus rilpivirine requires more clinical resources than oral ART. Staff must be trained in proper administration techniques; in addition, the prescribing clinician will need to ensure that pharmacy, insurance, and scheduling logistics are in place prior to offering this therapy. Moreover, patients need to travel to and from sites of administration, which may pose a barrier for some individuals.</p>            <a class="article-section-id-anchor" id="248771256"></a>
<p class="para">Even among patients who receive all of the scheduled injections in a timely fashion, there is a risk of treatment failure with emergent resistance, including both InSTI and NNRTI mutations in some. Although this risk is small (approximately 1%-2% in clinical trials), it is higher than for continued oral ART with dolutegravir- or bictegravir-based regimens, and patients should be informed of this risk prior to switching to long-acting injectable ART. The risk appears to be higher when giving cabotegravir plus rilpivirine every 8 weeks than every 4 weeks. Treatment options for those who experience treatment failure with long-acting cabotegravir plus rilpivirine and develop resistance will be limited, because neither NNRTI-based nor InSTI-based regimens are optimal choices.</p>            <a class="article-section-id-anchor" id="248771257"></a>
<p class="para">If scheduled doses of cabotegravir plus rilpivirine are missed, resumption of therapy should follow redosing guidance as outlined in the product prescribing information. For patients who have maintained viral suppression, switching from long-acting injectable cabotegravir plus rilpivirine back to daily oral therapy can be done without the need for proviral DNA resistance testing (evidence rating: BIII).</p>            <a class="article-section-id-anchor" id="248771258"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Switching for Virologic Failure
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771259"></a>
<p class="para">Virologic failure (defined as HIV RNA level &gt;200 copies/mL) should be confirmed by repeating a viral load measurement as soon as possible. If virologic failure is confirmed, genotype resistance testing should be performed, preferably while patients are taking the failing therapy. Resistance testing is still recommended even if a regimen has been discontinued or a person acknowledges poor medication adherence (evidence rating: AIII).</p>            <a class="article-section-id-anchor" id="248771260"></a>
<p class="para">Proviral DNA resistance testing can identify resistance even if HIV RNA level is less than 500 copies/mL (including undetectable levels), but results of such testing do not correlate reliably with standard genotypes and may miss important mutations, so results should be interpreted with caution.<sup><a href="#jsc220007r52" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">52</a></sup></p>            <a class="article-section-id-anchor" id="248771261"></a>
<p class="para">The most common reason for virologic failure is poor medication adherence. Additional potential causes such as food effects, drug interactions, and pharmacy dispensing errors should be investigated. If no resistance mutations are found, clinicians should offer tools to improve adherence and regimen change to improve simplicity or tolerability, if indicated. Based on the results of prospective clinical trials, dolutegravir plus 2 nRTIs (with at least 1 active nRTI as determined by genotypic testing) is recommended after treatment failure with an NNRTI plus 2 nRTIs (evidence rating: AIa).<sup><a href="#jsc220007r1" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">1</a></sup> Although not studied in virologic failure, BIC/FTC/TAF should have similar activity to dolutegravir plus TXF/XTC. If no active nRTIs are present after virologic failure and a boosted PI and an InSTI remain fully active, then treatment choices include boosted darunavir plus TXF/XTC (evidence rating: AIa) or dolutegravir plus a boosted PI with or without additional agent(s) (evidence rating: BIII). Dolutegravir plus TXF/XTC (evidence rating: AIa) is an alternative option to avoid drug interactions and maximize treatment simplicity, although this regimen has an approximate 4% risk of emergence of dolutegravir resistance.<sup><a href="#jsc220007r47" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">47</a></sup></p>            <a class="article-section-id-anchor" id="248771262"></a>
<p class="para">Management of InSTI resistance can be difficult. Owing to the rarity of such resistance, the common presence of extensive resistance to other drug classes, and relative paucity of prospective studies evaluating treatment outcomes in this population, guidance from an expert in HIV drug resistance is recommended for selection of an optimal regimen (evidence rating: AIII).</p>            <a class="article-section-id-anchor" id="248771263"></a>
<p class="para">If InSTI resistance is relatively limited (as commonly occurs after treatment failure with raltegravir or elvitegravir) and a new ART regimen is to include an InSTI, dolutegravir should be administered twice daily.<sup><a href="#jsc220007r53" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">53</a></sup> This regimen should also include at least 1 and preferably 2 other fully active drugs, optimally from drug classes not previously used. These might include fostemsavir (except for treatment of HIV subtype CRF01_AE, because available data suggest that this subtype has naturally occurring resistance to fostemsavir),<sup><a href="#jsc220007r54" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">54</a></sup> lenacapavir (currently approved in the European Union and under US Food and Drug Administration [FDA] review), maraviroc (if the patient’s virus is documented to be R5 tropic when tested), ibalizumab, or enfuvirtide. Recycling of nRTIs with partial antiretroviral activity may also be warranted.</p>            <a class="article-section-id-anchor" id="248771264"></a>
<p class="para">If there is both high-level InSTI resistance and decreased PI susceptibility, then a multidrug regimen with at least 2 fully active agents from these novel drug classes should be used, along with recycled nRTIs because of their ongoing partial antiviral activity (evidence rating: AIII).</p>            <a class="article-section-id-anchor" id="248771265"></a>
                        <div class="h3 cb section-type-section  ">

                            <div class="heading-text thm-col sb-sc">
                                Laboratory Monitoring in Individuals With Established HIV at HIV Diagnosis and Starting ART
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771266"></a>
<p class="para">Recommendations are summarized in <a href="#jsc220007t3" class="table-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 3</a>. Recommended laboratory monitoring before ART is started (evidence rating: AIII) should characterize (1) HIV stage (HIV RNA level, CD4 cell count), (2) general health (kidney and liver function, lipid levels, complete blood cell count, glucose level, and pregnancy), (3) ART resistance (reverse transcriptase–protease [RT-pro] genotype), and (4) presence of coinfections (viral hepatitis A, B, and C; tuberculosis; and sexually transmitted infections [STIs]). Unless there is a history of preexisting kidney or liver injury or a high likelihood of transmitted drug resistance, the results of these laboratory tests should not delay starting ART (evidence rating: BIII), but follow-up of these results should occur quickly to maximize safety. Given the low prevalence of transmitted InSTI resistance,<sup><a href="#jsc220007r55" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">55</a></sup> InSTI genotyping prior to ART initiation is not recommended unless there is suspicion that infection was transmitted from a partner with InSTI failure or if the patient previously received PrEP with cabotegravir (evidence rating: BIII).<sup><a href="#jsc220007r1" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">1</a></sup><sup>,<a href="#jsc220007r56" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">56</a></sup> An assessment for latent tuberculosis (initially, after immune reconstitution, and then if there is exposure) and, if the CD4 cell count is less than 100 cells/μL, cryptococcal antigen testing at presentation should be performed.</p>            <a class="article-section-id-anchor" id="248771268"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                During ART
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771269"></a>
<p class="para">Within 6 weeks of starting ART, assessment of treatment adherence and tolerability is recommended, along with the measurement of HIV RNA level (evidence rating: BIII). Although suppression of HIV RNA levels to undetectable may occur faster with InSTI-based regimens, it may take up to 24 weeks of continuous therapy.<sup><a href="#jsc220007r57" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">57</a></sup><sup>,<a href="#jsc220007r58" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">58</a></sup> If the HIV RNA level has not declined by 2 log<sub>10</sub> copies/mL within 12 weeks of therapy and adherence appears to be sufficient, then a genotype based on the patient’s regimen is recommended (evidence rating: AIII).<sup><a href="#jsc220007r1" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">1</a></sup></p>            <a class="article-section-id-anchor" id="248771270"></a>
<p class="para">If the patient remains virally suppressed, clinically stable, and adherent to medications, then HIV RNA levels should be monitored every 3 months until virally suppressed for at least 1 year. Afterward, the frequency of viral monitoring can be changed to every 6 months (evidence rating: AIII).</p>            <a class="article-section-id-anchor" id="248771271"></a>
<p class="para">Before starting an injectable ART regimen for a patient with viral suppression, proviral RT-pro genotype should be collected for those who do not have a documented pre-ART RT-pro genotype (evidence rating: BIII). Of note, NNRTI resistance may not always be detected by a proviral genotype, and proviral genotyping has not yet been validated as a method to decide whether it is safe to switch to injectable cabotegravir plus rilpivirine. If a patient has rilpivirine-associated mutations on genotypic testing or a history of virologic failure while receiving an NNRTI, injectable cabotegravir plus rilpivirine should be avoided (evidence rating: BIa).<sup><a href="#jsc220007r48" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">48</a></sup><sup>,<a href="#jsc220007r59" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">59</a></sup></p>            <a class="article-section-id-anchor" id="248771272"></a>
<p class="para">Once viral suppression occurs with ART, CD4 cell counts should be measured every 6 months until they are greater than 250 cells/μL for at least 1 year (evidence rating: AIII).<sup><a href="#jsc220007r1" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">1</a></sup> Afterward, CD4 cell counts do not need to be measured unless ART failure is identified or the patient experiences an immunosuppressive condition (evidence rating: AIII). Patients receiving tenofovir disoproxil fumarate should also have urinary glucose and protein monitoring when starting tenofovir disoproxil fumarate and at least every year thereafter (evidence rating: BIII).<sup><a href="#jsc220007r60" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">60</a></sup><sup>-<a href="#jsc220007r60" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">64</a></sup></p>            <a class="article-section-id-anchor" id="248771273"></a>
<p class="para">Patients should have regular age- and risk-appropriate screening for coinfections such as STIs (at all exposed mucosal sites), tuberculosis, and viral hepatitis; cancer screening (including for cervical and anal cancer); general health maintenance assessments; vaccinations; and evaluation for medication toxicity at each visit.<sup><a href="#jsc220007r65" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">65</a></sup></p>            <a class="article-section-id-anchor" id="248771274"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                At the Time of Virologic Failure and Before Starting New ART Regimen
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771275"></a>
<p class="para">If an HIV RNA level greater than 20 to 50 copies/mL is detected during ART after previous viral suppression, then an early repeat HIV RNA level and assessment of medication adherence, drug-drug interactions, and tolerability is recommended (evidence rating: AIa).<sup><a href="#jsc220007r1" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">1</a></sup> If HIV RNA level is greater than 200 copies/mL on 2 consecutive measurements, then HIV RT-pro genotype and InSTI genotype (if the patient was receiving an InSTI) testing are recommended (evidence rating: AIII).<sup><a href="#jsc220007r1" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">1</a></sup> For patients with intermittent or persistent low-level viremia between 50 and 200 copies/mL, assessments for ART adherence, tolerability, and toxic effects are recommended (evidence rating: CI), but changing ART regimens is not recommended unless ART toxicity or intolerability are identified (evidence rating: AIII). Of note, a common cause of low-level viremia in patients receiving an InSTI are interactions with multivalent cations (Ca<sup>2+</sup>, Fe<sup>3+</sup>, Mg<sup>2+</sup>, Al<sup>3+</sup>, Zn<sup>2+</sup>), such as those in mineral supplements and antacids.<sup><a href="#jsc220007r1" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">1</a></sup> Before starting maraviroc, testing for viral CCR5 tropism is recommended each time (unless X4 virus was previously detected), in which case maraviroc should not be used (evidence rating: AIa).</p>            <a class="article-section-id-anchor" id="248771276"></a>
                        <div class="h3 cb section-type-section  ">

                            <div class="heading-text thm-col sb-sc">
                                Weight Gain and Metabolic Complications With ART
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771277"></a>
<p class="para">Recommendations are summarized in <a href="#jsc220007b3" class="section-jump-link contents-tab-jump-link scroll-to box-link" data-tab-toggle=".tab-nav-full-text">Box 3</a>. Weight gain is generally observed within the first year following initiation of most ART regimens, but treatment with InSTI- and tenofovir alafenamide–based regimens is associated with greater weight gain than regimens containing tenofovir disoproxil fumarate, efavirenz, or a boosted PI. Weight gain can occur with (1) initiation of InSTI- or tenofovir alafenamide–containing ART in previously ART-naive individuals<sup><a href="#jsc220007r66" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">66</a></sup>; (2) switch to InSTI- or tenofovir alafenamide–containing ART in individuals with viral suppression<sup><a href="#jsc220007r67" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">67</a></sup>; or (3) initiation of tenofovir alafenamide or InSTI for PrEP.<sup><a href="#jsc220007r68" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">68</a></sup> This weight gain with ART is more likely to occur in women and Black and Hispanic individuals and appears to occur mostly within the first year of ART initiation<sup><a href="#jsc220007r69" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">69</a></sup> or switch.<sup><a href="#jsc220007r70" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">70</a></sup> In the ADVANCE trial, most of the weight gain in dolutegravir groups was fat gain in trunk and limbs, and it was higher with concomitant tenofovir alafenamide use.<sup><a href="#jsc220007r71" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">71</a></sup></p>            <a class="article-section-id-anchor" id="248771278"></a>
<a id="jsc220007b3" name="jsc220007b3"><span style="display:none;">Box Section Ref ID</span></a><div class="box-section  clip-last-child thm-bg"><div class="label">Box 3. </div><h4 class="box-section--title">Weight Gain and Metabolic Complications While Receiving Antiretroviral Therapy (ART)</h4><ul class="bullet"><li><p class="para">Documentation of weight and BMI at baseline and every 6 months is recommended for people with HIV initiating or switching regimens to identify those with excessive weight gain (evidence rating: AIIa)</p></li><li><p class="para">Counseling regarding possibility of weight gain and potential cardiometabolic complications is recommended for people with HIV initiating or switching ART (evidence rating: AIII)</p></li><li><p class="para">Yearly diabetes screening and assessment of cardiovascular risk score of patients receiving InSTI-based ART is recommended (evidence rating: BIII)</p></li><li><p class="para">Lifestyle changes (exercise and diet) are recommended to support people with HIV who gain greater than 5% body weight (evidence rating: AIII)</p></li></ul><p class="para"><p class="para">Abbreviations: BMI, body mass index; InSTI, integrase strand transfer inhibitor.</p></p></div>            <a class="article-section-id-anchor" id="248771279"></a>
<p class="para">Exposure to efavirenz or tenofovir disoproxil fumarate for ART or PrEP is associated with weight suppression, compared with other antiretroviral drugs or no ART exposure.<sup><a href="#jsc220007r72" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">72</a></sup> This might complicate assessment of weight gain after switching from tenofovir disoproxil fumarate to tenofovir alafenamide or after changing efavirenz to an InSTI.</p>            <a class="article-section-id-anchor" id="248771280"></a>
<p class="para">Weight gain while receiving an InSTI is likely mediated by adipocyte dysfunction, inducing adipogenesis, lipogenesis, oxidative stress, fibrosis, and insulin resistance.<sup><a href="#jsc220007r73" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">73</a></sup><sup>,<a href="#jsc220007r74" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">74</a></sup> CYP2B6 genotypes have been associated with greater weight gain after switch from efavirenz to InSTI-based ART.<sup><a href="#jsc220007r75" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">75</a></sup> Mechanism(s) of tenofovir alafenamide–associated weight gain remain incompletely elucidated. A switch from tenofovir disoproxil fumarate to tenofovir alafenamide is associated with increases in lipid levels and cardiovascular risk score, perhaps because tenofovir disoproxil fumarate lowers lipid levels.<sup><a href="#jsc220007r76" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">76</a></sup></p>            <a class="article-section-id-anchor" id="248771281"></a>
<p class="para">Although decreased in the general population, the risk of cardiovascular disease has not declined among people with HIV.<sup><a href="#jsc220007r77" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">77</a></sup> In addition to traditional risk factors and the chronic inflammation associated with HIV itself, some ART regimens may contribute to this risk, but more research is needed. Recent cohort studies suggest that InSTI-based ART may be associated with an increased risk of incident cardiovascular disease, new-onset diabetes, hyperglycemia,<sup><a href="#jsc220007r78" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">78</a></sup><sup>-<a href="#jsc220007r78" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">80</a></sup> elevated blood pressure,<sup><a href="#jsc220007r80" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">80</a></sup> and de novo hepatic steatosis. These cardiometabolic effects were not observed in other studies, and it remains unclear whether they are transient or sustained or whether InSTI exposure is causative. The retrospective nature and lack of availability of weight measurements in most data make it difficult to ascertain whether this risk (if confirmed) is a direct InSTI toxic effect or the result of InSTI-related weight gain. In one study, the InSTI-diabetes association was attenuated when accounting for 12-month weight change.<sup><a href="#jsc220007r81" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">81</a></sup> Nonetheless, data suggest that diabetes risk with weight gain at ART initiation is significant.<sup><a href="#jsc220007r82" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">82</a></sup> Further research is needed to evaluate the role of appetite, caloric intake, and energy expenditure in InSTI- and tenofovir alafenamide–related weight gain.</p>            <a class="article-section-id-anchor" id="248771282"></a>
<p class="para">Whether weight gain is reversible with switch to non-InSTI or non–tenofovir alafenamide regimens is unclear and under investigation (ClinicalTrials.gov Identifier: <a href="https://clinicaltrials.gov/ct2/show/NCT04636437">NCT04636437</a>). Data from the SALSA<sup><a href="#jsc220007r83" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">83</a></sup> and TANGO<sup><a href="#jsc220007r39" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">39</a></sup> studies suggest that switching off of tenofovir alafenamide does not lead to weight loss. Until there are data proving benefit, switching regimens because of weight gain is not recommended (evidence rating: BIIa); instead, lifestyle modifications, like exercise and diet intervention, are recommended (evidence rating: AIII). Semaglutide and other glucagon-like peptide 1 analogues that decrease weight in people without HIV are being studied in people with HIV.<sup><a href="#jsc220007r84" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">84</a></sup><sup>,<a href="#jsc220007r85" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">85</a></sup></p>            <a class="article-section-id-anchor" id="248771283"></a>
                        <div class="h3 cb section-type-section  ">

                            <div class="heading-text thm-col sb-sc">
                                HIV and Aging
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771284"></a>
<p class="para">Recommendations for older people with established HIV are summarized in <a href="#jsc220007b4" class="section-jump-link contents-tab-jump-link scroll-to box-link" data-tab-toggle=".tab-nav-full-text">Box 4</a>. Not only is the prevalence of HIV and diagnoses of new infections in people older than 50 years increasing, but more than half of older people with HIV are diagnosed at a late stage of disease (ie, CD4 cell count &lt;350/μL).<sup><a href="#jsc220007r86" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">86</a></sup><sup>,<a href="#jsc220007r87" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">87</a></sup> Delayed diagnosis is a lost opportunity to initiate ART early for maximal health benefits and for prevention of transmission.</p>            <a class="article-section-id-anchor" id="248771285"></a>
<a id="jsc220007b4" name="jsc220007b4"><span style="display:none;">Box Section Ref ID</span></a><div class="box-section  clip-last-child thm-bg"><div class="label">Box 4. </div><h4 class="box-section--title">Recommendations for Older People With HIV</h4><ul class="bullet"><li><p class="para">Screening for HIV is recommended in older individuals to prevent late diagnosis with advanced disease (evidence rating: AIIa)</p></li><li><p class="para">Initiation of ART is recommended as soon as possible after diagnosis, either the same day of diagnosis, first clinic visit, or within 7 days. Assessment of comorbidities, kidney function, and medications will influence the choice of ART (evidence rating: AIa)</p></li><li><p class="para">Assessment of polypharmacy and simplification of complex regimens, both ART and comorbidity treatments, is recommended to improve adherence, prevent adverse drug-drug interactions, reduce falls risk, and reduce costs (evidence rating: AIIb)</p></li><li><p class="para">Screening for comorbidities, impaired cognitive and function, poor mobility, frailty, and falls risk is recommended for older people with HIV, using validated tools. The frequency of assessment is determined by the baseline assessment (evidence rating: BIII)<sup><a href="#jsc220007r1" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">1</a></sup></p></li><li><p class="para">Consideration of integrated care models and Antiretroviral Stewardship models is recommended to improve outcomes and quality of life for people aging with HIV (evidence rating: BIII)</p></li></ul><p class="para"><p class="para">Abbreviation: ART, antiretroviral therapy.</p></p></div>            <a class="article-section-id-anchor" id="248771286"></a>
<p class="para">Early diagnosis and initiation of ART is particularly important in older persons because they are more likely to have a blunted immune response following ART initiation<sup><a href="#jsc220007r88" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">88</a></sup> and have a higher risk of serious non-AIDS complications. Choice of initial ART requires consideration of the background risk and burden of non-AIDS comorbidity, drug-drug interactions, and polypharmacy to manage multimorbidity in older people with HIV (evidence rating: BIII). Recommended initial ART includes InSTI-based regimens with TAF/FTC or DTG/3TC (see Initiation of ART section). Caution should be exercised in the use of tenofovir disoproxil fumarate because of its associated kidney and bone toxicity.<sup><a href="#jsc220007r89" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">89</a></sup> Studies of pharmacokinetics of ART are limited in older people with HIV. Whether clinically relevant pharmacokinetic changes and potential increased toxicity associated with aging require dose adjustment in older people with HIV remains unclear and is currently not warranted (evidence rating: AIII).<sup><a href="#jsc220007r90" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">90</a></sup></p>            <a class="article-section-id-anchor" id="248771287"></a>
<p class="para">Polypharmacy occurs more frequently in older people with HIV and is associated with increased risk of adverse health outcomes such as falls, frailty, hospitalization and mortality, and drug-drug interactions.<sup><a href="#jsc220007r91" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">91</a></sup> Management of polypharmacy includes (1) optimization of ART, including simplification of ART when possible (see When and How to Switch ART Regimens section), and (2) regular medication review with “pruning” of nonessential medications.<sup><a href="#jsc220007r92" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">92</a></sup><sup>,<a href="#jsc220007r93" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">93</a></sup> Antiretroviral stewardship programs effectively reduce medication errors, dose antiretroviral drugs appropriately for kidney and liver dysfunction, manage drug-drug interactions, and offer an opportunity to assess and deprescribe potentially inappropriate medication.<sup><a href="#jsc220007r94" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">94</a></sup></p>            <a class="article-section-id-anchor" id="248771288"></a>
<p class="para">There is an ongoing growing burden of neurocognitive dysfunction and frailty in people aging with HIV, which results in decreased quality of life, greater health care utilization, and higher mortality.<sup><a href="#jsc220007r95" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">95</a></sup><sup>,<a href="#jsc220007r96" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">96</a></sup> Recommendations for screening and management of comorbidities in older people with HIV, assessment of functional impairment and frailty, and evaluation of neurocognitive impairment are unchanged since the previous report.<sup><a href="#jsc220007r1" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">1</a></sup> Recent studies have shown that accumulation of comorbidities had greater negative effect on neurocognitive performance than did HIV disease parameters.<sup><a href="#jsc220007r97" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">97</a></sup><sup>,<a href="#jsc220007r98" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">98</a></sup> Intensification of ART with either dolutegravir or maraviroc did not improve cognitive impairment, despite lower cerebrospinal fluid HIV viral loads in the intensified group.<sup><a href="#jsc220007r99" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">99</a></sup> Aggressive management of comorbidities, rather than ART modification, may be the most beneficial strategy for improving neurocognitive function.</p>            <a class="article-section-id-anchor" id="248771289"></a>
<p class="para">By the end of this decade, the proportion of people with HIV who will be older than 65 years is projected to be almost 25%.<sup><a href="#jsc220007r100" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">100</a></sup> The aging of people with HIV has highlighted the need for integrated care models, including multidisciplinary teams of geriatricians, HIV specialists, pharmacists, and allied health practitioners (such as physiotherapists) offering holistic patient-centered care.<sup><a href="#jsc220007r101" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">101</a></sup><sup>-<a href="#jsc220007r101" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">103</a></sup></p>            <a class="article-section-id-anchor" id="248771290"></a>
                        <div class="h3 cb section-type-section  ">

                            <div class="heading-text thm-col sb-sc">
                                Prevention of HIV Infection
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771291"></a>
<p class="para">Recommendations for HIV prevention are summarized in <a href="#jsc220007t4" class="table-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 4</a>. Tools to prevent the acquisition of HIV infection are highly effective and continue to increase in breadth. Strategies to test, identify, link to care, and quickly treat and virally suppress individuals with HIV are crucial to prevention efforts (evidence rating: AIa); such efforts have health benefit for the individual and eliminate sexual transmission of HIV. Use of condoms continues to be recommended as the cornerstone of STI prevention efforts for all penetrative sex acts (evidence rating: AIIa). Medical circumcision for heterosexual males and harm reduction interventions (including but not limited to medication treatment for opioid use disorder and syringe access) are effective prevention strategies for applicable populations.</p>            <a class="article-section-id-anchor" id="248771293"></a>
<p class="para">PrEP should be discussed with all sexually active adolescents and adults and anyone who injects nonprescription drugs (eg, opioids, methamphetamine) or who has a substance use disorder, without specific criteria for risk behaviors or screening tools (evidence rating: AIII).<sup><a href="#jsc220007r105" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">105</a></sup> Populations with disproportionately high HIV incidence rates should be particularly encouraged to consider PrEP as part of their HIV prevention plans; these include cisgender men and transgender individuals who have sex with men; young adults and adolescents; people whose sexual partners are from regions of generalized HIV epidemic; persons who use nonprescription drugs and alcohol; individuals who exchange sex for money, goods, or services; partners of incarcerated individuals; and anyone with a recent bacterial STI. Prescription of PrEP for adolescents should be done with specific attention to their additional support and adherence needs (evidence rating: AIa) and with care around potential disclosure of sexual behaviors and gender identity to parents or guardians (evidence rating: AIII).</p>            <a class="article-section-id-anchor" id="248771294"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Choosing the PrEP Regimen
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771295"></a>
<p class="para">The optimal PrEP regimen for a given person is the one most acceptable to that person and congruent with their sexual behavior, ability to take medications reliably, likelihood of anticipating sexual activity, and adverse effect profile. The choice of PrEP regimen made initially may need to be reconsidered over time. For example, someone challenged by taking daily oral tablets is likely to have better prevention effectiveness from an injectable regimen; for someone who prefers to take an oral medication, that preference should be respected.</p>            <a class="article-section-id-anchor" id="248771296"></a>
                        <div class="h5 cb section-type-section  ">

                            <div class="heading-text ">
                                Oral PrEP Regimens
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771297"></a>
<p class="para">Daily oral TDF/FTC (including generic tenofovir formulations) remains a recommended PrEP regimen for all populations at risk (evidence rating: AIa). For cisgender males, oral dosing should be initiated with a double dose of TDF/FTC for the first day, followed by daily single tablets, and should not be discontinued until at least 2 doses after last sexual activity<sup><a href="#jsc220007r1" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">1</a></sup>; this approach is anticipated to provide protection within 24 hours of initial dosing. For non–cisgender male populations, 7 days of daily dosing is likely required to reach maximal protection and is recommended for at least 7 days after last risk activity.<sup><a href="#jsc220007r1" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">1</a></sup> This daily regimen is also recommended for people who are pregnant or breastfeeding (evidence rating: AIIa).</p>            <a class="article-section-id-anchor" id="248771298"></a>
<p class="para">On-demand (2-1-1) oral dosing is recommended for cisgender men of any sexual orientation, but there are insufficient data to support its use to prevent HIV acquisition via receptive vaginal sex (including neovaginal sex) or injection drug use. TDF/FTC 2-1-1 dosing is initiated with a double dose 2 to 24 hours before planned sexual activity and single additional doses 24 and 48 hours subsequent to the first dose; if additional sexual activity occurs within 7 days of the initial planned activity, daily single dosing should be continued until 2 doses after the last planned activity. The 2-1-1 regimen should be used with caution in transgender women receiving gender-affirming hormone therapy, particularly with first use, or reinitiation of TDF/FTC after prolonged hiatus, because rectal tissue concentrations may be somewhat lower early after starting 2-1-1 regimens and may have reduced efficacy.<sup><a href="#jsc220007r106" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">106</a></sup><sup>,<a href="#jsc220007r107" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">107</a></sup></p>            <a class="article-section-id-anchor" id="248771299"></a>
<p class="para">Daily oral TAF/FTC is preferred over TDF/FTC for individuals with creatinine clearance between 30 and 60 mL/min or when there is known osteopenia or osteoporosis. (Bone density scans are not necessary before starting TDF/FTC.) Further, TAF/FTC use should be limited to cisgender men of any sexual orientation and anyone whose risks do not include receptive vaginal sex (including neovaginal sex) or those whose risk is exclusively posed by injection drug use. Data on efficacy of TAF/FTC for preventing HIV acquisition through receptive vaginal sex are not available.</p>            <a class="article-section-id-anchor" id="248771300"></a>
<p class="para">Prescribing for all oral PrEP regimens (including the 2-1-1 regimen) should be for no more than 1 month initially and 3 months thereafter to ensure appropriate HIV testing intervals. Tenofovir-based oral PrEP regimens have extremely low failure rates when taken as prescribed.</p>            <a class="article-section-id-anchor" id="248771301"></a>
                        <div class="h5 cb section-type-section  ">

                            <div class="heading-text ">
                                Same-Day or Rapid PrEP Start
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771302"></a>
<p class="para">Delaying PrEP is not recommended for individuals at risk. If HIV test results are available from samples drawn within 7 days of initiation or if the result of a rapid (point-of-care) HIV antibody test is negative, then PrEP should be initiated while awaiting the results of HIV, hepatitis B, and kidney function testing, as long as the patient is willing to take such an approach. Clinicians should follow up on test results and make adjustments as needed. If a high-risk encounter occurred within the past 72 hours, then a 3-drug postexposure prophylaxis (PEP) regimen is recommended (evidence rating: AIa) (see below), which can be changed to PrEP on PEP completion.</p>            <a class="article-section-id-anchor" id="248771303"></a>
                        <div class="h5 cb section-type-section  ">

                            <div class="heading-text ">
                                Injectable PrEP Regimen
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771304"></a>
<p class="para">Long-acting injectable cabotegravir was approved by the FDA for the prevention of sexual acquisition of HIV infection in December 2021 and is recommended for prevention of sexual transmission of HIV across populations (evidence rating: AIa).<sup><a href="#jsc220007r20" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">20</a></sup><sup>,<a href="#jsc220007r108" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">108</a></sup> There are insufficient data to recommend its use for injection drug exposures, but if a person who injects drugs is also at risk for acquiring HIV through sex, cabotegravir is a recommended option (evidence rating: AIII). An oral lead-in of cabotegravir of approximately 1 month duration should be limited to those with severe atopic histories or concerns, because potential nonadherence to oral dosing may create a period of vulnerability to HIV acquisition (evidence rating: AIII). Injections should be administered gluteally at a dose of 600 mg (3 mL). The first 2 injections should be separated by 4 weeks, and subsequent injections by 8 weeks. Because the timing of onset of protection is unknown but is likely to be approximately 7 days after first injection, barrier protection is recommended in the first week of the first injection cycle. If an individual is more than 7 days late for any injection, it is recommended to “bridge” the period from that 7-day delay until the next injection can be given with an oral PrEP regimen (see Oral PrEP Regimens section above) (evidence rating: BIII). If a resumed injection schedule is 8 or more weeks late (that is, 12 or more weeks from previous for injection 2, or 16 or more weeks from previous for injections 3 and beyond), a “reloading” dose should be given with a 4-week interval between the 2 injections after the hiatus, before returning to every-8-weeks dosing (evidence rating: AIa). The recommended HIV testing algorithm at dispensation of oral bridging and at the time of injection resumption includes both antigen/antibody and HIV RNA testing (evidence rating: AIII).</p>            <a class="article-section-id-anchor" id="248771305"></a>
<p class="para">Because of the prolonged pharmacologic “tail” phase after discontinuation of cabotegravir injections (median 43.7 weeks for males, 67.3 weeks for females),<sup><a href="#jsc220007r109" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">109</a></sup> there has been concern for InSTI resistance should infection occur during this period. Individuals who are stopping injectable cabotegravir but who remain at risk for HIV acquisition should be transitioned to an oral PrEP regimen (see Oral PrEP Regimens section above), and that regimen should be continued during the period of ongoing risk (evidence rating: AIa). Injectable cabotegravir should be dose-adjusted for coadministration with rifabutin and should not be used with potent inducers of UDP-glucuronosyltransferase 1A1. It should be used with particular caution in individuals with gluteal implants or fillers. Strategies to optimize on-time injections should be implemented and may include reminder communications, clinic transportation support, or home visiting nursing services (evidence rating: AIII).</p>            <a class="article-section-id-anchor" id="248771306"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Laboratory Testing in People Receiving PrEP
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771307"></a>
<p class="para">Recommendations on frequency and type of laboratory testing are reported in <a href="#jsc220007t4" class="table-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 4</a>. In patients initiating an oral TXF-based regimen, recommended HIV screening includes a fourth- or fifth-generation laboratory-based, antigen-antibody assay. For cabotegravir-based regimens, HIV testing at initiation and at all visits should ideally include an HIV RNA test with a lower limit of quantification of 50 copies/mL or lower AND a laboratory-based antigen-antibody test (evidence rating: AIa). If RNA testing is not available, cabotegravir PrEP can still be considered using antigen/antibody screening only (evidence rating: BIa). Results of such testing do not need to be available to provide injections. Injectable cabotegravir may “mask” or delay the reactivity/positivity of conventional HIV testing owing to its high potency and prolonged pharmacokinetics, making breakthrough infections (ie, PrEP failures) challenging to identify. Such failures are often asymptomatic and characterized by inconsistent HIV assay results with very low levels of HIV RNA.<sup><a href="#jsc220007r110" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">110</a></sup> A high degree of suspicion for HIV infection should be maintained for any reactive/detectable HIV testing results in the setting of a recent HIV exposure or when there are delays in dosing.</p>            <a class="article-section-id-anchor" id="248771308"></a>
<p class="para">Discordant or difficult-to-interpret combinations of HIV test results should be discussed with experts, including the PrEP Warmline at the National Clinician Consultation Center, available at (855) HIV-PrEP.<sup><a href="#jsc220007r111" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">111</a></sup></p>            <a class="article-section-id-anchor" id="248771309"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Adherence to PrEP and Persistence/Retention
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771310"></a>
<p class="para">Individuals most at risk for acquiring HIV are often challenged by adhering to and persisting with oral PrEP medication and services, with high rates of loss to follow-up.<sup><a href="#jsc220007r112" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">112</a></sup><sup>,<a href="#jsc220007r113" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">113</a></sup> Numerous structural barriers contribute to this and are also likely to be applicable to long-acting cabotegravir PrEP.<sup><a href="#jsc220007r22" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">22</a></sup> Strategies to enhance adherence and persistence include PrEP navigators, telehealth or telephone check-ins, smartphone reminders, mobile service delivery, and pillboxes.</p>            <a class="article-section-id-anchor" id="248771311"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                ART Choice for PrEP Breakthrough Infections
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771312"></a>
<p class="para">In instances of breakthrough infections, which can occur rarely with oral or injectable PrEP, see the Initiation of ART in the Setting of PrEP Failure section above.</p>            <a class="article-section-id-anchor" id="248771313"></a>
                        <div class="h3 cb section-type-section  ">

                            <div class="heading-text thm-col sb-sc">
                                Postexposure Prophylaxis for HIV and Bacterial STIs
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771314"></a>
<p class="para">A 3-drug fully suppressive ART regimen for 28 days is recommended to be administered as rapidly as possible but within 72 hours of a percutaneous, mucous membrane, or sexual exposure to known or suspected HIV-positive blood, genital secretions, or visibly bloody secretions. The recommended regimen is TXF/XTC plus dolutegravir or bictegravir (evidence rating: AIII). PEP should be initiated even if awaiting results of HIV testing on the source person (evidence rating: BIII). If there is concern for drug-resistant HIV or in the setting of pregnancy or breastfeeding, expert consultation is advised (evidence rating: AIII) (for example, through the National Clinician Consultation Center).<sup><a href="#jsc220007r111" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">111</a></sup></p>            <a class="article-section-id-anchor" id="248771315"></a>
<p class="para">Randomized studies suggest benefit of postexposure doxycycline (200 mg once after condomless intercourse) to prevent acquisition of gonorrhea, chlamydia, and syphilis in men who have sex with men (MSM) and in transgender women.<sup><a href="#jsc220007r114" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">114</a></sup><sup>,<a href="#jsc220007r115" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">115</a></sup> Importantly, data on its use for cisgender women and its effects on antimicrobial resistance and the microbiome are still pending. Until more information is available, this strategy should be considered only on a case-by-case basis for individuals at high risk for acquiring syphilis, chlamydia, or gonorrhea.</p>            <a class="article-section-id-anchor" id="248771316"></a>
                        <div class="h3 cb section-type-section  ">

                            <div class="heading-text thm-col sb-sc">
                                Substance Use in Persons at Risk for and With HIV
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771317"></a>
<p class="para">Recommendations for persons at risk for and with HIV who use substances and who have substance use disorders (SUDs) are summarized in <a href="#jsc220007b5" class="section-jump-link contents-tab-jump-link scroll-to box-link" data-tab-toggle=".tab-nav-full-text">Box 5</a>. Substance use (eg, opioids, stimulants, alcohol) and SUD can interfere with all stages of the HIV prevention and treatment care continuum.<sup><a href="#jsc220007r116" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">116</a></sup> Substance use increases the risk of acquiring HIV through sharing injection drug use equipment and condomless sexual intercourse and may adversely affect HIV outcomes by interfering with ART adherence and the ability to achieve or maintain HIV suppression.<sup><a href="#jsc220007r117" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">117</a></sup><sup>-<a href="#jsc220007r117" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">119</a></sup></p>            <a class="article-section-id-anchor" id="248771318"></a>
<a id="jsc220007b5" name="jsc220007b5"><span style="display:none;">Box Section Ref ID</span></a><div class="box-section  clip-last-child thm-bg"><div class="label">Box 5. </div><h4 class="box-section--title">Recommendations for Persons at Risk for and With HIV Who Use Substances and Who Have Substance Use Disorders</h4><ul class="bullet"><li><p class="para">Provide screening and treatment for substance use disorders to all persons at risk for and living with HIV (evidence rating: AIa)</p></li><li><p class="para">Substance use treatment should be integrated into HIV prevention and treatment services (evidence rating: AIa)</p></li><li><p class="para">Persons with substance use disorders and HIV infection or risk for HIV should receive integrated addiction treatment with:</p><ul class="bullet"><li><p class="para">Pharmacotherapy for opioid and alcohol use disorders (evidence rating: AIa)</p></li><li><p class="para">Contingency management for stimulant use disorders (evidence rating: AIII)</p></li></ul></li><li><p class="para">Persons with opioid use and alcohol use disorders should be offered timely initiation of medications for substance use disorder regardless of HIV and HCV treatment plans (evidence rating: AIa)</p></li><li><p class="para">Peer/patient support staff, telehealth, extended hours, mobile clinics, and walk-in clinic options should be available to persons with substance use disorders who are receiving HIV treatment or prevention (evidence rating: AIIb)</p></li><li><p class="para">Peer/patient support staff, mobile health units, and pharmacy delivery services should be available to persons with substance use disorders who are receiving HIV treatment or prevention (evidence rating: AIIb)</p></li></ul><p class="para"><p class="para">Abbreviation: HCV, hepatitis C virus.</p></p></div>            <a class="article-section-id-anchor" id="248771319"></a>
<p class="para">Substance use and SUDs are more common among people with HIV than among the general population. Despite the high prevalence of SUDs, only a small number of people with HIV are linked to or initiate treatment for SUD. To increase diagnosis and treatment of SUDs, screening for and linkage to SUD treatment should be integrated into HIV prevention and treatment services (evidence rating: AIa) (eTable 4 in the <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-JSC220007-1">Supplement</a>).<sup><a href="#jsc220007r120" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">120</a></sup><sup>,<a href="#jsc220007r121" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">121</a></sup> Reducing substance use (even if abstinence is not achieved) is associated with improved HIV outcomes.<sup><a href="#jsc220007r122" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">122</a></sup> Therefore, offering addiction treatment, including pharmacotherapy and behavioral-based therapies, is recommended for all people with HIV with SUDs (evidence rating: AIa).<sup><a href="#jsc220007r118" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">118</a></sup></p>            <a class="article-section-id-anchor" id="248771320"></a>
<p class="para">Medication treatments for opioid use disorder (OUD), including buprenorphine, methadone, and extended-release naltrexone, reduce nonmedical opioid use and reduce risk for HIV and hepatitis C virus (eTable 5 in the <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-JSC220007-1">Supplement</a>).<sup><a href="#jsc220007r123" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">123</a></sup><sup>-<a href="#jsc220007r123" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">125</a></sup> For persons with alcohol use disorder (AUD), medications (extended-release naltrexone, oral naltrexone) reduce alcohol use, thereby reducing HIV risk (eTable 6 in the <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-JSC220007-1">Supplement</a>).<sup><a href="#jsc220007r126" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">126</a></sup> For those with HIV, medication treatment of OUD and AUD improves ART adherence and viral suppression and thus is recommended with ART (eFigure in the <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-JSC220007-1">Supplement</a>) (evidence rating: AIa).<sup><a href="#jsc220007r127" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">127</a></sup><sup>-<a href="#jsc220007r127" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">130</a></sup> Clinically significant drug-drug interactions between ART or hepatitis C virus direct-acting antiviral medications and medications used to treat SUDs are infrequent<sup><a href="#jsc220007r131" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">131</a></sup><sup>,<a href="#jsc220007r132" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">132</a></sup>; neither ART nor medication treatments for SUDs should be withheld (evidence rating: AIII). Although there are as yet no FDA-approved medications to treat stimulant use disorders (eg, methamphetamine, cocaine), there are data supporting the use of contingency management to promote reduced stimulant use.<sup><a href="#jsc220007r133" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">133</a></sup><sup>-<a href="#jsc220007r133" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">136</a></sup></p>            <a class="article-section-id-anchor" id="248771321"></a>
<p class="para">Interventions that reduce substance use, including medication treatments for OUD and AUD, may also improve PrEP outcomes for HIV prevention. Although oral PrEP is approved for reducing HIV transmission via injection drug use, TAF/FTC and injectable cabotegravir have not yet been evaluated for injection drug use–related risk among persons who inject drugs.<sup><a href="#jsc220007r137" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">137</a></sup> However, persons who use drugs may acquire HIV via condomless sexual intercourse; therefore, if they are at sexual risk of HIV acquisition, they should be offered PrEP (evidence rating: AIa).<sup><a href="#jsc220007r138" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">138</a></sup><sup>-<a href="#jsc220007r138" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">140</a></sup></p>            <a class="article-section-id-anchor" id="248771322"></a>
<p class="para">Among persons engaged in HIV prevention or treatment services, SUD can create an additional hurdle for retention in care. Structural barriers to retention, including lack of transportation, insurance, and housing, as well as criminal legal barriers, poverty, mental illness, racism, and stigma should be evaluated and addressed.<sup><a href="#jsc220007r141" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">141</a></sup> Innovative service delivery options, including telehealth, extended hours, mobile clinics, walk-in clinics, and staff who are peers or near-peers with lived experience with addiction, are recommended as ways to improve access for patients (evidence rating: AIIb).<sup><a href="#jsc220007r9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup><sup>,<a href="#jsc220007r142" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">142</a></sup><sup>,<a href="#jsc220007r143" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">143</a></sup> Rapid HIV testing combined with rapid ART or PrEP provision among persons at risk should be available to persons who use substances and who have SUDs (see above).</p>            <a class="article-section-id-anchor" id="248771323"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                COVID-19 and HIV
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771324"></a>
<p class="para">Recommendations are summarized in <a href="#jsc220007b6" class="section-jump-link contents-tab-jump-link scroll-to box-link" data-tab-toggle=".tab-nav-full-text">Box 6</a>. The COVID-19 pandemic disrupted access to and delivery of HIV care and services.<sup><a href="#jsc220007r144" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">144</a></sup><sup>-<a href="#jsc220007r144" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">147</a></sup> An extended review is beyond the scope of this document, but several key points should be considered.<sup><a href="#jsc220007r148" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">148</a></sup><sup>,<a href="#jsc220007r149" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">149</a></sup> Recent studies indicate that people with HIV are not at increased risk of acquisition of SARS-CoV-2 compared with people without HIV after controlling for underlying immunosuppression, viral suppression while receiving ART, and comorbidities.<sup><a href="#jsc220007r149" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">149</a></sup><sup>,<a href="#jsc220007r150" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">150</a></sup> Data are conflicting and influenced by regional heterogeneity about the independent contribution of HIV to higher risk of severe disease and mortality due to COVID-19.<sup><a href="#jsc220007r151" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">151</a></sup> The preponderance of data suggests that people with HIV who are receiving effective ART, virally suppressed with a CD4 cell count greater than 200/μL (or in some studies &gt;350 cells/μL), and without key comorbidities do not appear to be at substantially increased risk for severe disease or death compared with people without HIV.<sup><a href="#jsc220007r152" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">152</a></sup> There are 3 potential explanations for some of the contradictory findings. First, published reports did not control for (or may have been confounded by) higher prevalence among people with HIV of underlying comorbidities such as cardiovascular disease, diabetes, chronic kidney disease, chronic pulmonary disease, and obesity, all of which are associated with increased risk of severe COVID-19 and mortality.<sup><a href="#jsc220007r153" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">153</a></sup><sup>-<a href="#jsc220007r153" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">155</a></sup> Second, published reports had not accounted for HIV RNA, residual HIV-associated inflammation, or incomplete CD4 cell reconstitution in some people with HIV despite receiving ART. Third, social determinants of poor COVID-19 outcomes also intersect with higher prevalence of HIV among racial and ethnic minority populations.</p>            <a class="article-section-id-anchor" id="248771325"></a>
<a id="jsc220007b6" name="jsc220007b6"><span style="display:none;">Box Section Ref ID</span></a><div class="box-section  clip-last-child thm-bg"><div class="label">Box 6. </div><h4 class="box-section--title">Recommendations for COVID-19 and People With HIV</h4><ul class="bullet"><li><p class="para">Primary COVID-19 vaccination and vaccine boosting is recommended for all people with HIV (evidence rating: AIa). For those who have untreated HIV infection or a CD4 cell count less than 200/μL, the primary vaccination series should include at least 3 vaccine doses, and vaccine booster doses are recommended regardless of age (evidence rating: AIIa)</p></li><li><p class="para">If circulating SARS-CoV-2 variants anticipated to be susceptible, preexposure prophylaxis for susceptible subvariants with tixagevimab (300 mg) plus cilgavimab (300 mg) to prevent COVID-19 is recommended for adults and adolescents (aged ≥12 years and weighing ≥40 kg) with HIV who have untreated HIV infection or a CD4 cell count less than 200/μL or those not able to be fully vaccinated owing to a history of severe adverse reactions to a COVID-19 vaccine or its components (evidence rating: BIII)</p></li><li><p class="para">Postexposure prophylaxis is not recommended for people with HIV (evidence rating: AIII). Currently available monoclonal antibody agents have not been shown to be sufficiently effective against the predominant circulating Omicron variants and subvariants</p></li><li><p class="para">People with HIV who develop COVID-19 should be treated according to current guidelines for management of COVID-19, regardless of CD4 cell count or viral suppression (evidence rating: AIa)</p></li><li><p class="para">People with HIV with CD4 cell counts less than 200/μL or without viral suppression who develop mild-moderate COVID-19 infection should be treated with ritonavir-boosted nirmatrelvir (evidence rating: AIIa). With the exception of maraviroc, ART can be co-administered with ritonavir-boosted nirmatrelvir without dose adjustment (except as needed for estimated glomerular filtration rate &lt;60 mL/min), but people with HIV should be monitored closely for adverse effects while receiving this treatment. Drug-drug interactions may still limit the use of this treatment if medications used for underlying comorbidities or opportunistic infections are contraindicated with ritonavir-boosted nirmatrelvir</p></li><li><p class="para">People with HIV who recover from severe COVID-19 should be monitored for postacute sequelae of SARS-CoV-2 (long COVID) and HIV treatment should be optimized to the extent possible to further reduce inflammatory responses to COVID-19 and HIV (evidence rating: AIII)</p></li></ul><p class="para"><p class="para">Abbreviation: ART, antiretroviral therapy.</p></p></div>            <a class="article-section-id-anchor" id="248771326"></a>
<p class="para">Primary COVID-19 vaccination and vaccine boosting is recommended for all people with HIV (evidence rating: AIa). For those who have untreated HIV infection or a CD4 cell count less than 200/μL, the primary vaccination series should include at least 3 primary vaccine doses, and vaccine booster doses are recommended regardless of age (evidence rating: AIIa). For persons with HIV with viral suppression while receiving ART and with CD4 cell counts greater than 350/μL, antibody responses to SARS-CoV-2 infection or vaccines are not substantially different than among those without HIV. People with HIV also do not have higher rates of adverse events related to SARS-CoV-2 vaccines.<sup><a href="#jsc220007r156" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">156</a></sup><sup>-<a href="#jsc220007r156" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">158</a></sup> However, some studies suggest that vaccine efficacy, as measured by reduction in hospitalizations and mortality, and antibody response rates are lower for people with HIV with advanced immunosuppression, especially those with CD4 cell counts less than 200/μL or without viral suppression, than those without HIV.<sup><a href="#jsc220007r159" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">159</a></sup><sup>-<a href="#jsc220007r159" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">162</a></sup> Many of the large phase 3 vaccine trials excluded people with HIV or enrolled numbers too small to draw firm conclusions. Again, some published data on vaccine immunogenicity in people with HIV are conflicting, possibly owing to small numbers, insufficient controls for underlying age, comorbidities, HIV RNA levels, or other factors that may affect antibody responses.<sup><a href="#jsc220007r163" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">163</a></sup><sup>,<a href="#jsc220007r164" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">164</a></sup> People with HIV who have CD4 cell counts less than 200/μL or untreated HIV may benefit from PrEP with tixagevimab plus cilgavimab, but only if the circulating SARS-CoV-2 variants are susceptible (evidence rating: BIII). People with HIV, particularly those with CD4 cell counts less than 200/μL, do appear to be at increased risk of vaccine breakthrough infections.<sup><a href="#jsc220007r165" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">165</a></sup> This risk was lower for those with CD4 cell counts greater than 500/μL.</p>            <a class="article-section-id-anchor" id="248771327"></a>
<p class="para">Current COVID-19 treatment guidelines do not recommend that treatment be intensified, withheld, or altered based on HIV-related immunosuppression or ART.<sup><a href="#jsc220007r166" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">166</a></sup><sup>-<a href="#jsc220007r166" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">168</a></sup> One emerging issue is whether postacute sequelae of COVID-19 (“long COVID”) is more prevalent among people with HIV. Risk factors for postacute sequelae in people with HIV appear to be the same as for people without HIV.<sup><a href="#jsc220007r169" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">169</a></sup> The degree to which underlying immunosuppression, viral suppression while receiving ART, or other factors affect the risk of postacute sequealae remains to be determined.</p>            <a class="article-section-id-anchor" id="248771328"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Monkeypox Virus Infection
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771329"></a>
<p class="para">A global surge in monkeypox virus infections, primarily among MSM and with up to 50% occurring among people with HIV, was first identified in 2022. Most cases are related to skin-to-skin transmission during sexual encounters. Although the infection can be asymptomatic,<sup><a href="#jsc220007r170" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">170</a></sup> the predominant symptoms are skin lesions that progress from papules to pustules and ulcers, often associated with fever, lymphadenopathy, myalgias, headache, or fatigue.<sup><a href="#jsc220007r171" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">171</a></sup><sup>,<a href="#jsc220007r172" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">172</a></sup> Skin lesions are typically painful and can coalesce. Patients also often have anogenital or oral lesions, although lesions may exist without any symptoms. People with HIV and low CD4 cell counts or with no viral suppression may experience more severe disease.<sup><a href="#jsc220007r173" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">173</a></sup> Coinfection with other STIs is frequent and should be screened for when monkeypox is first recognized or suspected (evidence rating: AIII).</p>            <a class="article-section-id-anchor" id="248771330"></a>
<p class="para">Diagnosis of monkeypox currently requires nucleic acid amplification testing of lesions. Treatment recommendations are evolving, but those patients who are immunosuppressed or otherwise at high risk for progression or those with severe disease should receive oral or intravenous tecovirimat (evidence rating: BIII), an investigational agent with activity against smallpox and monkeypox viruses. Oral dosing is every 8 or 12 hours (depending on weight) for 14 days, administered within 30 minutes of a full fatty meal. Potential drug interactions exist between tecovirimat and rilpivirine, doravirine, and maraviroc, but dose adjustment is not required.<sup><a href="#jsc220007r174" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">174</a></sup></p>            <a class="article-section-id-anchor" id="248771331"></a>
<p class="para">The incubation time for monkeypox virus is approximately 12 days. For individuals with a known exposure, the JYNNEOS vaccine (smallpox and monkeypox vaccine, live, nonreplicating [Bavarian Nordic]) should be administered to asymptomatic contacts ideally within 4 days but up to 14 days (evidence rating: AIII). Primary JYNNEOS vaccination with 2 doses given at least 28 days apart is recommended for individuals at high risk (evidence rating: AIII) (eg, MSM with multiple sexual partners). It is crucial that health messaging center on an equity approach to ensure that education and services reach the most affected populations while simultaneously fighting the stigma increasingly directed toward these communities.</p>            <a class="article-section-id-anchor" id="248771332"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Promoting Equity in HIV Treatment and Prevention
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771333"></a>
<p class="para">Despite advances in HIV treatment and prevention, large disparities exist in the global HIV epidemic. The 2021 Global AIDS Update titled “Confronting Inequalities” describes the inequity that continues to drive the HIV epidemic in all regions of the world, with a focus on low- and middle-income countries.<sup><a href="#jsc220007r175" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">175</a></sup> However, HIV epidemics in high-income countries also are characterized by ongoing disparities. The US epidemic is a prime example: HIV disproportionately affects people who are Black or Hispanic, those who live in the US South, MSM, transgender individuals, and people who use drugs, compared with the general population.<sup><a href="#jsc220007r176" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">176</a></sup> In 2020, HIV testing and services were disrupted by the COVID-19 pandemic in the US, particularly among priority populations including men who have sex with men, transgender persons, and Black or African American and Hispanic persons.<sup><a href="#jsc220007r177" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">177</a></sup> In addition, Black/African American people were furthest from the Ending the HIV Epidemic Initiative targets for linkage to care (80%), viral suppression (60%), and PrEP coverage (9%).<sup><a href="#jsc220007r178" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">178</a></sup> Among Black people with HIV in the US, 52% reside in geographic areas with high social vulnerability index scores.<sup><a href="#jsc220007r179" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">179</a></sup> The greatest burden of HIV in the US is in the South, driven by structural factors including long-standing inequitable policies based in racism, and resulting in high levels of poverty, failure to expand health care access through Medicaid expansion, low educational attainment, intersectional stigma and discrimination, and clinician shortages that result in inequitable access to HIV prevention and treatment services. Striking disparities also exist across other high-income settings. For example, in the European Union and European Economic Area, 44% of new diagnoses in 2019 were among the migrant populations.<sup><a href="#jsc220007r180" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">180</a></sup></p>            <a class="article-section-id-anchor" id="248771334"></a>
<p class="para">Global disparities in PrEP utilization limit its ability to reduce HIV transmission,<sup><a href="#jsc220007r181" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">181</a></sup><sup>,<a href="#jsc220007r182" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">182</a></sup> and there is serious concern that, although long-acting cabotegravir for PrEP has the potential for considerable benefit,<sup><a href="#jsc220007r183" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">183</a></sup> its cost and implementation complexity will only widen disparities.</p>            <a class="article-section-id-anchor" id="248771335"></a>
<p class="para">The United Nations General Assembly Political Declaration on HIV and AIDS, titled “Ending Inequalities and Getting on Track to End AIDS by 2030,” offers roadmaps to address global health disparities, including those associated with HIV status, sex, gender, race, ethnicity, disability, age, income level, education, occupation, geographic disparities, migratory status, and incarceration.<sup><a href="#jsc220007r184" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">184</a></sup> Ending the HIV epidemic will require an equity approach that focuses resources on addressing societal disparities (for example, tackling poverty as an HIV prevention strategy), addressing stigma as a root cause of HIV risk, eliminating laws that target people with HIV, and ensuring access to care for all.</p>            <a class="article-section-id-anchor" id="248771336"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Limitations
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771337"></a>
<p class="para">First, this article is meant to provide general recommendations and is not designed as mandates or to replace clinical judgment. Second, the recommendations are based on the body of evidence that was available at the time of preparation and may change as new data become available. Third, the recommendations were developed for high- and medium-income settings, for which most of the drugs and tools are available. The specific recommendations may not be applicable in all resource-limited settings.</p>            <a class="article-section-id-anchor" id="248771338"></a>
                        <div class="h3 cb section-type-section  ">

                            <div class="heading-text thm-col sb-sc">
                                Conclusions
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="248771339"></a>
<p class="para">Advances in treatment and prevention of HIV continue to improve outcomes, but challenges and opportunities remain.</p>            <a class="article-section-id-anchor" id="248771340"></a>
                        <div class="h3 cb section-type-acknowledgements  has-back-to-top">
                                <a href="#top" class="section-jump-link back-to-top" data-tab-toggle=".tab-nav-full-text">Back to top</a>

                            <div class="heading-text thm-col sb-sc">
                                Article Information
                            </div>
                        </div>
<p class="authorInfoSection"><strong>Corresponding Author:</strong> Rajesh T. Gandhi, MD, Cox 548, Infectious Diseases Division, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114 (<a href="mailto:RGANDHI@mgh.harvard.edu" target="_blank">RGANDHI@mgh.harvard.edu</a>).</p><p class="para"><strong>Accepted for Publication:</strong> November 13, 2022.</p><p class="parapublished-online"><strong>Published Online:</strong> December 1, 2022. doi:10.1001/jama.2022.22246</p><p class="paraauthor-contributions"><strong>Author Contributions:</strong> Dr Gandhi had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p class="para"><i>Concept and design:</i> Gandhi, Bedimo, Hoy, Landovitz, Eaton, Lehmann, Sax, Thompson, Benson, Buchbinder, del Rio, Eron, Günthard, Jacobsen, Saag.</p><p class="para"><i>Acquisition, analysis, or interpretation of data:</i> Gandhi, Bedimo, Hoy, Landovitz, Smith, Eaton, Lehmann, Springer, Thompson, Benson, Buchbinder, del Rio, Eron, Günthard, Molina, Saag.</p><p class="para"><i>Drafting of the manuscript:</i> Gandhi, Bedimo, Hoy, Landovitz, Smith, Eaton, Lehmann, Springer, Sax, Thompson, Benson, del Rio, Jacobsen, Saag.</p><p class="para"><i>Critical revision of the manuscript for important intellectual content:</i> Gandhi, Bedimo, Hoy, Landovitz, Smith, Eaton, Lehmann, Springer, Thompson, Benson, Buchbinder, del Rio, Eron, Günthard, Molina, Saag.</p><p class="para"><i>Obtained funding:</i> Jacobsen.</p><p class="para"><i>Administrative, technical, or material support:</i> Landovitz, Smith, Eaton, Lehmann, Jacobsen, Saag.</p><p class="para"><i>Supervision:</i> Gandhi, Sax, Benson, Jacobsen, Saag.</p><p class="parafinancial-disclosure"><strong>Conflict of Interest Disclosures:</strong> Dr Gandhi reported receiving grants from the National Institutes of Health (NIH). Dr Bedimo reported receiving grants from Merck and ViiV Healthcare and serving on the scientific advisory board of Merck, ViiV Healthcare, Gilead Sciences, Theratechnologies, and Janssen Scientific. Dr Hoy reported serving on the advisory board of ViiV Healthcare and Gilead Sciences. Dr Landovitz reported serving on the scientific advisory board of Gilead Sciences and Merck; receiving consulting fees from Cepheid; and receiving grants from the NIH and ViiV Healthcare. Dr Smith reported receiving grants from the NIH San Diego Center for AIDS Research and receiving personal fees from Linear Therapies, Model Medicines, Pharma Holdings, Bayer Pharmaceuticals, and Evidera. Dr Eaton reported receiving grants paid to her institution from NIH and Bristol Myers Squibb and receiving consulting fees from Gilead Sciences. Dr Lehmann reported receiving personal fees from VIIV Healthcare, Gilead, Pfizer, Janssen, Novartis, BioNTech, and Merck Sharp &amp; Dohme and receiving grants from the German Center of Infection Research and the German Ministry of Research. Dr Springer reported receiving grants from the National Institute on Drug Abuse, National Center for Advancing Translational Science, and Veterans Affairs Cooperative Studies Program; receiving consulting fees from Alkermes Inc; and receiving in-kind drug donation from Alkermes Inc (Vivitrol) and Indivior (Sublocade) for NIH-sponsored research. Dr Sax reported receiving grants from Gilead and ViiV and receiving personal fees from Gilead, Janssen, Merck, and ViiV. Dr Thompson reported receiving research funding to the AIDS Research Consortium of Atlanta from Bristol Myers Squibb, Cepheid Inc, Cytodyne Inc, Frontier Biotechnologies, Gilead Sciences, GlaxoSmithKline, Merck Sharp &amp; Dohme, and ViiV and serving as chair of an independent data monitoring committee for Excision Biotherapeutics. Dr Benson reported receiving grants from NIH/National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Mental Health; receiving grants to her institution from Fogarty,  Gilead, and DNAe; receiving lecture/symposia honoraria from International Antiviral Society–USA; serving as deputy editor of <i>Clinical Infectious Diseases</i>; and receiving consulting fees from NDA Partners. Dr Buchbinder reported receiving grants from Gilead Sciences and ViiV Healthcare. Dr del Rio reported receiving grants from the NIH/NIAID Emory Center for AIDS Research and receiving consulting fees from Resverlogix. Dr Eron reported receiving personal fees from Merck, ViiV Healthcare, and Gilead Sciences and receiving grants from ViiV Healthcare, Gilead Sciences, and Janssen. Dr Günthard reported receiving grants from the Swiss National Science Foundation, NIH, Yvonne Jacob Foundation, Gilead, the Swiss HIV Cohort Study, and advisory board, consulting, and data and safety monitoring board fees from Merck, Gilead Sciences, ViiV Healthcare, GlaxoSmithKline, Janssen, Johnson &amp; Johnson, and Novartis. Dr Molina reported receiving grants from Gilead and serving on the advisory board for Gilead, Merck, and ViiV. Dr Saag reported receiving grants to his institution from ViiV Healthcare and Gilead Sciences and receiving consulting fees from TFF Pharmaceuticals and American Gene Technologies. No other disclosures were reported.</p><p class="parafunding-statement"><strong>Funding/Support:</strong> This work was sponsored and funded by the International Antiviral Society–USA (IAS-USA). IAS-USA is a mission-based, nonmembership, 501(c)(3) not-for-profit organization. No private sector or government funding was used to support the effort. Panel members are not compensated for participation in the effort.</p><p class="para"><strong>Role of the Funder/Sponsor:</strong> The IAS-USA determined the need to update recommendations, vetted and selected the panel members, and provided administrative support and oversight. The panel had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p class="para"><strong>Additional Contributions:</strong> We thank Paul A. Volberding, MD, who initiated the volunteer panel in 1995 and helped guide the committee for 25 years. We also thank Michelle Valderama, BS, production and web manager from the IAS-USA, for assistance in managing the manuscript versions; Sherry Wu, BS, for administrative support; and Kimberly R. Powell, MIS, a research impact informationist from Emory University for conducting the PubMed and Embase literature searches. Dr Volberding and Ms Powell received no financial compensation from the sponsor for this article. Ms Valderama and Ms Wu are salaried employees of the sponsor of this article.</p><p class="para"><strong>Additional Information:</strong> This article is dedicated to the memory of Scott M. Hammer, MD, founding member of the panel and former panel chair.</p>            <a class="article-section-id-anchor" id="248771341"></a>
                        <div class="h3 cb section-type-references  ">

                            <div class="heading-text thm-col sb-sc">
                                References
                            </div>
                        </div>
<div class="references"><div class="reference"><a class="reference-number" id="jsc220007r1">1.</a><div class="reference-content">Saag
         MS﻿, Gandhi
         RT﻿, Hoy
         JF﻿, 
     et al.  Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA Panel. ﻿ <i xmlns:helper="urn:XsltStringHelper"> JAMA</i>. 2020;324(16):1651-1669. doi:<a href="http://jamanetwork.com/article.aspx?doi=10.1001/jama.2020.17025">10.1001/jama.2020.17025</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Antiretroviral%20drugs%20for%20treatment%20and%20prevention%20of%20HIV%20infection%20in%20adults%3A%202020%20recommendations%20of%20the%20International%20Antiviral%20Society-USA%20Panel.&amp;author=MS%20Saag&amp;author=RT%20Gandhi&amp;author=JF%20Hoy&amp;publication_year=2020&amp;journal=JAMA&amp;volume=324&amp;pages=1651-1669" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1001/jama.2020.17025" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1001/jama.2020.17025" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r2">2.</a><div class="reference-content">Canadian Task Force on the Periodic Health Examination.  The periodic health examination. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Can Med Assoc J</i>. 1979;121(9):1193-1254.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/115569" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20periodic%20health%20examination.&amp;publication_year=1979&amp;journal=Can%20Med%20Assoc%20J&amp;volume=121&amp;pages=1193-1254" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r3">3.</a><div class="reference-content">Pathela
         P﻿, Jamison
         K﻿, Braunstein
         SL﻿, 
     et al.  Initiating antiretroviral treatment for newly diagnosed HIV patients in sexual health clinics greatly improves timeliness of viral suppression. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2021;35(11):1805-1812. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000002937">10.1097/QAD.0000000000002937</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Initiating%20antiretroviral%20treatment%20for%20newly%20diagnosed%20HIV%20patients%20in%20sexual%20health%20clinics%20greatly%20improves%20timeliness%20of%20viral%20suppression.&amp;author=P%20Pathela&amp;author=K%20Jamison&amp;author=SL%20Braunstein&amp;publication_year=2021&amp;journal=AIDS&amp;volume=35&amp;pages=1805-1812" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000002937" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000002937" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r4">4.</a><div class="reference-content">Michienzi
         SM﻿, Barrios
         M﻿, Badowski
         ME﻿.  Evidence regarding rapid initiation of antiretroviral therapy in patients living with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Curr Infect Dis Rep</i>. 2021;23(5):7. doi:<a href="http://dx.doi.org/10.1007/s11908-021-00750-5">10.1007/s11908-021-00750-5</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Evidence%20regarding%20rapid%20initiation%20of%20antiretroviral%20therapy%20in%20patients%20living%20with%20HIV.&amp;author=SM%20Michienzi&amp;author=M%20Barrios&amp;author=ME%20Badowski&amp;publication_year=2021&amp;journal=Curr%20Infect%20Dis%20Rep&amp;volume=23&amp;pages=7" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1007/s11908-021-00750-5" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1007/s11908-021-00750-5" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r5">5.</a><div class="reference-content">Huhn
         GD﻿, Crofoot
         G﻿, Ramgopal
         M﻿, 
     et al.  Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in a rapid-initiation model of care for human immunodeficiency virus type 1 infection: primary analysis of the DIAMOND study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2020;71(12):3110-3117. doi:<a href="http://dx.doi.org/10.1093/cid/ciz1213">10.1093/cid/ciz1213</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Darunavir%2Fcobicistat%2Femtricitabine%2Ftenofovir%20alafenamide%20in%20a%20rapid-initiation%20model%20of%20care%20for%20human%20immunodeficiency%20virus%20type%201%20infection%3A%20primary%20analysis%20of%20the%20DIAMOND%20study.&amp;author=GD%20Huhn&amp;author=G%20Crofoot&amp;author=M%20Ramgopal&amp;publication_year=2020&amp;journal=Clin%20Infect%20Dis&amp;volume=71&amp;pages=3110-3117" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciz1213" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciz1213" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r6">6.</a><div class="reference-content">Baisley
         K﻿, Orne-Gliemann
         J﻿, Larmarange
         J﻿, 
     et al.  Early HIV treatment and survival over six years of observation in the ANRS 12249 treatment as prevention trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> HIV Med</i>. 2022;23(8):922-928. doi:<a href="http://dx.doi.org/10.1111/hiv.13263">10.1111/hiv.13263</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Early%20HIV%20treatment%20and%20survival%20over%20six%20years%20of%20observation%20in%20the%20ANRS%2012249%20treatment%20as%20prevention%20trial.&amp;author=K%20Baisley&amp;author=J%20Orne-Gliemann&amp;author=J%20Larmarange&amp;publication_year=2022&amp;journal=HIV%20Med&amp;volume=23&amp;pages=922-928" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1111/hiv.v23.8" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1111/hiv.v23.8" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r7">7.</a><div class="reference-content">Stanic
         A﻿, Rybin
         D﻿, Cannata
         F﻿, 
     et al.  The impact of the housing status on clinical outcomes and health care utilization among individuals living with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS Care</i>. 2021;33(1):1-9. doi:<a href="http://dx.doi.org/10.1080/09540121.2019.1695728">10.1080/09540121.2019.1695728</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20impact%20of%20the%20housing%20status%20on%20clinical%20outcomes%20and%20health%20care%20utilization%20among%20individuals%20living%20with%20HIV.&amp;author=A%20Stanic&amp;author=D%20Rybin&amp;author=F%20Cannata&amp;publication_year=2021&amp;journal=AIDS%20Care&amp;volume=33&amp;pages=1-9" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1080/09540121.2019.1695728" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1080/09540121.2019.1695728" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r8">8.</a><div class="reference-content">Maragh-Bass
         AC﻿, Gamble
         T﻿, El-Sadr
         WM﻿, Hanscom
         B﻿, Tolley
         EE﻿.  Exploring individual-level barriers to HIV medication adherence among men who have sex with men in the HIV Prevention Trials Network (HPTN 065) study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS Care</i>. 2021;33(11):1404-1413. doi:<a href="http://dx.doi.org/10.1080/09540121.2020.1828799">10.1080/09540121.2020.1828799</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Exploring%20individual-level%20barriers%20to%20HIV%20medication%20adherence%20among%20men%20who%20have%20sex%20with%20men%20in%20the%20HIV%20Prevention%20Trials%20Network%20%28HPTN%20065%29%20study.&amp;author=AC%20Maragh-Bass&amp;author=T%20Gamble&amp;author=WM%20El-Sadr&amp;author=B%20Hanscom&amp;author=EE%20Tolley&amp;publication_year=2021&amp;journal=AIDS%20Care&amp;volume=33&amp;pages=1404-1413" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1080/09540121.2020.1828799" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1080/09540121.2020.1828799" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r9">9.</a><div class="reference-content">Higa
         DH﻿, Crepaz
         N﻿, Mullins
         MM﻿, 
     et al.  Strategies to improve HIV care outcomes for people with HIV who are out of care. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2022;36(6):853-862. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000003172">10.1097/QAD.0000000000003172</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Strategies%20to%20improve%20HIV%20care%20outcomes%20for%20people%20with%20HIV%20who%20are%20out%20of%20care.&amp;author=DH%20Higa&amp;author=N%20Crepaz&amp;author=MM%20Mullins&amp;publication_year=2022&amp;journal=AIDS&amp;volume=36&amp;pages=853-862" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000003172" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000003172" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r10">10.</a><div class="reference-content">National Academies of Sciences Engineering and Medicine. <i xmlns:helper="urn:XsltStringHelper"> Opportunities to Improve Opioid Use Disorder and Infectious Disease Services</i>.  National Academies Press; 2020.</div></div><div class="reference"><a class="reference-number" id="jsc220007r11">11.</a><div class="reference-content">Martin
         TCS﻿, Abrams
         M﻿, Anderson
         C﻿, Little
         SJ﻿.  Rapid antiretroviral therapy among individuals with acute and early HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2021;73(1):130-133. doi:<a href="http://dx.doi.org/10.1093/cid/ciaa1174">10.1093/cid/ciaa1174</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Rapid%20antiretroviral%20therapy%20among%20individuals%20with%20acute%20and%20early%20HIV.&amp;author=TCS%20Martin&amp;author=M%20Abrams&amp;author=C%20Anderson&amp;author=SJ%20Little&amp;publication_year=2021&amp;journal=Clin%20Infect%20Dis&amp;volume=73&amp;pages=130-133" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciaa1174" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciaa1174" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r12">12.</a><div class="reference-content">Chéret
         A﻿, Bauer
         R﻿, Meiffrédy
         V﻿, 
     et al.  Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, phase 3 trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Antimicrob Chemother</i>. 2022;77(9):2506-2515. doi:<a href="http://dx.doi.org/10.1093/jac/dkac207">10.1093/jac/dkac207</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Once-daily%20dolutegravir%20versus%20darunavir%20plus%20cobicistat%20in%20adults%20at%20the%20time%20of%20primary%20HIV-1%20infection%3A%20the%20OPTIPRIM2-ANRS%20169%20randomized%2C%20open-label%2C%20phase%203%20trial.&amp;author=A%20Chéret&amp;author=R%20Bauer&amp;author=V%20Meiffrédy&amp;publication_year=2022&amp;journal=J%20Antimicrob%20Chemother&amp;volume=77&amp;pages=2506-2515" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/jac/dkac207" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/jac/dkac207" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r13">13.</a><div class="reference-content">Rasmussen
         TA﻿, Ahuja
         SK﻿, Kuwanda
         L﻿, 
     et al.  Antiretroviral initiation at ≥800 CD4+ cells/mm3 associated with lower human immunodeficiency virus reservoir size. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2022;75(10):1781-1791. doi:<a href="http://dx.doi.org/10.1093/cid/ciac249">10.1093/cid/ciac249</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Antiretroviral%20initiation%20at%20%E2%89%A5800%20CD4%2B%20cells%2Fmm3%20associated%20with%20lower%20human%20immunodeficiency%20virus%20reservoir%20size.&amp;author=TA%20Rasmussen&amp;author=SK%20Ahuja&amp;author=L%20Kuwanda&amp;publication_year=2022&amp;journal=Clin%20Infect%20Dis&amp;volume=75&amp;pages=1781-1791" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciac249" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciac249" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r14">14.</a><div class="reference-content">Hunt
         PW﻿, Brenchley
         J﻿, Sinclair
         E﻿, 
     et al.  Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Infect Dis</i>. 2008;197:126-133. doi:<a href="http://dx.doi.org/10.1086/524143">10.1086/524143</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Relationship%20between%20T%20cell%20activation%20and%20CD4%2B%20T%20cell%20count%20in%20HIV-seropositive%20individuals%20with%20undetectable%20plasma%20HIV%20RNA%20levels%20in%20the%20absence%20of%20therapy.&amp;author=PW%20Hunt&amp;author=J%20Brenchley&amp;author=E%20Sinclair&amp;publication_year=2008&amp;journal=J%20Infect%20Dis&amp;volume=197&amp;pages=126-133" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1086/529001" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1086/529001" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r15">15.</a><div class="reference-content">Li
         JZ﻿, Segal
         FP﻿, Bosch
         RJ﻿, 
     et al; AIDS Clinical Trials Group Study A5308 Team.  Antiretroviral therapy reduces T-cell activation and immune exhaustion markers in human immunodeficiency virus controllers. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2020;70(8):1636-1642. doi:<a href="http://dx.doi.org/10.1093/cid/ciz442">10.1093/cid/ciz442</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31131858" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Antiretroviral%20therapy%20reduces%20T-cell%20activation%20and%20immune%20exhaustion%20markers%20in%20human%20immunodeficiency%20virus%20controllers.&amp;author=JZ%20Li&amp;author=FP%20Segal&amp;author=RJ%20Bosch&amp;publication_year=2020&amp;journal=Clin%20Infect%20Dis&amp;volume=70&amp;pages=1636-1642" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciz442" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciz442" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r16">16.</a><div class="reference-content">Plaçais
         L﻿, Boufassa
         F﻿, Lécuroux
         C﻿, 
     et al; ANRS CO21 Study Group.  Antiretroviral therapy for HIV controllers: reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort. ﻿ <i xmlns:helper="urn:XsltStringHelper"> EClinicalMedicine</i>. 2021;37:100963. doi:<a href="http://dx.doi.org/10.1016/j.eclinm.2021.100963">10.1016/j.eclinm.2021.100963</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34195579" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Antiretroviral%20therapy%20for%20HIV%20controllers%3A%20reasons%20for%20initiation%20and%20outcomes%20in%20the%20French%20ANRS-CO21%20CODEX%20cohort.&amp;author=L%20Plaçais&amp;author=F%20Boufassa&amp;author=C%20Lécuroux&amp;publication_year=2021&amp;journal=EClinicalMedicine&amp;volume=37&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.eclinm.2021.100963" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.eclinm.2021.100963" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r17">17.</a><div class="reference-content">Girometti
         N﻿, Lander
         F﻿, McOwan
         A﻿, Nwokolo
         N﻿, Boffito
         M﻿, Whitlock
         G﻿; Dean Street Collaborative Group.  Rapid ART start in early HIV infection: time to viral load suppression and retention in care in a London cohort. ﻿ <i xmlns:helper="urn:XsltStringHelper"> HIV Med</i>. 2020;21(9):613-615. doi:<a href="http://dx.doi.org/10.1111/hiv.12900">10.1111/hiv.12900</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32869951" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Rapid%20ART%20start%20in%20early%20HIV%20infection%3A%20time%20to%20viral%20load%20suppression%20and%20retention%20in%20care%20in%20a%20London%20cohort.&amp;author=N%20Girometti&amp;author=F%20Lander&amp;author=A%20McOwan&amp;author=N%20Nwokolo&amp;author=M%20Boffito&amp;author=G%20Whitlock&amp;publication_year=2020&amp;journal=HIV%20Med&amp;volume=21&amp;pages=613-615" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1111/hiv.v21.9" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1111/hiv.v21.9" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r18">18.</a><div class="reference-content">Jaschinski
         N﻿, Greenberg
         L﻿, Neesgaard
         B﻿, 
     et al; RESPOND Study Group.  Recent abacavir use and incident cardiovascular disease in contemporary treated people living with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. Published online August 24, 2022. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000003373">10.1097/QAD.0000000000003373</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/36001525" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Recent%20abacavir%20use%20and%20incident%20cardiovascular%20disease%20in%20contemporary%20treated%20people%20living%20with%20HIV.&amp;author=N%20Jaschinski&amp;author=L%20Greenberg&amp;author=B%20Neesgaard&amp;publication_year=2022&amp;journal=AIDS&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000003373" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000003373" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r19">19.</a><div class="reference-content">Christopoulos
         KA﻿, Grochowski
         J﻿, Mayorga-Munoz
         F﻿, 
     et al.  First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable HIV viremia in an urban HIV clinic. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. Published online August 1, 2022. doi:<a href="http://dx.doi.org/10.1093/cid/ciac631">10.1093/cid/ciac631</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35913500" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=First%20demonstration%20project%20of%20long-acting%20injectable%20antiretroviral%20therapy%20for%20persons%20with%20and%20without%20detectable%20HIV%20viremia%20in%20an%20urban%20HIV%20clinic.&amp;author=KA%20Christopoulos&amp;author=J%20Grochowski&amp;author=F%20Mayorga-Munoz&amp;publication_year=2022&amp;journal=Clin%20Infect%20Dis&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciac631" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciac631" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r20">20.</a><div class="reference-content">Landovitz
         RJ﻿, Donnell
         D﻿, Clement
         ME﻿, 
     et al; HPTN 083 Study Team.  Cabotegravir for HIV prevention in cisgender men and transgender women. ﻿ <i xmlns:helper="urn:XsltStringHelper"> N Engl J Med</i>. 2021;385(7):595-608. doi:<a href="http://dx.doi.org/10.1056/NEJMoa2101016">10.1056/NEJMoa2101016</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34379922" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cabotegravir%20for%20HIV%20prevention%20in%20cisgender%20men%20and%20transgender%20women.&amp;author=RJ%20Landovitz&amp;author=D%20Donnell&amp;author=ME%20Clement&amp;publication_year=2021&amp;journal=N%20Engl%20J%20Med&amp;volume=385&amp;pages=595-608" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMoa2101016" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMoa2101016" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r21">21.</a><div class="reference-content">Eshleman
         SH﻿, Fogel
         JM﻿, Piwowar-Manning
         E﻿, 
     et al.  Characterization of human immunodeficiency virus (HIV) infections in women who received injectable cabotegravir or tenofovir disoproxil fumarate/emtricitabine for HIV prevention: HPTN 084. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Infect Dis</i>. 2022;225(10):1741-1749. doi:<a href="http://dx.doi.org/10.1093/infdis/jiab576">10.1093/infdis/jiab576</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35301540" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Characterization%20of%20human%20immunodeficiency%20virus%20%28HIV%29%20infections%20in%20women%20who%20received%20injectable%20cabotegravir%20or%20tenofovir%20disoproxil%20fumarate%2Femtricitabine%20for%20HIV%20prevention%3A%20HPTN%20084.&amp;author=SH%20Eshleman&amp;author=JM%20Fogel&amp;author=E%20Piwowar-Manning&amp;publication_year=2022&amp;journal=J%20Infect%20Dis&amp;volume=225&amp;pages=1741-1749" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/infdis/jiab576" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/infdis/jiab576" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r22">22.</a><div class="reference-content">Landovitz
         R﻿, Donnell
         D﻿, Tran
         H﻿, 
     et al.  Updated efficacy, safety, and case studies in HPTN 083: CAB-LA vs TDF/FTC for PrEP [Abstract 96] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Top Antiv Med</i>. 2022;30(1 suppl):37.<a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Updated%20efficacy%2C%20safety%2C%20and%20case%20studies%20in%20HPTN%20083%3A%20CAB-LA%20vs%20TDF%2FFTC%20for%20PrEP%20%5BAbstract%2096%5D%20in%20special%20issue%3A%20Abstracts%20From%20the%202022%20Conference%20on%20Retroviruses%20and%20Opportunistic%20Infections.&amp;author=R%20Landovitz&amp;author=D%20Donnell&amp;author=H%20Tran&amp;publication_year=2022&amp;journal=Top%20Antiv%20Med&amp;volume=30&amp;pages=37" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r23">23.</a><div class="reference-content">Department of Health and Human Services. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. ClinicalInfo. Updated March 17, 2022. Accessed November 9, 2022. <a href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new-guidelines?view=full">https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new-guidelines?view=full</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r24">24.</a><div class="reference-content">Zash
         R﻿, Holmes
         LB﻿, Diseko
         M﻿, 
     et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana. Poster presented at: 11th IAS Conference on HIV Science; July 18-21, 2022.</div></div><div class="reference"><a class="reference-number" id="jsc220007r25">25.</a><div class="reference-content">Lockman
         S﻿, Brummel
         SS﻿, Ziemba
         L﻿, 
     et al; IMPAACT 2010/VESTED Study Team and Investigators.  Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet</i>. 2021;397(10281):1276-1292. doi:<a href="http://dx.doi.org/10.1016/S0140-6736(21)00314-7">10.1016/S0140-6736(21)00314-7</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33812487" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Efficacy%20and%20safety%20of%20dolutegravir%20with%20emtricitabine%20and%20tenofovir%20alafenamide%20fumarate%20or%20tenofovir%20disoproxil%20fumarate%2C%20and%20efavirenz%2C%20emtricitabine%2C%20and%20tenofovir%20disoproxil%20fumarate%20HIV%20antiretroviral%20therapy%20regimens%20started%20in%20pregnancy%20%28IMPAACT%202010%2FVESTED%29%3A%20a%20multicentre%2C%20open-label%2C%20randomised%2C%20controlled%2C%20phase%203%20trial.&amp;author=S%20Lockman&amp;author=SS%20Brummel&amp;author=L%20Ziemba&amp;publication_year=2021&amp;journal=Lancet&amp;volume=397&amp;pages=1276-1292" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S0140-6736(21)00314-7" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S0140-6736(21)00314-7" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r26">26.</a><div class="reference-content">Stranix-Chibanda
         L﻿, Ziemba
         L﻿, Brummer
         S﻿, 
     et al.  Growth of infants with perinatal exposure to maternal DTG vs EFV and TDF vs TAF [Abstract 30] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Top Antiv Med</i>. 2022;30(1 suppl):10-11.<a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Growth%20of%20infants%20with%20perinatal%20exposure%20to%20maternal%20DTG%20vs%20EFV%20and%20TDF%20vs%20TAF%20%5BAbstract%2030%5D%20in%20special%20issue%3A%20Abstracts%20From%20the%202022%20Conference%20on%20Retroviruses%20and%20Opportunistic%20Infections.&amp;author=L%20Stranix-Chibanda&amp;author=L%20Ziemba&amp;author=S%20Brummer&amp;publication_year=2022&amp;journal=Top%20Antiv%20Med&amp;volume=30&amp;pages=10-11" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r27">27.</a><div class="reference-content">Patel
         K﻿, Huo
         Y﻿, Jao
         J﻿, 
     et al; Pediatric HIV/AIDS Cohort Study; Swiss Mother and Child HIV Cohort Study.  Dolutegravir in pregnancy as compared with current HIV regimens in the United States. ﻿ <i xmlns:helper="urn:XsltStringHelper"> N Engl J Med</i>. 2022;387(9):799-809. doi:<a href="http://dx.doi.org/10.1056/NEJMoa2200600">10.1056/NEJMoa2200600</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/36053505" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Dolutegravir%20in%20pregnancy%20as%20compared%20with%20current%20HIV%20regimens%20in%20the%20United%20States.&amp;author=K%20Patel&amp;author=Y%20Huo&amp;author=J%20Jao&amp;publication_year=2022&amp;journal=N%20Engl%20J%20Med&amp;volume=387&amp;pages=799-809" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMoa2200600" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMoa2200600" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r28">28.</a><div class="reference-content">Burke
         RM﻿, Rickman
         HM﻿, Singh
         V﻿, 
     et al.  What is the optimum time to start antiretroviral therapy in people with HIV and tuberculosis coinfection? a systematic review and meta-analysis. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Int AIDS Soc</i>. 2021;24(7):e25772. doi:<a href="http://dx.doi.org/10.1002/jia2.25772">10.1002/jia2.25772</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34289243" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=What%20is%20the%20optimum%20time%20to%20start%20antiretroviral%20therapy%20in%20people%20with%20HIV%20and%20tuberculosis%20coinfection%3F%20a%20systematic%20review%20and%20meta-analysis.&amp;author=RM%20Burke&amp;author=HM%20Rickman&amp;author=V%20Singh&amp;publication_year=2021&amp;journal=J%20Int%20AIDS%20Soc&amp;volume=24&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1002/jia2.v24.7" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1002/jia2.v24.7" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r29">29.</a><div class="reference-content">Ingle
         SM﻿, Miro
         JM﻿, Furrer
         H﻿, 
     et al. Impact of ART on mortality in cryptococcal meningitis patients: high-income settings. Poster presented at: 22nd Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, Washington.</div></div><div class="reference"><a class="reference-number" id="jsc220007r30">30.</a><div class="reference-content">National Institutes of Health, Centers for Disease Control and Prevention, and HIV Medicine Association of the Infectious Disease Society of America. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Updated September 28, 2022. Accessed November 9, 2022. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections</a>﻿ <a href="https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection">https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r31">31.</a><div class="reference-content">Dooley
         KE﻿, Kaplan
         R﻿, Mwelase
         N﻿, 
     et al; International Study of Patients With HIV on Rifampicin ING Study Group.  Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2020;70(4):549-556.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/30918967" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Dolutegravir-based%20antiretroviral%20therapy%20for%20patients%20coinfected%20with%20tuberculosis%20and%20human%20immunodeficiency%20virus%3A%20a%20multicenter%2C%20noncomparative%2C%20open-label%2C%20randomized%20trial.&amp;author=KE%20Dooley&amp;author=R%20Kaplan&amp;author=N%20Mwelase&amp;publication_year=2020&amp;journal=Clin%20Infect%20Dis&amp;volume=70&amp;pages=549-556" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r32">32.</a><div class="reference-content">De Castro
         N﻿, Marcy
         O﻿, Chazallon
         C﻿, 
     et al; ANRS 12300 Reflate TB2 Study Group.  Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet Infect Dis</i>. 2021;21(6):813-822. doi:<a href="http://dx.doi.org/10.1016/S1473-3099(20)30869-0">10.1016/S1473-3099(20)30869-0</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33667406" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Standard%20dose%20raltegravir%20or%20efavirenz-based%20antiretroviral%20treatment%20for%20patients%20co-infected%20with%20HIV%20and%20tuberculosis%20%28ANRS%2012%20300%20Reflate%20TB%202%29%3A%20an%20open-label%2C%20non-inferiority%2C%20randomised%2C%20phase%203%20trial.&amp;author=N%20De Castro&amp;author=O%20Marcy&amp;author=C%20Chazallon&amp;publication_year=2021&amp;journal=Lancet%20Infect%20Dis&amp;volume=21&amp;pages=813-822" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S1473-3099(20)30869-0" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S1473-3099(20)30869-0" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r33">33.</a><div class="reference-content">Grinsztejn
         B﻿, Hosseinipour
         MC﻿, Ribaudo
         HJ﻿, 
     et al; HPTN 052-ACTG Study Team.  Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet Infect Dis</i>. 2014;14(4):281-290. doi:<a href="http://dx.doi.org/10.1016/S1473-3099(13)70692-3">10.1016/S1473-3099(13)70692-3</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/24602844" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20early%20versus%20delayed%20initiation%20of%20antiretroviral%20treatment%20on%20clinical%20outcomes%20of%20HIV-1%20infection%3A%20results%20from%20the%20phase%203%20HPTN%20052%20randomised%20controlled%20trial.&amp;author=B%20Grinsztejn&amp;author=MC%20Hosseinipour&amp;author=HJ%20Ribaudo&amp;publication_year=2014&amp;journal=Lancet%20Infect%20Dis&amp;volume=14&amp;pages=281-290" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S1473-3099(13)70692-3" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S1473-3099(13)70692-3" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r34">34.</a><div class="reference-content">Marcy
         O﻿, De Castro
         N﻿, Chazallon
         C﻿, 
     et al. Adherence and factors associated with virologic success in HIV-1 infected adults witH tuberculosis receiving raltegravir or efavirenz in the ANRS 12300 Reflate TB2 trial. Poster presented at: International AIDS Conference; 2020.</div></div><div class="reference"><a class="reference-number" id="jsc220007r35">35.</a><div class="reference-content">Osiyemi
         O﻿, De Wit
         S﻿, Ajana
         F﻿, 
     et al.  Efficacy and safety of switching to dolutegravir/lamivudine (DTG/3TC) versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with HIV-1: results through week 144 from the phase 3, non-inferiority TANGO randomized trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2022;75(6):975-986. doi:<a href="http://dx.doi.org/10.1093/cid/ciac036">10.1093/cid/ciac036</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Efficacy%20and%20safety%20of%20switching%20to%20dolutegravir%2Flamivudine%20%28DTG%2F3TC%29%20versus%20continuing%20a%20tenofovir%20alafenamide-based%203-%20or%204-drug%20regimen%20for%20maintenance%20of%20virologic%20suppression%20in%20adults%20living%20with%20HIV-1%3A%20results%20through%20week%20144%20from%20the%20phase%203%2C%20non-inferiority%20TANGO%20randomized%20trial.&amp;author=O%20Osiyemi&amp;author=S%20De Wit&amp;author=F%20Ajana&amp;publication_year=2022&amp;journal=Clin%20Infect%20Dis&amp;volume=75&amp;pages=975-986" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciac036" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciac036" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r36">36.</a><div class="reference-content">Llibre
         JM﻿, Brites
         C﻿, Cheng
         CY﻿, 
     et al.  Efficacy and safety of switching to the 2-drug regimen dolutegravir/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with HIV-1: week 48 results from the phase 3, non-inferiority SALSA randomized trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. Published online March 2, 2022. doi:<a href="http://dx.doi.org/10.1093/cid/ciac130">10.1093/cid/ciac130</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35235656" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Efficacy%20and%20safety%20of%20switching%20to%20the%202-drug%20regimen%20dolutegravir%2Flamivudine%20versus%20continuing%20a%203-%20or%204-drug%20regimen%20for%20maintaining%20virologic%20suppression%20in%20adults%20living%20with%20HIV-1%3A%20week%2048%20results%20from%20the%20phase%203%2C%20non-inferiority%20SALSA%20randomized%20trial.&amp;author=JM%20Llibre&amp;author=C%20Brites&amp;author=CY%20Cheng&amp;publication_year=2022&amp;journal=Clin%20Infect%20Dis&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciac130" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciac130" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r37">37.</a><div class="reference-content">van Wyk
         J﻿, Orkin
         C﻿, Rubio
         R﻿, 
     et al.  Brief report: durable suppression and low rate of virologic failure 3 years after switch to dolutegravir + rilpivirine 2-drug regimen: 148-week results from the SWORD-1 and SWORD-2 randomized clinical trials. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Acquir Immune Defic Syndr</i>. 2020;85(3):325-330. doi:<a href="http://dx.doi.org/10.1097/QAI.0000000000002449">10.1097/QAI.0000000000002449</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32675772" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Brief%20report%3A%20durable%20suppression%20and%20low%20rate%20of%20virologic%20failure%203%20years%20after%20switch%20to%20dolutegravir%20%2B%20rilpivirine%202-drug%20regimen%3A%20148-week%20results%20from%20the%20SWORD-1%20and%20SWORD-2%20randomized%20clinical%20trials.&amp;author=J%20van Wyk&amp;author=C%20Orkin&amp;author=R%20Rubio&amp;publication_year=2020&amp;journal=J%20Acquir%20Immune%20Defic%20Syndr&amp;volume=85&amp;pages=325-330" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAI.0000000000002449" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAI.0000000000002449" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r38">38.</a><div class="reference-content">Greenberg
         L﻿, Ryom
         L﻿, Neesgaard
         B﻿, 
     et al; RESPOND (International Cohort Consortium of Infectious Diseases) Study Group.  Clinical outcomes of 2-drug regimens vs 3-drug regimens in antiretroviral treatment-experienced people living with human immunodeficiency virus. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2021;73(7):e2323-e2333. doi:<a href="http://dx.doi.org/10.1093/cid/ciaa1878">10.1093/cid/ciaa1878</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33354721" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Clinical%20outcomes%20of%202-drug%20regimens%20vs%203-drug%20regimens%20in%20antiretroviral%20treatment-experienced%20people%20living%20with%20human%20immunodeficiency%20virus.&amp;author=L%20Greenberg&amp;author=L%20Ryom&amp;author=B%20Neesgaard&amp;publication_year=2021&amp;journal=Clin%20Infect%20Dis&amp;volume=73&amp;pages=e2323-e2333" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciaa1878" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciaa1878" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r39">39.</a><div class="reference-content">van Wyk
         J﻿, Ajana
         F﻿, Bisshop
         F﻿, 
     et al.  Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2020;71(8):1920-1929. doi:<a href="http://dx.doi.org/10.1093/cid/ciz1243">10.1093/cid/ciz1243</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31905383" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Efficacy%20and%20safety%20of%20switching%20to%20dolutegravir%2Flamivudine%20fixed-dose%202-drug%20regimen%20vs%20continuing%20a%20tenofovir%20alafenamide-based%203-%20or%204-drug%20regimen%20for%20maintenance%20of%20virologic%20suppression%20in%20adults%20living%20with%20human%20immunodeficiency%20virus%20type%201%3A%20phase%203%2C%20randomized%2C%20noninferiority%20TANGO%20study.&amp;author=J%20van Wyk&amp;author=F%20Ajana&amp;author=F%20Bisshop&amp;publication_year=2020&amp;journal=Clin%20Infect%20Dis&amp;volume=71&amp;pages=1920-1929" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciz1243" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciz1243" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r40">40.</a><div class="reference-content">Underwood
         M﻿, Osiyemi
         O﻿, Rubio
         R﻿, 
     et al.  Archived resistance and response to &lt;40 c/mL &amp; TND–DTG/3TC FDC at week 48 in SALSA [Abstract 481] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Top Antiv Med</i>. 2022;30(1 suppl):184.<a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Archived%20resistance%20and%20response%20to%20%3C40%20c%2FmL%20%26%20TND%E2%80%93DTG%2F3TC%20FDC%20at%20week%2048%20in%20SALSA%20%5BAbstract%20481%5D%20in%20special%20issue%3A%20Abstracts%20From%20the%202022%20Conference%20on%20Retroviruses%20and%20Opportunistic%20Infections.&amp;author=M%20Underwood&amp;author=O%20Osiyemi&amp;author=R%20Rubio&amp;publication_year=2022&amp;journal=Top%20Antiv%20Med&amp;volume=30&amp;pages=184" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r41">41.</a><div class="reference-content">Marks
         K﻿, Kang
         M﻿, Umbleja
         T﻿, 
     et al. High HBsAb seroprotection achieved 4 weeks after 3 doses of HepB-CpG vaccine in people living with HIV (PLWH) without Prior HBV vaccination (ACTG A5379 Group B Preliminary Results). Poster presented at: ID Week; October 11-15, 2022; Washington, DC.</div></div><div class="reference"><a class="reference-number" id="jsc220007r42">42.</a><div class="reference-content">Ombajo
         LA﻿, Penner
         J﻿, Nkuranga
         J﻿, 
     et al.  A randomized trial of switching treatment-experienced adults from PI/r to DTG [Abstract 136] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Top Antiv Med</i>. 2022;30(1 suppl):52.<a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20randomized%20trial%20of%20switching%20treatment-experienced%20adults%20from%20PI%2Fr%20to%20DTG%20%5BAbstract%20136%5D%20in%20special%20issue%3A%20Abstracts%20From%20the%202022%20Conference%20on%20Retroviruses%20and%20Opportunistic%20Infections.&amp;author=LA%20Ombajo&amp;author=J%20Penner&amp;author=J%20Nkuranga&amp;publication_year=2022&amp;journal=Top%20Antiv%20Med&amp;volume=30&amp;pages=52" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r43">43.</a><div class="reference-content">Sax
         PE﻿, Rockstroh
         JK﻿, Luetkemeyer
         AF﻿, 
     et al; GS-US-380–4030 Investigators.  Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2021;73(2):e485-e493. doi:<a href="http://dx.doi.org/10.1093/cid/ciaa988">10.1093/cid/ciaa988</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32668455" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Switching%20to%20bictegravir%2C%20emtricitabine%2C%20and%20tenofovir%20alafenamide%20in%20virologically%20suppressed%20adults%20with%20human%20immunodeficiency%20virus.&amp;author=PE%20Sax&amp;author=JK%20Rockstroh&amp;author=AF%20Luetkemeyer&amp;publication_year=2021&amp;journal=Clin%20Infect%20Dis&amp;volume=73&amp;pages=e485-e493" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciaa988" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciaa988" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r44">44.</a><div class="reference-content">Hagins
         D﻿, Kumar
         P﻿, Saag
         M﻿, 
     et al; BRAAVE2020 Investigators.  Switching to bictegravir/emtricitabine/tenofovir alafenamide in Black Americans with HIV-1: a randomized phase 3b, multicenter, open-label study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Acquir Immune Defic Syndr</i>. 2021;88(1):86-95. doi:<a href="http://dx.doi.org/10.1097/QAI.0000000000002731">10.1097/QAI.0000000000002731</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34397746" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Switching%20to%20bictegravir%2Femtricitabine%2Ftenofovir%20alafenamide%20in%20Black%20Americans%20with%20HIV-1%3A%20a%20randomized%20phase%203b%2C%20multicenter%2C%20open-label%20study.&amp;author=D%20Hagins&amp;author=P%20Kumar&amp;author=M%20Saag&amp;publication_year=2021&amp;journal=J%20Acquir%20Immune%20Defic%20Syndr&amp;volume=88&amp;pages=86-95" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAI.0000000000002731" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAI.0000000000002731" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r45">45.</a><div class="reference-content">Sax
         PE﻿, Andreatta
         K﻿, Molina
         JM﻿, 
     et al.  High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2022;36(11):1511-1520. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000003244">10.1097/QAD.0000000000003244</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35466963" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=High%20efficacy%20of%20switching%20to%20bictegravir%2Femtricitabine%2Ftenofovir%20alafenamide%20in%20people%20with%20suppressed%20HIV%20and%20preexisting%20M184V%2FI.&amp;author=PE%20Sax&amp;author=K%20Andreatta&amp;author=JM%20Molina&amp;publication_year=2022&amp;journal=AIDS&amp;volume=36&amp;pages=1511-1520" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000003244" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000003244" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r46">46.</a><div class="reference-content">Aboud
         M﻿, Kaplan
         R﻿, Lombaard
         J﻿, 
     et al.  Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet Infect Dis</i>. 2019;19(3):253-264. doi:<a href="http://dx.doi.org/10.1016/S1473-3099(19)30036-2">10.1016/S1473-3099(19)30036-2</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/30732940" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Dolutegravir%20versus%20ritonavir-boosted%20lopinavir%20both%20with%20dual%20nucleoside%20reverse%20transcriptase%20inhibitor%20therapy%20in%20adults%20with%20HIV-1%20infection%20in%20whom%20first-line%20therapy%20has%20failed%20%28DAWNING%29%3A%20an%20open-label%2C%20non-inferiority%2C%20phase%203b%20trial.&amp;author=M%20Aboud&amp;author=R%20Kaplan&amp;author=J%20Lombaard&amp;publication_year=2019&amp;journal=Lancet%20Infect%20Dis&amp;volume=19&amp;pages=253-264" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S1473-3099(19)30036-2" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S1473-3099(19)30036-2" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r47">47.</a><div class="reference-content">Paton
         NI﻿, Musaazi
         J﻿, Kityo
         C﻿, 
     et al; NADIA Trial Team.  Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2022;9(6):e381-e393. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(22)00092-3">10.1016/S2352-3018(22)00092-3</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35460601" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Efficacy%20and%20safety%20of%20dolutegravir%20or%20darunavir%20in%20combination%20with%20lamivudine%20plus%20either%20zidovudine%20or%20tenofovir%20for%20second-line%20treatment%20of%20HIV%20infection%20%28NADIA%29%3A%20week%2096%20results%20from%20a%20prospective%2C%20multicentre%2C%20open-label%2C%20factorial%2C%20randomised%2C%20non-inferiority%20trial.&amp;author=NI%20Paton&amp;author=J%20Musaazi&amp;author=C%20Kityo&amp;publication_year=2022&amp;journal=Lancet%20HIV&amp;volume=9&amp;pages=e381-e393" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(22)00092-3" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(22)00092-3" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r48">48.</a><div class="reference-content">Rizzardini
         G﻿, Overton
         ET﻿, Orkin
         C﻿, 
     et al.  Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Acquir Immune Defic Syndr</i>. 2020;85(4):498-506. doi:<a href="http://dx.doi.org/10.1097/QAI.0000000000002466">10.1097/QAI.0000000000002466</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33136751" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Long-acting%20injectable%20cabotegravir%20%2B%20rilpivirine%20for%20HIV%20maintenance%20therapy%3A%20week%2048%20pooled%20analysis%20of%20phase%203%20ATLAS%20and%20FLAIR%20trials.&amp;author=G%20Rizzardini&amp;author=ET%20Overton&amp;author=C%20Orkin&amp;publication_year=2020&amp;journal=J%20Acquir%20Immune%20Defic%20Syndr&amp;volume=85&amp;pages=498-506" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAI.0000000000002466" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAI.0000000000002466" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r49">49.</a><div class="reference-content">Overton
         ET﻿, Richmond
         G﻿, Rizzardini
         G﻿, 
     et al.  Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet</i>. 2021;396(10267):1994-2005. doi:<a href="http://dx.doi.org/10.1016/S0140-6736(20)32666-0">10.1016/S0140-6736(20)32666-0</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33308425" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Long-acting%20cabotegravir%20and%20rilpivirine%20dosed%20every%202%20months%20in%20adults%20with%20HIV-1%20infection%20%28ATLAS-2M%29%2C%2048-week%20results%3A%20a%20randomised%2C%20multicentre%2C%20open-label%2C%20phase%203b%2C%20non-inferiority%20study.&amp;author=ET%20Overton&amp;author=G%20Richmond&amp;author=G%20Rizzardini&amp;publication_year=2021&amp;journal=Lancet&amp;volume=396&amp;pages=1994-2005" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S0140-6736(20)32666-0" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S0140-6736(20)32666-0" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r50">50.</a><div class="reference-content">Murray
         M﻿, Antela
         A﻿, Mills
         A﻿, 
     et al.  Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48 weeks. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS Behav</i>. 2020;24(12):3533-3544. doi:<a href="http://dx.doi.org/10.1007/s10461-020-02929-8">10.1007/s10461-020-02929-8</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32447500" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Patient-reported%20outcomes%20in%20ATLAS%20and%20FLAIR%20participants%20on%20long-acting%20regimens%20of%20cabotegravir%20and%20rilpivirine%20over%2048%20weeks.&amp;author=M%20Murray&amp;author=A%20Antela&amp;author=A%20Mills&amp;publication_year=2020&amp;journal=AIDS%20Behav&amp;volume=24&amp;pages=3533-3544" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1007/s10461-020-02929-8" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1007/s10461-020-02929-8" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r51">51.</a><div class="reference-content">Orkin
         C﻿, Bernal Morell
         E﻿, Tan
         DHS﻿, 
     et al.  Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2021;8(11):e668-e678. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(21)00184-3">10.1016/S2352-3018(21)00184-3</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34656207" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Initiation%20of%20long-acting%20cabotegravir%20plus%20rilpivirine%20as%20direct-to-injection%20or%20with%20an%20oral%20lead-in%20in%20adults%20with%20HIV-1%20infection%3A%20week%20124%20results%20of%20the%20open-label%20phase%203%20FLAIR%20study.&amp;author=C%20Orkin&amp;author=E%20Bernal Morell&amp;author=DHS%20Tan&amp;publication_year=2021&amp;journal=Lancet%20HIV&amp;volume=8&amp;pages=e668-e678" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(21)00184-3" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(21)00184-3" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r52">52.</a><div class="reference-content">Ellis
         KE﻿, Nawas
         GT﻿, Chan
         C﻿, 
     et al.  Clinical outcomes following the use of archived proviral HIV-1 DNA genotype to guide antiretroviral therapy adjustment. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Open Forum Infect Dis</i>. 2019;7(1):ofz533. doi:<a href="http://dx.doi.org/10.1093/ofid/ofz533">10.1093/ofid/ofz533</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31915714" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Clinical%20outcomes%20following%20the%20use%20of%20archived%20proviral%20HIV-1%20DNA%20genotype%20to%20guide%20antiretroviral%20therapy%20adjustment.&amp;author=KE%20Ellis&amp;author=GT%20Nawas&amp;author=C%20Chan&amp;publication_year=2019&amp;journal=Open%20Forum%20Infect%20Dis&amp;volume=7&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/ofid/ofz533" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/ofid/ofz533" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r53">53.</a><div class="reference-content">Castagna
         A﻿, Maggiolo
         F﻿, Penco
         G﻿, 
     et al; VIKING-3 Study Group.  Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Infect Dis</i>. 2014;210(3):354-362. doi:<a href="http://dx.doi.org/10.1093/infdis/jiu051">10.1093/infdis/jiu051</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/24446523" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Dolutegravir%20in%20antiretroviral-experienced%20patients%20with%20raltegravir-%20and%2For%20elvitegravir-resistant%20HIV-1%3A%2024-week%20results%20of%20the%20phase%20III%20VIKING-3%20study.&amp;author=A%20Castagna&amp;author=F%20Maggiolo&amp;author=G%20Penco&amp;publication_year=2014&amp;journal=J%20Infect%20Dis&amp;volume=210&amp;pages=354-362" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/infdis/jiu051" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/infdis/jiu051" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r54">54.</a><div class="reference-content">Fostemsavir [prescribing information]. ViiV Healthcare; 2020.</div></div><div class="reference"><a class="reference-number" id="jsc220007r55">55.</a><div class="reference-content">Kamelian
         K﻿, Lepik
         KJ﻿, Chau
         W﻿, 
     et al.  Prevalence of human immunodeficiency virus-1 integrase strand transfer inhibitor resistance in British Columbia, Canada between 2009 and 2016: a longitudinal analysis. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Open Forum Infect Dis</i>. 2019;6(3):ofz060. doi:<a href="http://dx.doi.org/10.1093/ofid/ofz060">10.1093/ofid/ofz060</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/30895202" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Prevalence%20of%20human%20immunodeficiency%20virus-1%20integrase%20strand%20transfer%20inhibitor%20resistance%20in%20British%20Columbia%2C%20Canada%20between%202009%20and%202016%3A%20a%20longitudinal%20analysis.&amp;author=K%20Kamelian&amp;author=KJ%20Lepik&amp;author=W%20Chau&amp;publication_year=2019&amp;journal=Open%20Forum%20Infect%20Dis&amp;volume=6&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/ofid/ofz060" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/ofid/ofz060" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r56">56.</a><div class="reference-content">Koullias
         Y﻿, Sax
         PE﻿, Fields
         NF﻿, Walensky
         RP﻿, Hyle
         EP﻿.  Should we be testing for baseline integrase resistance in patients newly diagnosed with human immunodeficiency virus? ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2017;65(8):1274-1281. doi:<a href="http://dx.doi.org/10.1093/cid/cix542">10.1093/cid/cix542</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/28605418" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Should%20we%20be%20testing%20for%20baseline%20integrase%20resistance%20in%20patients%20newly%20diagnosed%20with%20human%20immunodeficiency%20virus%3F&amp;author=Y%20Koullias&amp;author=PE%20Sax&amp;author=NF%20Fields&amp;author=RP%20Walensky&amp;author=EP%20Hyle&amp;publication_year=2017&amp;journal=Clin%20Infect%20Dis&amp;volume=65&amp;pages=1274-1281" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/cix542" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/cix542" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r57">57.</a><div class="reference-content">Zhu
         J﻿, Rozada
         I﻿, David
         J﻿, 
     et al.  The potential impact of initiating antiretroviral therapy with integrase inhibitors on HIV transmission risk in British Columbia, Canada. ﻿ <i xmlns:helper="urn:XsltStringHelper"> EClinicalMedicine</i>. 2019;13:101-111. doi:<a href="http://dx.doi.org/10.1016/j.eclinm.2019.07.001">10.1016/j.eclinm.2019.07.001</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31517267" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20potential%20impact%20of%20initiating%20antiretroviral%20therapy%20with%20integrase%20inhibitors%20on%20HIV%20transmission%20risk%20in%20British%20Columbia%2C%20Canada.&amp;author=J%20Zhu&amp;author=I%20Rozada&amp;author=J%20David&amp;publication_year=2019&amp;journal=EClinicalMedicine&amp;volume=13&amp;pages=101-111" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.eclinm.2019.07.001" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.eclinm.2019.07.001" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r58">58.</a><div class="reference-content">Berenguer
         J﻿, Parrondo
         J﻿, Landovitz
         RJ﻿.  Mathematical modeling of HIV-1 transmission risk from condomless anal intercourse in HIV-infected MSM by the type of initial ART. ﻿ <i xmlns:helper="urn:XsltStringHelper"> PLoS One</i>. 2019;14(7):e0219802. doi:<a href="http://dx.doi.org/10.1371/journal.pone.0219802">10.1371/journal.pone.0219802</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31323075" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Mathematical%20modeling%20of%20HIV-1%20transmission%20risk%20from%20condomless%20anal%20intercourse%20in%20HIV-infected%20MSM%20by%20the%20type%20of%20initial%20ART.&amp;author=J%20Berenguer&amp;author=J%20Parrondo&amp;author=RJ%20Landovitz&amp;publication_year=2019&amp;journal=PLoS%20One&amp;volume=14&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1371/journal.pone.0219802" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1371/journal.pone.0219802" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r59">59.</a><div class="reference-content">Charpentier
         C﻿, Storto
         A﻿, Soulié
         C﻿, 
     et al.  Prevalence of genotypic baseline risk factors for cabotegravir   + rilpivirine failure among ARV-naive patients. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Antimicrob Chemother</i>. 2021;76(11):2983-2987. doi:<a href="http://dx.doi.org/10.1093/jac/dkab161">10.1093/jac/dkab161</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34015097" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Prevalence%20of%20genotypic%20baseline%20risk%20factors%20for%20cabotegravir%E2%80%89%E2%80%8A%E2%80%89%2B%E2%80%8Arilpivirine%20failure%20among%20ARV-naive%20patients.&amp;author=C%20Charpentier&amp;author=A%20Storto&amp;author=C%20Soulié&amp;publication_year=2021&amp;journal=J%20Antimicrob%20Chemother&amp;volume=76&amp;pages=2983-2987" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/jac/dkab161" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/jac/dkab161" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r60">60.</a><div class="reference-content">Sise
         ME﻿, Hirsch
         JS﻿, Canetta
         PA﻿, Herlitz
         L﻿, Mohan
         S﻿.  Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2015;29(8):941-946. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000000628">10.1097/QAD.0000000000000628</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/25784440" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Nonalbumin%20proteinuria%20predominates%20in%20biopsy-proven%20tenofovir%20nephrotoxicity.&amp;author=ME%20Sise&amp;author=JS%20Hirsch&amp;author=PA%20Canetta&amp;author=L%20Herlitz&amp;author=S%20Mohan&amp;publication_year=2015&amp;journal=AIDS&amp;volume=29&amp;pages=941-946" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000000628" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000000628" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r61">61.</a><div class="reference-content">Samarawickrama
         A﻿, Cai
         M﻿, Smith
         ER﻿, 
     et al.  Simultaneous measurement of urinary albumin and total protein may facilitate decision-making in HIV-infected patients with proteinuria. ﻿ <i xmlns:helper="urn:XsltStringHelper"> HIV Med</i>. 2012;13(9):526-532. doi:<a href="http://dx.doi.org/10.1111/j.1468-1293.2012.01003.x">10.1111/j.1468-1293.2012.01003.x</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/22413854" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Simultaneous%20measurement%20of%20urinary%20albumin%20and%20total%20protein%20may%20facilitate%20decision-making%20in%20HIV-infected%20patients%20with%20proteinuria.&amp;author=A%20Samarawickrama&amp;author=M%20Cai&amp;author=ER%20Smith&amp;publication_year=2012&amp;journal=HIV%20Med&amp;volume=13&amp;pages=526-532" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1111/j.1468-1293.2012.01003.x" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1111/j.1468-1293.2012.01003.x" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r62">62.</a><div class="reference-content">Joshi
         K﻿, Boettiger
         D﻿, Kerr
         S﻿, 
     et al.  Changes in renal function with long-term exposure to antiretroviral therapy in HIV-infected adults in Asia. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Pharmacoepidemiol Drug Saf</i>. 2018;27(11):1209-1216. doi:<a href="http://dx.doi.org/10.1002/pds.4657">10.1002/pds.4657</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/30246898" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Changes%20in%20renal%20function%20with%20long-term%20exposure%20to%20antiretroviral%20therapy%20in%20HIV-infected%20adults%20in%20Asia.&amp;author=K%20Joshi&amp;author=D%20Boettiger&amp;author=S%20Kerr&amp;publication_year=2018&amp;journal=Pharmacoepidemiol%20Drug%20Saf&amp;volume=27&amp;pages=1209-1216" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1002/pds.4657" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1002/pds.4657" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r63">63.</a><div class="reference-content">Kaboré
         NF﻿, Poda
         A﻿, Zoungrana
         J﻿, 
     et al.  Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting. ﻿ <i xmlns:helper="urn:XsltStringHelper"> BMC Nephrol</i>. 2019;20(1):155. doi:<a href="http://dx.doi.org/10.1186/s12882-019-1335-9">10.1186/s12882-019-1335-9</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31064340" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Chronic%20kidney%20disease%20and%20HIV%20in%20the%20era%20of%20antiretroviral%20treatment%3A%20findings%20from%20a%2010-year%20cohort%20study%20in%20a%20west%20African%20setting.&amp;author=NF%20Kaboré&amp;author=A%20Poda&amp;author=J%20Zoungrana&amp;publication_year=2019&amp;journal=BMC%20Nephrol&amp;volume=20&amp;pages=155" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1186/s12882-019-1335-9" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1186/s12882-019-1335-9" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r64">64.</a><div class="reference-content">Jotwani
         V﻿, Scherzer
         R﻿, Estrella
         MM﻿, 
     et al.  HIV infection, tenofovir, and urine α1-microglobulin: a cross-sectional analysis in the Multicenter AIDS Cohort Study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Am J Kidney Dis</i>. 2016;68(4):571-581. doi:<a href="http://dx.doi.org/10.1053/j.ajkd.2016.03.430">10.1053/j.ajkd.2016.03.430</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/27287300" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=HIV%20infection%2C%20tenofovir%2C%20and%20urine%20%CE%B11-microglobulin%3A%20a%20cross-sectional%20analysis%20in%20the%20Multicenter%20AIDS%20Cohort%20Study.&amp;author=V%20Jotwani&amp;author=R%20Scherzer&amp;author=MM%20Estrella&amp;publication_year=2016&amp;journal=Am%20J%20Kidney%20Dis&amp;volume=68&amp;pages=571-581" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1053/j.ajkd.2016.03.430" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1053/j.ajkd.2016.03.430" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r65">65.</a><div class="reference-content">Thompson
         MA﻿, Horberg
         MA﻿, Agwu
         AL﻿, 
     et al.  Primary care guidance for persons with human immunodeficiency virus: 2020 update by the HIV Medicine Association of the Infectious Diseases Society of America. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2021;73(11):e3572-e3605. doi:<a href="http://dx.doi.org/10.1093/cid/ciaa1391">10.1093/cid/ciaa1391</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33225349" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Primary%20care%20guidance%20for%20persons%20with%20human%20immunodeficiency%20virus%3A%202020%20update%20by%20the%20HIV%20Medicine%20Association%20of%20the%20Infectious%20Diseases%20Society%20of%20America.&amp;author=MA%20Thompson&amp;author=MA%20Horberg&amp;author=AL%20Agwu&amp;publication_year=2021&amp;journal=Clin%20Infect%20Dis&amp;volume=73&amp;pages=e3572-e3605" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciaa1391" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciaa1391" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r66">66.</a><div class="reference-content">Sax
         PE﻿, Erlandson
         KM﻿, Lake
         JE﻿, 
     et al.  Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2020;71(6):1379-1389. doi:<a href="http://dx.doi.org/10.1093/cid/ciz999">10.1093/cid/ciz999</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31606734" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Weight%20gain%20following%20initiation%20of%20antiretroviral%20therapy%3A%20risk%20factors%20in%20randomized%20comparative%20clinical%20trials.&amp;author=PE%20Sax&amp;author=KM%20Erlandson&amp;author=JE%20Lake&amp;publication_year=2020&amp;journal=Clin%20Infect%20Dis&amp;volume=71&amp;pages=1379-1389" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciz999" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciz999" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r67">67.</a><div class="reference-content">Surial
         B﻿, Mugglin
         C﻿, Calmy
         A﻿, 
     et al; Swiss HIV Cohort Study.  Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: a cohort study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Ann Intern Med</i>. 2021;174(6):758-767. doi:<a href="http://dx.doi.org/10.7326/M20-4853">10.7326/M20-4853</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33721521" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Weight%20and%20metabolic%20changes%20after%20switching%20from%20tenofovir%20disoproxil%20fumarate%20to%20tenofovir%20alafenamide%20in%20people%20living%20with%20HIV%3A%20a%20cohort%20study.&amp;author=B%20Surial&amp;author=C%20Mugglin&amp;author=A%20Calmy&amp;publication_year=2021&amp;journal=Ann%20Intern%20Med&amp;volume=174&amp;pages=758-767" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.7326/M20-4853" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.7326/M20-4853" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r68">68.</a><div class="reference-content">Ogbuagu
         O﻿, Ruane
         PJ﻿, Podzamczer
         D﻿, 
     et al; DISCOVER Study Team.  Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2021;8(7):e397-e407. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(21)00071-0">10.1016/S2352-3018(21)00071-0</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34197772" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Long-term%20safety%20and%20efficacy%20of%20emtricitabine%20and%20tenofovir%20alafenamide%20vs%20emtricitabine%20and%20tenofovir%20disoproxil%20fumarate%20for%20HIV-1%20pre-exposure%20prophylaxis%3A%20week%2096%20results%20from%20a%20randomised%2C%20double-blind%2C%20placebo-controlled%2C%20phase%203%20trial.&amp;author=O%20Ogbuagu&amp;author=PJ%20Ruane&amp;author=D%20Podzamczer&amp;publication_year=2021&amp;journal=Lancet%20HIV&amp;volume=8&amp;pages=e397-e407" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(21)00071-0" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(21)00071-0" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r69">69.</a><div class="reference-content">Bourgi
         K﻿, Jenkins
         CA﻿, Rebeiro
         PF﻿, 
     et al; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).  Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Int AIDS Soc</i>. 2020;23(4):e25484. doi:<a href="http://dx.doi.org/10.1002/jia2.25484">10.1002/jia2.25484</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32294337" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Weight%20gain%20among%20treatment-na%C3%AFve%20persons%20with%20HIV%20starting%20integrase%20inhibitors%20compared%20to%20non-nucleoside%20reverse%20transcriptase%20inhibitors%20or%20protease%20inhibitors%20in%20a%20large%20observational%20cohort%20in%20the%20United%20States%20and%20Canada.&amp;author=K%20Bourgi&amp;author=CA%20Jenkins&amp;author=PF%20Rebeiro&amp;publication_year=2020&amp;journal=J%20Int%20AIDS%20Soc&amp;volume=23&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1002/jia2.v23.4" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1002/jia2.v23.4" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r70">70.</a><div class="reference-content">Mallon
         PW﻿, Brunet
         L﻿, Hsu
         RK﻿, 
     et al.  Weight gain before and after switch from TDF to TAF in a U.S. cohort study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Int AIDS Soc</i>. 2021;24(4):e25702. doi:<a href="http://dx.doi.org/10.1002/jia2.25702">10.1002/jia2.25702</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33838004" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Weight%20gain%20before%20and%20after%20switch%20from%20TDF%20to%20TAF%20in%20a%20U.S.%20cohort%20study.&amp;author=PW%20Mallon&amp;author=L%20Brunet&amp;author=RK%20Hsu&amp;publication_year=2021&amp;journal=J%20Int%20AIDS%20Soc&amp;volume=24&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1002/jia2.v24.4" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1002/jia2.v24.4" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r71">71.</a><div class="reference-content">Venter
         WDF﻿, Sokhela
         S﻿, Simmons
         B﻿, 
     et al.  Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2020;7(10):e666-e676. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(20)30241-1">10.1016/S2352-3018(20)30241-1</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33010240" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Dolutegravir%20with%20emtricitabine%20and%20tenofovir%20alafenamide%20or%20tenofovir%20disoproxil%20fumarate%20versus%20efavirenz%2C%20emtricitabine%2C%20and%20tenofovir%20disoproxil%20fumarate%20for%20initial%20treatment%20of%20HIV-1%20infection%20%28ADVANCE%29%3A%20week%2096%20results%20from%20a%20randomised%2C%20phase%203%2C%20non-inferiority%20trial.&amp;author=WDF%20Venter&amp;author=S%20Sokhela&amp;author=B%20Simmons&amp;publication_year=2020&amp;journal=Lancet%20HIV&amp;volume=7&amp;pages=e666-e676" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(20)30241-1" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(20)30241-1" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r72">72.</a><div class="reference-content">Bischoff
         J﻿, Gu
         W﻿, Schwarze-Zander
         C﻿, 
     et al.  Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART). ﻿ <i xmlns:helper="urn:XsltStringHelper"> EClinicalMedicine</i>. 2021;40:101116. doi:<a href="http://dx.doi.org/10.1016/j.eclinm.2021.101116">10.1016/j.eclinm.2021.101116</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34522873" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Stratifying%20the%20risk%20of%20NAFLD%20in%20patients%20with%20HIV%20under%20combination%20antiretroviral%20therapy%20%28cART%29.&amp;author=J%20Bischoff&amp;author=W%20Gu&amp;author=C%20Schwarze-Zander&amp;publication_year=2021&amp;journal=EClinicalMedicine&amp;volume=40&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.eclinm.2021.101116" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.eclinm.2021.101116" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r73">73.</a><div class="reference-content">Gorwood
         J﻿, Bourgeois
         C﻿, Pourcher
         V﻿, 
     et al.  The integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in human/simian adipose tissue and human adipocytes. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2020;71(10):e549-e560. doi:<a href="http://dx.doi.org/10.1093/cid/ciaa259">10.1093/cid/ciaa259</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32166319" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20integrase%20inhibitors%20dolutegravir%20and%20raltegravir%20exert%20proadipogenic%20and%20profibrotic%20effects%20and%20induce%20insulin%20resistance%20in%20human%2Fsimian%20adipose%20tissue%20and%20human%20adipocytes.&amp;author=J%20Gorwood&amp;author=C%20Bourgeois&amp;author=V%20Pourcher&amp;publication_year=2020&amp;journal=Clin%20Infect%20Dis&amp;volume=71&amp;pages=e549-e560" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciaa259" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciaa259" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r74">74.</a><div class="reference-content">González-Cordón
         A﻿, Assoumou
         L﻿, Moyle
         G﻿, 
     et al; NEAT022 Study Group.  Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Antimicrob Chemother</i>. 2021;76(9):2380-2393. doi:<a href="http://dx.doi.org/10.1093/jac/dkab158">10.1093/jac/dkab158</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34120186" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Switching%20from%20boosted%20PIs%20to%20dolutegravir%20decreases%20soluble%20CD14%20and%20adiponectin%20in%20high%20cardiovascular%20risk%20people%20living%20with%20HIV.&amp;author=A%20González-Cordón&amp;author=L%20Assoumou&amp;author=G%20Moyle&amp;publication_year=2021&amp;journal=J%20Antimicrob%20Chemother&amp;volume=76&amp;pages=2380-2393" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/jac/dkab158" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/jac/dkab158" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r75">75.</a><div class="reference-content">Leonard
         MA﻿, Cindi
         Z﻿, Bradford
         Y﻿, 
     et al.  Efavirenz pharmacogenetics and weight gain following switch to integrase inhibitor-containing regimens. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2021;73(7):e2153-e2163. doi:<a href="http://dx.doi.org/10.1093/cid/ciaa1219">10.1093/cid/ciaa1219</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32829410" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Efavirenz%20pharmacogenetics%20and%20weight%20gain%20following%20switch%20to%20integrase%20inhibitor-containing%20regimens.&amp;author=MA%20Leonard&amp;author=Z%20Cindi&amp;author=Y%20Bradford&amp;publication_year=2021&amp;journal=Clin%20Infect%20Dis&amp;volume=73&amp;pages=e2153-e2163" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciaa1219" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciaa1219" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r76">76.</a><div class="reference-content">Plum
         PE﻿, Maes
         N﻿, Sauvage
         AS﻿, 
     et al.  Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> BMC Infect Dis</i>. 2021;21(1):910. doi:<a href="http://dx.doi.org/10.1186/s12879-021-06479-9">10.1186/s12879-021-06479-9</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34488664" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Impact%20of%20switch%20from%20tenofovir%20disoproxil%20fumarate-based%20regimens%20to%20tenofovir%20alafenamide-based%20regimens%20on%20lipid%20profile%2C%20weight%20gain%20and%20cardiovascular%20risk%20score%20in%20people%20living%20with%20HIV.&amp;author=PE%20Plum&amp;author=N%20Maes&amp;author=AS%20Sauvage&amp;publication_year=2021&amp;journal=BMC%20Infect%20Dis&amp;volume=21&amp;pages=910" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1186/s12879-021-06479-9" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1186/s12879-021-06479-9" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r77">77.</a><div class="reference-content">Silverberg
         MJ﻿, Lyass
         A﻿, Hurley
         L﻿, 
     et al.  Trends in myocardial infarction risk by HIV status in 2 US healthcare systems [Abstract 39] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Top Antiv Med</i>. 2022;30(1 suppl):15.<a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Trends%20in%20myocardial%20infarction%20risk%20by%20HIV%20status%20in%202%20US%20healthcare%20systems%20%5BAbstract%2039%5D%20in%20special%20issue%3A%20Abstracts%20From%20the%202022%20Conference%20on%20Retroviruses%20and%20Opportunistic%20Infections.&amp;author=MJ%20Silverberg&amp;author=A%20Lyass&amp;author=L%20Hurley&amp;publication_year=2022&amp;journal=Top%20Antiv%20Med&amp;volume=30&amp;pages=15" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r78">78.</a><div class="reference-content">Nolan
         NS﻿, Adamson
         S﻿, Reeds
         D﻿, O’Halloran
         JA﻿.  Bictegravir-based antiretroviral therapy-associated accelerated hyperglycemia and diabetes mellitus. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Open Forum Infect Dis</i>. 2021;8(5):ofab077. doi:<a href="http://dx.doi.org/10.1093/ofid/ofab077">10.1093/ofid/ofab077</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33981777" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Bictegravir-based%20antiretroviral%20therapy-associated%20accelerated%20hyperglycemia%20and%20diabetes%20mellitus.&amp;author=NS%20Nolan&amp;author=S%20Adamson&amp;author=D%20Reeds&amp;author=JA%20O’Halloran&amp;publication_year=2021&amp;journal=Open%20Forum%20Infect%20Dis&amp;volume=8&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/ofid/ofab077" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/ofid/ofab077" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r79">79.</a><div class="reference-content">O’Halloran
         JA﻿, Sahrmann
         J﻿, Parra-Rodriguez
         L﻿, 
     et al.  Integrase strand transfer inhibitors are associated with incident diabetes mellitus in people with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. Published online May 6, 2022. doi:<a href="http://dx.doi.org/10.1093/cid/ciac355">10.1093/cid/ciac355</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35521785" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Integrase%20strand%20transfer%20inhibitors%20are%20associated%20with%20incident%20diabetes%20mellitus%20in%20people%20with%20HIV.&amp;author=JA%20O’Halloran&amp;author=J%20Sahrmann&amp;author=L%20Parra-Rodriguez&amp;publication_year=2022&amp;journal=Clin%20Infect%20Dis&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciac355" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciac355" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r80">80.</a><div class="reference-content">Summers
         NA﻿, Lahiri
         CD﻿, Angert
         CD﻿, 
     et al.  Metabolic changes associated with the use of integrase strand transfer inhibitors among virally controlled women. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Acquir Immune Defic Syndr</i>. 2020;85(3):355-362. doi:<a href="http://dx.doi.org/10.1097/QAI.0000000000002447">10.1097/QAI.0000000000002447</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33060420" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Metabolic%20changes%20associated%20with%20the%20use%20of%20integrase%20strand%20transfer%20inhibitors%20among%20virally%20controlled%20women.&amp;author=NA%20Summers&amp;author=CD%20Lahiri&amp;author=CD%20Angert&amp;publication_year=2020&amp;journal=J%20Acquir%20Immune%20Defic%20Syndr&amp;volume=85&amp;pages=355-362" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAI.0000000000002447" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAI.0000000000002447" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r81">81.</a><div class="reference-content">Rebeiro
         PF﻿, Jenkins
         CA﻿, Bian
         A﻿, 
     et al.  Risk of incident diabetes mellitus, weight gain, and their relationships with integrase inhibitor-based initial antiretroviral therapy among persons with human immunodeficiency virus in the United States and Canada. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2021;73(7):e2234-e2242. doi:<a href="http://dx.doi.org/10.1093/cid/ciaa1403">10.1093/cid/ciaa1403</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32936919" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Risk%20of%20incident%20diabetes%20mellitus%2C%20weight%20gain%2C%20and%20their%20relationships%20with%20integrase%20inhibitor-based%20initial%20antiretroviral%20therapy%20among%20persons%20with%20human%20immunodeficiency%20virus%20in%20the%20United%20States%20and%20Canada.&amp;author=PF%20Rebeiro&amp;author=CA%20Jenkins&amp;author=A%20Bian&amp;publication_year=2021&amp;journal=Clin%20Infect%20Dis&amp;volume=73&amp;pages=e2234-e2242" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciaa1403" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciaa1403" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r82">82.</a><div class="reference-content">Petoumenos
         K﻿, Kuwanda
         L﻿, Ryom
         L﻿, 
     et al; D:A:D Study Group.  Effect of changes in body mass index on the risk of cardiovascular disease and diabetes mellitus in HIV-positive individuals: results from the D:A:D study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Acquir Immune Defic Syndr</i>. 2021;86(5):579-586. doi:<a href="http://dx.doi.org/10.1097/QAI.0000000000002603">10.1097/QAI.0000000000002603</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33351531" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effect%20of%20changes%20in%20body%20mass%20index%20on%20the%20risk%20of%20cardiovascular%20disease%20and%20diabetes%20mellitus%20in%20HIV-positive%20individuals%3A%20results%20from%20the%20D%3AA%3AD%20study.&amp;author=K%20Petoumenos&amp;author=L%20Kuwanda&amp;author=L%20Ryom&amp;publication_year=2021&amp;journal=J%20Acquir%20Immune%20Defic%20Syndr&amp;volume=86&amp;pages=579-586" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAI.0000000000002603" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAI.0000000000002603" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r83">83.</a><div class="reference-content">Hagins
         D﻿, Mussini
         C﻿, Zhang
         F﻿, 
     et al.  Week-48 metabolic health after switch to DTG/3TC vs CAR by baseline regimen: SALSA [Abstract 603] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Top Antiv Med</i>. 2022;30(1 suppl):236.<a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Week-48%20metabolic%20health%20after%20switch%20to%20DTG%2F3TC%20vs%20CAR%20by%20baseline%20regimen%3A%20SALSA%20%5BAbstract%20603%5D%20in%20special%20issue%3A%20Abstracts%20From%20the%202022%20Conference%20on%20Retroviruses%20and%20Opportunistic%20Infections.&amp;author=D%20Hagins&amp;author=C%20Mussini&amp;author=F%20Zhang&amp;publication_year=2022&amp;journal=Top%20Antiv%20Med&amp;volume=30&amp;pages=236" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r84">84.</a><div class="reference-content">Wilding
         JPH﻿, Batterham
         RL﻿, Calanna
         S﻿, 
     et al; STEP 1 Study Group.  Once-weekly semaglutide in adults with overweight or obesity. ﻿ <i xmlns:helper="urn:XsltStringHelper"> N Engl J Med</i>. 2021;384(11):989-1002. doi:<a href="http://dx.doi.org/10.1056/NEJMoa2032183">10.1056/NEJMoa2032183</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33567185" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Once-weekly%20semaglutide%20in%20adults%20with%20overweight%20or%20obesity.&amp;author=JPH%20Wilding&amp;author=RL%20Batterham&amp;author=S%20Calanna&amp;publication_year=2021&amp;journal=N%20Engl%20J%20Med&amp;volume=384&amp;pages=989-1002" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMoa2032183" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMoa2032183" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r85">85.</a><div class="reference-content">Semaglutide’s efficacy in achieving weight loss for those with HIV (SWIFT) [NCT04174755]. ClinicalTrials.gov. Accessed November 9, 2022. <a href="https://clinicaltrials.gov/ct2/show/NCT04174755">https://clinicaltrials.gov/ct2/show/NCT04174755</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r86">86.</a><div class="reference-content">Justice
         AC﻿, Goetz
         MB﻿, Stewart
         CN﻿, 
     et al.  Delayed presentation of HIV among older individuals: a growing problem. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2022;9(4):e269-e280. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(22)00003-0">10.1016/S2352-3018(22)00003-0</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35218732" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Delayed%20presentation%20of%20HIV%20among%20older%20individuals%3A%20a%20growing%20problem.&amp;author=AC%20Justice&amp;author=MB%20Goetz&amp;author=CN%20Stewart&amp;publication_year=2022&amp;journal=Lancet%20HIV&amp;volume=9&amp;pages=e269-e280" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(22)00003-0" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(22)00003-0" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r87">87.</a><div class="reference-content">Lee
         JS﻿, Humes
         E﻿, Hogan
         BC﻿, 
     et al; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).  Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004-18: a cohort study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2022;9(suppl 1):S2. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(22)00067-4">10.1016/S2352-3018(22)00067-4</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35304844" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Observed%20CD4%20counts%20at%20entry%20into%20HIV%20care%20and%20at%20antiretroviral%20therapy%20prescription%20by%20age%20in%20the%20USA%2C%202004-18%3A%20a%20cohort%20study.&amp;author=JS%20Lee&amp;author=E%20Humes&amp;author=BC%20Hogan&amp;publication_year=2022&amp;journal=Lancet%20HIV&amp;volume=9&amp;pages=S2" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(22)00067-4" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(22)00067-4" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r88">88.</a><div class="reference-content">Zhabokritsky
         A﻿, Szadkowski
         L﻿, Burchell
         AN﻿, 
     et al; Canadian Observational Cohort (CANOC) Collaboration.  Immunological and virological response to initial antiretroviral therapy among older people living with HIV in the Canadian Observational Cohort (CANOC). ﻿ <i xmlns:helper="urn:XsltStringHelper"> HIV Med</i>. 2021;22(8):759-769. doi:<a href="http://dx.doi.org/10.1111/hiv.13125">10.1111/hiv.13125</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34075683" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Immunological%20and%20virological%20response%20to%20initial%20antiretroviral%20therapy%20among%20older%20people%20living%20with%20HIV%20in%20the%20Canadian%20Observational%20Cohort%20%28CANOC%29.&amp;author=A%20Zhabokritsky&amp;author=L%20Szadkowski&amp;author=AN%20Burchell&amp;publication_year=2021&amp;journal=HIV%20Med&amp;volume=22&amp;pages=759-769" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1111/hiv.v22.8" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1111/hiv.v22.8" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r89">89.</a><div class="reference-content">Richterman
         A﻿, Sax
         PE﻿.  Antiretroviral therapy in older people with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Curr Opin HIV AIDS</i>. 2020;15(2):118-125. doi:<a href="http://dx.doi.org/10.1097/COH.0000000000000614">10.1097/COH.0000000000000614</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31990705" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Antiretroviral%20therapy%20in%20older%20people%20with%20HIV.&amp;author=A%20Richterman&amp;author=PE%20Sax&amp;publication_year=2020&amp;journal=Curr%20Opin%20HIV%20AIDS&amp;volume=15&amp;pages=118-125" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/COH.0000000000000614" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/COH.0000000000000614" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r90">90.</a><div class="reference-content">Courlet
         P﻿, Stader
         F﻿, Guidi
         M﻿, 
     et al; Swiss HIV Cohort Study.  Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2020;34(1):103-108. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000002372">10.1097/QAD.0000000000002372</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31490233" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Pharmacokinetic%20profiles%20of%20boosted%20darunavir%2C%20dolutegravir%20and%20lamivudine%20in%20aging%20people%20living%20with%20HIV.&amp;author=P%20Courlet&amp;author=F%20Stader&amp;author=M%20Guidi&amp;publication_year=2020&amp;journal=AIDS&amp;volume=34&amp;pages=103-108" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000002372" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000002372" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r91">91.</a><div class="reference-content">Smith
         L﻿, Letendre
         S﻿, Erlandson
         KM﻿, Ma
         Q﻿, Ellis
         RJ﻿, Farhadian
         SF﻿.  Polypharmacy in older adults with HIV infection: effects on the brain. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Am Geriatr Soc</i>. 2022;70(3):924-927. doi:<a href="http://dx.doi.org/10.1111/jgs.17569">10.1111/jgs.17569</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34855982" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Polypharmacy%20in%20older%20adults%20with%20HIV%20infection%3A%20effects%20on%20the%20brain.&amp;author=L%20Smith&amp;author=S%20Letendre&amp;author=KM%20Erlandson&amp;author=Q%20Ma&amp;author=RJ%20Ellis&amp;author=SF%20Farhadian&amp;publication_year=2022&amp;journal=J%20Am%20Geriatr%20Soc&amp;volume=70&amp;pages=924-927" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1111/jgs.v70.3" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1111/jgs.v70.3" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r92">92.</a><div class="reference-content">Blanco
         JR﻿, Morillo
         R﻿, Abril
         V﻿, 
     et al; Gesida and SEFH.  Deprescribing of non-antiretroviral therapy in HIV-infected patients. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Eur J Clin Pharmacol</i>. 2020;76(3):305-318. doi:<a href="http://dx.doi.org/10.1007/s00228-019-02785-z">10.1007/s00228-019-02785-z</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31865412" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Deprescribing%20of%20non-antiretroviral%20therapy%20in%20HIV-infected%20patients.&amp;author=JR%20Blanco&amp;author=R%20Morillo&amp;author=V%20Abril&amp;publication_year=2020&amp;journal=Eur%20J%20Clin%20Pharmacol&amp;volume=76&amp;pages=305-318" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1007/s00228-019-02785-z" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1007/s00228-019-02785-z" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r93">93.</a><div class="reference-content">López-Centeno
         B﻿, Badenes-Olmedo
         C﻿, Mataix-Sanjuan
         A﻿, 
     et al.  Potentially inappropriate medications in older adults living with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> HIV Med</i>. 2020;21(8):541-546. doi:<a href="http://dx.doi.org/10.1111/hiv.12883">10.1111/hiv.12883</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32516849" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Potentially%20inappropriate%20medications%20in%20older%20adults%20living%20with%20HIV.&amp;author=B%20López-Centeno&amp;author=C%20Badenes-Olmedo&amp;author=A%20Mataix-Sanjuan&amp;publication_year=2020&amp;journal=HIV%20Med&amp;volume=21&amp;pages=541-546" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1111/hiv.v21.8" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1111/hiv.v21.8" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r94">94.</a><div class="reference-content">Koren
         DE﻿, Scarsi
         KK﻿, Farmer
         EK﻿, 
     et al.  A call to action: the role of antiretroviral stewardship in inpatient practice, a joint policy paper of the Infectious Diseases Society of America, HIV Medicine Association, and American Academy of HIV Medicine. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2020;70(11):2241-2246. doi:<a href="http://dx.doi.org/10.1093/cid/ciz792">10.1093/cid/ciz792</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32445480" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20call%20to%20action%3A%20the%20role%20of%20antiretroviral%20stewardship%20in%20inpatient%20practice%2C%20a%20joint%20policy%20paper%20of%20the%20Infectious%20Diseases%20Society%20of%20America%2C%20HIV%20Medicine%20Association%2C%20and%20American%20Academy%20of%20HIV%20Medicine.&amp;author=DE%20Koren&amp;author=KK%20Scarsi&amp;author=EK%20Farmer&amp;publication_year=2020&amp;journal=Clin%20Infect%20Dis&amp;volume=70&amp;pages=2241-2246" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciz792" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciz792" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r95">95.</a><div class="reference-content">Greene
         M﻿, Shi
         Y﻿, Boscardin
         J﻿, Sudore
         R﻿, Gandhi
         M﻿, Covinsky
         K﻿.  Geriatric conditions and healthcare utilisation in older adults living with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Age Ageing</i>. 2022;51(5):afac093. doi:<a href="http://dx.doi.org/10.1093/ageing/afac093">10.1093/ageing/afac093</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35511728" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Geriatric%20conditions%20and%20healthcare%20utilisation%20in%20older%20adults%20living%20with%20HIV.&amp;author=M%20Greene&amp;author=Y%20Shi&amp;author=J%20Boscardin&amp;author=R%20Sudore&amp;author=M%20Gandhi&amp;author=K%20Covinsky&amp;publication_year=2022&amp;journal=Age%20Ageing&amp;volume=51&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/ageing/afac093" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/ageing/afac093" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r96">96.</a><div class="reference-content">Liu
         S﻿, Yan
         Q﻿, Jiang
         Y﻿, 
     et al.  The impact of frailty on all-cause mortality in patients with HIV infection: a systematic review and meta-analysis. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS Res Hum Retroviruses</i>. 2022;38(9):692-699. doi:<a href="http://dx.doi.org/10.1089/aid.2021.0155">10.1089/aid.2021.0155</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35658605" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20impact%20of%20frailty%20on%20all-cause%20mortality%20in%20patients%20with%20HIV%20infection%3A%20a%20systematic%20review%20and%20meta-analysis.&amp;author=S%20Liu&amp;author=Q%20Yan&amp;author=Y%20Jiang&amp;publication_year=2022&amp;journal=AIDS%20Res%20Hum%20Retroviruses&amp;volume=38&amp;pages=692-699" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1089/aid.2021.0155" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1089/aid.2021.0155" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r97">97.</a><div class="reference-content">Ellis
         RJ﻿, Paolillo
         E﻿, Saloner
         R﻿, Heaton
         RK﻿.  Higher comorbidity burden predicts worsening neurocognitive trajectories in people with human immunodeficiency virus. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2022;74(8):1323-1328. doi:<a href="http://dx.doi.org/10.1093/cid/ciab655">10.1093/cid/ciab655</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34329400" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Higher%20comorbidity%20burden%20predicts%20worsening%20neurocognitive%20trajectories%20in%20people%20with%20human%20immunodeficiency%20virus.&amp;author=RJ%20Ellis&amp;author=E%20Paolillo&amp;author=R%20Saloner&amp;author=RK%20Heaton&amp;publication_year=2022&amp;journal=Clin%20Infect%20Dis&amp;volume=74&amp;pages=1323-1328" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciab655" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciab655" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r98">98.</a><div class="reference-content">Aung
         HL﻿, Gates
         TM﻿, Mao
         L﻿, Brew
         BJ﻿, Rourke
         SB﻿, Cysique
         LA﻿.  Abnormal cognitive aging in people with HIV: evidence from data integration between two countries’ cohort studies. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2022;36(8):1171-1179. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000003230">10.1097/QAD.0000000000003230</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35471252" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Abnormal%20cognitive%20aging%20in%20people%20with%20HIV%3A%20evidence%20from%20data%20integration%20between%20two%20countries%E2%80%99%20cohort%20studies.&amp;author=HL%20Aung&amp;author=TM%20Gates&amp;author=L%20Mao&amp;author=BJ%20Brew&amp;author=SB%20Rourke&amp;author=LA%20Cysique&amp;publication_year=2022&amp;journal=AIDS&amp;volume=36&amp;pages=1171-1179" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000003230" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000003230" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r99">99.</a><div class="reference-content">Letendre
         SL﻿, Roa
         J﻿, Chen
         H﻿, 
     et al.  ACTG A5324: a randomized trial of ART intensification for cognitive impairment in PWH [Abstract 133] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Top Antiv Med</i>. 2022;30(1 suppl):50-51.<a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=ACTG%20A5324%3A%20a%20randomized%20trial%20of%20ART%20intensification%20for%20cognitive%20impairment%20in%20PWH%20%5BAbstract%20133%5D%20in%20special%20issue%3A%20Abstracts%20From%20the%202022%20Conference%20on%20Retroviruses%20and%20Opportunistic%20Infections.&amp;author=SL%20Letendre&amp;author=J%20Roa&amp;author=H%20Chen&amp;publication_year=2022&amp;journal=Top%20Antiv%20Med&amp;volume=30&amp;pages=50-51" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r100">100.</a><div class="reference-content">Althoff
         KN﻿, Stewart
         CN﻿, Humes
         E﻿, 
     et al.  The shifting age distribution of people with HIV using antiretroviral therapy in the United States. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2022;36(3):459-471. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000003128">10.1097/QAD.0000000000003128</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34750289" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20shifting%20age%20distribution%20of%20people%20with%20HIV%20using%20antiretroviral%20therapy%20in%20the%20United%20States.&amp;author=KN%20Althoff&amp;author=CN%20Stewart&amp;author=E%20Humes&amp;publication_year=2022&amp;journal=AIDS&amp;volume=36&amp;pages=459-471" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000003128" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000003128" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r101">101.</a><div class="reference-content">Davis
         AJ﻿, Greene
         M﻿, Siegler
         E﻿, 
     et al.  Strengths and challenges of various models of geriatric consultation for older adults living with human immunodeficiency virus. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2022;74(6):1101-1106. doi:<a href="http://dx.doi.org/10.1093/cid/ciab682">10.1093/cid/ciab682</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34358303" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Strengths%20and%20challenges%20of%20various%20models%20of%20geriatric%20consultation%20for%20older%20adults%20living%20with%20human%20immunodeficiency%20virus.&amp;author=AJ%20Davis&amp;author=M%20Greene&amp;author=E%20Siegler&amp;publication_year=2022&amp;journal=Clin%20Infect%20Dis&amp;volume=74&amp;pages=1101-1106" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciab682" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciab682" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r102">102.</a><div class="reference-content">Kiplagat
         J﻿, Tran
         DN﻿, Barber
         T﻿, 
     et al.  How health systems can adapt to a population ageing with HIV and comorbid disease. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2022;9(4):e281-e292. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(22)00009-1">10.1016/S2352-3018(22)00009-1</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35218734" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=How%20health%20systems%20can%20adapt%20to%20a%20population%20ageing%20with%20HIV%20and%20comorbid%20disease.&amp;author=J%20Kiplagat&amp;author=DN%20Tran&amp;author=T%20Barber&amp;publication_year=2022&amp;journal=Lancet%20HIV&amp;volume=9&amp;pages=e281-e292" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(22)00009-1" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(22)00009-1" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r103">103.</a><div class="reference-content">Lazarus
         JV﻿, Safreed-Harmon
         K﻿, Kamarulzaman
         A﻿, 
     et al.  Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Nat Commun</i>. 2021;12(1):4450. doi:<a href="http://dx.doi.org/10.1038/s41467-021-24673-w">10.1038/s41467-021-24673-w</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34272399" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Consensus%20statement%20on%20the%20role%20of%20health%20systems%20in%20advancing%20the%20long-term%20well-being%20of%20people%20living%20with%20HIV.&amp;author=JV%20Lazarus&amp;author=K%20Safreed-Harmon&amp;author=A%20Kamarulzaman&amp;publication_year=2021&amp;journal=Nat%20Commun&amp;volume=12&amp;pages=4450" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1038/s41467-021-24673-w" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1038/s41467-021-24673-w" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r104">104.</a><div class="reference-content">Syphilis. Centers for Disease Control and Prevention. Updated March 24, 2022. Accessed November 9, 2022. <a href="https://www.cdc.gov/std/treatment-guidelines/syphilis.htm">https://www.cdc.gov/std/treatment-guidelines/syphilis.htm</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r105">105.</a><div class="reference-content">US Public Health Service. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States–2021 Update: A Clinical Practice Guideline. Centers for Disease Control and Prevention. Published 2021. Accessed July 28, 2022. <a href="https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf">https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r106">106.</a><div class="reference-content">Shieh
         E﻿, Marzinke
         MA﻿, Fuchs
         EJ﻿, 
     et al.  Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Int AIDS Soc</i>. 2019;22(11):e25405. doi:<a href="http://dx.doi.org/10.1002/jia2.25405">10.1002/jia2.25405</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31692269" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Transgender%20women%20on%20oral%20HIV%20pre-exposure%20prophylaxis%20have%20significantly%20lower%20tenofovir%20and%20emtricitabine%20concentrations%20when%20also%20taking%20oestrogen%20when%20compared%20to%20cisgender%20men.&amp;author=E%20Shieh&amp;author=MA%20Marzinke&amp;author=EJ%20Fuchs&amp;publication_year=2019&amp;journal=J%20Int%20AIDS%20Soc&amp;volume=22&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1002/jia2.v22.11" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1002/jia2.v22.11" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r107">107.</a><div class="reference-content">Yager
         JL﻿, Anderson
         PL﻿.  Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Expert Opin Drug Metab Toxicol</i>. 2020;16(6):463-474. doi:<a href="http://dx.doi.org/10.1080/17425255.2020.1752662">10.1080/17425255.2020.1752662</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32250177" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Pharmacology%20and%20drug%20interactions%20with%20HIV%20PrEP%20in%20transgender%20persons%20receiving%20gender%20affirming%20hormone%20therapy.&amp;author=JL%20Yager&amp;author=PL%20Anderson&amp;publication_year=2020&amp;journal=Expert%20Opin%20Drug%20Metab%20Toxicol&amp;volume=16&amp;pages=463-474" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1080/17425255.2020.1752662" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1080/17425255.2020.1752662" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r108">108.</a><div class="reference-content">Delany-Moretlwe
         S﻿, Hughes
         JP﻿, Bock
         P﻿, 
     et al; HPTN 084 Study Group.  Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet</i>. 2022;399(10337):1779-1789. doi:<a href="http://dx.doi.org/10.1016/S0140-6736(22)00538-4">10.1016/S0140-6736(22)00538-4</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35378077" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cabotegravir%20for%20the%20prevention%20of%20HIV-1%20in%20women%3A%20results%20from%20HPTN%20084%2C%20a%20phase%203%2C%20randomised%20clinical%20trial.&amp;author=S%20Delany-Moretlwe&amp;author=JP%20Hughes&amp;author=P%20Bock&amp;publication_year=2022&amp;journal=Lancet&amp;volume=399&amp;pages=1779-1789" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S0140-6736(22)00538-4" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S0140-6736(22)00538-4" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r109">109.</a><div class="reference-content">Landovitz
         RJ﻿, Li
         S﻿, Eron
         JJ
         Jr﻿, 
     et al.  Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2020;7(7):e472-e481. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(20)30106-5">10.1016/S2352-3018(20)30106-5</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32497491" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Tail-phase%20safety%2C%20tolerability%2C%20and%20pharmacokinetics%20of%20long-acting%20injectable%20cabotegravir%20in%20HIV-uninfected%20adults%3A%20a%20secondary%20analysis%20of%20the%20HPTN%20077%20trial.&amp;author=RJ%20Landovitz&amp;author=S%20Li&amp;author=JJ%20Eron&amp;publication_year=2020&amp;journal=Lancet%20HIV&amp;volume=7&amp;pages=e472-e481" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(20)30106-5" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(20)30106-5" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r110">110.</a><div class="reference-content">Eshleman
         S﻿, Fogel
         JM﻿, Halvas
         EK﻿, 
     et al.  CA-LA PrEP: early detection of HIV infection may reduce InSTI resistance risk [Abstract LB95] in special issue: Abstracts From the 2022 Conference on Retroviruses and Opportunistic Infections. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Top Antiv Med</i>. 2022;30(1 suppl):36-37.<a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=CA-LA%20PrEP%3A%20early%20detection%20of%20HIV%20infection%20may%20reduce%20InSTI%20resistance%20risk%20%5BAbstract%20LB95%5D%20in%20special%20issue%3A%20Abstracts%20From%20the%202022%20Conference%20on%20Retroviruses%20and%20Opportunistic%20Infections.&amp;author=S%20Eshleman&amp;author=JM%20Fogel&amp;author=EK%20Halvas&amp;publication_year=2022&amp;journal=Top%20Antiv%20Med&amp;volume=30&amp;pages=36-37" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r111">111.</a><div class="reference-content">National Clinician Consultation Center website. Accessed November 9, 2022. <a href="https://aidsetc.org/aetc-program/national-clinician-consulation-center">https://aidsetc.org/aetc-program/national-clinician-consulation-center</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r112">112.</a><div class="reference-content">Krakower
         D﻿, Maloney
         KM﻿, Powell
         VE﻿, 
     et al.  Patterns and clinical consequences of discontinuing HIV preexposure prophylaxis during primary care. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Int AIDS Soc</i>. 2019;22(2):e25250. doi:<a href="http://dx.doi.org/10.1002/jia2.25250">10.1002/jia2.25250</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/30768762" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Patterns%20and%20clinical%20consequences%20of%20discontinuing%20HIV%20preexposure%20prophylaxis%20during%20primary%20care.&amp;author=D%20Krakower&amp;author=KM%20Maloney&amp;author=VE%20Powell&amp;publication_year=2019&amp;journal=J%20Int%20AIDS%20Soc&amp;volume=22&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1002/jia2.2019.22.issue-2" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1002/jia2.2019.22.issue-2" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r113">113.</a><div class="reference-content">Marcus
         JL﻿, Hurley
         LB﻿, Dentoni-Lasofsky
         D﻿, 
     et al.  Barriers to preexposure prophylaxis use among individuals with recently acquired HIV infection in Northern California. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS Care</i>. 2019;31(5):536-544. doi:<a href="http://dx.doi.org/10.1080/09540121.2018.1533238">10.1080/09540121.2018.1533238</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/30304942" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Barriers%20to%20preexposure%20prophylaxis%20use%20among%20individuals%20with%20recently%20acquired%20HIV%20infection%20in%20Northern%20California.&amp;author=JL%20Marcus&amp;author=LB%20Hurley&amp;author=D%20Dentoni-Lasofsky&amp;publication_year=2019&amp;journal=AIDS%20Care&amp;volume=31&amp;pages=536-544" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1080/09540121.2018.1533238" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1080/09540121.2018.1533238" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r114">114.</a><div class="reference-content">Molina
         JM﻿, Squires
         K﻿, Sax
         PE﻿, 
     et al; DRIVE-FORWARD Study Group.  Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2018;5(5):e211-e220. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(18)30021-3">10.1016/S2352-3018(18)30021-3</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/29592840" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Doravirine%20versus%20ritonavir-boosted%20darunavir%20in%20antiretroviral-naive%20adults%20with%20HIV-1%20%28DRIVE-FORWARD%29%3A%2048-week%20results%20of%20a%20randomised%2C%20double-blind%2C%20phase%203%2C%20non-inferiority%20trial.&amp;author=JM%20Molina&amp;author=K%20Squires&amp;author=PE%20Sax&amp;publication_year=2018&amp;journal=Lancet%20HIV&amp;volume=5&amp;pages=e211-e220" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(18)30021-3" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(18)30021-3" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r115">115.</a><div class="reference-content">Luetkemeyer
         A﻿, Dombroski
         J﻿, Cohen
         S﻿. Doxycycline post-exposure prophylaxis for STI prevention among MSM and transgender women on HIV PrEP or living with HIV: high efficacy to reduce incident STIs in a randomised trial [Abstract OALBX0103]. Poster presented at: 24th International AIDS Conference; 2022; Montreal, Quebec, Canada.</div></div><div class="reference"><a class="reference-number" id="jsc220007r116">116.</a><div class="reference-content">Wagman
         JA﻿, Wynn
         A﻿, Matsuzaki
         M﻿, 
     et al.  Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2020;34(15):2285-2294. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000002716">10.1097/QAD.0000000000002716</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33048870" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Hazardous%20alcohol%20use%2C%20antiretroviral%20therapy%20receipt%2C%20and%20viral%20suppression%20in%20people%20living%20with%20HIV%20who%20inject%20drugs%20in%20the%20United%20States%2C%20India%2C%20Russia%2C%20and%20Vietnam.&amp;author=JA%20Wagman&amp;author=A%20Wynn&amp;author=M%20Matsuzaki&amp;publication_year=2020&amp;journal=AIDS&amp;volume=34&amp;pages=2285-2294" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000002716" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000002716" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r117">117.</a><div class="reference-content">Springer
         SA﻿, Larney
         S﻿, Alam-Mehrjerdi
         Z﻿, Altice
         FL﻿, Metzger
         D﻿, Shoptaw
         S﻿.  Drug treatment as HIV prevention among women and girls who inject drugs from a global perspective: progress, gaps, and future directions. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Acquir Immune Defic Syndr</i>. 2015;69(suppl 2):S155-S161. doi:<a href="http://dx.doi.org/10.1097/QAI.0000000000000637">10.1097/QAI.0000000000000637</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/25978482" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Drug%20treatment%20as%20HIV%20prevention%20among%20women%20and%20girls%20who%20inject%20drugs%20from%20a%20global%20perspective%3A%20progress%2C%20gaps%2C%20and%20future%20directions.&amp;author=SA%20Springer&amp;author=S%20Larney&amp;author=Z%20Alam-Mehrjerdi&amp;author=FL%20Altice&amp;author=D%20Metzger&amp;author=S%20Shoptaw&amp;publication_year=2015&amp;journal=J%20Acquir%20Immune%20Defic%20Syndr&amp;volume=69&amp;pages=S155-S161" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAI.0000000000000637" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAI.0000000000000637" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r118">118.</a><div class="reference-content">Feelemyer
         J﻿, Arasteh
         K﻿, Huong
         DT﻿, 
     et al; DRIVE Study Team.  Associations between methamphetamine use and lack of viral suppression among a cohort of HIV-positive persons who inject drugs in Hai Phong, Vietnam. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2020;34(13):1875-1882. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000002680">10.1097/QAD.0000000000002680</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32910061" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Associations%20between%20methamphetamine%20use%20and%20lack%20of%20viral%20suppression%20among%20a%20cohort%20of%20HIV-positive%20persons%20who%20inject%20drugs%20in%20Hai%20Phong%2C%20Vietnam.&amp;author=J%20Feelemyer&amp;author=K%20Arasteh&amp;author=DT%20Huong&amp;publication_year=2020&amp;journal=AIDS&amp;volume=34&amp;pages=1875-1882" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000002680" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000002680" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r119">119.</a><div class="reference-content">Satre
         DD﻿, Sarovar
         V﻿, Leyden
         W﻿, 
     et al.  Changes in days of unhealthy alcohol use and antiretroviral therapy adherence, HIV RNA levels, and condomless sex: a secondary analysis of clinical trial data. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS Behav</i>. 2020;24(6):1784-1792. doi:<a href="http://dx.doi.org/10.1007/s10461-019-02742-y">10.1007/s10461-019-02742-y</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31773444" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Changes%20in%20days%20of%20unhealthy%20alcohol%20use%20and%20antiretroviral%20therapy%20adherence%2C%20HIV%20RNA%20levels%2C%20and%20condomless%20sex%3A%20a%20secondary%20analysis%20of%20clinical%20trial%20data.&amp;author=DD%20Satre&amp;author=V%20Sarovar&amp;author=W%20Leyden&amp;publication_year=2020&amp;journal=AIDS%20Behav&amp;volume=24&amp;pages=1784-1792" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1007/s10461-019-02742-y" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1007/s10461-019-02742-y" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r120">120.</a><div class="reference-content">Springer
         SA﻿, Merluzzi
         AP﻿, Del Rio
         C﻿.  Integrating responses to the opioid use disorder and infectious disease epidemics: a report from the National Academies of Sciences, Engineering, and Medicine. ﻿ <i xmlns:helper="urn:XsltStringHelper"> JAMA</i>. 2020;324(1):37-38. doi:<a href="http://jamanetwork.com/article.aspx?doi=10.1001/jama.2020.2559">10.1001/jama.2020.2559</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32159771" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Integrating%20responses%20to%20the%20opioid%20use%20disorder%20and%20infectious%20disease%20epidemics%3A%20a%20report%20from%20the%20National%20Academies%20of%20Sciences%2C%20Engineering%2C%20and%20Medicine.&amp;author=SA%20Springer&amp;author=AP%20Merluzzi&amp;author=C%20Del Rio&amp;publication_year=2020&amp;journal=JAMA&amp;volume=324&amp;pages=37-38" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1001/jama.2020.2559" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1001/jama.2020.2559" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r121">121.</a><div class="reference-content">Springer
         SA﻿, Barocas
         JA﻿, Wurcel
         A﻿, 
     et al.  Federal and state action needed to end the infectious complications of illicit drug use in the United States: IDSA and HIVMA’s advocacy agenda. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Infect Dis</i>. 2020;222(suppl 5):S230-S238. doi:<a href="http://dx.doi.org/10.1093/infdis/jiz673">10.1093/infdis/jiz673</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32877568" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Federal%20and%20state%20action%20needed%20to%20end%20the%20infectious%20complications%20of%20illicit%20drug%20use%20in%20the%20United%20States%3A%20IDSA%20and%20HIVMA%E2%80%99s%20advocacy%20agenda.&amp;author=SA%20Springer&amp;author=JA%20Barocas&amp;author=A%20Wurcel&amp;publication_year=2020&amp;journal=J%20Infect%20Dis&amp;volume=222&amp;pages=S230-S238" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/infdis/jiz673" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/infdis/jiz673" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r122">122.</a><div class="reference-content">Nance
         RM﻿, Trejo
         MEP﻿, Whitney
         BM﻿, 
     et al.  Impact of abstinence and of reducing illicit drug use without abstinence on human immunodeficiency virus viral load. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2020;70(5):867-874. doi:<a href="http://dx.doi.org/10.1093/cid/ciz299">10.1093/cid/ciz299</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/30994900" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Impact%20of%20abstinence%20and%20of%20reducing%20illicit%20drug%20use%20without%20abstinence%20on%20human%20immunodeficiency%20virus%20viral%20load.&amp;author=RM%20Nance&amp;author=MEP%20Trejo&amp;author=BM%20Whitney&amp;publication_year=2020&amp;journal=Clin%20Infect%20Dis&amp;volume=70&amp;pages=867-874" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciz299" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciz299" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r123">123.</a><div class="reference-content">Hoffman
         KA﻿, Baker
         R﻿, Fanucchi
         LC﻿, 
     et al.  Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Addict Sci Clin Pract</i>. 2021;16(1):67. doi:<a href="http://dx.doi.org/10.1186/s13722-021-00277-z">10.1186/s13722-021-00277-z</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34758887" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Perspectives%20on%20extended-release%20naltrexone%20induction%20among%20patients%20living%20with%20HIV%20and%20opioid%20use%20disorder%3A%20a%20qualitative%20analysis.&amp;author=KA%20Hoffman&amp;author=R%20Baker&amp;author=LC%20Fanucchi&amp;publication_year=2021&amp;journal=Addict%20Sci%20Clin%20Pract&amp;volume=16&amp;pages=67" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1186/s13722-021-00277-z" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1186/s13722-021-00277-z" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r124">124.</a><div class="reference-content">Korthuis
         PT﻿, Cook
         RR﻿, Lum
         PJ﻿, 
     et al.  HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Addiction</i>. 2022;117(7):1961-1971. doi:<a href="http://dx.doi.org/10.1111/add.15836">10.1111/add.15836</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35129242" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=HIV%20clinic-based%20extended-release%20naltrexone%20versus%20treatment%20as%20usual%20for%20people%20with%20HIV%20and%20opioid%20use%20disorder%3A%20a%20non-blinded%2C%20randomized%20non-inferiority%20trial.&amp;author=PT%20Korthuis&amp;author=RR%20Cook&amp;author=PJ%20Lum&amp;publication_year=2022&amp;journal=Addiction&amp;volume=117&amp;pages=1961-1971" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1111/add.v117.7" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1111/add.v117.7" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r125">125.</a><div class="reference-content">Mitra
         S﻿, Grant
         C﻿, Nolan
         S﻿, Mohd Salleh
         NA﻿, Milloy
         MJ﻿, Richardson
         L﻿.  Assessing the temporality between transitions onto opioid agonist therapy and engagement with antiretroviral therapy in a cohort of HIV-positive people who use opioids daily. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS Behav</i>. 2022;26(6):1933-1942. doi:<a href="http://dx.doi.org/10.1007/s10461-021-03543-y">10.1007/s10461-021-03543-y</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34977956" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Assessing%20the%20temporality%20between%20transitions%20onto%20opioid%20agonist%20therapy%20and%20engagement%20with%20antiretroviral%20therapy%20in%20a%20cohort%20of%20HIV-positive%20people%20who%20use%20opioids%20daily.&amp;author=S%20Mitra&amp;author=C%20Grant&amp;author=S%20Nolan&amp;author=NA%20Mohd Salleh&amp;author=MJ%20Milloy&amp;author=L%20Richardson&amp;publication_year=2022&amp;journal=AIDS%20Behav&amp;volume=26&amp;pages=1933-1942" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1007/s10461-021-03543-y" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1007/s10461-021-03543-y" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r126">126.</a><div class="reference-content">Puryear
         SB﻿, Balzer
         LB﻿, Ayieko
         J﻿, 
     et al.  Associations between alcohol use and HIV care cascade outcomes among adults undergoing population-based HIV testing in East Africa. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2020;34(3):405-413. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000002427">10.1097/QAD.0000000000002427</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31725431" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Associations%20between%20alcohol%20use%20and%20HIV%20care%20cascade%20outcomes%20among%20adults%20undergoing%20population-based%20HIV%20testing%20in%20East%20Africa.&amp;author=SB%20Puryear&amp;author=LB%20Balzer&amp;author=J%20Ayieko&amp;publication_year=2020&amp;journal=AIDS&amp;volume=34&amp;pages=405-413" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000002427" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000002427" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r127">127.</a><div class="reference-content">McNamara
         KF﻿, Biondi
         BE﻿, Hernández-Ramírez
         RU﻿, Taweh
         N﻿, Grimshaw
         AA﻿, Springer
         SA﻿.  A systematic review and meta-analysis of studies evaluating the effect of medication treatment for opioid use disorder on infectious disease outcomes. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Open Forum Infect Dis</i>. 2021;8(8):ofab289. doi:<a href="http://dx.doi.org/10.1093/ofid/ofab289">10.1093/ofid/ofab289</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34430670" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20systematic%20review%20and%20meta-analysis%20of%20studies%20evaluating%20the%20effect%20of%20medication%20treatment%20for%20opioid%20use%20disorder%20on%20infectious%20disease%20outcomes.&amp;author=KF%20McNamara&amp;author=BE%20Biondi&amp;author=RU%20Hernández-Ramírez&amp;author=N%20Taweh&amp;author=AA%20Grimshaw&amp;author=SA%20Springer&amp;publication_year=2021&amp;journal=Open%20Forum%20Infect%20Dis&amp;volume=8&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/ofid/ofab289" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/ofid/ofab289" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r128">128.</a><div class="reference-content">Springer
         SA﻿, Qiu
         J﻿, Saber-Tehrani
         AS﻿, Altice
         FL﻿.  Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. ﻿ <i xmlns:helper="urn:XsltStringHelper"> PLoS One</i>. 2012;7(5):e38335. doi:<a href="http://dx.doi.org/10.1371/journal.pone.0038335">10.1371/journal.pone.0038335</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/22719814" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Retention%20on%20buprenorphine%20is%20associated%20with%20high%20levels%20of%20maximal%20viral%20suppression%20among%20HIV-infected%20opioid%20dependent%20released%20prisoners.&amp;author=SA%20Springer&amp;author=J%20Qiu&amp;author=AS%20Saber-Tehrani&amp;author=FL%20Altice&amp;publication_year=2012&amp;journal=PLoS%20One&amp;volume=7&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1371/journal.pone.0038335" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1371/journal.pone.0038335" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r129">129.</a><div class="reference-content">Springer
         SA﻿, Di Paola
         A﻿, Azar
         MM﻿, 
     et al.  Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV with opioid use disorders transitioning to the community: results of a double-blind, placebo-controlled randomized trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Acquir Immune Defic Syndr</i>. 2018;78(1):43-53. doi:<a href="http://dx.doi.org/10.1097/QAI.0000000000001634">10.1097/QAI.0000000000001634</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/29373393" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Extended-release%20naltrexone%20improves%20viral%20suppression%20among%20incarcerated%20persons%20living%20with%20HIV%20with%20opioid%20use%20disorders%20transitioning%20to%20the%20community%3A%20results%20of%20a%20double-blind%2C%20placebo-controlled%20randomized%20trial.&amp;author=SA%20Springer&amp;author=A%20Di Paola&amp;author=MM%20Azar&amp;publication_year=2018&amp;journal=J%20Acquir%20Immune%20Defic%20Syndr&amp;volume=78&amp;pages=43-53" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAI.0000000000001634" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAI.0000000000001634" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r130">130.</a><div class="reference-content">Springer
         SA﻿, Di Paola
         A﻿, Barbour
         R﻿, Azar
         MM﻿, Altice
         FL﻿.  Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV and alcohol use disorders transitioning to the community: results from a double-blind, placebo-controlled trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Acquir Immune Defic Syndr</i>. 2018;79(1):92-100. doi:<a href="http://dx.doi.org/10.1097/QAI.0000000000001759">10.1097/QAI.0000000000001759</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/29781884" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Extended-release%20naltrexone%20improves%20viral%20suppression%20among%20incarcerated%20persons%20living%20with%20HIV%20and%20alcohol%20use%20disorders%20transitioning%20to%20the%20community%3A%20results%20from%20a%20double-blind%2C%20placebo-controlled%20trial.&amp;author=SA%20Springer&amp;author=A%20Di Paola&amp;author=R%20Barbour&amp;author=MM%20Azar&amp;author=FL%20Altice&amp;publication_year=2018&amp;journal=J%20Acquir%20Immune%20Defic%20Syndr&amp;volume=79&amp;pages=92-100" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAI.0000000000001759" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAI.0000000000001759" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r131">131.</a><div class="reference-content">Fanucchi
         L﻿, Springer
         SA﻿, Korthuis
         PT﻿.  Medications for treatment of opioid use disorder among persons living with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Curr HIV/AIDS Rep</i>. 2019;16(1):1-6. doi:<a href="http://dx.doi.org/10.1007/s11904-019-00436-7">10.1007/s11904-019-00436-7</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/30684117" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Medications%20for%20treatment%20of%20opioid%20use%20disorder%20among%20persons%20living%20with%20HIV.&amp;author=L%20Fanucchi&amp;author=SA%20Springer&amp;author=PT%20Korthuis&amp;publication_year=2019&amp;journal=Curr%20HIV%2FAIDS%20Rep&amp;volume=16&amp;pages=1-6" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1007/s11904-019-00436-7" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1007/s11904-019-00436-7" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r132">132.</a><div class="reference-content">Seval
         N﻿, Eaton
         E﻿, Springer
         SA﻿.  Beyond antibiotics: a practical guide for the infectious disease physician to treat opioid use disorder in the setting of associated infectious diseases. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Open Forum Infect Dis</i>. 2019;7(1):ofz539. doi:<a href="http://dx.doi.org/10.1093/ofid/ofz539">10.1093/ofid/ofz539</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31993454" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Beyond%20antibiotics%3A%20a%20practical%20guide%20for%20the%20infectious%20disease%20physician%20to%20treat%20opioid%20use%20disorder%20in%20the%20setting%20of%20associated%20infectious%20diseases.&amp;author=N%20Seval&amp;author=E%20Eaton&amp;author=SA%20Springer&amp;publication_year=2019&amp;journal=Open%20Forum%20Infect%20Dis&amp;volume=7&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/ofid/ofz539" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/ofid/ofz539" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r133">133.</a><div class="reference-content">Silverman
         K﻿, Holtyn
         AF﻿, Rodewald
         AM﻿, 
     et al.  Incentives for viral suppression in people living with HIV: a randomized clinical trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS Behav</i>. 2019;23(9):2337-2346. doi:<a href="http://dx.doi.org/10.1007/s10461-019-02592-8">10.1007/s10461-019-02592-8</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31297681" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Incentives%20for%20viral%20suppression%20in%20people%20living%20with%20HIV%3A%20a%20randomized%20clinical%20trial.&amp;author=K%20Silverman&amp;author=AF%20Holtyn&amp;author=AM%20Rodewald&amp;publication_year=2019&amp;journal=AIDS%20Behav&amp;volume=23&amp;pages=2337-2346" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1007/s10461-019-02592-8" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1007/s10461-019-02592-8" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r134">134.</a><div class="reference-content">Prendergast
         M﻿, Podus
         D﻿, Finney
         J﻿, Greenwell
         L﻿, Roll
         J﻿.  Contingency management for treatment of substance use disorders: a meta-analysis. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Addiction</i>. 2006;101(11):1546-1560. doi:<a href="http://dx.doi.org/10.1111/j.1360-0443.2006.01581.x">10.1111/j.1360-0443.2006.01581.x</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/17034434" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Contingency%20management%20for%20treatment%20of%20substance%20use%20disorders%3A%20a%20meta-analysis.&amp;author=M%20Prendergast&amp;author=D%20Podus&amp;author=J%20Finney&amp;author=L%20Greenwell&amp;author=J%20Roll&amp;publication_year=2006&amp;journal=Addiction&amp;volume=101&amp;pages=1546-1560" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1111/add.2006.101.issue-11" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1111/add.2006.101.issue-11" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r135">135.</a><div class="reference-content">Menza
         TW﻿, Jameson
         DR﻿, Hughes
         JP﻿, Colfax
         GN﻿, Shoptaw
         S﻿, Golden
         MR﻿.  Contingency management to reduce methamphetamine use and sexual risk among men who have sex with men: a randomized controlled trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> BMC Public Health</i>. 2010;10:774. doi:<a href="http://dx.doi.org/10.1186/1471-2458-10-774">10.1186/1471-2458-10-774</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/21172026" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Contingency%20management%20to%20reduce%20methamphetamine%20use%20and%20sexual%20risk%20among%20men%20who%20have%20sex%20with%20men%3A%20a%20randomized%20controlled%20trial.&amp;author=TW%20Menza&amp;author=DR%20Jameson&amp;author=JP%20Hughes&amp;author=GN%20Colfax&amp;author=S%20Shoptaw&amp;author=MR%20Golden&amp;publication_year=2010&amp;journal=BMC%20Public%20Health&amp;volume=10&amp;pages=774" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1186/1471-2458-10-774" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1186/1471-2458-10-774" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r136">136.</a><div class="reference-content">Landovitz
         RJ﻿, Fletcher
         JB﻿, Shoptaw
         S﻿, Reback
         CJ﻿.  Contingency management facilitates the use of postexposure prophylaxis among stimulant-using men who have sex with men. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Open Forum Infect Dis</i>. 2015;2(1):ofu114. doi:<a href="http://dx.doi.org/10.1093/ofid/ofu114">10.1093/ofid/ofu114</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/25884003" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Contingency%20management%20facilitates%20the%20use%20of%20postexposure%20prophylaxis%20among%20stimulant-using%20men%20who%20have%20sex%20with%20men.&amp;author=RJ%20Landovitz&amp;author=JB%20Fletcher&amp;author=S%20Shoptaw&amp;author=CJ%20Reback&amp;publication_year=2015&amp;journal=Open%20Forum%20Infect%20Dis&amp;volume=2&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/ofid/ofu114" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/ofid/ofu114" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r137">137.</a><div class="reference-content">Mistler
         CB﻿, Copenhaver
         MM﻿, Shrestha
         R﻿.  The pre-exposure prophylaxis (PrEP) care cascade in people who inject drugs: a systematic review. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS Behav</i>. 2021;25(5):1490-1506. doi:<a href="http://dx.doi.org/10.1007/s10461-020-02988-x">10.1007/s10461-020-02988-x</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32749627" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20pre-exposure%20prophylaxis%20%28PrEP%29%20care%20cascade%20in%20people%20who%20inject%20drugs%3A%20a%20systematic%20review.&amp;author=CB%20Mistler&amp;author=MM%20Copenhaver&amp;author=R%20Shrestha&amp;publication_year=2021&amp;journal=AIDS%20Behav&amp;volume=25&amp;pages=1490-1506" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1007/s10461-020-02988-x" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1007/s10461-020-02988-x" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r138">138.</a><div class="reference-content">Assoumou
         SA﻿, Paniagua
         SM﻿, Gonzalez
         P﻿, 
     et al.  HIV pre-exposure prophylaxis and buprenorphine at a drug detoxification center during the opioid epidemic: opportunities and challenges. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS Behav</i>. 2021;25(8):2591-2598. doi:<a href="http://dx.doi.org/10.1007/s10461-021-03220-0">10.1007/s10461-021-03220-0</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33751315" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=HIV%20pre-exposure%20prophylaxis%20and%20buprenorphine%20at%20a%20drug%20detoxification%20center%20during%20the%20opioid%20epidemic%3A%20opportunities%20and%20challenges.&amp;author=SA%20Assoumou&amp;author=SM%20Paniagua&amp;author=P%20Gonzalez&amp;publication_year=2021&amp;journal=AIDS%20Behav&amp;volume=25&amp;pages=2591-2598" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1007/s10461-021-03220-0" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1007/s10461-021-03220-0" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r139">139.</a><div class="reference-content">Beck
         L﻿, Parlier-Ahmad
         AB﻿, Martin
         CE﻿.  Pre-exposure prophylaxis (PrEP) indication and uptake among people receiving buprenorphine for the treatment of opioid use disorder. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Subst Abuse Treat</i>. 2022;132:108506. doi:<a href="http://dx.doi.org/10.1016/j.jsat.2021.108506">10.1016/j.jsat.2021.108506</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34098202" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Pre-exposure%20prophylaxis%20%28PrEP%29%20indication%20and%20uptake%20among%20people%20receiving%20buprenorphine%20for%20the%20treatment%20of%20opioid%20use%20disorder.&amp;author=L%20Beck&amp;author=AB%20Parlier-Ahmad&amp;author=CE%20Martin&amp;publication_year=2022&amp;journal=J%20Subst%20Abuse%20Treat&amp;volume=132&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.jsat.2021.108506" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.jsat.2021.108506" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r140">140.</a><div class="reference-content">Belludi
         A﻿, McFall
         AM﻿, Solomon
         SS﻿, 
     et al.  Awareness of and willingness to use pre-exposure prophylaxis (PrEP) among people who inject drugs and men who have sex with men in India: results from a multi-city cross-sectional survey. ﻿ <i xmlns:helper="urn:XsltStringHelper"> PLoS One</i>. 2021;16(2):e0247352. doi:<a href="http://dx.doi.org/10.1371/journal.pone.0247352">10.1371/journal.pone.0247352</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33630909" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Awareness%20of%20and%20willingness%20to%20use%20pre-exposure%20prophylaxis%20%28PrEP%29%20among%20people%20who%20inject%20drugs%20and%20men%20who%20have%20sex%20with%20men%20in%20India%3A%20results%20from%20a%20multi-city%20cross-sectional%20survey.&amp;author=A%20Belludi&amp;author=AM%20McFall&amp;author=SS%20Solomon&amp;publication_year=2021&amp;journal=PLoS%20One&amp;volume=16&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1371/journal.pone.0247352" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1371/journal.pone.0247352" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r141">141.</a><div class="reference-content">Broz
         D﻿, Zibbell
         J﻿, Foote
         C﻿, 
     et al.  Multiple injections per injection episode: high-risk injection practice among people who injected pills during the 2015 HIV outbreak in Indiana. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Int J Drug Policy</i>. 2018;52:97-101. doi:<a href="http://dx.doi.org/10.1016/j.drugpo.2017.12.003">10.1016/j.drugpo.2017.12.003</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/29278838" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Multiple%20injections%20per%20injection%20episode%3A%20high-risk%20injection%20practice%20among%20people%20who%20injected%20pills%20during%20the%202015%20HIV%20outbreak%20in%20Indiana.&amp;author=D%20Broz&amp;author=J%20Zibbell&amp;author=C%20Foote&amp;publication_year=2018&amp;journal=Int%20J%20Drug%20Policy&amp;volume=52&amp;pages=97-101" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.drugpo.2017.12.003" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.drugpo.2017.12.003" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r142">142.</a><div class="reference-content">Eaton
         EF﻿, Tamhane
         A﻿, Turner
         W﻿, Raper
         JL﻿, Saag
         MS﻿, Cropsey
         KL﻿.  Safer in care: a pandemic-tested model of integrated HIV/OUD care. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Drug Alcohol Depend</i>. 2022;231:109241. doi:<a href="http://dx.doi.org/10.1016/j.drugalcdep.2021.109241">10.1016/j.drugalcdep.2021.109241</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35007957" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Safer%20in%20care%3A%20a%20pandemic-tested%20model%20of%20integrated%20HIV%2FOUD%20care.&amp;author=EF%20Eaton&amp;author=A%20Tamhane&amp;author=W%20Turner&amp;author=JL%20Raper&amp;author=MS%20Saag&amp;author=KL%20Cropsey&amp;publication_year=2022&amp;journal=Drug%20Alcohol%20Depend&amp;volume=231&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.drugalcdep.2021.109241" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.drugalcdep.2021.109241" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r143">143.</a><div class="reference-content">Taweh
         N﻿, Schlossberg
         E﻿, Frank
         C﻿, 
     et al.  Linking criminal justice-involved individuals to HIV, hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: progress, gaps, and future directions. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Int J Drug Policy</i>. 2021;96:103283. doi:<a href="http://dx.doi.org/10.1016/j.drugpo.2021.103283">10.1016/j.drugpo.2021.103283</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34020864" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Linking%20criminal%20justice-involved%20individuals%20to%20HIV%2C%20hepatitis%20C%2C%20and%20opioid%20use%20disorder%20prevention%20and%20treatment%20services%20upon%20release%20to%20the%20community%3A%20progress%2C%20gaps%2C%20and%20future%20directions.&amp;author=N%20Taweh&amp;author=E%20Schlossberg&amp;author=C%20Frank&amp;publication_year=2021&amp;journal=Int%20J%20Drug%20Policy&amp;volume=96&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.drugpo.2021.103283" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.drugpo.2021.103283" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r144">144.</a><div class="reference-content">Jiang
         T﻿, Liu
         C﻿, Zhang
         J﻿, Huang
         X﻿, Xu
         J﻿.  Impact of the COVID-19 pandemic on the UNAIDS six 95% HIV control targets. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Front Med (Lausanne)</i>. 2022;9:818054. doi:<a href="http://dx.doi.org/10.3389/fmed.2022.818054">10.3389/fmed.2022.818054</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35252256" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Impact%20of%20the%20COVID-19%20pandemic%20on%20the%20UNAIDS%20six%2095%25%20HIV%20control%20targets.&amp;author=T%20Jiang&amp;author=C%20Liu&amp;author=J%20Zhang&amp;author=X%20Huang&amp;author=J%20Xu&amp;publication_year=2022&amp;journal=Front%20Med%20%28Lausanne%29&amp;volume=9&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.3389/fmed.2022.818054" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.3389/fmed.2022.818054" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r145">145.</a><div class="reference-content">Santos
         GM﻿, Hong
         C﻿, Wilson
         N﻿, 
     et al.  Persistent disparities in COVID-19-associated impacts on HIV prevention and care among a global sample of sexual and gender minority individuals. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Glob Public Health</i>. 2022;17(6):827-842. doi:<a href="http://dx.doi.org/10.1080/17441692.2022.2063362">10.1080/17441692.2022.2063362</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35435149" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Persistent%20disparities%20in%20COVID-19-associated%20impacts%20on%20HIV%20prevention%20and%20care%20among%20a%20global%20sample%20of%20sexual%20and%20gender%20minority%20individuals.&amp;author=GM%20Santos&amp;author=C%20Hong&amp;author=N%20Wilson&amp;publication_year=2022&amp;journal=Glob%20Public%20Health&amp;volume=17&amp;pages=827-842" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1080/17441692.2022.2063362" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1080/17441692.2022.2063362" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r146">146.</a><div class="reference-content">Dear
         N﻿, Duff
         E﻿, Esber
         A﻿, 
     et al; AFRICOS Study Group.  Transient reductions in human immunodeficiency virus (HIV) clinic attendance and food security during the coronavirus disease 2019 (COVID-19) pandemic for people living with HIV in 4 African countries. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2021;73(10):1901-1905. doi:<a href="http://dx.doi.org/10.1093/cid/ciab379">10.1093/cid/ciab379</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33906235" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Transient%20reductions%20in%20human%20immunodeficiency%20virus%20%28HIV%29%20clinic%20attendance%20and%20food%20security%20during%20the%20coronavirus%20disease%202019%20%28COVID-19%29%20pandemic%20for%20people%20living%20with%20HIV%20in%204%20African%20countries.&amp;author=N%20Dear&amp;author=E%20Duff&amp;author=A%20Esber&amp;publication_year=2021&amp;journal=Clin%20Infect%20Dis&amp;volume=73&amp;pages=1901-1905" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciab379" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciab379" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r147">147.</a><div class="reference-content">Jewell
         BL﻿, Mudimu
         E﻿, Stover
         J﻿, 
     et al; HIV Modelling Consortium.  Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2020;7(9):e629-e640. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(20)30211-3">10.1016/S2352-3018(20)30211-3</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32771089" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Potential%20effects%20of%20disruption%20to%20HIV%20programmes%20in%20sub-Saharan%20Africa%20caused%20by%20COVID-19%3A%20results%20from%20multiple%20mathematical%20models.&amp;author=BL%20Jewell&amp;author=E%20Mudimu&amp;author=J%20Stover&amp;publication_year=2020&amp;journal=Lancet%20HIV&amp;volume=7&amp;pages=e629-e640" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(20)30211-3" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(20)30211-3" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r148">148.</a><div class="reference-content">Ambrosioni
         J﻿, Blanco
         JL﻿, Reyes-Urueña
         JM﻿, 
     et al; COVID-19 in HIV Investigators.  Overview of SARS-CoV-2 infection in adults living with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2021;8(5):e294-e305. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(21)00070-9">10.1016/S2352-3018(21)00070-9</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33915101" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Overview%20of%20SARS-CoV-2%20infection%20in%20adults%20living%20with%20HIV.&amp;author=J%20Ambrosioni&amp;author=JL%20Blanco&amp;author=JM%20Reyes-Urueña&amp;publication_year=2021&amp;journal=Lancet%20HIV&amp;volume=8&amp;pages=e294-e305" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(21)00070-9" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(21)00070-9" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r149">149.</a><div class="reference-content">Brown
         LB﻿, Spinelli
         MA﻿, Gandhi
         M﻿.  The interplay between HIV and COVID-19: summary of the data and responses to date. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Curr Opin HIV AIDS</i>. 2021;16(1):63-73. doi:<a href="http://dx.doi.org/10.1097/COH.0000000000000659">10.1097/COH.0000000000000659</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33186229" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20interplay%20between%20HIV%20and%20COVID-19%3A%20summary%20of%20the%20data%20and%20responses%20to%20date.&amp;author=LB%20Brown&amp;author=MA%20Spinelli&amp;author=M%20Gandhi&amp;publication_year=2021&amp;journal=Curr%20Opin%20HIV%20AIDS&amp;volume=16&amp;pages=63-73" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/COH.0000000000000659" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/COH.0000000000000659" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r150">150.</a><div class="reference-content">Park
         LS﻿, McGinnis
         KA﻿, Gordon
         KS﻿, 
     et al; CIVET Collaboration of the NA-ACCORD of IeDEA.  SARS-CoV-2 testing and positivity among persons with and without HIV in 6 US cohorts. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Acquir Immune Defic Syndr</i>. 2022;90(3):249-255. doi:<a href="http://dx.doi.org/10.1097/QAI.0000000000002943">10.1097/QAI.0000000000002943</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35195574" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=SARS-CoV-2%20testing%20and%20positivity%20among%20persons%20with%20and%20without%20HIV%20in%206%20US%20cohorts.&amp;author=LS%20Park&amp;author=KA%20McGinnis&amp;author=KS%20Gordon&amp;publication_year=2022&amp;journal=J%20Acquir%20Immune%20Defic%20Syndr&amp;volume=90&amp;pages=249-255" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAI.0000000000002943" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAI.0000000000002943" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r151">151.</a><div class="reference-content">Treskova-Schwarzbach
         M﻿, Haas
         L﻿, Reda
         S﻿, 
     et al.  Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence. ﻿ <i xmlns:helper="urn:XsltStringHelper"> BMC Med</i>. 2021;19(1):212. doi:<a href="http://dx.doi.org/10.1186/s12916-021-02058-6">10.1186/s12916-021-02058-6</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34446016" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Pre-existing%20health%20conditions%20and%20severe%20COVID-19%20outcomes%3A%20an%20umbrella%20review%20approach%20and%20meta-analysis%20of%20global%20evidence.&amp;author=M%20Treskova-Schwarzbach&amp;author=L%20Haas&amp;author=S%20Reda&amp;publication_year=2021&amp;journal=BMC%20Med&amp;volume=19&amp;pages=212" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1186/s12916-021-02058-6" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1186/s12916-021-02058-6" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r152">152.</a><div class="reference-content">Nomah
         DK﻿, Reyes-Urueña
         J﻿, Díaz
         Y﻿, 
     et al; PISCIS Study Group.  Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2021;8(11):e701-e710. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(21)00240-X">10.1016/S2352-3018(21)00240-X</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34655549" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Sociodemographic%2C%20clinical%2C%20and%20immunological%20factors%20associated%20with%20SARS-CoV-2%20diagnosis%20and%20severe%20COVID-19%20outcomes%20in%20people%20living%20with%20HIV%3A%20a%20retrospective%20cohort%20study.&amp;author=DK%20Nomah&amp;author=J%20Reyes-Urueña&amp;author=Y%20Díaz&amp;publication_year=2021&amp;journal=Lancet%20HIV&amp;volume=8&amp;pages=e701-e710" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(21)00240-X" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(21)00240-X" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r153">153.</a><div class="reference-content">Shapiro
         AE﻿, Bender Ignacio
         RA﻿, Whitney
         BM﻿, 
     et al; CFAR Network of Integrated Clinical Systems.  Factors associated with severity of COVID-19 disease in a multicenter cohort of people with HIV in the United States, March-December 2020. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Acquir Immune Defic Syndr</i>. 2022;90(4):369-376. doi:<a href="http://dx.doi.org/10.1097/QAI.0000000000002989">10.1097/QAI.0000000000002989</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35364600" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Factors%20associated%20with%20severity%20of%20COVID-19%20disease%20in%20a%20multicenter%20cohort%20of%20people%20with%20HIV%20in%20the%20United%20States%2C%20March-December%202020.&amp;author=AE%20Shapiro&amp;author=RA%20Bender Ignacio&amp;author=BM%20Whitney&amp;publication_year=2022&amp;journal=J%20Acquir%20Immune%20Defic%20Syndr&amp;volume=90&amp;pages=369-376" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAI.0000000000002989" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAI.0000000000002989" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r154">154.</a><div class="reference-content">Braunstein
         SL﻿, Lazar
         R﻿, Wahnich
         A﻿, Daskalakis
         DC﻿, Blackstock
         OJ﻿.  Coronavirus disease 2019 (COVID-19) infection among people with human immunodeficiency virus in New York City: a population-level analysis of linked surveillance data. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2021;72(12):e1021-e1029. doi:<a href="http://dx.doi.org/10.1093/cid/ciaa1793">10.1093/cid/ciaa1793</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33252620" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Coronavirus%20disease%202019%20%28COVID-19%29%20infection%20among%20people%20with%20human%20immunodeficiency%20virus%20in%20New%20York%20City%3A%20a%20population-level%20analysis%20of%20linked%20surveillance%20data.&amp;author=SL%20Braunstein&amp;author=R%20Lazar&amp;author=A%20Wahnich&amp;author=DC%20Daskalakis&amp;author=OJ%20Blackstock&amp;publication_year=2021&amp;journal=Clin%20Infect%20Dis&amp;volume=72&amp;pages=e1021-e1029" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciaa1793" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciaa1793" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r155">155.</a><div class="reference-content">Dandachi
         D﻿, Geiger
         G﻿, Montgomery
         MW﻿, 
     et al.  Characteristics, comorbidities, and outcomes in a multicenter registry of patients with human immunodeficiency virus and coronavirus disease 2019. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2021;73(7):e1964-e1972. doi:<a href="http://dx.doi.org/10.1093/cid/ciaa1339">10.1093/cid/ciaa1339</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32905581" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Characteristics%2C%20comorbidities%2C%20and%20outcomes%20in%20a%20multicenter%20registry%20of%20patients%20with%20human%20immunodeficiency%20virus%20and%20coronavirus%20disease%202019.&amp;author=D%20Dandachi&amp;author=G%20Geiger&amp;author=MW%20Montgomery&amp;publication_year=2021&amp;journal=Clin%20Infect%20Dis&amp;volume=73&amp;pages=e1964-e1972" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciaa1339" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciaa1339" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r156">156.</a><div class="reference-content">Woldemeskel
         BA﻿, Karaba
         AH﻿, Garliss
         CC﻿, 
     et al.  The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with human immunodeficiency virus (HIV). ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2022;74(7):1268-1270. doi:<a href="http://dx.doi.org/10.1093/cid/ciab648">10.1093/cid/ciab648</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34293114" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20BNT162b2%20mRNA%20vaccine%20elicits%20robust%20humoral%20and%20cellular%20immune%20responses%20in%20people%20living%20with%20human%20immunodeficiency%20virus%20%28HIV%29.&amp;author=BA%20Woldemeskel&amp;author=AH%20Karaba&amp;author=CC%20Garliss&amp;publication_year=2022&amp;journal=Clin%20Infect%20Dis&amp;volume=74&amp;pages=1268-1270" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciab648" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciab648" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r157">157.</a><div class="reference-content">González de Aledo
         M﻿, Cañizares
         A﻿, Vázquez-Rodríguez
         P﻿, 
     et al.  Safety and Immunogenicity of SARS-CoV-2 vaccines in people with HIV. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2022;36(5):691-695. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000003161">10.1097/QAD.0000000000003161</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34999608" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Safety%20and%20Immunogenicity%20of%20SARS-CoV-2%20vaccines%20in%20people%20with%20HIV.&amp;author=M%20González de Aledo&amp;author=A%20Cañizares&amp;author=P%20Vázquez-Rodríguez&amp;publication_year=2022&amp;journal=AIDS&amp;volume=36&amp;pages=691-695" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000003161" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000003161" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r158">158.</a><div class="reference-content">Lee
         ARYB﻿, Wong
         SY﻿, Chai
         LYA﻿, 
     et al.  Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. ﻿ <i xmlns:helper="urn:XsltStringHelper"> BMJ</i>. 2022;376:e068632. doi:<a href="http://dx.doi.org/10.1136/bmj-2021-068632">10.1136/bmj-2021-068632</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35236664" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Efficacy%20of%20covid-19%20vaccines%20in%20immunocompromised%20patients%3A%20systematic%20review%20and%20meta-analysis.&amp;author=ARYB%20Lee&amp;author=SY%20Wong&amp;author=LYA%20Chai&amp;publication_year=2022&amp;journal=BMJ&amp;volume=376&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1136/bmj-2021-068632" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1136/bmj-2021-068632" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r159">159.</a><div class="reference-content">Hassold
         N﻿, Brichler
         S﻿, Ouedraogo
         E﻿, 
     et al.  Impaired antibody response to COVID-19 vaccination in advanced HIV infection. ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2022;36(4):F1-F5. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000003166">10.1097/QAD.0000000000003166</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35013085" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Impaired%20antibody%20response%20to%20COVID-19%20vaccination%20in%20advanced%20HIV%20infection.&amp;author=N%20Hassold&amp;author=S%20Brichler&amp;author=E%20Ouedraogo&amp;publication_year=2022&amp;journal=AIDS&amp;volume=36&amp;pages=F1-F5" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000003166" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000003166" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r160">160.</a><div class="reference-content">Xu
         X﻿, Vesterbacka
         J﻿, Aleman
         S﻿, Nowak
         P﻿; COVAXID Study Group.  High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV—but HIV viremia matters? ﻿ <i xmlns:helper="urn:XsltStringHelper"> AIDS</i>. 2022;36(3):479-481. doi:<a href="http://dx.doi.org/10.1097/QAD.0000000000003135">10.1097/QAD.0000000000003135</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35084386" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=High%20seroconversion%20rate%20after%20vaccination%20with%20mRNA%20BNT162b2%20vaccine%20against%20SARS-CoV-2%20among%20people%20with%20HIV%E2%80%94but%20HIV%20viremia%20matters%3F&amp;author=X%20Xu&amp;author=J%20Vesterbacka&amp;author=S%20Aleman&amp;author=P%20Nowak&amp;publication_year=2022&amp;journal=AIDS&amp;volume=36&amp;pages=479-481" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1097/QAD.0000000000003135" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1097/QAD.0000000000003135" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r161">161.</a><div class="reference-content">Haidar
         G﻿, Agha
         M﻿, Bilderback
         A﻿, 
     et al.  Prospective evaluation of coronavirus disease 2019 (COVID-19) vaccine responses across a broad spectrum of immunocompromising conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS) study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. 2022;75(1):e630-e644. doi:<a href="http://dx.doi.org/10.1093/cid/ciac103">10.1093/cid/ciac103</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35179197" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Prospective%20evaluation%20of%20coronavirus%20disease%202019%20%28COVID-19%29%20vaccine%20responses%20across%20a%20broad%20spectrum%20of%20immunocompromising%20conditions%3A%20the%20COVID-19%20Vaccination%20in%20the%20Immunocompromised%20Study%20%28COVICS%29%20study.&amp;author=G%20Haidar&amp;author=M%20Agha&amp;author=A%20Bilderback&amp;publication_year=2022&amp;journal=Clin%20Infect%20Dis&amp;volume=75&amp;pages=e630-e644" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/cid/ciac103" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/cid/ciac103" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r162">162.</a><div class="reference-content">Nault
         L﻿, Marchitto
         L﻿, Goyette
         G﻿, 
     et al.  Covid-19 vaccine immunogenicity in people living with HIV-1. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Vaccine</i>. 2022;40(26):3633-3637. doi:<a href="http://dx.doi.org/10.1016/j.vaccine.2022.04.090">10.1016/j.vaccine.2022.04.090</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35568588" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Covid-19%20vaccine%20immunogenicity%20in%20people%20living%20with%20HIV-1.&amp;author=L%20Nault&amp;author=L%20Marchitto&amp;author=G%20Goyette&amp;publication_year=2022&amp;journal=Vaccine&amp;volume=40&amp;pages=3633-3637" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.vaccine.2022.04.090" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.vaccine.2022.04.090" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r163">163.</a><div class="reference-content">Schmidt
         KG﻿, Harrer
         EG﻿, Tascilar
         K﻿, 
     et al.  Characterization of serum and mucosal SARS-CoV-2-antibodies in HIV-1-infected subjects after BNT162b2 mRNA vaccination or SARS-CoV-2 infection. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Viruses</i>. 2022;14(3):651. doi:<a href="http://dx.doi.org/10.3390/v14030651">10.3390/v14030651</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35337058" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Characterization%20of%20serum%20and%20mucosal%20SARS-CoV-2-antibodies%20in%20HIV-1-infected%20subjects%20after%20BNT162b2%20mRNA%20vaccination%20or%20SARS-CoV-2%20infection.&amp;author=KG%20Schmidt&amp;author=EG%20Harrer&amp;author=K%20Tascilar&amp;publication_year=2022&amp;journal=Viruses&amp;volume=14&amp;pages=651" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.3390/v14030651" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.3390/v14030651" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r164">164.</a><div class="reference-content">Madhi
         SA﻿, Moodley
         D﻿, Hanley
         S﻿, 
     et al; 2019nCoV-501 Study Group.  Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2022;9(5):e309-e322. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(22)00041-8">10.1016/S2352-3018(22)00041-8</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35489376" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Immunogenicity%20and%20safety%20of%20a%20SARS-CoV-2%20recombinant%20spike%20protein%20nanoparticle%20vaccine%20in%20people%20living%20with%20and%20without%20HIV-1%20infection%3A%20a%20randomised%2C%20controlled%2C%20phase%202A%2F2B%20trial.&amp;author=SA%20Madhi&amp;author=D%20Moodley&amp;author=S%20Hanley&amp;publication_year=2022&amp;journal=Lancet%20HIV&amp;volume=9&amp;pages=e309-e322" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(22)00041-8" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(22)00041-8" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r165">165.</a><div class="reference-content">Coburn
         SB﻿, Humes
         E﻿, Lang
         R﻿, 
     et al; Corona-Infectious-Virus Epidemiology Team (CIVETs) of the NA-ACCORD of IeDEA.  Analysis of postvaccination breakthrough COVID-19 infections among adults with HIV in the United States. ﻿ <i xmlns:helper="urn:XsltStringHelper"> JAMA Netw Open</i>. 2022;5(6):e2215934. doi:<a href="http://jamanetwork.com/article.aspx?doi=10.1001/jamanetworkopen.2022.15934">10.1001/jamanetworkopen.2022.15934</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35671054" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Analysis%20of%20postvaccination%20breakthrough%20COVID-19%20infections%20among%20adults%20with%20HIV%20in%20the%20United%20States.&amp;author=SB%20Coburn&amp;author=E%20Humes&amp;author=R%20Lang&amp;publication_year=2022&amp;journal=JAMA%20Netw%20Open&amp;volume=5&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1001/jamanetworkopen.2022.15934" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1001/jamanetworkopen.2022.15934" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r166">166.</a><div class="reference-content">Guidance for COVID-19 and People with HIV. Guidelines Working Groups of the NIH Office of AIDS Research Advisory Council and US Department of Health and Human Services (HHS). Updated February 22, 2022. Accessed July 28, 2022. <a href="https://clinicalinfo.hiv.gov/en/guidelines/guidance-covid-19-and-people-hiv/whats-new-covid-19-and-hiv-guidance">https://clinicalinfo.hiv.gov/en/guidelines/guidance-covid-19-and-people-hiv/whats-new-covid-19-and-hiv-guidance</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r167">167.</a><div class="reference-content">National Institutes of Health. COVID-19 treatment guidelines. Accessed November 9, 2022. <a href="https://www.covid19treatmentguidelines.nih.gov/">https://www.covid19treatmentguidelines.nih.gov/</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r168">168.</a><div class="reference-content">Bhimraj
         A﻿, Morgan
         RL﻿, Shumaker
         AH﻿, 
     et al.  Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Clin Infect Dis</i>. Published online April 27, 2020. <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32338708" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Infectious%20Diseases%20Society%20of%20America%20guidelines%20on%20the%20treatment%20and%20management%20of%20patients%20with%20COVID-19.&amp;author=A%20Bhimraj&amp;author=RL%20Morgan&amp;author=AH%20Shumaker&amp;publication_year=2020&amp;journal=Clin%20Infect%20Dis&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r169">169.</a><div class="reference-content">Mazzitelli
         M﻿, Trunfio
         M﻿, Sasset
         L﻿, 
     et al.  Factors associated with severe COVID-19 and post-acute COVID-19 syndrome in a cohort of people living with HIV on antiretroviral treatment and with undetectable HIV RNA. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Viruses</i>. 2022;14(3):493. doi:<a href="http://dx.doi.org/10.3390/v14030493">10.3390/v14030493</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35336900" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Factors%20associated%20with%20severe%20COVID-19%20and%20post-acute%20COVID-19%20syndrome%20in%20a%20cohort%20of%20people%20living%20with%20HIV%20on%20antiretroviral%20treatment%20and%20with%20undetectable%20HIV%20RNA.&amp;author=M%20Mazzitelli&amp;author=M%20Trunfio&amp;author=L%20Sasset&amp;publication_year=2022&amp;journal=Viruses&amp;volume=14&amp;pages=493" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.3390/v14030493" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.3390/v14030493" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r170">170.</a><div class="reference-content">Ferré
         VM﻿, Bachelard
         A﻿, Zaidi
         M﻿, 
     et al.  Detection of monkeypox virus in anorectal swabs from asymptomatic men who have sex with men in a sexually transmitted infection screening program in Paris, France. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Ann Intern Med</i>. 2022;175(10):1491-1492. doi:<a href="http://dx.doi.org/10.7326/M22-2183">10.7326/M22-2183</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35969863" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Detection%20of%20monkeypox%20virus%20in%20anorectal%20swabs%20from%20asymptomatic%20men%20who%20have%20sex%20with%20men%20in%20a%20sexually%20transmitted%20infection%20screening%20program%20in%20Paris%2C%20France.&amp;author=VM%20Ferré&amp;author=A%20Bachelard&amp;author=M%20Zaidi&amp;publication_year=2022&amp;journal=Ann%20Intern%20Med&amp;volume=175&amp;pages=1491-1492" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.7326/M22-2183" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.7326/M22-2183" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r171">171.</a><div class="reference-content">Loncharich
         MF﻿, Anderson
         CW﻿.  Interferon inhibition for lupus with anifrolumab: critical appraisal of the evidence leading to FDA approval. ﻿ <i xmlns:helper="urn:XsltStringHelper"> ACR Open Rheumatol</i>. 2022;4(6):486-491. doi:<a href="http://dx.doi.org/10.1002/acr2.11414">10.1002/acr2.11414</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35157371" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Interferon%20inhibition%20for%20lupus%20with%20anifrolumab%3A%20critical%20appraisal%20of%20the%20evidence%20leading%20to%20FDA%20approval.&amp;author=MF%20Loncharich&amp;author=CW%20Anderson&amp;publication_year=2022&amp;journal=ACR%20Open%20Rheumatol&amp;volume=4&amp;pages=486-491" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1002/acr2.v4.6" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1002/acr2.v4.6" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r172">172.</a><div class="reference-content">Thornhill
         JP﻿, Barkati
         S﻿, Walmsley
         S﻿, 
     et al; SHARE-net Clinical Group.  Monkeypox virus infection in humans across 16 countries—April-June 2022. ﻿ <i xmlns:helper="urn:XsltStringHelper"> N Engl J Med</i>. 2022;387(8):679-691. doi:<a href="http://dx.doi.org/10.1056/NEJMoa2207323">10.1056/NEJMoa2207323</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35866746" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Monkeypox%20virus%20infection%20in%20humans%20across%2016%20countries%E2%80%94April-June%202022.&amp;author=JP%20Thornhill&amp;author=S%20Barkati&amp;author=S%20Walmsley&amp;publication_year=2022&amp;journal=N%20Engl%20J%20Med&amp;volume=387&amp;pages=679-691" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMoa2207323" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMoa2207323" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r173">173.</a><div class="reference-content">Health Alert Network (HAN). Severe manifestations of monkeypox among people who are immunocompromised due to HIV or other conditions. Published September 29, 2022. Accessed November 1, 2022. <a href="https://emergency.cdc.gov/han/2022/han00475.asp">https://emergency.cdc.gov/han/2022/han00475.asp</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r174">174.</a><div class="reference-content">Clinical Info HIV. Guidelines for the use of antretroviral agents in adults and adolescents with HIV. Updated September 1, 2022. Accessed November 9, 2022. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/overview?view=full">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/overview?view=full</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r175">175.</a><div class="reference-content">UNAIDS. 2021 UNAIDS Global AIDS Update: Confronting Inequalities—Lessons for Pandemic Responses From 40 Years of AIDS. Published July 14, 2021. Accessed November 9, 2022. <a href="https://www.unaids.org/en/resources/documents/2021/2021-global-aids-update">https://www.unaids.org/en/resources/documents/2021/2021-global-aids-update</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r176">176.</a><div class="reference-content">Sullivan
         PS﻿, Satcher Johnson
         A﻿, Pembleton
         ES﻿, 
     et al.  Epidemiology of HIV in the USA: epidemic burden, inequities, contexts, and responses. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet</i>. 2021;397(10279):1095-1106. doi:<a href="http://dx.doi.org/10.1016/S0140-6736(21)00395-0">10.1016/S0140-6736(21)00395-0</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/33617774" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Epidemiology%20of%20HIV%20in%20the%20USA%3A%20epidemic%20burden%2C%20inequities%2C%20contexts%2C%20and%20responses.&amp;author=PS%20Sullivan&amp;author=A%20Satcher Johnson&amp;author=ES%20Pembleton&amp;publication_year=2021&amp;journal=Lancet&amp;volume=397&amp;pages=1095-1106" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S0140-6736(21)00395-0" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S0140-6736(21)00395-0" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r177">177.</a><div class="reference-content">DiNenno
         EA﻿, Delaney
         KP﻿, Pitasi
         MA﻿, 
     et al.  HIV testing before and during the COVID-19 pandemic—United States, 2019-2020. ﻿ <i xmlns:helper="urn:XsltStringHelper"> MMWR Morb Mortal Wkly Rep</i>. 2022;71(25):820-824. doi:<a href="http://dx.doi.org/10.15585/mmwr.mm7125a2">10.15585/mmwr.mm7125a2</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35737573" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=HIV%20testing%20before%20and%20during%20the%20COVID-19%20pandemic%E2%80%94United%20States%2C%202019-2020.&amp;author=EA%20DiNenno&amp;author=KP%20Delaney&amp;author=MA%20Pitasi&amp;publication_year=2022&amp;journal=MMWR%20Morb%20Mortal%20Wkly%20Rep&amp;volume=71&amp;pages=820-824" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.15585/mmwr.mm7125a2" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.15585/mmwr.mm7125a2" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r178">178.</a><div class="reference-content">Centers for Disease Control and Prevention (CDC).  Diagnoses of HIV infection in the United States and dependent areas 2020.  Accessed November 9, 2022. <a href="https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-33/index.html">https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-33/index.html</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r179">179.</a><div class="reference-content">Dailey
         AF﻿, Gant
         Z﻿, Hu
         X﻿, Johnson Lyons
         S﻿, Okello
         A﻿, Satcher Johnson
         A﻿.  Association between social vulnerability and rates of HIV diagnoses among black adults, by selected characteristics and region of residence—United States, 2018. ﻿ <i xmlns:helper="urn:XsltStringHelper"> MMWR Morb Mortal Wkly Rep</i>. 2022;71(5):167-170. doi:<a href="http://dx.doi.org/10.15585/mmwr.mm7105a2">10.15585/mmwr.mm7105a2</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/35113849" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Association%20between%20social%20vulnerability%20and%20rates%20of%20HIV%20diagnoses%20among%20black%20adults%2C%20by%20selected%20characteristics%20and%20region%20of%20residence%E2%80%94United%20States%2C%202018.&amp;author=AF%20Dailey&amp;author=Z%20Gant&amp;author=X%20Hu&amp;author=S%20Johnson Lyons&amp;author=A%20Okello&amp;author=A%20Satcher Johnson&amp;publication_year=2022&amp;journal=MMWR%20Morb%20Mortal%20Wkly%20Rep&amp;volume=71&amp;pages=167-170" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.15585/mmwr.mm7105a2" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.15585/mmwr.mm7105a2" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r180">180.</a><div class="reference-content">HIV/AIDS Surveillance in Europe 2021: 2020 data. European Centre for Disease Prevention and Control. Published 2021. Accessed November 9, 2022. <a href="https://www.ecdc.europa.eu/sites/default/files/documents/2021-Annual_HIV_Report_0.pdf">https://www.ecdc.europa.eu/sites/default/files/documents/2021-Annual_HIV_Report_0.pdf</a></div></div><div class="reference"><a class="reference-number" id="jsc220007r181">181.</a><div class="reference-content">Schaefer
         R﻿, Schmidt
         HA﻿, Ravasi
         G﻿, 
     et al.  Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet HIV</i>. 2021;8(8):e502-e510. doi:<a href="http://dx.doi.org/10.1016/S2352-3018(21)00127-2">10.1016/S2352-3018(21)00127-2</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/34265283" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Adoption%20of%20guidelines%20on%20and%20use%20of%20oral%20pre-exposure%20prophylaxis%3A%20a%20global%20summary%20and%20forecasting%20study.&amp;author=R%20Schaefer&amp;author=HA%20Schmidt&amp;author=G%20Ravasi&amp;publication_year=2021&amp;journal=Lancet%20HIV&amp;volume=8&amp;pages=e502-e510" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2352-3018(21)00127-2" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2352-3018(21)00127-2" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r182">182.</a><div class="reference-content">Keen
         P﻿, Bavinton
         BR﻿.  Could disparities in PrEP uptake limit the public health benefit? ﻿ <i xmlns:helper="urn:XsltStringHelper"> Lancet Public Health</i>. 2020;5(9):e467-e468. doi:<a href="http://dx.doi.org/10.1016/S2468-2667(20)30183-3">10.1016/S2468-2667(20)30183-3</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32888440" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Could%20disparities%20in%20PrEP%20uptake%20limit%20the%20public%20health%20benefit%3F&amp;author=P%20Keen&amp;author=BR%20Bavinton&amp;publication_year=2020&amp;journal=Lancet%20Public%20Health&amp;volume=5&amp;pages=e467-e468" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S2468-2667(20)30183-3" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S2468-2667(20)30183-3" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r183">183.</a><div class="reference-content">Smith
         JA﻿, Garnett
         GP﻿, Hallett
         TB﻿.  The potential impact of long-acting cabotegravir for HIV prevention in South Africa: a mathematical modeling study. ﻿ <i xmlns:helper="urn:XsltStringHelper"> J Infect Dis</i>. 2021;224(7):1179-1186. doi:<a href="http://dx.doi.org/10.1093/infdis/jiaa296">10.1093/infdis/jiaa296</a>﻿ <a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32492704" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20potential%20impact%20of%20long-acting%20cabotegravir%20for%20HIV%20prevention%20in%20South%20Africa%3A%20a%20mathematical%20modeling%20study.&amp;author=JA%20Smith&amp;author=GP%20Garnett&amp;author=TB%20Hallett&amp;publication_year=2021&amp;journal=J%20Infect%20Dis&amp;volume=224&amp;pages=1179-1186" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/infdis/jiaa296" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/infdis/jiaa296" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jsc220007r184">184.</a><div class="reference-content">Political Declaration on HIV and AIDS: Ending Inequalities and Getting on Track to End AIDS by 2030. UNAIDS. Published June 9, 2021. Accessed July 28, 2022. <a href="https://www.unaids.org/sites/default/files/media_asset/2021_political-declaration-on-hiv-and-aids_en.pdf">https://www.unaids.org/sites/default/files/media_asset/2021_political-declaration-on-hiv-and-aids_en.pdf</a></div></div></div>

</div>
 
    </div>

        <div class="movable-ad bta">
    <div class="widget-WidgetLoader widget-instance-AMA_AdTag_textbreak_bta_dual">
        
    <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_textbreak_bta_dual" data-params="{&quot;parameters&quot;:{&quot;siteName&quot;:&quot;jama&quot;,&quot;siteId&quot;:3,&quot;journalId&quot;:67,&quot;adDisplay&quot;:8,&quot;adSection&quot;:&quot;textbreak&quot;,&quot;adPosition&quot;:&quot;bta&quot;,&quot;fromGoogle&quot;:false},&quot;dynamicParameters&quot;:{}}"></div>
 
    </div>

        </div>
    </div> 

</div> 

<div class="hidden-jobs-ad hide">
    <div class="widget-WidgetLoader widget-instance-AMA_JobsAd">
        
<div class="SCM-SharedWidgets-AsyncJobsAdLoader" data-url="/AMA/JobsAd/AMA_JobsAd" data-params="{&quot;parameters&quot;:{&quot;SiteId&quot;:3},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}"></div>
 
    </div>

</div>



<script>
                var App = App || {};
                App.ArticleSplitScreen = App.ArticleSplitScreen || {};
                App.ArticleSplitScreen.siteName = 'jama';
                App.ArticleSplitScreen.siteId = 3;
                App.ArticleSplitScreen.journalId = 67;
                App.ArticleSplitScreen.adDisplay = 'ArticleContentsSkyBox';
                App.ArticleSplitScreen.adSection = "scholarly";
                App.ArticleSplitScreen.adPosition = "contab";
                App.ArticleSplitScreen.controlId = "AMA_AdTag_Contents_Skybox";
                App.ArticleSplitScreen.fromGoogle = "False";
                App.ArticleSplitScreen.slotLocationOverride = "50";

</script> 
    </div>


 
    </div>

    </section>


    <section id="secFooterControl" class="master-footer">
        

        <script>
            var App = App || {};

            function scmByClass(className) {
                return document.getElementsByClassName(className);
            }

            function scmById(id) {
                return document.getElementById(id);
            }

            function scmquery(selector) {
                return document.querySelector(selector);
            }

            function queryAll(selector) {
                return document.querySelectorAll(selector);
            }

            function isTrueString(string) {
                if (typeof string === 'string') {
                    return string.toLowerCase() === 'true';
                }

                return undefined;
            }

            function updateViewportDimensions() {
                var w = window, d = document, e = d.documentElement, g = d.getElementsByTagName('body')[0], x = w.innerWidth || e.clientWidth || g.clientWidth, y = w.innerHeight || e.clientHeight || g.clientHeight;
                return { width: x, height: y };
            }

            var viewport = updateViewportDimensions();

            var debounce = function (func, wait, immediate) {
                var timeout;
                return function () {
                    var context = this, args = arguments;
                    var later = function () {
                        timeout = null;
                        if (!immediate) func.apply(context, args);
                    };
                    var callNow = immediate && !timeout;
                    clearTimeout(timeout);
                    timeout = setTimeout(later, wait);
                    if (callNow) func.apply(context, args);
                };
            };

            (function (App) {
                App.mobileUpperBreakpoint = 767;
                App.mobileAltBreakpoint = 640;
                App.mobileMinBreakpoint = 547;
                App.tabletUpperBreakpoint = 1023;

                function setVariables() {
                    viewport = updateViewportDimensions();
                    App.isMobile = (viewport.width <= App.mobileUpperBreakpoint);
                    App.isMobileAlt = (viewport.width <= App.mobileAltBreakpoint);
                    App.isTablet = (viewport.width > App.mobileUpperBreakpoint && viewport.width <= App.tabletUpperBreakpoint);
                    App.isTabletDown = (viewport.width <= App.tabletUpperBreakpoint);
                    App.isDesktop = (viewport.width > App.tabletUpperBreakpoint);
                    App.activeViewport = App.isMobile ? 'small' : App.isTablet ? 'med' : 'large';
                }

                setVariables();

                App.cachedViewport = App.isMobile ? 'small' : App.isTablet ? 'med' : 'large';
                App.isAnyArticle = !!(scmByClass('widget-ArticleFullView').length || scmByClass('pg_abstract').length
                    || scmByClass('widget-MagazineView').length || scmByClass('widget-ChannelsMagazineView').length);
                App.isSplitScreen = !!scmByClass('widget-ArticleFullView').length;
                App.isAbstract = !!scmByClass('pg_abstract').length;
                App.isMag = !!(scmByClass('widget-MagazineView').length);
                App.isChannel = !!(scmByClass('channel-site').length);
                App.isChannelMag = !!(scmByClass('widget-ChannelsMagazineView').length);
                App.isFreeArticle = !!(scmquery('.widget-ArticleTopInfo .free-access') ||
                                        scmquery('.widget-ArticleTopInfo .open-access') ||
                                        scmquery('.widget-ArticleTopInfo .icon-free') || 
                                        scmquery('.widget-ChannelsMagazineView .free-access'));
                App.isTollFreeAccess = false;
                App.isIssue = !!scmByClass('pg_issue').length || !!scmByClass('pg_newonline').length || !!scmByClass('pg_currentissue').length || !!scmByClass('pg_pastissues').length;
                App.isNewOnline = !!scmByClass('pg_newonline').length;
                App.isCurrentIssue = !!scmByClass('pg_currentissue').length;
                App.isPastIssues = !!scmByClass('pg_pastissues').length;
                App.isJournal = !!scmByClass('pg_journal').length;
                App.isNetworkHome = !!scmByClass('pg_index').length;
                App.isSearch = !!scmByClass('pg_searchresults').length;
                App.isAdvancedSearch = !!scmByClass('pg_advancedsearch').length;
                App.isPlayer= !!scmByClass('pg_multimediaplayer').length;
                App.isSelfServe = !!scmByClass('pg_sspage').length;
                App.isCmsPage = !!scmByClass('pg_cmspage').length; 
                App.isMyAccount = !!scmByClass('pg_myaccount').length;
                App.supportsFlexbox = !!scmByClass('flexbox').length;
                App.isCollection = !!scmByClass('pg_collection').length;
                App.isPaidUser = isTrueString(scmById('hfAppIsPaidUser').getAttribute('value'));
                App.isMember = isTrueString(scmById('hfAppIsMember').getAttribute('value'));
                App.isIndividual = isTrueString(scmById('hfAppIsIndividual').getAttribute('value'));
                App.hasAccess = isTrueString(scmById('hfAppHasAccess').getAttribute('value'));
                App.isReferredFromGoogle = isTrueString(scmById('hfAppIsReferredFromGoogle').getAttribute('value'));
                var subscribedTo = scmById('hfAppSubscribedTo').getAttribute('value');
                App.userSubscribedTo = subscribedTo ? subscribedTo.split(',') : undefined;
                App.isLucy = isTrueString(scmById('hfAppIsLucy').getAttribute('value'));
                App.currentJournalCount = 26;
                App.isChannelPage = !!(scmByClass('channels-page'));
                App.updateAppVariables = debounce(function () {
                    setVariables();
                }, 50, false);
            })(App);
        </script>
        

        
<div class="footer-ad-wrapper">
    <div id="BodyContent_Footer_divAds" class="footer-ad desktop-only">
        
            <div class="widget-WidgetLoader widget-instance-AMA_AdTag_AnchorboardAd_btf">
        
    <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_AnchorboardAd_btf" data-params="{&quot;parameters&quot;:{&quot;siteName&quot;:&quot;jama&quot;,&quot;siteId&quot;:3,&quot;journalId&quot;:67,&quot;adDisplay&quot;:11,&quot;adSection&quot;:&quot;scholarly&quot;,&quot;adPosition&quot;:&quot;btf&quot;,&quot;fromGoogle&quot;:false},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}"></div>
 
    </div>
</div>
</div>

 
 <div class="ad-riser-wrap desktop-only">
     <div class="ad-riser--dismiss t-c">X</div>
         <div class="widget-WidgetLoader widget-instance-AMA_AdTag_Riser">
        
    <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_Riser" data-params="{&quot;parameters&quot;:{&quot;siteName&quot;:&quot;jama&quot;,&quot;siteId&quot;:3,&quot;journalId&quot;:67,&quot;adDisplay&quot;:12,&quot;adSection&quot;:&quot;scholarly&quot;,&quot;adPosition&quot;:&quot;Riser&quot;,&quot;fromGoogle&quot;:false},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}"></div>
 
    </div>

 </div>


<div class="footer-wrap">
    
    <footer class="footer" id="footer">
        
        <div id="footer-microsite" class="footer-microsite">
            



    <input type="hidden" class="SelfServeContentId" value="v2_Footer_Left" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    @media (min-width: 1024px) {.split-screen .footer-microsite-contents {border-bottom:0 !important;}}
    .footer-microsite-contents {margin-bottom:1em;width:100%;}
    .footer-network-other .link-apps:before {width: 23px;}
    .footer-network-other .link-institutions-librarians:before {width: 23px;}
    .jn-ss-footer-border-top {border-top:1px solid #555;padding-top:15px;}
    .jn-ss-footer-border-bottom {border-bottom:1px solid #555;padding-bottom:10px;padding-right:3px;}
</style>
<div class="footer-heading-wrap">
<h3 id="BodyContent_Footer_h3SiteName" class="footer-heading is-b footer-microsite-heading" data-mobile-tog-target=".footer-microsite-links-wrap">JAMA</h3>
</div>
<div class="footer-microsite-links-wrap">
<div class="footer-microsite-contents  jn-ss-footer-border-bottom">
<h4 id="BodyContent_Footer_ContentHeader" class="footer-subheading">Content</h4>
<a href="/journals/jama">Home</a>
<a href="/journals/jama/newonline">New Online</a>
<a href="/journals/jama/currentissue">Current Issue</a>
</div>
<div class="footer-microsite-contents  jn-ss-footer-border-bottom">
<h4 class="footer-subheading">Podcasts</h4>
<a href="/journals/jama/pages/covid-19-interviews#audio">Coronavirus (COVID-19)&nbsp;Q&amp;A</a>
<a href="/journals/jama/pages/jama-clinical-reviews">Clinical Reviews</a>
<a href="/journals/jama/pages/jama-editors-summary">Editors' Summary</a>
<a href="/journals/jama/pages/jama-medical-news">Medical News</a>
<a href="/journals/jama/pages/jama-author-interviews">Author Interviews</a>
<a href="/journals/jama/pages/jamaevidence-jama-guide-to-statistics-and-methods">JAMAevidence: <em>JAMA Guide to Statistics and Methods</em></a>
<a href="/journals/jama/pages/jamaevidence-the-rational-clinical-examination">JAMAevidence: The Rational Clinical Examination</a>
<a href="/journals/jama/pages/jamaevidence-users-guides-to-the-medical-literature">JAMAevidence: Users' Guides to the Medical Literature</a>
</div>
<div class="footer-microsite-services cf">
<h4 id="BodyContent_Footer_ServiceHeader" class="footer-subheading">Journal Information</h4>
<a href="/journals/jama/pages/for-authors">For Authors</a>
<a href="/journals/jama/pages/jama-editors">JAMA Editors</a>
<a href="/journals/jama/editors-and-publishers">Editors &amp; Publishers</a>
<a href="/pages/rss">RSS</a>
<a href="/journals/jama/pages/contact-us">Contact Us</a>
</div>
<div class="footer-network-other  jn-ss-footer-border-bottom">
<a href="https://edhub.ama-assn.org/jn-learning" class="link-network-other is-b link-learning">JN Learning / CME</a>
<a href="https://store.jamanetwork.com" class="link-network-other is-b link-store" target="_blank">Store</a>
<a href="/pages/apps" class="link-network-other is-b link-mobile" target="_blank">Apps</a>
<a href="https://careers.jamanetwork.com/" class="link-network-other is-b link-jobs" target="_blank">Jobs</a>
<a href="/pages/resources-for-librarians" class="link-network-other is-b link-institutions-librarians" target="_blank">Institutions</a>
<a href="/pages/reprints-and-permissions" class="link-network-other is-b link-reprints-permissions">Reprints &amp; Permissions</a>
</div>
<div id="BodyContent_Footer_divSubscribe" class="footer-microsite-subscribe">
<img src="//cdn.jamanetwork.com/UI/app/img/covers/jama.jpg" class="subscribe-image" alt="Journal Cover">
<div class="subscribe-meta">
<h4 class="subscribe-heading footer-subheading">Subscribe</h4>
<a href="https://store.jamanetwork.com/productDetails.aspx?productcodeID=64" class="subscribe-submit btn">Go</a>
</div>
</div>
</div>





        </div>

        
        <div id="footer-network" class="footer-network">
            



    <input type="hidden" class="SelfServeContentId" value="v2_Footer_Middle" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    .footer-network-sites {width: 62.85542%;}
    .footer-network-info {width: 35.93976%}
    .jn-ss-subheading-mt {margin-top: 1.5em;}
    .jn-registered:after {content: "\00AE";font-size: 50%;vertical-align: top;}
    .jn-trademark:after {content: "\2122";font-size: 50%;vertical-align: top;}
</style>
<div class="footer-heading-wrap">
<h3 class="footer-heading is-b jn-registered" data-mobile-tog-target=".footer-network-links-wrap"><strong>JAMA</strong> Network</h3>
</div>
<div class="footer-network-links-wrap">
<div class="footer-network-sites">
<div class="internal">
<h4 id="BodyContent_Footer_JournalHeader" class="footer-subheading">Publications</h4>
<a href="/journals/jama">JAMA</a>
<a href="/journals/jamanetworkopen" target="_blank">JAMA Network Open</a>
<a href="/journals/jamacardiology">JAMA Cardiology</a>
<a href="/journals/jamadermatology">JAMA Dermatology</a>
<a href="/journals/jama-health-forum">JAMA Health Forum</a>
<a href="/journals/jamainternalmedicine">JAMA Internal Medicine</a>
<a href="/journals/jamaneurology">JAMA Neurology</a>
<a href="/journals/jamaoncology">JAMA Oncology</a>
<a href="/journals/jamaophthalmology">JAMA Ophthalmology</a>
<a href="/journals/jamaotolaryngology">JAMA Otolaryngology–Head &amp; Neck Surgery</a>
<a href="/journals/jamapediatrics">JAMA Pediatrics</a>
<a href="/journals/jamapsychiatry">JAMA Psychiatry</a>
<a href="/journals/jamasurgery">JAMA Surgery</a>
<a href="/journals/archneurpsyc">Archives of Neurology &amp; Psychiatry (1919-1959)</a>
</div>
<div class="external">
<h4 class="footer-subheading">Sites</h4>
<div id="BodyContent_Footer_ssFooterSiteMenu">
<div class="selfServe">
<a target="_blank" href="https://sites.jamanetwork.com/art-and-images-in-psychiatry/">Art and Images in Psychiatry</a>
<a target="_blank" href="/channels/ai">Artificial Intelligence (AI) Resource Center</a>
<a target="_blank" href="/journals/jama/pages/2023-most-viewed-jama">Best of the JAMA Network</a>
<a target="_blank" href="/channels/caring-for-the-critically-ill-patient">Caring for the Critically Ill Patient</a>
<a target="_blank" href="/journals/jama/pages/crosswords">Clinical Crosswords from JAMA</a>
<a target="_blank" href="/journals/jama/pages/coronavirus-alert">Coronavirus Resource Center</a>
<a target="_blank" href="https://ebm.jamanetwork.com/index.html">Evidence-Based Medicine: An Oral History</a>
<a target="_blank" href="/pages/fishbein-fellowship">Fishbein Fellowship</a>
<a target="_blank" href="/channels/genomics/">Genomics and Precision Health</a>
<a target="_blank" href="/channels/hypertension">Hypertension</a>
<a target="_blank" href="/channels/health-forum/archive">JAMA Forum Archive</a>
<a target="_blank" href="https://sites.jamanetwork.com/audio">JAMA Network Audio</a>
<a target="_blank" href="/pages/video">JAMA Network Video</a>
<a target="_blank" href="/pages/conferences">JAMA Network Conferences </a>
<a target="_blank" href="/pages/jama-summit">JAMA Summit </a>
<a target="_blank" href="/journals/jamasurgery/pages/statistics-and-methods">JAMA Surgery Guide to Statistics and Methods</a>
<a target="_blank" href="/channels/medical-news">Medical News</a>
<a target="_blank" href="/channels/monkeypox">Mpox (Monkeypox)</a>
<a target="_blank" href="https://sites.jamanetwork.com/research-ethics/">Research Ethics</a>
<a target="_blank" href="/pages/collections">Topics and Collections</a>
<a target="_blank" href="/pages/visual-abstracts">Visual Abstracts</a>
<a target="_blank" href="/channels/war">War and Health</a>
<a target="_blank" href="/channels/womens-health">Women's Health</a>
<h4 class="footer-subheading jn-ss-subheading-mt">Featured Articles</h4>
<a href="/journals/jama/fullarticle/2799240">Antiretroviral Drugs for HIV Treatment and Prevention in Adults - 2022 IAS-USA Recommendations</a>
<a href="/journals/jama/fullarticle/2781397">CONSERVE 2021 Guidelines for Reporting Trials Modified for the COVID-19 Pandemic</a>
<a href="/journals/jama/fullarticle/2808296">Creation and Adoption of Large Language Models in&nbsp;Medicine</a>
<a href="/journals/jamaoncology/fullarticle/2787350">Global Burden of Cancer, 2010-2019</a>
<a href="/journals/jama/fullarticle/2797443">Global Burden of Long COVID</a>
<a href="/journals/jamadermatology/fullarticle/2790344">Global Burden of Melanoma</a>
<a href="/journals/jamadermatology/fullarticle/2787350">Global Burden of Skin Diseases, 1990-2017</a>
<a href="/journals/jamaneurology/fullarticle/2793874">Global Disparities in Parkinson Disease</a>
<a href="/journals/jama/fullarticle/2799547">Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension</a>
<a href="/journals/jamapsychiatry/fullarticle/2799486">Mass Violence and the Complex Spectrum of Mental Illness and Mental Functioning</a>
<a href="/journals/jamapsychiatry/fullarticle/2793903">Neuropsychiatry Sequelae of COVID-19</a>
<a href="/journals/jamaneurology/fullarticle/2810313">A New Framework for Dementia Nomenclature</a>
<a href="/journals/jama/fullarticle/2800656">Organization and Performance of US Health Systems</a>
<a href="/journals/jama-health-forum/fullarticle/2791195">Pharmacy Benefit Managers: History, Business Practices, Economics, and Policy</a>
<a href="/journals/jama-health-forum/fullarticle/2791195">Promoting EDI in Genetics Research</a>
<a href="/journals/jamacardiology/fullarticle/2781972">PTSD and Cardiovascular Disease</a>
<a href="/journals/jama/fullarticle/2810754">Red Blood Cell Transfusion: 2023 AABB International Guidelines</a>
<a href="/journals/jamapediatrics/fullarticle/2797600">Reimagining Children’s Rights in the US</a>
<a href="/journals/jama/fullarticle/2794049">Spirituality in Serious Illness and Health</a>
<a href="/journals/jama/fullarticle/2796374">The US Medicaid Program: Coverage, Financing, Reforms, and Implications for Health Equity</a>
<h4 class="footer-subheading jn-ss-subheading-mt">USPSTF Recommendation Statements</h4>
<a href="/journals/jama/fullarticle/2779985">Screening for Colorectal Cancer</a>
<a href="/journals/jama/fullarticle/2779190">Screening for Hypertension</a>
<a href="/journals/jama/fullarticle/2777244">Screening for Lung Cancer</a>
<a href="/journals/jama/fullarticle/2796244">Screening for Prediabetes and Type 2 Diabetes In Children</a>
<a href="/journals/jama/fullarticle/2783414">Screening for Prediabetes and Type 2 Diabetes In Adults</a>
<a href="/journals/jama/fullarticle/2795521">Statins for Primary Prevention of Cardiovascular Disease</a>
<a href="/journals/jama/fullarticle/2793446">Vitamin and Mineral Supplements for Primary Prevention of of Cardiovascular Disease and Cancer</a>
<h4 class="footer-subheading jn-ss-subheading-mt">Blogs</h4>
<a target="_blank" href="https://amastyleinsider.com/">AMA Style Insider</a>
</div>
</div>
</div>
</div>
<div id="footer-network-info" class="footer-network-info">
<div class="information-for-links">
<h4 id="BodyContent_Footer_InfoHeader" class="footer-subheading">Information</h4>
<a href="/pages/for-authors">For Authors</a>
<a href="/pages/resources-for-librarians">For Institutions &amp; Librarians</a>
<a href="/pages/advertisers">For Advertisers</a>
<a href="/pages/subscription-agents">For Subscription Agents</a>
<a href="https://careers.jamanetwork.com/" target="_blank">For Employers &amp; Job Seekers</a>
<a href="https://media.jamanetwork.com" rel="nofollow" target="_blank">For the Media</a>
<a href="/pages/equity-diversity-inclusion">Equity, Diversity, Inclusion</a>
<a href="/pages/commenting-policy">Online Commenting Policy</a>
<a href="/pages/access-at-jama-network">Public Access and Open Access Policy</a>
<a href="/pages/offensive-content-statement">Statement on Potentially Offensive Content</a>
</div>
<div class="services-links">
<h4 id="BodyContent_Footer_JAMANetworkProductsHeader" class="footer-subheading">JAMA Network Products</h4>
<a href="http://www.amamanualofstyle.com/" class="footer-service-link" target="_blank">AMA Manual of Style</a>
<a href="https://jamaevidence.mhmedical.com/" class="footer-service-link" target="_blank"><span class="jn-registered">JAMAevidence</span></a>
<a href="http://www.peerreviewcongress.org/" class="footer-service-link" target="_blank">Peer Review Congress</a>
</div>
<div class="learning-links">
<h4 id="BodyContent_Footer_LearningHeader" class="footer-subheading">JN Learning</h4>
<a href="https://edhub.ama-assn.org/jn-learning">Home</a>
<a href="https://edhub.ama-assn.org/jn-learning/state-cme">State CME</a>
<a href="https://edhub.ama-assn.org/jn-learning/pages/clinical-challenge-courses">Clinical Challenge CME</a>
<a href="https://edhub.ama-assn.org/jn-learning/course/288 ">Atrial Fibrillation Course</a>
<a href="https://edhub.ama-assn.org/jn-learning/course/294 ">Women's Health Course</a>
<a target="_blank" href="https://edhub.ama-assn.org/pages/auto-credit-reporting">CME / MOC Reporting Preferences</a>
<a href="https://edhub.ama-assn.org/jn-learning/pages/about-cme">About CME &amp; MOC</a>
</div>
</div>
</div>





        </div>
        
        <div id="footer-resources-wrap" class="footer-resources-wrap">
            



    <input type="hidden" class="SelfServeContentId" value="v2_Footer_Right" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    .footer-resources-wrap .footer-subheading {color: grey;display:block !important;font-size: 1.17647em;font-weight: 400;text-transform: uppercase;}
</style>
<div class="footer-heading-wrap">
<h3 class="footer-heading is-b footer-resources-heading" data-mobile-tog-target=".footer-resources">Help</h3>
</div>
<div class="footer-resources">
<a href="https://store.jamanetwork.com" class="footer-service-link" target="_blank">Subscriptions &amp; Renewals</a>
<a href="https://jamanetwork.com/oauthsignin?return_url=http%3A%2F%2Fjamanetwork.com%2Fmyaccount%23my-alerts" class="footer-service-link" rel="nofollow">Manage Emails</a>
<a href="https://jamanetwork.com/oauthsignin?return_url=http%3A%2F%2Fjamanetwork.com%2Fmyaccount%23my-profile" class="footer-service-link" rel="nofollow">Update My Address</a>
<a href="https://support.jamanetwork.com/hc/en-us" class="footer-service-link">Support Center</a>
<a href="/myaccount " class="footer-service-link">My Account</a>
<h4 class="footer-subheading jn-ss-subheading-mt">JAMA Career Center</h4>
<a href="https://careers.jamanetwork.com/" class="footer-service-link" target="_blank">Physician Job Listings</a>
</div>








    <input type="hidden" class="SelfServeContentId" value="v2_Footer_Socials" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    .widget-instance-AMA_Journal_Home_Socials .iconsocial {display: inline-block !important;width: 34px;height: 34px;min-width: unset !important;margin: 0 2px !important;background-color: #fff;border-radius: 20px;border: 1px solid #191919;vertical-align: middle;}
    .widget-instance-AMA_Journal_Home_Socials .iconsocial.instagram {background-image: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-black.svg);background-position: 7px 7px;background-repeat: no-repeat;background-size: 18px;}
    .widget-instance-AMA_Journal_Home_Socials .iconsocial.instagram:hover, .widget-instance-AMA_Journal_Home_Socials .iconsocial.instagram:focus {background-image: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-fill.png);border-color: #C13584;}
    .footer-resources-wrap .iconsocial {display: inline-block !important;width: 32px;height: 32px;min-width: unset !important;margin: 0 2px 0 3px !important;background-color: #fff;border-radius: 20px;border: 1px solid #191919;vertical-align: middle;}
    .footer-resources-wrap .iconsocial.instagram {background-image: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-black.svg);background-position: 6px 6px;background-repeat: no-repeat;background-size: 18px;}
    .footer-resources-wrap .iconsocial.instagram:hover, .footer-resources-wrap .iconsocial.instagram:focus {background-color: #C13584;border-color: #191919;}
    #load-instagram-image { background: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-fill.png) no-repeat -9999px -9999px; }
</style>
<div id="BodyContent_Footer_divSocial" class="social-links footer-social-links">
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.facebook.com/JAMAJournal/" class="social-link is-b facebook"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://twitter.com/JAMA_current" class="social-link is-b twitter"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.instagram.com/jamanetwork/?hl=en" class="iconsocial instagram"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.linkedin.com/company/jamanetwork/" class="social-link is-b linked-in"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.youtube.com/jamanetwork" class="social-link is-b you-tube"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.pinterest.com/jamanetwork/" class="social-link is-b pinterest"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="/rss/site_3/67.xml" class="social-link is-b rss"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://jamanetwork.com/journals/jama/pages/jama-editors-summary" class="social-link is-b podcast"></a>
<div id="load-instagram-image">&nbsp;</div>
</div>




<div id="BodyContent_Footer_divEmailUpdate" class="footer-email-updates">
                
                    <div class="widget-EmailListSignUp widget-instance-AMAv2_EmailListSignUp_Footer">
        <div class="email-signup">
    
    <div class="email-signup--text sb-pc">Get the latest from JAMA</div>
    <div class="email-signup--input-wrap is-b">
        <input type="text" name="email" class="email-signup--input" placeholder="Email address" title="Email address" />
        <a rel="nofollow" href="javascript:;" class="email-signup--submit sb-sc btn">Sign Up</a>
    </div>
    <div class="email-signup--link"> <a class="email-signup--privacy" href="/pages/privacy-policy">Privacy Policy</a> | <a class="email-signup--terms" href="/pages/terms-of-use">Terms of Use</a></div>
    <div class="email-signup--user-message"></div>
</div> 
    </div>
</div>
        </div>

        
        <div class="footer-bar" itemscope itemtype="https://schema.org/Organization">
            



    <input type="hidden" class="SelfServeContentId" value="v2_Footer_Bottom_Bar" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    .nav-journals a.theme-jama-health-forum:before {background: #133763;}
    .jn-bottom-bar {color: #fff; float: left;font-size: 10px;padding: 13px 20px;width: 33.33%;}
    .jn-bottom-bar p {line-height: 2;}
    @media (max-width: 900px) {.jn-bottom-bar {float: none;width: 100%;}}
    .jn-footer-copyright {font-size:12px;line-height:1.5;margin-bottom:10px;}
    .jn-footer-pipe {margin:0 10px;}
    .footer-bar-jn-logo img {width: 230px;}
    @media (max-width: 900px) {.footer-bar-jn-logo img {width: 200px;}}
    [data-thm=umb] .jobs-ad--text h6 {color: #d71635 !important;}
    [data-thm=jama] .jobs-ad--text h6 {color: #d71635 !important;}
    [data-thm=jaman] .jobs-ad--text h6 {color: #ed0973 !important;}
    [data-thm=cardi] .jobs-ad--text h6 {color: #be1e32 !important;}
    [data-thm=derm] .jobs-ad--text h6 {color: #006f3b !important;}
    [data-thm=faci] .jobs-ad--text h6 {color: #ed1c24 !important;}
    [data-thm=jama-] .jobs-ad--text h6 {color: #fb5252 !important;}
    [data-thm=intem] .jobs-ad--text h6 {color: #006e96 !important;}
    [data-thm=neur] .jobs-ad--text h6 {color: #981b1e !important;}
    [data-thm=oncol] .jobs-ad--text h6 {color: #3b923f !important;}
    [data-thm=ophth] .jobs-ad--text h6 {color: #66bc29 !important;}
    [data-thm=otol] .jobs-ad--text h6 {color: #34b6e4 !important;}
    [data-thm=peds] .jobs-ad--text h6 {color: #0084c0 !important;}
    [data-thm=psych] .jobs-ad--text h6 {color: #005276 !important;}
    [data-thm=surg] .jobs-ad--text h6 {color: #f47920 !important;}
    .blockquote .para {margin: 0 0 1em 1em;}
    .jn-footer-copyright {display: block;}
    .inline-block {display: inline-block;}
    #selfserve-maintenance {display:block;margin:20px 0;max-height:none !important;min-height:200px;visibility:visible;}
</style>
<a class="footer-bar-jn-logo d-b no-mw mb1" href="/" title="JAMA Network Home"><img class="mw-100" src="https://cdn.jamanetwork.com/ImageLibrary/global/jn-signature-reversed-r.svg?versionId=81373" alt="Jama Network Logo"></a>
<div class="jn-bottom-bar">
<p>
<span class="jn-footer-copyright">© 2024 American Medical Association. <span class="inline-block">All rights reserved,</span> including those for text and data mining, AI training, <span class="inline-block">and similar technologies.</span></span>
<span class="inline-block"><a href="https://www.ama-assn.org/about/terms-use" rel="nofollow" class="p0">Terms of Use</a><span class="jn-footer-pipe">|</span></span>
<span class="inline-block"><a href="https://www.ama-assn.org/about/privacy-policy" rel="nofollow" class="p0">Privacy Policy</a><span class="jn-footer-pipe">|</span></span>
<span class="inline-block"><a href="https://www.ama-assn.org/about/accessibility-statement" rel="nofollow" class="p0">Accessibility Statement</a><span class="jn-footer-pipe">|</span></span>
<span class="inline-block"><a onclick="OneTrust.ToggleInfoDisplay()" rel="nofollow" class="p0" id="CookieFooter">Cookie Settings</a></span>
</p>
</div>
<!-- 
	#selfserve-maintenance {display:block;margin:20px 0;max-height:none !important;min-height:200px;visibility:visible;}
	-->





            <a class="footer-bar-sis no-mw relative nudge-down" href="https://www.silverchair.com" target="_blank"><img class="footer-bar-sis-img mt05 mw-100" width="600" height="70" src="//cdn.jamanetwork.com/UI/app/img/powered.png" alt="Silverchair Logo" /></a>
        </div>
    </footer>

</div>
<div class="ss-ui-only">
        <div class="widget-SelfServeContent widget-instance-AMA_SS_UI_Only">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SsUiOnly" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

.


</div>

 
    </div>

</div>

    </section>


        

        
        
        <div id="revealModal" class="reveal-modal" data-reveal>
            <div id="revealContent"></div>
            <a class="close-reveal-modal icon-close"></a>
        </div>

        
        <div class="artmet-modal" id="MetricsModal">
            <div class="artmet-modal-contents">
                <a class="artmet-close-modal">&#215;</a>
            </div>
        </div>

        
        
    


            <div class="widget-SigninModals widget-instance-AMA_SigninModals">
        <div class="js-modal-no-access-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Access your subscriptions</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f2799240">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

            <div class="widget-AmaAdvancedSeamlessAccess widget-instance-AMA_NoAccess_AdvancedSeamlessAccessButton">
        <div class="seamless-access-button--wrap">
    <button class="d-flex sa-button align-items-center" role="button" type="button">
        <div class="sa-button-logo-wrap">
            <img src="//cdn.jamanetwork.com/UI/app/svg/seamless-access.svg" class="sa-button-logo" alt="Seamless Access Logo" />
        </div>
        <div class="d-flex justify-content-center align-items-center sa-button-text text-truncate">
            <div class="sa-button-text-primary text-truncate">Access through your institution</div>
        </div>
    </button>
    <div class="sa-access-text text-truncate hide">
        <div class="sa-cta-access"><span>Add or change institution</span></div>
    </div>
</div>
 
    </div>

    <div class="widget-SelfServeContent widget-instance-AMA_NoAccess_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
            <div class="widget-SelfServeContent widget-instance-AMA_NoAccess_SigninModal_PurchaseOptions_NoAccessAndPaidPDF">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_NoAccessAndPaidPDF" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Purchase access</div>
<hr>
<button class="modal--btn js-btn-subscribe-journal" type="button" role="button">
<div class="text-truncate">Subscribe to journal</div>
</button>
<div class="modal--btn-desc">Get full journal access for 1 year</div>
<button class="modal--btn js-btn-purchase-article" type="button" role="button">
<div class="text-truncate">Buy article</div>
</button>
<div class="modal--btn-desc">Get unlimited access and a printable PDF ($40.00)—<br>
<em>Sign in or create a free account</em></div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_PurchaseOptions_NoAccessAndPaidPDF</div>-->


</div>

 
    </div>

            <div class="widget-DeepDyve widget-instance-AMA_NoAccess_DeepDyve">
                <button type="button" role="button" class="modal--btn js-deepdyve-link hiddenRentalLink" data-deepdyveurl="https://www.deepdyve.com/doc-view?docId=10.1001/jama.2022.22246&amp;fieldName=journal_doi&amp;affiliateId=JAMA" data-doi="10.1001/jama.2022.22246" data-fieldname="journal_doi" 
                data-issneissn="0098-7484" data-affiliate="JAMA">Rent article</button>
        <div class="modal--btn-desc js-deepdyve-desc hiddenRentalLink">Rent this article from DeepDyve</div>
 
    </div>

    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="js-modal-paid-pdf-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Access your subscriptions</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f2799240">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

            <div class="widget-AmaAdvancedSeamlessAccess widget-instance-AMA_PaidPdf_AdvancedSeamlessAccessButton">
        <div class="seamless-access-button--wrap">
    <button class="d-flex sa-button align-items-center" role="button" type="button">
        <div class="sa-button-logo-wrap">
            <img src="//cdn.jamanetwork.com/UI/app/svg/seamless-access.svg" class="sa-button-logo" alt="Seamless Access Logo" />
        </div>
        <div class="d-flex justify-content-center align-items-center sa-button-text text-truncate">
            <div class="sa-button-text-primary text-truncate">Access through your institution</div>
        </div>
    </button>
    <div class="sa-access-text text-truncate hide">
        <div class="sa-cta-access"><span>Add or change institution</span></div>
    </div>
</div>
 
    </div>

    <div class="widget-SelfServeContent widget-instance-AMA_PaidPdf_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
            <div class="widget-SelfServeContent widget-instance-AMA_PaidPdf_SigninModal_PurchaseOptions_NoAccessAndPaidPDF">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_NoAccessAndPaidPDF" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Purchase access</div>
<hr>
<button class="modal--btn js-btn-subscribe-journal" type="button" role="button">
<div class="text-truncate">Subscribe to journal</div>
</button>
<div class="modal--btn-desc">Get full journal access for 1 year</div>
<button class="modal--btn js-btn-purchase-article" type="button" role="button">
<div class="text-truncate">Buy article</div>
</button>
<div class="modal--btn-desc">Get unlimited access and a printable PDF ($40.00)—<br>
<em>Sign in or create a free account</em></div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_PurchaseOptions_NoAccessAndPaidPDF</div>-->


</div>

 
    </div>

            <div class="widget-DeepDyve widget-instance-AMA_PaidPDF_DeepDyve">
                <button type="button" role="button" class="modal--btn js-deepdyve-link hiddenRentalLink" data-deepdyveurl="https://www.deepdyve.com/doc-view?docId=10.1001/jama.2022.22246&amp;fieldName=journal_doi&amp;affiliateId=JAMA" data-doi="10.1001/jama.2022.22246" data-fieldname="journal_doi" 
                data-issneissn="0098-7484" data-affiliate="JAMA">Rent article</button>
        <div class="modal--btn-desc js-deepdyve-desc hiddenRentalLink">Rent this article from DeepDyve</div>
 
    </div>

    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="js-modal-free-pdf-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Sign in to access free PDF</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f2799240">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

            <div class="widget-AmaAdvancedSeamlessAccess widget-instance-AMA_FreePdf_AdvancedSeamlessAccessButton">
        <div class="seamless-access-button--wrap">
    <button class="d-flex sa-button align-items-center" role="button" type="button">
        <div class="sa-button-logo-wrap">
            <img src="//cdn.jamanetwork.com/UI/app/svg/seamless-access.svg" class="sa-button-logo" alt="Seamless Access Logo" />
        </div>
        <div class="d-flex justify-content-center align-items-center sa-button-text text-truncate">
            <div class="sa-button-text-primary text-truncate">Access through your institution</div>
        </div>
    </button>
    <div class="sa-access-text text-truncate hide">
        <div class="sa-cta-access"><span>Add or change institution</span></div>
    </div>
</div>
 
    </div>

    <div class="widget-SelfServeContent widget-instance-AMA_FreePdf_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="js-modal-save-search-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Save your search</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f2799240">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

    <div class="widget-SelfServeContent widget-instance-AMA_SaveSearch_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
            <div class="widget-SelfServeContent widget-instance-AMA_SigninModal_PurchaseOptions_SaveSearch">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_SaveSearch" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Purchase access</div>
		<hr />
		<button class="modal--btn js-btn-subscribe-now">Subscribe now</button>
		<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_PurchaseOptions_SaveSearch</div>-->


</div>

 
    </div>

    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="js-modal-follow-collection-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Customize your interests</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f2799240">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

    <div class="widget-SelfServeContent widget-instance-AMA_FollowCollection_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
            <div class="widget-SelfServeContent widget-instance-AMA_SigninModal_PurchaseOptions_FollowCollection">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_FollowCollection" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--sub-title">Create a personal account or sign in to:</div>
		<ul>
			<li>Register for email alerts with links to free full-text articles</li>
			<li>Access PDFs of free articles</li>
			<li>Manage your interests</li>
			<li>Save searches and receive search alerts</li>
		<ul>
		<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_PurchaseOptions_FollowCollection</div>-->


</div>

 
    </div>

            <div class="modal--link-wrap">
        <a class="modal--link" href="/pages/privacy-policy" rel="nofollow">Privacy Policy</a>
    </div>

    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="js-modal-user-comment-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Make a comment</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f2799240">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

    <div class="widget-SelfServeContent widget-instance-AMA_UserComment_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
            <div class="widget-SelfServeContent widget-instance-AMA_SigninModal_PurchaseOptions_UserComment">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_UserComment" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--sub-title">Create a personal account or sign in to:</div>
		<ul>
			<li>Register for email alerts with links to free full-text articles</li>
			<li>Access PDFs of free articles</li>
			<li>Manage your interests</li>
			<li>Save searches and receive search alerts</li>
		<ul>
		<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_PurchaseOptions_UserComment</div>-->


</div>

 
    </div>

            <div class="modal--link-wrap">
        <a class="modal--link" href="/pages/privacy-policy" rel="nofollow">Privacy Policy</a>
    </div>

    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="hidden-true js-modal-page-data"
     data-store-url="https://store.jamanetwork.com"
     data-store-purchase-url="https://jamanetwork.com/oauthsignin?return_url=https://store.jamanetwork.com"
     data-store-subscribe-url="https://store.jamanetwork.com/index.aspx?productcode=64">
</div>






 
    </div>

        

        
        <script src="//cdn.jamanetwork.com/UI/app/vendor/jquery-2.2.4.min.js?v=638473295270790799"></script>
        <script>window.jQuery || document.write('<script src="/UI/app/vendor/jquery-2.2.4.min.js">\x3C/script>')</script>

        <script src="//cdn.jamanetwork.com/UI/app/dist/app.min.js?v=638488852374030681"></script>
        
    
    
    <script src="//cdn.jsdelivr.net/chartist.js/latest/chartist.min.js" type="text/javascript"></script>

    
    
        <script src="//d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script>
    
    <script defer src='//js.trendmd.com/trendmd.min.js' data-trendmdconfig='{"element":"#trendmd-suggestions"}'></script>
        <script type='text/javascript' src='https://platform-api.sharethis.com/js/sharethis.js#property=643701de45aa460012e1032e&amp;product=sop' async='async'></script>


    <script>
        var App = App || {};
        App.showCmePromo = false;
    </script>


    </form>
    

    
    
    <link rel="stylesheet" href="//cdn.jamanetwork.com/UI/app/scss/modules/_trendMD.css">
</body>
</html>

 contentType 9 text/html url 61 https://jamanetwork.com:443/journals/jama/fullarticle/2799240 responseCode 3 200 